<SEC-DOCUMENT>0001628280-21-015869.txt : 20210805
<SEC-HEADER>0001628280-21-015869.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161835
ACCESSION NUMBER:		0001628280-21-015869
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		211148473

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sgmo-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0,d:88a2484078e34264a08acc98742bbce0--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:sgmo="http://www.sangamo.com/20210630" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20210630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV8yLTEtMS0xLTA_e0c28a91-06b5-4d41-aced-9ee912d48ca1">false</ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV8zLTEtMS0xLTA_d7f97516-b100-4979-a0ed-a956045ba09b">2021</ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV80LTEtMS0xLTA_79439e88-38ab-42c1-afa4-f01c460352f6">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV81LTEtMS0xLTA_577edadb-48fe-4f2b-8fe6-5cc49e44c1e1">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV82LTEtMS0xLTA_033e1896-7a70-4b09-8741-3cb6f3d79d25">--12-31</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i1418093930b2494c9efc86566330110c_I20201231" decimals="-5" name="sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xMzEwL2ZyYWc6NWJkZTgxYmM3Y2I2NDg2ZjllZjIxNjBiY2NlMzRkYzIvdGV4dHJlZ2lvbjo1YmRlODFiYzdjYjY0ODZmOWVmMjE2MGJjY2UzNGRjMl8zODQ4MjkwNjk3Mzc2_cf548017-480d-4395-91d7-dd1254b1f172">0</ix:nonFraction><ix:nonNumeric contextRef="ia0480773874148cfac5726298c1d7995_I20210630" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjc3_08762a14-8ec2-41bb-9293-f9377bdafc34">P5Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ic8ea400821bf458997c74f535136745d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8bcb1501dfde480bb4a686c561586117_I20210802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia45a1fa516b24d509732822dedf80969_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if53d95c4f09b452589c92741496adec4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id509e95c58494ac8b19b3740eed626fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451bb316444e433b8be0465675c9e502_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fbd6f12c9b40f7abf2b4e635ce09f8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2532553bed14edca6798c93d083aa90_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie634578fb36048be98621104559edee6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f40f023c8ff401bbb0eea92048c2752_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6818cea0cc0b4106acfd0ca299befb47_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76400ba7a5394ae4bc48e57baf0b6966_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4050e8c74a1147cc858267b0e1b8c758_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d7313265bb442da33ae6f84d7c4862_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7f4351eee949c28a8776c4fe2c8654_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad53a190fa514e688060deebfd68d2e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8378ff7fc294b15a732b761ec44147c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb4957d21874146891b6c52f9a92192_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a8701b92bee4274ac683fe19bd1cfb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if136e6082b014302baf06eb9f33155bf_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c17820b63e4da5941380170aa10773_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b9e78a2e83c4087b0d4cbfa66208b48_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafb3ae2aae5a4f0da0dca70b744f197b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91aa883725fe42df83a8efd02d7c81ac_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381ca00d71c943629317c963c76a5403_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7187c32f2e32406b93490265952a56f2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6222a8ff3b04b6a8b4ecb256e9b6bdc_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b4beb7f3064e62bae7ad43156944d3_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i799d8cc66f694906a0ab37290354d60d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c9bc741cc74c3f88015c7a849b517b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12281bdefbdf476c8cfaf9303e3c4896_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb82e1104246402e998da7e18d3ac175_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a22c45761394b75af4d6906696260fb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d851e70bb94ec78db2876e006a48d5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bb63471d3c4a7ba84788fd8f7005ad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1885d06587d454d8be9824fa3e6e68f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e35e880a7ba447eb1db041c02cd0fc8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4afcf835853b4cad93648a7670596835_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e76a7f09ff044139311009878988bb1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d94baa04ca43eb8d75f34105ed0623_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df4f65d331a42e78e2fa83fb2c3971e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43fb5fc4bec0489486d7be362a594089_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160cf032b081413bb08a84005c04a475_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dcbc0880e6f4929a436952cda81d81b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826478ddac2547de9623bc77195eae38_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06147cd0f2824f5c829d965b134af50c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977b331cae2c44558ac4d8807d9beb5e_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24e0372fb79547c0ab5707e59b555660_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7cdf486da744840ae163e4c93082f83_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id443d9ba83d14bce9aa23f4e3906af56_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3900ce573569432e830a630426d6a8c7_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3993368d6f34912853e783bfc42062f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46690bda004c48dc8fe1a34394fe2539_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id650bde047e54d44a28d7f3cf2147fba_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3e1f0817d14b5082132f338ddf990a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f8df10acdf47de8be2793787e32c3f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6273dd375cbe431e851bf02f766c7d30_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3713011fcaf74d139f418e2d8b93a054_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id56b04a6fd3d4593b0228bf4b5070845_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f9b84d68624a3d8da6266d4a51b5f0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2323e4b2ca47436ab949fc5059e374c8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id901d356b1b34e939be8837407f81c5e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede1b461482d4aed82d73d8a69942f6c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc0cd49c9d441feab4a2812269fe281_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i077c5113d6c84b65a3cd01c8c474aebf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9e21d00fd54ff8a09781d3bb15014b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d0b873fa0149c8b7057a9015e35d00_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id562a87f24e64a2389a1d8d8af690954_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib805bf377aca43d18a31ed9b25cbd937_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if450e0b0e1ee4143a860c134efa23684_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0349e23895b7421f8e06a6dbc6671d20_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8183472477d84945864fdedade5b202f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5414aecb9154731b24f5050b5dbda09_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db22379ed084ff283dba3989fe52b6e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5029632c41647f2876db827348be963_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7def2ac71bde401591646c0426604256_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68379fd4ffaf45be8859410fd6c6d092_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64b7b79fb378470c800337959c76517b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i505b398cb72a4af8af945f5b2a8a5a17_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8eb9c45d4c408ba0e7213a7b21a8e3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4e0c6ce0cdc4cdc85330469e1cebf83_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b46bcd8bc6494a8ffa054541480b01_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i720ec452f326424cae2d555e85cbe793_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63e206d594384d51a4a4ea755c3ecac8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecdcf307636f43bea5bac2dc2e4668ea_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12cf9801c6e4bbd868ce62fb93d0483_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1309e7273bd24e24a45b18f385fbd498_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92fba028dc354b2eb96680caecf3f6e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i362bde0e7ad9484fb5748204542558d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i908904f75ecc47cca4d8fca5927696db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98e5bee530c449aaba799aaeba075e38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa17aef4be24c9488134ae6b2d112e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec88d85ad284f01bb0601faca0f26d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11554ac8395246c1b797508e7c8e254a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifca71a895253445d9bab2b29a4f24697_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6afbf16e0ce49a4bbc2a2f2ca704329_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d98818a61914dc19882f4a5fe585eef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i303ee2bb6e9a4ebaa06e5883c4402433_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c30dc9b677a4b0ca056c73e4e52b5c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib77476f69b30416498dda50883c18ac1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7061108114744e25af56d34f408d6462_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d79151e513b4079a0407f83cc2655fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbaf1eb6abc0483f8d83c17330ca0080_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb3dfe79994423bbacf9f8d84283e72_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13dbd67b064846a580f0e2753a85487c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad85f098bcf421c8794add0b139710b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1617c6130bb4fcd814b7b116daca30e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a854ccb6ff4f32aff9c08dace430ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce000386f6f43ecb585bb2bddba79ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22c7a6ee30f40759935f2f2d7d05834_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i963546ecd5104507ad517a04791a50c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706c0c1baf274bb08c2015e44b1886de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a9adeab28a45ad91025a9d341cc25a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1328c5aeb1034e05853f1890344e7e0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32c8d36f055d46c0bbb5f38ae8ded7f8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dad1abe8fca4c9dabb1a22b9f475901_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i381be31f4a96421eaace1530a63600f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc3d33b771494438a51064004b2d92d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6117a419ac54480ab8e969b26e8ae160_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie3ba6686f885449fbf9782164f707326_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide00909279d94c5a9ba8d214c592b3ff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81061d827331480d88e9dc8cbe6d82cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if916a4018cf94a308d569e7cc671aeb8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4194918b5c8f4b7b829c28cf27413388_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c37f58da8234bf5b594e14ec1be3875_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1418093930b2494c9efc86566330110c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e9e7ac993e4ab7b129b505e24d788f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c99173dbfe418bab2ee3066dfea7db_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ce71d590cc54013935014a27b276620_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e6ef0b9d424f72856f86ece181ec9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92334fc47614d2ab175150cbbea1d90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe7231be7af84f809a1dd4836d13b306_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4760033181744f46bfacb2148a09aa31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b87a7579154dcb87d6a2eacbe03968_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad6e61fa5a14049a4a165e22c9557b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie97ab57d631741109dd7c1a32d722ecf_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b4febff3d343589497559b4dbc5f8b_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b84cec3c18f41669b32e9a32a83d4da_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8586e51ff5384c2b9ada2a4f735e3e0f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e4879cf2b1844a59c47a50b6bf44286_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fbe30a7032d47a7a786786e1076584a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cff57d2627245a98dea197fe78cc195_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic486fd39de0248c3bf81822737de9125_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib688d56d6edc44adbe31811d44707d1b_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835ea8e2ca074d12bcb1b9c6349fbd74_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9188107d02544fb9b95edda10fc6daf_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d858ffe5d284f3fb40b15c110d4d661_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc0a358e8ea34e7d96de8f674d8a0733_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf78996e51842fd8c577ced5c319f9e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c078f8f84f44092b1c987d2f9ba3780_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd324fe4f6a48e79647a1e6e13a939d_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f0fa707fab440019c997c6ac3943ca0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5850fbbe650b4f7ca149d58bba066b5b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9cb92b6b80443c83fcad54e2dcea08_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee042a0e57b44b08fcec9b88eb3ff1b_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia808be1f58f54cccaab1ff5dea2e968c_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80a6feacaa574ddd9bd1767b41d0d48e_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c1b1cdac1240e2ab1190ed09b03af4_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0d594216f84c7c8299b126f82ebab2_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2feef78f3b79481c95ab041ca41b6d27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91eecccd242942a7817f59f45d876655_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6aabab5ee264688a6d71a905f925e4b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc2dd941800420886a2af2fa1765639_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbabaf0c6e544c5696a66609bb1a32f2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d932e2741554bd4a83bff4554127b46_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia45f3ae8095146d9b1f030e6d1b3c45e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd23694ec1c40ae9f6a4c23849d8ab3_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03284b31d89d49b79fcb22265c258ce9_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic897ac864eec4950857bfb672f25b043_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4323b438c56c49ddbd9f8c4452cc5cbb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64d854a46e26420aba7a79befd4d3e77_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i633a41af52284d31bdc9e6504274de2c_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3572522eb86c427da2f7e25c65c67b1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b2f05be78a47058af5e123836007ae_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0d564efa3a54efdbab0331632c968f5_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7b52cec79ab48a2ba640cefacfbece0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8501312825a4e209788ef85d358bc38_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96eec01b5a724940ba35b94c5052e547_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i513cb6fdd03a4af6a95f35c66fa0287f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d915090bdc4052aaca779390bc0142_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieee2cbdd740b48d58e90428fd2477bdb_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80babf04d54545919679cc087e35d0f7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a3cd7910e54e3ba3fb080b6faa69ac_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d5461382a74ce0b82725ff6d4dffd8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb3c41b97bcb4c6893772a2384819bbd_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc29534661e4306917bc72380c1ea3d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i972f741b215341248c20287be9d34ec4_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2f6b10a317f4701aac7778e60fc00f1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc812ad521304f0ab6d3a2b04029f0f8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654a42c3511c4a73913c506f1153cab0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i284384bda5c84aba85f546f831ef8980_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59545cce221e43deb1db8aa0c8c8619f_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4902644de3a643778c13659e688fac50_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf27be7caa634555848e2064b64db08a_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1599f0d2349045a39ceba19a613ae914_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="i75557659a8d24752a662921819a09f1c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="royaltyfee"><xbrli:measure>sgmo:royaltyFee</xbrli:measure></xbrli:unit><xbrli:context id="icafc6c9e5da64fc39cba314fee725d9a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f42ad77a67406fbca238b8af8a5ff2_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2ac5d2705044b993a63db847d92bd0_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedd52702a7604029a53060995365270a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02d5cb930a144a9cbb549d7b9e0cb689_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i123d6bac6b904da084b4648b22e9cceb_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d3391092d7417eac346ff77c7d0fcc_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc852cf62580436a97598e1e2e7bf50b_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f2298db25940a68086c2f2eb497a03_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dff6bb9876a41ea8f14c14d974128b0_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i816dc751251a43bc8a0c475d4f25692d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8b8b826b1842fc8ed899c4dbf877d6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4750f84c1fc4cd28df96b044fc89692_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id613ed24d16b4765acccce91ced04655_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265ca64c9422418893702f8fafcef2d2_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e4aeedad67245b6b57656cba94ee249_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae65106e3a964b398c60b12ac672bd06_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b2e93e3f8e44d4f8070ca3215e04801_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65fc4f7975b44d38bd7edb0af5fa7902_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f67506e89ce44568390610e8d2b4c62_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89c77516ab934aaaa96b5a86b02b8088_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie375b8492a12465a99eabff9410bf3a4_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1512a9ddf574d86903b981a4ce57329_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i585d0b863b2e455eb3b8ea38806281f2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7cd206e83e4758904b5e5fc3f1286e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i710717b98c6d41c0b46518ae1f4899ff_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18d41eac62204415b943de1ef2ecb501_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05b743385b4d48ca9fe7791ecbb5bb8f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6900d77cd9b42d4b868148dfc43e2dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ac0654b4e2f48dbaec56149181d417a_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b5cd1c78eb547b6a7cf66897094551c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f6533454f547909bd615768ac32c21_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8302d557aa5476eb1873deb8ef6875d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bbca3607d7f4b9dbfe618a574b3cf7f_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38026dfb9ff54ab38444e2c29717dc5d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8627855bb84142d381d3d87efbd3557b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3deb558477ad44f6a2d0a235b31ff428_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703707af95494f1883c80ff59a982ada_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1f96a8d30f2472682f523526a58819b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbaf08395b3f410388bfae8549a7f1ec_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaafcd0ad264e48e3aa1e5d6b42480cf1_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d369449f64a4fe9802fbfa50d7c5894_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i486e45b737f34ead89ccdfd67614cc80_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if65442cfd04e40d3ae655da86b882810_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a2fee8655546779fce8418e68deeb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ia382d9bdbbdf435a8b54bc9a6f870e20_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf88ce12a67f455e9a78d4bf52333bd6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ccec543f23406c8dce0f2a0b6c2285_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0480773874148cfac5726298c1d7995_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54bc17f50cf74a93848b137afc7fba91_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie759a817c5c842dc869ef8337be7e5b5_I20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic293643aa8de4967836920062840361b_I20210129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib32b37dab57243ff923131f59634e7db_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4481f3dcb92a483898be17cb32b7bf7f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id91afce1bd2045ce87ebb34073d3ebb3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dbf6eee474c485286ce46451d007985_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9b0b01e53e4cc1ad161df3748b4306_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2337f42bb8a494cb58c83594f9439eb_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife2d5e93bac84cb9b315459ace950026_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c0de19663e46b5a34f83368fe2a0c0_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193dfd8314f24ec6b3d6b58709ed8e14_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e988a6d8f274d49aef75fec334e2456_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i287279db3cc248a09fec60c8d435c802_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68bfdf24a47d45d792d479c5f84033cb_D20210701-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ced8520ef3f4fabbda53a780b5dc09d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i192244a99ff14df4a634c33f2294f707_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302cfc143c434200849acab7c19e79ec_D20200101-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d0d661e140c49a08925fdca70921940_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaedb801aae5d487896c33c8747f89875_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i88a2484078e34264a08acc98742bbce0_1"></div><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:100%">FORM <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcw_6b25b739-e76e-4500-aff4-f2d95998f2ca">10-Q</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6YzU0YWFmODQ4ZWJmNDgyOGFkZTA1N2UzZGQ3ZDc2NGMvdGFibGVyYW5nZTpjNTRhYWY4NDhlYmY0ODI4YWRlMDU3ZTNkZDdkNzY0Y18wLTAtMS0xLTA_9c1f1c3c-1ab8-48a3-b31a-56d2f333fc3d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMzM_64bfb901-361a-4259-84f2-45746e1209ca">June 30, 2021</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:booleanfalse" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MTI0YjRjYTU3MGIyNGRiNGJiMDRiNzM1ZjY3YWRkMDAvdGFibGVyYW5nZToxMjRiNGNhNTcwYjI0ZGI0YmIwNGI3MzVmNjdhZGQwMF8wLTAtMS0xLTA_1c67944c-8548-45cc-8f5d-c94f1fdeab99">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc1_388d6c0c-6264-4554-8e1d-a26be19dce98">000-30171</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcx_77f0ce96-efad-4932-a6d3-93335c63b308">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:30.193%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.165%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18wLTAtMS0xLTA_88d99557-23c9-4715-aa06-7b812fb35445">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18wLTQtMS0xLTA_d44bcf5d-be5a-4a2d-aef5-8bc18a8b51dc">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN180_c0bd870d-a582-4c8e-9e55-70daa0c5bdf1">7000 Marina Blvd.</ix:nonNumeric>, <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN184_61d34e23-4099-4a64-bab9-ba3ee5228d95">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN18xMg_c704a47f-6dbd-4ce5-b358-3b0d79899ddc">California</ix:nonNumeric>, <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN18xNg_26c74176-1fbc-4373-8a10-bebd1a0dd93b">94005</ix:nonNumeric></span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices) (Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcy_00582d55-10b7-4812-a2e5-c2f5e80b0fd7">510</ix:nonNumeric>) <ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc3_6f30b53b-e0e3-43c4-b1be-884a4852bdf0">970-6000</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">________________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTAtMS0xLTA_f8d34911-0889-482d-be39-449773a11b86">Common Stock, par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTItMS0xLTA_58fd0fa6-454c-4118-944d-9216934a681f">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTQtMS0xLTA_9b38c973-52ce-422d-a613-349db8e614d5">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjY5_548420df-5dba-4562-b48d-fd8b199ff2d8">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcz_400cc6dd-836d-43fa-9a6e-6e6580d84c55">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.722%"><tr><td style="width:1.0%"></td><td style="width:21.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8wLTAtMS0xLTA_0d298b53-6498-4c01-b9f0-e8d302b16123">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8xLTQtMS0xLTA_0643d76a-7871-4043-aceb-3390db004637">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8yLTQtMS0xLTA_d7a86d91-7459-4ae0-95d4-1853d529841e">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc0_fe57dfc0-1df5-4ab9-bd59-81836498d081">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#160; &#9746;</span></div><div style="margin-top:2pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of August&#160;2, 2021, <ix:nonFraction unitRef="shares" contextRef="i8bcb1501dfde480bb4a686c561586117_I20210802" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMTgz_00feb054-7951-47ea-8446-236e7a1e0401">145,337,046</ix:nonFraction> shares of the issuer&#8217;s common stock, par value $0.01 per share, were outstanding.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.527%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="15" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.180%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_16">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_19">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_19">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">Condensed Consolidated Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">June 30</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">, 2021 and December 31, 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_25">Condensed Consolidated Statements of Operations for the Three and Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">June 30, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_25"> and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_25">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_28">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">June 30, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_28"> and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_31">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">June 30, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_31"> and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_31">9</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_34">Condensed Consolidated Statements of Cash Flows for the Six Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_22">June 30, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_34"> and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_34">11</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_37">12</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_73">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_73">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_91">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_91">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_91">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_94">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_94">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_94">39</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_97">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_100">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_100">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_100">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_103">Item&#160;1A</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_103">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_103">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_106">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_106">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_106">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_106">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_106">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_109">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_109">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_109">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_109">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_109">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_112">Item</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_112">&#160;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_112">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_112">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_115">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_115">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_115">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_118">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_118">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_118">46</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_121">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i88a2484078e34264a08acc98742bbce0_121">47</a></span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated or the context suggests otherwise, references in this Quarterly Report on Form 10-Q, or Quarterly Report, to &#8220;Sangamo,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Sangamo Therapeutics, Inc. and our subsidiaries, including Sangamo Therapeutics France S.A.S. and Sangamo Therapeutics UK Ltd.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any third-party trade names, trademarks and service marks appearing in this Quarterly Report are the property of their respective holders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development, manufacturing and commercialization activities, clinical trials, operating results and financial condition. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators and strategic partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of our product candidates, including the durability of therapeutic effects;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our gene therapy and cell therapy technologies, our zinc finger protein technology platform, zinc finger nucleases and zinc finger protein transcription factors;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers or from our own in-house manufacturing facilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates and the timing and costs associated with obtaining regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive developments, including the impact on our competitive position of rival products and product candidates and our ability to meet competition from rival products and product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by use of future dates or by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;project,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;goal&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, without limitation:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates and durability of therapeutic effects to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel zinc finger protein technologies that have yet to yield any approved commercially viable therapeutic products.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We require additional capital to fund our operations and continue operating as a viable business. This additional capital may not be available to us on favorable terms or at all.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations expire or terminate for any reason, our revenues and product development efforts would be negatively impacted.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors are developing rival technologies and products that may be superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third-party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which has been and may continue to be challenging given the intense competition for these individuals.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The evolving COVID-19 pandemic has adversely affected and could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional discussion of the risks, uncertainties and other factors described above, as well as other risks and uncertainties material to our business, can be found under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on February&#160;24, 2021, as supplemented by the risks described under &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form 10-Q, and we encourage you to refer to that additional discussion. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our plans, objectives, estimates, expectations and intentions only as of the date of this filing. You should read this report completely and with the understanding that our actual future results and the timing of events may be materially different from what we expect, and we cannot otherwise guarantee that any forward-looking statement will be realized. We hereby qualify all of our forward-looking statements by these cautionary statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as required by law, we undertake no obligation to update or supplement any forward-looking statements publicly, or to update or supplement the reasons that actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You are advised, however, to consult any further disclosures we make on related subjects. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes discussion of certain clinical studies and trials relating to various product candidates. These studies typically are part of a larger body of clinical data relating to such product candidates, and the discussion herein should be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered in the context of the larger body of data. In addition, clinical data are subject to differing interpretations, and even if we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i88a2484078e34264a08acc98742bbce0_19"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div id="i88a2484078e34264a08acc98742bbce0_22"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMy0xLTEtMS0w_8c3b2185-f69a-4c26-8e00-cb6f501407f3">169,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMy0zLTEtMS0w_2a393978-ad35-44b7-ad97-43e8b9bdcfad">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNC0xLTEtMS0w_cacd96ae-e9c3-4019-b1c2-7987abeccee4">359,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNC0zLTEtMS0w_22474d78-111d-4822-a812-a43a943988aa">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNS0xLTEtMS0w_04f15e30-c508-4dbd-9648-c479a5bffc49">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNS0zLTEtMS0w_8259b61b-0a18-487b-aba5-fc6e834dc912">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNi0xLTEtMS0w_91528e66-e1d7-4ff1-9a9e-08658ff8dcab">6,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNi0zLTEtMS0w_89804a65-a0bc-4f49-9a39-0b6a0bbbd901">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNy0xLTEtMS0w_76463c2e-56d4-4c86-9387-bb6a02cae626">16,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNy0zLTEtMS0w_e68d8e95-e0db-4a29-8dc9-c8b15aaaffc0">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOC0xLTEtMS0w_17af1ff9-0ce7-46bb-a9ed-eecfce9c8fbb">554,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOC0zLTEtMS0w_ad5d5178-e2d1-4be9-8f0b-ddfa1f76c74f">659,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOS0xLTEtMS0w_81e94bb4-bc6a-4cb1-8a62-039c72bddf4b">49,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOS0zLTEtMS0w_84c48610-99b1-471a-bfba-e34122b06d86">50,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTAtMS0xLTEtMA_b39131d9-a279-44f1-814f-5530fe70e5c8">49,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTAtMy0xLTEtMA_f3daf367-62c7-4217-b3a4-22a60307e731">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTEtMS0xLTEtMA_2c00994d-12f9-4864-8b6a-eb7648890fe1">56,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTEtMy0xLTEtMA_61a2ecf7-ccc9-49ec-81df-093aba91b607">58,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTItMS0xLTEtMA_3b357f8d-5e81-4110-b880-c5a5309d436c">41,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTItMy0xLTEtMA_ef862ef6-d394-4fee-a99e-6f38a22cbec5">42,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTMtMS0xLTEtMA_46b74521-59e7-4e46-87f4-0d91943757ff">68,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTMtMy0xLTEtMA_01c7bad8-e697-4e30-8363-4a2ef25db786">71,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTQtMS0xLTEtMA_58021c51-9cb3-4fc8-9784-d2a1e7099c38">14,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTQtMy0xLTEtMA_e4e3a20a-dcf5-4f80-83d2-5466ce5a75c1">13,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTUtMS0xLTEtMA_846a0478-5baf-4f21-b24f-20a764f4797a">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTUtMy0xLTEtMA_0b969638-2f22-47fb-a132-94f92c3ad81e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTYtMS0xLTEtMA_2dd2f4db-8fbb-4607-a7c9-ebee22a8d263">835,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTYtMy0xLTEtMA_b09e79f2-5c05-4e30-a10c-ecfa02ac00cf">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTktMS0xLTEtMA_cce96a49-cf19-448d-a661-73695d4cb4dd">10,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTktMy0xLTEtMA_812943dd-60b5-4d5d-bac0-09242000bd4e">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjAtMS0xLTEtMA_18e8844d-2b01-498a-93b5-045951092515">17,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjAtMy0xLTEtMA_8707a518-c3a9-4c3d-9c01-a2fdc84d49a0">20,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjEtMS0xLTEtMA_53bc3724-d2ba-4305-9210-175276e6abbd">15,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjEtMy0xLTEtMA_fccc50b2-6c87-495b-8594-95a252e70e93">18,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjItMS0xLTEtMA_2938cc41-d4a1-4cbf-8e03-18962ecd4c85">93,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjItMy0xLTEtMA_24959f5f-b2fe-428b-862c-ab6284001ba2">91,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjMtMS0xLTEtMA_44d3c75a-7f29-409f-9e4d-2c31cb05467d">136,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjMtMy0xLTEtMA_bd8ab807-b29f-4d6d-8eba-2c389bff8a81">143,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjQtMS0xLTEtMA_d6e5cd51-0f90-49a8-9df5-ebda86db30c5">201,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjQtMy0xLTEtMA_5e27b232-895b-4da7-947c-e889512b99a2">245,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjUtMS0xLTEtMA_a81c7a50-3022-4d21-821e-30d7b0037421">37,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjUtMy0xLTEtMA_4c6a1e47-9dd9-44fc-a4c7-14304cc1f318">38,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjYtMS0xLTEtMA_cff707ef-d90a-4f34-9be8-f33af1764d21">6,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjYtMy0xLTEtMA_01ea0df1-a9fa-48e9-bc18-976b8e6764a6">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjctMS0xLTEtMA_12f559b8-e131-4a26-85fd-c29233908759">7,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjctMy0xLTEtMA_2c29edaf-6254-4e9e-bee9-a705cb96ad18">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjgtMS0xLTEtMA_d66dc86a-fdd3-46b3-816f-ff6c62916d55">389,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjgtMy0xLTEtMA_9c079daf-6170-48b9-acd7-7f2abe8311e7">441,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjktMS0xLTEtMA_b05f4a30-a1fd-49b3-8097-3563f2d921cb"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjktMy0xLTEtMA_fa38cd96-c9c8-4e7f-ac34-2ef437bd1636"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzEtMS0xLTEtMA_1df77f95-053a-4d79-bfe9-a7d03a6fdd34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzEtMy0xLTEtMA_79472aa5-db15-443d-bfef-6117a337ef3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzItMS0xLTEtMA_d5a98df0-5e51-4428-95c4-b5e16e7e8fc1">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzItMy0xLTEtMA_bdaa3f78-3ce4-43ce-b0a6-031e47c2dab3">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzMtMS0xLTEtMA_26351cb3-6c54-494a-8d16-6bd009209eb3">1,313,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzMtMy0xLTEtMA_2603151a-9d09-47a2-aff7-6a0c9ff3f144">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzQtMS0xLTEtMA_a7595f52-321b-41ac-92ac-8088cb713f9f">871,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzQtMy0xLTEtMA_95e8de4b-1a00-4612-bcfd-80e0e102eb0d">777,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzUtMS0xLTEtMA_23c47656-b28e-4732-ac91-6286c1091667">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzUtMy0xLTEtMA_3dea4416-5d27-4361-be58-d5bf4d15ca72">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzYtMS0xLTEtMA_7b7ad35a-bc58-462b-92f1-37c62897f269">445,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzYtMy0xLTEtMA_daf34205-a28b-4762-9f43-c591fea4cf1d">498,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzctMS0xLTEtMA_fa2271fd-d19b-4a55-94ce-ff518fbb2abf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzctMy0xLTEtMA_bb9f27f1-7972-4f69-aa0a-0de9d5234f4d">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzgtMS0xLTEtMA_c6c4c503-a56b-4fb3-8309-60744bc329da">445,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzgtMy0xLTEtMA_ff94a03d-9d32-4d92-bfa6-841e3bea7752">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzktMS0xLTEtMA_c214a8f7-d3e8-482a-a7be-907afb1032db">835,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzktMy0xLTEtMA_ee850870-0540-4508-a5b9-dd4efc7c2626">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except per share amounts)</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0xLTEtMS04MQ_6e6d520b-c0db-4aae-82bc-e29b622474d1">27,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0zLTEtMS03OA_43566cbf-29d4-44e4-bed7-896754d15858">21,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0yLTEtMS0w_a272ce4a-1acb-480d-a974-dc58ebf3a28f">54,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi00LTEtMS0w_b5159c3d-1c44-493a-8b1b-13e980fb7ba9">34,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0xLTEtMS04MQ_c9e2b12d-e9b5-40a6-97c5-8d4e4637db08">60,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0zLTEtMS03OA_4c2c20b2-ae80-4628-8456-00a8350102f1">41,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0yLTEtMS0w_e15592d7-ad29-4c11-b5de-66fd15f55e7c">116,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC00LTEtMS0w_d871f443-1ab7-417d-a77a-aa9cfc4ca7b7">83,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0xLTEtMS04MQ_58138e7c-be89-4de4-8647-46960d9beafc">16,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0zLTEtMS03OA_55f8381a-8b40-43aa-911d-a66a03cdd1ec">17,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0yLTEtMS0w_6da1220e-0f47-431a-aec4-45ac7ce1c121">32,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS00LTEtMS0w_8d5c4336-688b-4acd-b6ec-2321b39bcf22">34,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0xLTEtMS04MQ_77296df1-6e44-4bb3-9178-d3184d3a7b2d">76,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0zLTEtMS03OA_cf53dc7d-ca48-429f-95eb-873520b6720e">59,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0yLTEtMS0w_81f38c47-8490-4318-a2a0-d306322115aa">149,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi00LTEtMS0w_bd849a11-40da-4de8-bbae-fab83a1d981a">117,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0xLTEtMS04MQ_23d43f78-4a20-409e-b5f1-f1d5ef3024d1">48,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0zLTEtMS03OA_8b69f69f-63a0-421e-b0e0-755882ea76f5">37,897</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0yLTEtMS0w_7c0a74d9-5fe2-4f07-909b-796e995ee7bd">95,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy00LTEtMS0w_a3bed0fa-8730-459f-8a93-a3bc6b4f83a1">82,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0xLTEtMS04MQ_25c90d7e-ce68-4524-a7ec-f0b0e52503b3">1,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0zLTEtMS03OA_ceab933d-b458-411f-9194-95e5c6dad1d8">1,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0yLTEtMS0w_610f6384-a648-4a75-9c6d-bab831d3e3dd">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC00LTEtMS0w_7ccd0f19-df0c-4e9d-8012-e469f4edd871">3,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0xLTEtMS04MQ_0c137bdd-a361-45d0-9b3f-16aff842c1fc">47,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0zLTEtMS03OA_ad0e4223-0745-4eb3-9764-f794def4373f">35,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0yLTEtMS0w_0c8a0ed3-6f9c-4769-ae3d-f154030fe325">92,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS00LTEtMS0w_c165f78f-4591-464c-be98-18c0390e4e5a">78,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMS0xLTEtODE_bd274728-8be3-4e1f-8cd7-8c0575a44394">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMy0xLTEtNzg_14645e47-e2f7-4bf7-b589-8461e1bb1417">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMi0xLTEtMA_b695d366-6e2b-428a-8a43-f17d354ebc5a">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtNC0xLTEtMA_79c7fac7-9cf6-4977-9a8b-3eccd089086a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMS0xLTEtODE_3660158b-9be7-44a6-ab71-206209c8f7f9">47,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMy0xLTEtNzg_050f5c98-6a10-4aa3-9124-8fa128a38cc9">35,965</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMi0xLTEtMA_1b2aba0e-a5b7-4b97-81ce-349a9b21fc5f">93,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtNC0xLTEtMA_e3b5a7bb-25a5-4192-953a-70f06880bc55">78,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMS0xLTEtODE_ff89a354-aef9-4ae8-8ff5-ad6e402e42ee">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMy0xLTEtNzg_332a95c5-f055-4aaf-897b-7d82ca6b7c8d">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMi0xLTEtMA_0a6e379c-4987-4614-b640-2f8b506882a0">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItNC0xLTEtMA_dcd00b86-3eb0-4775-9a9d-2ba5a6b2be2e">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMS0xLTEtODE_2e6c3b2d-ee16-4970-a493-2b6a47591c99">47,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMy0xLTEtNzg_cfce3b55-9ebd-4227-9f47-3d8f5ccb686d">35,929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMi0xLTEtMA_fd6de286-15a3-4b33-9b35-17c3d66ef0d5">93,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtNC0xLTEtMA_b0b2cb29-0a9f-4b92-a01d-89421eb0970c">78,842</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMS0xLTEtODE_21d1a89c-e3b6-4b18-9d9c-fb97cd1acc51"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMS0xLTEtODE_34db838d-c729-4cb1-ba62-d159926a403e">0.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMy0xLTEtNzg_1ef7312b-95c5-43d0-b047-a847bc552e93"><ix:nonFraction unitRef="usdPerShare" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMy0xLTEtNzg_8bba98ee-98df-4030-93fe-f4eee92e280c">0.26</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMi0xLTEtMA_d9fa1e63-238c-46ed-8fc5-51eb8356f175"><ix:nonFraction unitRef="usdPerShare" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMi0xLTEtMA_ed36776d-c2d5-468e-a29c-945409cdab9f">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtNC0xLTEtMA_9da5364d-4ed3-4d4c-9fd7-3fce3c0c4bb0"><ix:nonFraction unitRef="usdPerShare" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtNC0xLTEtMA_f14fe437-e3ea-43b9-b57b-da9bcef5967d">0.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMS0xLTEtODE_47c37ac2-f3cd-403d-a992-38f7f995c4c9"><ix:nonFraction unitRef="shares" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMS0xLTEtODE_fd963f12-1fab-4acd-aea2-79cbe38a7435">143,984</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMy0xLTEtNzg_9655f77e-2a36-4178-8a04-4b58b0408770"><ix:nonFraction unitRef="shares" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMy0xLTEtNzg_9fd5db31-8d1d-48b0-aa62-f05645eddaca">138,977</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMi0xLTEtMA_318fa5d5-abf3-4245-b3d6-3ce83e0c08f4"><ix:nonFraction unitRef="shares" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMi0xLTEtMA_45c5b2b7-ed2d-4b24-9e13-95f2511668fa">143,550</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtNC0xLTEtMA_0f8dafcd-29cb-4ef0-9ffd-a595d18bc7e6"><ix:nonFraction unitRef="shares" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtNC0xLTEtMA_9a110d55-7f9b-4fa9-9750-dc33b36a842d">127,519</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0xLTEtMS0xMDU_b26f6fc2-5a71-4af0-9926-98ae994e48fc">47,174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0zLTEtMS0xMTY_72dbd736-bfcd-4c46-9809-45751dd0bb51">35,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0yLTEtMS0w_1b2aba0e-a5b7-4b97-81ce-349a9b21fc5f">93,113</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi00LTEtMS0w_808cd9f7-3c0a-44d3-b38a-de09b4e7f4e7">78,939</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0xLTEtMS0xMDU_f67ab08f-490d-4a88-bbf9-a2075fb55d3c">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0zLTEtMS0xMTY_e07dcbb9-aaf3-4ebd-8864-f4e452599a52">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0yLTEtMS0w_3b2ea64e-067d-472f-93ff-f521be366b96">3,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy00LTEtMS0w_a9cfb806-f6ab-46d0-af94-7910a860655f">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0xLTEtMS0xMDg_0c1834d5-3710-479e-80f2-0ab75de68cdf">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0zLTEtMS0xMTk_415c294f-6119-4fc9-ad7f-d022cd32a8e8">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0yLTEtMS0w_0c9849ab-3aa3-4e70-be99-bd0b78f31f57">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC00LTEtMS0w_8cf6473e-74ce-4a35-ab2f-d56b16548dd5">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0xLTEtMS0xMTE_24f09e29-aa19-4210-b3a5-ecba3fb509cb">45,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0zLTEtMS0xMTE_bc5a6be2-232b-481c-8bab-5eab8b7e60db">33,790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0yLTEtMS0w_eacf00eb-4813-4949-92af-1e4245edd3e3">96,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi00LTEtMS0w_66af0e0e-934a-41ff-830c-e11ab9b660af">78,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0xLTEtMS0xMTE_492688c1-e928-4566-ac8e-5c289664b864">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0zLTEtMS0xMTE_6c636e8d-eb05-4433-ae14-84e78a7f8f89">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0yLTEtMS0w_9d734e38-f0a9-40ea-9253-9472772e5874">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy00LTEtMS0w_bbe7f6ad-3fb6-4787-8e3f-24f17b1c32cc">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0xLTEtMS0xMTE_dce693ee-3051-402d-b098-58388901b4ba">45,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0zLTEtMS0xMTE_f1b32dd3-7939-459d-9d60-cac9ebe9154a">33,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0yLTEtMS0w_7fed8ede-3470-4105-8b9f-cbcbac5ba972">96,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC00LTEtMS0w_96dca144-36f4-4c64-8d2a-23e8d285b8e8">78,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:26.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xLTEtMS0w_82748c47-452b-4d12-8bd0-3ad44013a480">143,713,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0zLTEtMS0w_a341b924-dcd2-4ca1-ae4e-6638a182f79c">1,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id509e95c58494ac8b19b3740eed626fa_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy01LTEtMS0w_0a7c36fc-c5b9-462a-ba6d-69c4df0a965b">1,292,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i451bb316444e433b8be0465675c9e502_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy03LTEtMS0w_4e6461bc-c17c-42a6-ae07-5a1609d41cf0">823,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fbd6f12c9b40f7abf2b4e635ce09f8_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy05LTEtMS0w_7db8e842-0b66-4962-b3dd-0d5cc38c334d">714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2532553bed14edca6798c93d083aa90_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xMS0xLTEtMA_e12424b0-da30-4cab-9fa6-059a63420651">938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie634578fb36048be98621104559edee6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xMy0xLTEtMA_d09c4fef-a3d2-4f06-aec1-65d395bf10a0">469,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock in connection with at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0xLTEtMS0w_49534776-2e42-4553-b82b-c55ec859a96b">770,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0zLTEtMS0w_6d73ed85-4f03-474d-8742-af94038a30ca">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC01LTEtMS0w_ab0f6121-a855-417f-ad8d-a4ed82b2c7d4">9,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0xMy0xLTEtMA_f1e28f4d-5d92-421a-bf24-89e545740792">9,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0xLTEtMS0w_b1440e50-858a-42bd-b42b-587bd0cbb72e">378,101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0zLTEtMS0w_4374f95a-d3a4-4e81-8849-c7a3ecc6686c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS01LTEtMS0w_807ef63d-2c2f-4dc8-a822-214efdfe7cbf">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0xMy0xLTEtMA_bb44719b-8223-4164-bf2a-c285781391df">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0xLTEtMS0w_60ba53b5-d6a5-4981-bee4-fa722b3ad5b5">244,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0zLTEtMS0w_0b05bc78-ee3f-41f6-824f-6aed565db0f6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi01LTEtMS0w_3805072d-2c83-4764-9236-86b46f336112">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0xMy0xLTEtMA_93f7eb7c-1837-4473-a1aa-22af2eac10f8">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNy01LTEtMS0w_1bc729fd-a827-42ba-9813-637016c2b0a3">9,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNy0xMy0xLTEtMA_33d2c4a3-8ef5-4cd5-a7b8-1ea4d3c17533">9,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOC01LTEtMS0w_c50f10eb-14df-4648-b618-e20f1f19ee81">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOC0xMy0xLTEtMA_faad1ea8-343a-44f5-b955-ebdb3ee82af1">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOS05LTEtMS0w_1121e6b9-09e4-4a96-bc26-58da30bd48a6">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOS0xMy0xLTEtMA_d0e59c9a-ed70-4e3c-852d-e66a63515638">1,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized loss on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTAtOS0xLTEtMA_fbc23fe8-50c7-46fc-b864-c6a790b7e37e">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTAtMTMtMS0xLTA_ff91a1b9-b292-432d-b6d6-72dd65e6c8b8">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buy-out of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItNS0xLTEtMzY4Nw_586b4c67-3af5-49b1-bf40-742ddf66679d">943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTEtMS0xLTM2ODc_188e177e-e9f2-410c-8c9e-d8a12eb20b06">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f40f023c8ff401bbb0eea92048c2752_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItNy0xLTEtMA_d942f6fa-98fc-41f4-8c9f-48ef154708f9">47,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTEtMS0xLTA_8bcf7999-5dd8-44cc-9e40-9fa7e11281ee">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTMtMS0xLTA_2630edd3-2dc7-4d3c-a806-6a6251853f75">47,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMS0xLTEtMA_d6eb706d-849c-4b24-aab2-07c2ff5fd5e9">145,106,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMy0xLTEtMA_153cfc7f-e38b-4436-91a4-4fa840d0a9b7">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6818cea0cc0b4106acfd0ca299befb47_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtNS0xLTEtMA_e4cecd47-1a5c-428e-a862-dd49b57d86d8">1,313,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76400ba7a5394ae4bc48e57baf0b6966_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtNy0xLTEtMA_08118841-8913-4f24-a763-80f403c18515">871,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050e8c74a1147cc858267b0e1b8c758_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtOS0xLTEtMA_b662f1b7-2baa-44e9-bc6f-526d28d28de4">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d7313265bb442da33ae6f84d7c4862_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMTEtMS0xLTA_aaceb23e-78a8-476a-a11a-9bc7b7149fcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMTMtMS0xLTA_6e3ce006-3dd8-4898-9c57-d512d685f929">445,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:26.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6c7f4351eee949c28a8776c4fe2c8654_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xLTEtMS0w_95d2a523-cd48-40ae-b475-b5b6b34d01f0">142,063,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7f4351eee949c28a8776c4fe2c8654_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0zLTEtMS0w_9d361e64-c659-43c0-8466-0e86c085d207">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad53a190fa514e688060deebfd68d2e5_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy01LTEtMS0w_d80b5e9c-b723-4e7b-9016-ad4000ab2710">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8378ff7fc294b15a732b761ec44147c_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy03LTEtMS0w_a74f9298-9a93-4f82-94b0-96082703e9d3">777,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eb4957d21874146891b6c52f9a92192_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy05LTEtMS0w_b7dcd009-6d37-4bf3-b27f-77d5d430ef3f">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a8701b92bee4274ac683fe19bd1cfb3_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xMS0xLTEtMA_6510170f-0654-4118-a0c2-251801c703b4">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xMy0xLTEtMA_feb4a750-a780-439f-9262-3728f7dd97e5">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuance of common stock in connection with at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xLTEtMS00NjA_3b736761-2fae-42bb-b3a5-c345b59d2d4c">1,805,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0zLTEtMS00NjA_44f35197-6697-46b6-8e6f-08f1cd950d2f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC01LTEtMS00NjA_324648c2-d269-4f82-8ab4-1a7effda385f">24,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xMy0xLTEtNDYw_46be2fd4-f720-4b2b-a0b6-96eb1feaa402">24,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xLTEtMS0w_5195ffd5-5412-4a57-86cf-6ad97b445faf">993,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0zLTEtMS0w_ba9a0aa1-f893-45f0-8193-8eb98db330ac">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC01LTEtMS0w_d58ef121-3290-45a3-8856-06d026a6347e">967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xMy0xLTEtMA_0d040db7-85dc-4274-b5a4-80e2d6f10dc9">977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xLTEtMS00NjA_8bfb7e50-e698-4235-bf27-907713dec139">244,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0zLTEtMS00NjA_c26d98ab-a370-4712-afe9-66086f1da696">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi01LTEtMS00NjA_7295d88f-672f-44e4-b1a9-5b646a9a8f84">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xMy0xLTEtNDYw_ab5d9453-4d37-4582-bbb5-27c35be3f87a">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNS01LTEtMS0w_0322d353-284d-4bb0-8d19-be78fc3915da">17,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNS0xMy0xLTEtMA_e3c373f5-ccb6-46b7-b1b8-11d1747381ce">17,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC01LTEtMS00NjA_3737dc30-f36b-4251-b011-aacc73c62f01">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMS0xLTEtNDYw_716bbe90-4154-4625-b3ee-1009d860d3e1">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMy0xLTEtNDYw_df2c7d75-f9a5-43fd-9ed8-2d108aaa9a72">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if136e6082b014302baf06eb9f33155bf_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi05LTEtMS0w_3992130b-95fe-4603-9f0e-c9f47d97a511">3,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xMy0xLTEtMA_4fcf76b3-435e-4e26-80fe-b02680ffea2f">3,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if136e6082b014302baf06eb9f33155bf_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNy05LTEtMS0w_a69b3ebe-5dbd-461a-bb68-770ac470aeb0">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNy0xMy0xLTEtMA_7512ad8c-44e5-47f2-b634-237c7b8fa55a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Buy-out of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTItNS0xLTEtMzk4MQ_16d9e4f8-cb8e-4c8d-8e02-72565a0a3797">943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTItMTEtMS0xLTM5ODE_a2a0af7f-d0a6-4235-91b7-d2359ee280d3">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97c17820b63e4da5941380170aa10773_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC03LTEtMS0w_f9bdad34-5808-4482-aaa7-59fbf0bcbe5c">93,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMS0xLTEtMA_4e555605-44b8-434d-a838-a69ae00163cb">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMy0xLTEtMA_8d9caa56-37c5-46c2-b354-9e8be496ff10">93,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMS0xLTEtMzcwNw_4354786b-7564-49d8-b36d-ae1279f79cac">145,106,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMy0xLTEtMzcwNw_3ea85542-2fd0-4bfe-92cc-5d0173dd4df3">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6818cea0cc0b4106acfd0ca299befb47_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtNS0xLTEtMzcwMQ_def40d92-78c2-4be8-b39b-5ce522096a72">1,313,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76400ba7a5394ae4bc48e57baf0b6966_I20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtNy0xLTEtMzcwNw_0db8a476-df1a-4488-98c2-c0392fc6c28f">871,083</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4050e8c74a1147cc858267b0e1b8c758_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtOS0xLTEtMzcwNw_94796f71-15d9-4e48-a9bc-9a450dc31387">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d7313265bb442da33ae6f84d7c4862_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMTEtMS0xLTM3MDE_3f801b04-aaaf-46d8-8562-131338b9d4c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMTMtMS0xLTM3MDE_55e423cc-d75d-4116-967f-3c8f2f3fd70c">445,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:26.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2020</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xLTEtMS0zNDA_95572606-1219-414f-bbb1-b3aab34e9378">116,278,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0zLTEtMS0zNDA_511ced70-a275-4f57-bde9-973e5066d5c0">1,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9e78a2e83c4087b0d4cbfa66208b48_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy01LTEtMS0zNDA_0ae8f49c-5c44-47ed-9cd0-1c6fa8d63369">1,096,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafb3ae2aae5a4f0da0dca70b744f197b_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy03LTEtMS0zNDA_02569a63-9d26-4bca-bb84-bf7e0253ea36">699,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91aa883725fe42df83a8efd02d7c81ac_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy05LTEtMS0zNDA_f0973bda-d857-406b-81b1-616e9d97028f">3,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381ca00d71c943629317c963c76a5403_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xMS0xLTEtMzQw_ccdaee9f-8fa0-4110-bd4e-05ffa990a17a">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7187c32f2e32406b93490265952a56f2_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xMy0xLTEtMzQw_7e4fc3cb-0de1-4e60-a48d-959885c44e76">394,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0xLTEtMS0zNDA_566009ab-bbfc-465e-bfe8-191b20f439fc">103,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0zLTEtMS0zNDA_e238c673-4537-4605-9c7f-fdc9e590c437">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS01LTEtMS0zNDA_60fbe962-df83-4ee2-99ce-73d59fc5b3b2">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0xMy0xLTEtMzQw_921b1e78-2ba7-4f25-b550-fb051ca9a67f">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xLTEtMS0zNDA_4770c4d7-0443-4bd9-9bf7-1313881b1934">171,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0zLTEtMS0zNDA_1f0fb31d-9f44-4ce0-b547-13474fe559d2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi01LTEtMS0zNDA_fcde1cd5-86c3-4c0e-be3c-8e1695a9eeb1">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xMy0xLTEtMzQw_d9793a5e-c7d3-4c54-9485-dd2764effab0">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Biogen collaboration agreement, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xLTEtMS0zNzM_d7a8660e-d8f0-43c4-a232-6bdc403a7ffd">24,420,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0zLTEtMS0zNzM_a5936e52-015f-4389-8838-974c94ba5cdc">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi01LTEtMS0zNzM_df78ad57-a22d-415a-b6ca-c10399e17855">142,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xMy0xLTEtMzcz_3fdaf981-4dc4-467f-a22a-498c695bab22">142,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNy01LTEtMS0zNDA_64528dbb-d91c-41a3-8b7a-8ad9c02e3e90">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNy0xMy0xLTEtMzQw_87c3846d-a048-45e1-853a-b208eae92263">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOC0xMS0xLTEtMzQw_5d978101-67ae-4427-b748-b4397c16e943">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOC0xMy0xLTEtMzQw_f13a902d-6bcb-4596-89de-aa87ca2b3909">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOS05LTEtMS0zNDA_46ede9c7-f439-47e1-80d5-505dc5f5f298">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOS0xMy0xLTEtMzQw_27e8d0d0-1f2e-455b-8ad7-17f15b16504d">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTAtOS0xLTEtMzQw_9b1ae52f-ac3f-4640-817a-024ccdbfb1f9">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTAtMTMtMS0xLTM0MA_1b81a139-f2bc-4b26-8b50-d71363dc7994">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6222a8ff3b04b6a8b4ecb256e9b6bdc_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItNy0xLTEtMzQw_5bf0c668-47d9-4bd7-9522-d74e7e506a9b">35,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItMTEtMS0xLTM0MA_b441daa9-041d-4418-9efe-8b43f3b0b588">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItMTMtMS0xLTM0MA_a86ed5da-6fae-47f5-91d2-200225f45b2d">35,965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMS0xLTEtMzQw_5d614941-7a89-4e3f-9230-58cbeacb33b2">140,973,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMy0xLTEtMzQw_a132a625-cba4-4855-b428-8250bce73966">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b4beb7f3064e62bae7ad43156944d3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtNS0xLTEtMzQw_e770f3a1-12f2-4892-a197-fdb2b9fbdd71">1,247,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i799d8cc66f694906a0ab37290354d60d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtNy0xLTEtMzQw_f6c022d9-d544-4491-bd31-2828fe7be1b1">735,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c9bc741cc74c3f88015c7a849b517b_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtOS0xLTEtMzQw_4ef07222-88b4-402a-879e-4222bf6a6659">1,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12281bdefbdf476c8cfaf9303e3c4896_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMTEtMS0xLTM0MA_b37f477f-d2ce-4b17-a008-f46561c9ac67">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMTMtMS0xLTM0MA_7fa4f4fe-aeaf-4646-b0f8-9f0c5dc0127d">511,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:26.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.189%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:24pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a22c45761394b75af4d6906696260fb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xLTEtMS0zODk_83040b14-3c50-4deb-9f71-71a6f36777ec">115,972,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a22c45761394b75af4d6906696260fb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0zLTEtMS0zODk_d8cb8418-638f-441f-abb3-01c2c6136f4c">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d851e70bb94ec78db2876e006a48d5_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy01LTEtMS0zODk_60482b6c-96ab-42d4-bdf3-39a538f9aea8">1,090,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18bb63471d3c4a7ba84788fd8f7005ad_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy03LTEtMS0zODk_dfed06d1-0eae-40cc-a113-8a4af938723c">656,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1885d06587d454d8be9824fa3e6e68f_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy05LTEtMS0zODk_4d2b10d3-4e1f-4565-a72d-a9c007ff19fe">2,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e35e880a7ba447eb1db041c02cd0fc8_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xMS0xLTEtMzg5_334d4b72-4441-418c-aa70-d4d0dd58c04a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afcf835853b4cad93648a7670596835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xMy0xLTEtMzg5_0fe4d208-da7c-48e2-b94a-90a16f421aa1">432,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0xLTEtMS0zODk_cb8d7b24-00e3-42f6-8fb0-46ec1b7889c1">409,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0zLTEtMS0zODk_e7396693-7b3e-47ba-9373-28d55346f7ee">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC01LTEtMS0zODk_07ae9cd1-87d8-4a4e-b526-d68cf7e54cb4">848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0xMy0xLTEtMzg5_e86073f0-8aa3-418b-a836-431d1894e9e4">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0xLTEtMS0zODk_255ea59e-0c27-4d93-adcb-eaae0a242e73">171,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0zLTEtMS0zODk_395d6479-448c-49c9-9b2e-046256ab7e6e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS01LTEtMS0zODk_0b34f73f-960d-497a-8001-8e413ad762e3">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0xMy0xLTEtMzg5_946443d4-4474-4aca-9b39-421689f1248b">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Biogen collaboration agreement, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0xLTEtMS0zODk_fdb9b13c-2a14-4679-ba06-f9c677dea510">24,420,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0zLTEtMS0zODk_e466829f-d010-4432-be2e-bf08f4e022d4">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi01LTEtMS0zODk_ad308c11-c2f5-4895-b9a7-eb3a62a81796">142,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0xMy0xLTEtMzg5_d9a3b9ca-0d41-439d-b4f0-ac8d9a1c3c23">142,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNy01LTEtMS0zODk_76f27c48-0d3b-41c2-b397-92c230bddf81">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNy0xMy0xLTEtMzg5_2b534d34-20ab-4e13-863a-a51c159d4aae">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOC0xMS0xLTEtMzg5_a0198be9-7e35-4348-b251-c80300644402">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOC0xMy0xLTEtMzg5_ccef869a-e2e0-4ac9-8704-30a810797125">339</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e76a7f09ff044139311009878988bb1_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOS05LTEtMS0zODk_34d10f2d-ebfe-48ab-a1f5-44560219ed2b">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOS0xMy0xLTEtMzg5_0bc5f928-9205-4d0e-bdfb-8b0e28764757">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net unrealized gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e76a7f09ff044139311009878988bb1_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTEtOS0xLTEtMzg5_b5fe9d47-aed7-4ff2-8306-4d85a7802d33">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTEtMTMtMS0xLTM4OQ_83893a34-1fb0-46f9-a5a4-2f013c4cd5f5">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18d94baa04ca43eb8d75f34105ed0623_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItNy0xLTEtMzg5_d5599790-5ba3-461a-9390-f9c092f089e5">78,842</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItMTEtMS0xLTM4OQ_e1f5a7bf-b6fb-4abc-a003-bbc9c47bf6de">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItMTMtMS0xLTM4OQ_64a774b3-9c02-48ea-9b01-0ed870c0ed1c">78,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balances at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMS0xLTEtMzg5_d43b0a0d-38b7-4708-a261-9165c9d15412">140,973,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMy0xLTEtMzg5_f0c0c61c-1723-4eb6-9195-45862e899a06">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b4beb7f3064e62bae7ad43156944d3_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtNS0xLTEtMzg5_2327ba5d-3151-47d7-9f1b-b18709e9bd6d">1,247,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i799d8cc66f694906a0ab37290354d60d_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtNy0xLTEtMzg5_f55f988f-5369-43fe-8580-bccf49820df9">735,827</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c9bc741cc74c3f88015c7a849b517b_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtOS0xLTEtMzg5_204feecd-ed10-4410-8961-df4fde1b0d6f">1,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12281bdefbdf476c8cfaf9303e3c4896_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMTEtMS0xLTM4OQ_b3692fe0-13d9-4447-8b4d-aaeb1aa6f66b">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMTMtMS0xLTM4OQ_26a3e8c0-c94f-4b51-97b3-0c842c2f37c4">511,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMy0xLTEtMS0w_e9f4250e-4b5c-4d1e-82d8-08ceba690fd1">93,113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMy0zLTEtMS0w_d20f20ce-3362-4ab6-a386-65766bd5c284">78,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNS0xLTEtMS0w_bfd0613c-e86c-4093-bc64-8248952bb498">4,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNS0zLTEtMS0w_a0975943-75d9-4c0d-ab1e-16f96c2f1958">2,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premium (discount) on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNi0xLTEtMS0w_b2e210b6-7afb-4dcd-a6e4-a85f8f5afac7">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNi0zLTEtMS0w_7330ae69-d354-4b14-8c3c-98717648905a">1,146</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization and other changes in operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNy0xLTEtMS0w_52aada19-234f-4252-bd93-2b8efd19bf97">4,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNy0zLTEtMS0w_1910dc28-7d24-45d3-906d-ff51ba5c9d70">3,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on free shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOC0xLTEtMS0w_be4372c4-a6d3-44de-a3df-52659b9975ce">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="sgmo:GainLossOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOC0zLTEtMS0w_63887a3a-2c35-4736-aeaf-986e1f79d31f">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOS0xLTEtMS0w_1e83f478-c89c-4602-a998-cc57f6edcd70">17,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOS0zLTEtMS0w_1d532e46-8d10-4e19-8f0e-0130c1cbd353">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTItMS0xLTEtMA_6e8257f2-cb7f-4681-bbc4-12feecb745fe">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTItMy0xLTEtMA_073d0123-6be8-4ab8-9175-655c0c3afdb6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTMtMS0xLTEtMA_3ae69a62-b305-4297-8355-305fb5a78237">1,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTMtMy0xLTEtMA_b6592c91-085b-47d0-8a18-8d254c93986a">31,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTQtMS0xLTEtMA_93c23fa9-d5b6-4ac7-b7f1-433f61809a09">4,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTQtMy0xLTEtMA_7bf894a9-1c74-4aff-b12d-0df4705fc779">7,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTUtMS0xLTEtMA_8e688d7f-4a9b-4408-8007-03e4fa8bc74e">3,204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTUtMy0xLTEtMA_ccb564a0-9745-4bac-9725-0cd749c6edc7">1,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTYtMS0xLTEtMA_ebdb69d2-f01c-4b99-a258-93bd46a9ff92">3,253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTYtMy0xLTEtMA_630575bb-3e81-4951-b045-60d71259d640">248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTctMS0xLTEtMA_5b40eaaa-69e7-495b-b385-b260509d8fc9">41,481</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTctMy0xLTEtMA_80ff0679-a932-4f25-815a-ef3ec63e2e2f">178,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTgtMS0xLTEtMA_67113c75-2fda-4e5d-95c9-f0283a5368db">2,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTgtMy0xLTEtMA_92eb2619-f319-4ccc-86b9-0ffa28a99337">1,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTktMS0xLTEtMA_0b1ce357-7a1e-4345-82cb-6f9b65d6385a">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTktMy0xLTEtMA_72094f6b-18de-482c-bf6b-856c9705b32b">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjAtMS0xLTEtMA_fccdc1d9-e50d-4a3b-9f95-11947a74a5ef">121,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjAtMy0xLTEtMA_f4514931-3357-4335-861c-531acd861453">141,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjItMS0xLTEtMA_e0565b0e-2669-49f7-a580-cfeb15f98414">180,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjItMy0xLTEtMA_216caf70-4534-443f-ab0a-7fe93f8d59d3">43,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjMtMS0xLTEtMA_c9ebd480-10ee-4d4b-a3bf-a1b17b6b110e">323,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjMtMy0xLTEtMA_286c4f71-291f-47b7-8c6c-a8c3cbb4fb50">151,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjQtMS0xLTEtMA_c21f69aa-5a16-47ea-9db3-151e9d9a3fc1">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjQtMy0xLTEtMA_bd0649a3-794d-44a2-99d7-66b10a26e0ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjUtMS0xLTEtMA_9e20bf36-a7e4-4e3a-b61f-b54fa371b46b">15,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjUtMy0xLTEtMA_8c29aa93-2d83-4a44-9a4c-2de7b45e3ae0">6,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase of additional shares of Sangamo France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjYtMS0xLTEtMA_6869e3fd-682e-4dad-834e-aa1fe221ffe2">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjYtMy0xLTEtMA_4a1a9606-2731-4f47-8a86-803b2eb03bb4">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjgtMS0xLTEtMA_6152a804-9825-4089-b294-a0bddada0c00">134,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjgtMy0xLTEtMA_a72433b1-3c3f-4c29-9e81-54d2e094e789">101,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from at-the-market offering, net of offering expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromAtTheMarketOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzAtMS0xLTEtMA_44963642-05e2-4719-ba4e-a04afb5c38f6">22,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="sgmo:NetProceedsFromAtTheMarketOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzAtMy0xLTEtMA_ee4adf06-040e-42c3-b5ae-f9b46b771dc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:zerodash" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMS0xLTEtMTcyOA_08b89630-43d1-4f2c-965a-212fc9279e89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMy0xLTEtMTcyOA_17817573-3747-4899-adff-5e0505e1ebbf">142,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzEtMS0xLTEtMA_e4165b71-43f7-4250-bbc4-9350f67179d5">2,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzEtMy0xLTEtMA_208d7a14-88de-48a9-a5ac-222272acc12d">455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMS0xLTEtMA_ca034055-779c-4997-94fc-c2ed9374eb47">3,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMy0xLTEtMA_ec43151b-6087-48dc-bc11-d239cd08ce4b">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMS0xLTEtMTczOQ_813bb56c-9520-40c6-aa60-d97e8fb782e5">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMy0xLTEtMTczOQ_86b76896-6443-4083-89ff-87e49c08b8b4">1,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzQtMS0xLTEtMA_cf17fc69-8623-458e-ac3b-8be0eacc03a4">25,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzQtMy0xLTEtMA_c532106c-be16-4a48-bc57-ff675f55bae7">144,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMS0xLTEtMA_077b2922-3b4d-4bfe-8ad4-bb3adf6783e3">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMy0xLTEtMA_da00f033-6670-4e6d-a0e4-51e28b555abf">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzYtMS0xLTEtMA_4217072a-07dd-4428-8955-ee2708af8873">38,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzYtMy0xLTEtMA_685f2473-b551-4971-852f-3f1ce5a976db">387,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzctMS0xLTEtMA_0eb5201f-9f31-4522-8917-2d2a06678456">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afcf835853b4cad93648a7670596835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzctMy0xLTEtMA_8f79697f-08e5-4e71-a098-29b17cfec406">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzgtMS0xLTEtMA_3a7cefb1-eb3c-4654-8a4d-338389d47464">171,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzgtMy0xLTEtMA_38b03d69-97d6-4ffd-9913-54763d17bb03">468,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDAtMS0xLTEtMA_7b1747c6-cb4a-4ffc-ab09-4bd14c6b953f">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDAtMy0xLTEtMA_ccbe859e-02ef-447f-a3e5-d7067bffa8fd">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDEtMS0xLTEtMA_5db0f0da-b96e-448f-9053-cd4e9c19f094">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDEtMy0xLTEtMA_3b840532-35f7-4bfd-b867-01b3469b8626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-out of non-controlling interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDQtMS0xLTEtMzg0OA_f68f5b94-d022-487f-8daf-1562558c47e0">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDQtMy0xLTEtMzg0OA_0c2ffe79-33d7-4f03-9067-99ca1c0cb470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying Notes to Condensed Consolidated Financial Statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i88a2484078e34264a08acc98742bbce0_40"></div><div style="margin-top:12pt;padding-left:45pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDU_88d9c88b-9958-4ab1-a9a5-9b66d3974ce9" continuedAt="i04d2c15159934e21bfaf0c31700e6ae2" escape="true">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i04d2c15159934e21bfaf0c31700e6ae2" continuedAt="i9a1448ce3d69432590f994022e2982b9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTY_63a87710-e549-4949-8f90-4198219bf338" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDQ_ed888562-9723-492f-bdb8-c9aa5700d472" continuedAt="i534ac51c357847fbbcfa9960b88a5ce2" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i9a1448ce3d69432590f994022e2982b9" continuedAt="ib49ff612c701464a90a716c9ed443da6"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i534ac51c357847fbbcfa9960b88a5ce2">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</ix:continuation> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjI3NA_c0cbd8e4-03d0-4355-a48f-b163778e022b">3.1</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjI4OA_019d527a-069e-4787-93a4-a743d7360bac">3.1</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjMwMg_0ab2a216-0a52-433b-b0a0-4dbf4d358d5f">0.02</ix:nonFraction> for the six months ended June&#160;30, 2020.</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDI_80a7ee09-9829-498e-b491-331de6e15527" continuedAt="i0b93c000d18745b4af2adfbf9a0ae25e" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="ib49ff612c701464a90a716c9ed443da6" continuedAt="i3bc0f9f213f547ec83d61c1ab7c16cee"><ix:continuation id="i0b93c000d18745b4af2adfbf9a0ae25e"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjM_52637f40-af35-49be-9f19-98d2b5e1537e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi0xLTEtMS0w_6c655e2f-217c-4a83-8df5-b26e4c7b9089">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6df4f65d331a42e78e2fa83fb2c3971e_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi0zLTEtMS0w_d9a4faf0-b1cb-4a93-8206-79c499c2e242">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43fb5fc4bec0489486d7be362a594089_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi01LTEtMS02ODU_76cf165a-de9f-491e-a1e7-9c75633a71ab">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i160cf032b081413bb08a84005c04a475_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi03LTEtMS02Njg_75f66368-55c1-4e5e-a64b-3bf2ed41dcb5">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dcbc0880e6f4929a436952cda81d81b_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy0xLTEtMS0w_836f19bf-84b6-41f7-b5c4-44f3e6683100">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i826478ddac2547de9623bc77195eae38_D20200401-20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy0zLTEtMS0w_79fc200e-c24a-4741-883b-ce5070881bbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06147cd0f2824f5c829d965b134af50c_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy01LTEtMS02ODI_63439180-9b0c-42fe-99b7-8f49305f541c">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i977b331cae2c44558ac4d8807d9beb5e_D20200101-20200630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy03LTEtMS02NzE_cd4f75eb-7fb5-42d8-a9d3-b48f3b8a16bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24e0372fb79547c0ab5707e59b555660_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC0xLTEtMS0w_70adf803-9b65-4f44-9f79-f524e0d0ce00">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7cdf486da744840ae163e4c93082f83_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC0zLTEtMS0w_2b087ef4-af57-4a59-94e8-e3a553834520">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id443d9ba83d14bce9aa23f4e3906af56_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC01LTEtMS02ODg_3cecd521-19b7-4540-9fb8-2f626b8e3d81">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3900ce573569432e830a630426d6a8c7_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC03LTEtMS02NjY_09d6e442-cb61-43e2-aa1a-87f758e9048e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3993368d6f34912853e783bfc42062f_D20210401-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS0xLTEtMS0w_6e1e3ca9-a265-452f-a695-e70036f526d7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46690bda004c48dc8fe1a34394fe2539_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS0zLTEtMS0w_37627139-a4d5-45e3-89be-45cf8b002eeb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id650bde047e54d44a28d7f3cf2147fba_D20210101-20210630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS01LTEtMS02Nzk_9e0028a7-7cb2-4fb8-a961-78b27a5b41f1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb3e1f0817d14b5082132f338ddf990a_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS03LTEtMS02NzQ_260e6b31-0156-4051-a322-16761b6da4f2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i44f8df10acdf47de8be2793787e32c3f_D20210401-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi0xLTEtMS0w_1e95b397-8c37-42b7-8522-b63491abf0ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6273dd375cbe431e851bf02f766c7d30_D20200401-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi0zLTEtMS0w_a567da77-d14d-4dc0-88d2-dca7e28a703b">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3713011fcaf74d139f418e2d8b93a054_D20210101-20210630" decimals="2" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi01LTEtMS02Nzc_044e2ede-fb08-46a8-add2-19f386985693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id56b04a6fd3d4593b0228bf4b5070845_D20200101-20200630" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi03LTEtMS02NjQ_c92ce08c-378e-4078-9891-ce64e61e8db4">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTk_098948e5-996b-4e53-9aa8-41fa3679c132" escape="true"><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTA_8f79c7d2-5404-44fb-a34c-3b9d3610d4c8" continuedAt="idcac6647f43743b38faa0a185bf0bbe9" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idcac6647f43743b38faa0a185bf0bbe9">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</ix:continuation> As of June&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTM2Mjg_f7504ba0-5de5-4419-8a38-23f0f83ad757">no</ix:nonFraction> impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjQ_1eb59497-dbbb-4cc1-b63d-763b8ab1f928" continuedAt="i6ea327799f834f188649635565d7babb" escape="true">Valuation of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ea327799f834f188649635565d7babb">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</ix:continuation> As of June&#160;30, 2021, <ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTQzNzk_d676e89e-d640-44c8-8e5b-e16915fc84bc">no</ix:nonFraction> impairment of long-lived assets was identified.</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjA_e00d7a9b-7c5f-432d-a95c-99d663d888c3" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted as needed to approximate fair value.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i3bc0f9f213f547ec83d61c1ab7c16cee" continuedAt="i97243b7a29a8407bba92acf26ce6767e"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjU_fb3b1a70-06c5-47ef-b5de-d63c020a35a7" continuedAt="i5103e58eff8a4e7c8109f4364c3ee294" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5103e58eff8a4e7c8109f4364c3ee294">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.</ix:continuation> Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTUyMzg_664d949f-44ac-4e6c-b7b4-9738c3c9d5b1">1.5</ix:nonFraction>&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjY_056cdffb-30fe-42d1-b55c-493333428a90" escape="true"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjY_98ee33cc-7877-44bc-b2f0-d3339f936811" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS0xLTEtMS0w_32dfad31-bf8c-4ad8-b23b-3e7261cd49bb">169,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS0zLTEtMS0w_14f5fed1-3514-4fef-9ee8-7891c57fafe6">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS01LTEtMS0w_6b415e85-8116-476d-b95c-55061b2fc15a">467,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afcf835853b4cad93648a7670596835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS03LTEtMS0w_c0447e2e-1edd-4081-aa17-2d0da7edf7db">80,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi0xLTEtMS0w_5037e816-e236-42ca-a5ea-e324b46c8f51">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi0zLTEtMS0w_811f97ad-43b7-4a66-93b3-7445ac6f5253">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi01LTEtMS0w_fc6e99a2-a367-4e83-a2d1-5c588963f8bb">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afcf835853b4cad93648a7670596835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi03LTEtMS0w_3a115be3-8a39-409c-b748-3c7bf35ef161">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy0xLTEtMS0w_894c81b7-7289-4223-80f1-2755dfef824c">171,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy0zLTEtMS0w_c9c244a1-4dd6-4045-a908-c83ac493ff3b">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy01LTEtMS0w_29ed871a-1c1d-4103-930f-639de924421f">468,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4afcf835853b4cad93648a7670596835_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy03LTEtMS0w_75ce7f14-0699-456c-a2eb-ec959a52bfb9">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTg_96c3b6e9-18b7-478c-8acc-e8b6b7086926" escape="true"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjE_b3d2be71-9030-468f-af5f-2b80b536fbc7" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions or issuers of investments holding its cash, cash equivalents and investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDc_f4360362-c0ee-4686-b20f-25e8a4782880" continuedAt="ia33ea679b6bb4931ac52469e048f7125" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i97243b7a29a8407bba92acf26ce6767e"><ix:continuation id="ia33ea679b6bb4931ac52469e048f7125"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:continuation><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjI_7624ae1b-8fc1-4f5c-b925-e0c3b9d66663" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDg_b49ff59d-583c-4c6e-a043-e4298706c9e3" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric></ix:continuation><div id="i88a2484078e34264a08acc98742bbce0_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1NA_dc81bdd2-0ae3-4187-8b03-f2d438d523c5" continuedAt="i3bdd3658990c47489d71c045d756fae3" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i3bdd3658990c47489d71c045d756fae3" continuedAt="id3194c9e8efa42829063ad01410c33cf"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="id3194c9e8efa42829063ad01410c33cf" continuedAt="i4e8d5b1a2cb94b598ea69a087c07471b"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1Ng_95ea223d-c604-4b5a-a039-98bb76643676" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7f9b84d68624a3d8da6266d4a51b5f0_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS0xLTEtMS0w_01825443-a056-4421-b609-5a8bcdcc1b51">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2323e4b2ca47436ab949fc5059e374c8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS0zLTEtMS0w_e34b2409-9468-4581-a474-c04a9907dce7">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id901d356b1b34e939be8837407f81c5e_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS01LTEtMS0w_3b71d7f7-9f10-4da4-87d5-83865c0a8d07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede1b461482d4aed82d73d8a69942f6c_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS03LTEtMS0w_fabb763b-dbce-400b-b928-9364c4a15389">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy0xLTEtMS0w_a837b6c4-394f-4ef9-a713-c07ada9c6433">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy0zLTEtMS0w_30f21f7c-684f-49d6-82d8-fb761e47bfed">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy01LTEtMS0w_bd7fbb26-f1f7-456c-8734-c1dd53c3e690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy03LTEtMS0w_470077ad-5d07-4e59-b940-25f6494077a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd9e21d00fd54ff8a09781d3bb15014b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0xLTEtMS0xODM0_2d24276d-b177-40f2-be13-bcc90f215cde">160,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24d0b873fa0149c8b7057a9015e35d00_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0zLTEtMS0xODM0_9e6286db-13d7-4aed-b433-070cd9716750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id562a87f24e64a2389a1d8d8af690954_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS01LTEtMS0xODM0_1ba5bbf3-8f6c-403b-9650-23947b2b58cd">160,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib805bf377aca43d18a31ed9b25cbd937_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS03LTEtMS0xODM0_d85b4b40-16d7-4e12-ac6b-a09fa1e5726a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if450e0b0e1ee4143a860c134efa23684_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0xLTEtMS0w_37b451e4-6c4d-483c-a61c-03469bd1cdda">143,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0349e23895b7421f8e06a6dbc6671d20_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0zLTEtMS0w_d6e532f3-ff89-4baa-8f1b-550f2cca9c7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8183472477d84945864fdedade5b202f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS01LTEtMS0w_56d6ac92-1254-4722-88be-4900864954c9">143,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5414aecb9154731b24f5050b5dbda09_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS03LTEtMS0w_56328ef2-b968-4f63-8188-8224d67b8595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db22379ed084ff283dba3989fe52b6e_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtMS0xLTEtMA_d12db64c-e91f-4277-8dc5-0aeafe6f4fd0">36,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5029632c41647f2876db827348be963_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtMy0xLTEtMA_d9f6c2c7-334e-480d-a479-db4ebd155ee3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7def2ac71bde401591646c0426604256_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtNS0xLTEtMA_bbc1a4f5-eb61-4734-9313-4de50ab31722">36,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68379fd4ffaf45be8859410fd6c6d092_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtNy0xLTEtMA_8027031b-f933-4e97-b36b-1a7d7f0b2b60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64b7b79fb378470c800337959c76517b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItMS0xLTEtMTg3Mg_5cf637f6-8983-43ce-ae17-e46dc2b87db8">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505b398cb72a4af8af945f5b2a8a5a17_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItMy0xLTEtMTg3Mg_42605745-7296-4417-9498-6cb4ed4616ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8eb9c45d4c408ba0e7213a7b21a8e3_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItNS0xLTEtMTg3Mg_f9326487-e35b-46a9-908c-43be96d97fed">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e0c6ce0cdc4cdc85330469e1cebf83_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItNy0xLTEtMTg3Mg_59d010fd-f45f-4e75-84eb-abd677ac04e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b46bcd8bc6494a8ffa054541480b01_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtMS0xLTEtMA_6136d950-a1a4-4303-b0ad-cdf32d57f0d0">22,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i720ec452f326424cae2d555e85cbe793_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtMy0xLTEtMA_87e3e6cc-66b0-4df9-aba6-52434bf41c4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63e206d594384d51a4a4ea755c3ecac8_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtNS0xLTEtMA_c8ddf97a-3040-45fd-b88a-2b92aea89a12">22,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecdcf307636f43bea5bac2dc2e4668ea_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtNy0xLTEtMA_adaac5da-7c1c-46cf-af92-2c4002cc6c83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtMS0xLTEtMA_6d9e528d-3eef-487c-a7ba-4667aa314da7">408,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtMy0xLTEtMA_93a2887b-be46-4493-bc99-47d7959cdcaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtNS0xLTEtMA_f8c5e7e8-a2b9-4b57-8f11-a7bc0c5b2b8f">408,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtNy0xLTEtMA_26d25d6b-a901-4973-8ba0-d31e1804368f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtMS0xLTEtMA_7154a8c7-f89f-40d9-81e4-719d8181f049">466,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtMy0xLTEtMA_e84e3100-67b5-46d7-a8d6-d179928ac6cb">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtNS0xLTEtMA_2be27da0-ad95-46c0-8f88-6f6a945cedeb">408,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtNy0xLTEtMA_cd99467d-4a4f-4fde-bbcf-232676b4f8da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12cf9801c6e4bbd868ce62fb93d0483_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS0xLTEtMS0w_46990797-6a0b-4ec3-9356-edbd5232f038">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1309e7273bd24e24a45b18f385fbd498_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS0zLTEtMS0w_ddc9a98e-1941-40f9-933d-8d981608c774">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92fba028dc354b2eb96680caecf3f6e7_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS01LTEtMS0w_c348b80f-0a86-4cc8-89d9-570439d2663f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i362bde0e7ad9484fb5748204542558d2_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS03LTEtMS0w_7e138160-3659-44c8-b7cb-a9537b71da1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi0xLTEtMS0w_a60d8ad5-06db-4131-9e50-2875e432b339">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi0zLTEtMS0w_978d91f5-5d25-4861-8081-dfba8abebfdb">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi01LTEtMS0w_275d366b-a52c-42f2-978b-bf7701afd2a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi03LTEtMS0w_a400a823-8ca4-4413-9f1c-ba64fd42b17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec88d85ad284f01bb0601faca0f26d8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0xLTEtMS0xNzg3_3b7de7f5-6bde-4602-925a-c152e160fcc3">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11554ac8395246c1b797508e7c8e254a_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0zLTEtMS0xNzg3_2646a6ae-f8aa-4363-9f44-1cbaade47a5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca71a895253445d9bab2b29a4f24697_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC01LTEtMS0xNzg3_86e246b4-56e1-46aa-8f0e-6873d6aa05c7">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6afbf16e0ce49a4bbc2a2f2ca704329_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC03LTEtMS0xNzg3_db705134-907b-490b-bdb5-1f541215bf6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d98818a61914dc19882f4a5fe585eef_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0xLTEtMS0w_34a47f5b-8b98-469e-88c6-12c392058782">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i303ee2bb6e9a4ebaa06e5883c4402433_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0zLTEtMS0w_760ee898-ffa7-40bd-ae7a-255a1e8b6155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c30dc9b677a4b0ca056c73e4e52b5c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC01LTEtMS0w_0033b048-de44-4cd0-a39a-c93c25ae77ca">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77476f69b30416498dda50883c18ac1_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC03LTEtMS0w_137be6ee-6618-48a3-ae38-e5ee071b7d4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7061108114744e25af56d34f408d6462_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS0xLTEtMS0w_4c9f0889-f9e4-41a0-9dc8-b966613acd92">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d79151e513b4079a0407f83cc2655fd_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS0zLTEtMS0w_d9d888c9-2bd1-4461-8336-b25083f6b3d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbaf1eb6abc0483f8d83c17330ca0080_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS01LTEtMS0w_0241f681-f04e-410a-bae3-deecd268b54e">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb3dfe79994423bbacf9f8d84283e72_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS03LTEtMS0w_46686761-8c26-4175-93db-2c18663ebf82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13dbd67b064846a580f0e2753a85487c_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtMS0xLTEtMTgwNg_66037c52-b19a-4b70-ada1-9b4ec6234b53">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad85f098bcf421c8794add0b139710b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtMy0xLTEtMTgwNg_ef207f52-2460-43cf-bd2e-05b8b89e69e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1617c6130bb4fcd814b7b116daca30e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtNS0xLTEtMTgwNg_223b773d-71e2-45bb-a2a0-24ef6e40c0b5">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a854ccb6ff4f32aff9c08dace430ff_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtNy0xLTEtMTgwNg_fd7d04fe-613d-42a1-9bd1-f8b8e7affcdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce000386f6f43ecb585bb2bddba79ed_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtMS0xLTEtMA_71333f46-fae3-4c7e-ae37-3cd5b4949d7f">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22c7a6ee30f40759935f2f2d7d05834_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtMy0xLTEtMA_2f598514-1851-4b2a-ab96-e837d77ae930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i963546ecd5104507ad517a04791a50c1_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtNS0xLTEtMA_a6805b74-2d4b-4f22-b61d-4be25351a80f">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i706c0c1baf274bb08c2015e44b1886de_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtNy0xLTEtMA_078586c1-fd2c-44f8-bf8c-01cc537fc53f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtMS0xLTEtMA_d1c56a97-7e87-4a82-ba00-02745f08a86b">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtMy0xLTEtMA_e5ea3cfc-0f12-4e57-9a22-1b1e8c1c68bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtNS0xLTEtMA_de364d55-eb3c-4205-a855-566f400d00b6">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtNy0xLTEtMA_5e7c64f2-8328-4e1a-8479-2da59489e98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtMS0xLTEtMA_a7bd5c31-3de9-4b8f-904e-1e7f28bb856b">613,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtMy0xLTEtMA_ca626a2a-4185-499e-9db1-2c5026140346">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtNS0xLTEtMA_bd9cda98-a34f-4ce1-8f44-3e907673bc93">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtNy0xLTEtMA_3f0489a4-5bda-489d-9fce-bc386273b387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a9adeab28a45ad91025a9d341cc25a_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtMS0xLTEtMA_33e4b783-5aba-409d-9568-aee253c247bc">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1328c5aeb1034e05853f1890344e7e0b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtMy0xLTEtMA_328e63ae-8463-4a19-8226-c0a4c4fcb377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32c8d36f055d46c0bbb5f38ae8ded7f8_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtNS0xLTEtMA_8480d5a0-4b62-46b3-a761-188b1e5e5992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dad1abe8fca4c9dabb1a22b9f475901_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtNy0xLTEtMA_49755042-403c-4e15-8f53-60e77c5fe31c">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjU3MQ_9f5050b0-16fc-4345-adff-53c9f7797856">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><ix:continuation id="i4e8d5b1a2cb94b598ea69a087c07471b"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mid-2021 (a put option). As of June&#160;30, 2021, the Company had purchased all <ix:nonFraction unitRef="shares" contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjg4OA_9e130e04-62d7-4a55-b8db-ab733b68064d">477,000</ix:nonFraction> free shares for an aggregate cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjk0Ng_adf6bf4a-5198-496c-aac9-fa5fc5fbdad7">1.1</ix:nonFraction>&#160;million, upon exercise of the put options. As of June&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzg0ODI5MDcwMTYwMw_d753fca5-d460-405d-a7d8-1778cba3f1f6">no</ix:nonFraction> free shares outstanding subject to purchase by the Company. The fair value of the free shares&#8217; asset was <ix:nonFraction unitRef="usd" contextRef="icc3d33b771494438a51064004b2d92d3_I20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzg0ODI5MDcwMTYxMg_3e64b2c0-0755-4de3-a336-97c82af2b338">zero</ix:nonFraction> at June&#160;30, 2021 and immaterial at December&#160;31, 2020.</span><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1Mw_334ce240-c727-4a62-ae95-c7e2c0be4e90" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:86.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6117a419ac54480ab8e969b26e8ae160_I20201231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMS00LTEtMS0w_40ff7f6e-6c71-419d-b324-4ac60bd81394">15.61</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="ie3ba6686f885449fbf9782164f707326_I20201231" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMi00LTEtMS0w_9191a06c-cfb0-46ae-9e0b-300aef4b0bb4">3.85</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide00909279d94c5a9ba8d214c592b3ff_I20201231" decimals="2" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMy00LTEtMS0w_92cbc88c-6d48-48ae-b744-deab1e603b76">0.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81061d827331480d88e9dc8cbe6d82cd_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNC00LTEtMS0w_63aada21-e669-465c-a88c-12107555fbb3">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if916a4018cf94a308d569e7cc671aeb8_I20201231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNS00LTEtMS0w_0c38dece-d8f5-4b5a-a4b2-043e1baadb83">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4194918b5c8f4b7b829c28cf27413388_I20201231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNi00LTEtMS0w_58aa6144-72e5-49fb-8c2f-cadd70bcbdf7">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c37f58da8234bf5b594e14ec1be3875_I20201231" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNy00LTEtMS0w_beb3f80c-934d-40b0-97b1-4d8ff85f0f1d">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk2MA_eaec5de9-b8df-4e9a-8b71-f031bdea6872" continuedAt="i7f82da4e1777474ea439eec3ab73ec1e" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i7f82da4e1777474ea439eec3ab73ec1e" continuedAt="icc28105b4ea2434a9f02bf0e67dc46df"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk2Mw_06f4b63d-84cd-4a38-9887-8da8f0d26ff5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC0yLTEtMS0w_80e98228-79a7-4f46-ae55-0de616be5622">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC00LTEtMS0w_98ad99d6-a940-4cf3-a0e0-a565e2039937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC02LTEtMS0w_d070ed22-2244-42b1-af37-d725ae4272db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC04LTEtMS0w_cd43c8fb-9930-45f9-b1f6-bbacfe5bb54b">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi0yLTEtMS0w_2a29200a-ea95-4580-8861-1d396c1ee177">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi00LTEtMS0w_f2abbcdc-1017-4657-8b31-d0599563587f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi02LTEtMS0w_c556d21a-62ca-43b8-84a0-3c00be1d13ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi04LTEtMS0w_71237b54-6f39-4b89-8cf5-26258b411644">57,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0xLTEtMS0xOTQy_3b77282c-fde4-41b0-be7e-069e325233df">160,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0zLTEtMS0xOTQy_7179812f-bbe8-4643-a8d5-64e34af9a271">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC01LTEtMS0xOTQy_d62c9bc8-7b2e-4db5-9035-4d19537d88fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC03LTEtMS0xOTQy_fe98dfc5-5bea-40de-a847-a80679d78815">160,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0yLTEtMS0w_5dc036a8-a7b8-41c8-8507-aa658bf35625">143,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC00LTEtMS0w_58918899-b4ee-46fe-8e72-b008b685591e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC02LTEtMS0w_3ec30227-9c36-46b0-9b3c-2d93faad9cec">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC04LTEtMS0w_3becf26b-3805-4244-8e10-227727257f64">143,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce71d590cc54013935014a27b276620_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS0yLTEtMS0w_b5acba09-3db7-43f6-ab77-cb401dc44e48">36,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce71d590cc54013935014a27b276620_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS00LTEtMS0w_4115d21e-88d1-4675-b0e7-d69bfa6e3a2d">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ce71d590cc54013935014a27b276620_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS02LTEtMS0w_32feddcc-dffe-494e-b6ec-0760660d1a7a">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ce71d590cc54013935014a27b276620_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS04LTEtMS0w_bd963541-7944-45ec-9598-f45212d513e4">36,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtMS0xLTEtMTk2Ng_628f44d2-1b1c-481a-9c23-4f2d932a163b">45,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtMy0xLTEtMTk2Ng_27f56df5-0274-4f97-b414-28a0060596d0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtNS0xLTEtMTk2Ng_9bb8fc4a-c20d-44c5-8344-e3304d1c54b1">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtNy0xLTEtMTk2Ng_59fa6554-29e1-4be8-90e8-436f95ed1c64">45,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtMi0xLTEtMA_65967309-aae8-400f-abf8-9f61016ad16b">22,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtNC0xLTEtMA_66d72104-98ab-42d7-a221-308b56dcceb5">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtNi0xLTEtMA_aee4cddd-68d2-4382-9e74-4c2688234981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtOC0xLTEtMA_a21f627f-5452-484b-a87e-ca9cc176b797">22,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtMi0xLTEtMA_1e36a328-c321-465d-8037-e575ffec19f5">408,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtNC0xLTEtMA_c403aa5a-2aaf-4745-adcf-7aa83af9b5bf">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtNi0xLTEtMA_1c269f4a-2f05-4a4e-a428-1ed901508184">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtOC0xLTEtMA_2bc11f36-c936-4ee1-b646-184ae8c30668">408,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtMi0xLTEtMA_b5f3c47c-0eea-4e9e-bae1-7f501fa315d5">466,293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtNC0xLTEtMA_fa7f8a26-167e-4dad-8a43-dadb1db2984d">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtNi0xLTEtMA_297ec28d-fade-4811-9d4c-35163c4f5b85">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtOC0xLTEtMA_b1682242-dd81-4f0e-97c1-0e278b99faa0">466,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktMi0xLTEtMA_ec470d9d-c117-43c5-a828-4af829fa0beb">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktNC0xLTEtMA_5d24cfb0-2d36-4402-bd59-90091dadd9e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktNi0xLTEtMA_819abb69-91e5-4742-a84b-24d1be5fa2ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktOC0xLTEtMA_6603518d-b878-42fb-930c-069621964baf">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtMi0xLTEtMA_1fbe1582-9276-4ca9-8daf-9afcd9ee454c">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtNC0xLTEtMA_c5e9a77e-38fa-4c30-b189-9e29154bc916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtNi0xLTEtMA_d9fb43e4-cbd9-4a5f-8f8e-43f2cfd4f9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtOC0xLTEtMA_4755970b-5ce8-47a1-9765-5ecf9300066a">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMS0xLTEtMTkwMA_25b460aa-0957-43af-9f89-7d389d850c88">257,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMy0xLTEtMTkwMA_a78c56f7-cbb1-43f5-84b9-dea6cf119bdb">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNS0xLTEtMTkwMA_d632b79b-2b04-4ed6-b8cb-bc2444a3dfa6">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNy0xLTEtMTkwMA_a97b863c-afed-47bc-afee-28b9c2c15e25">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMi0xLTEtMA_46a7843b-e673-49ea-afac-1c9dd166df7f">213,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNC0xLTEtMA_e08798bd-042d-4a6e-b490-727d4453462c">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNi0xLTEtMA_a7744d92-7fe0-485d-8059-e644105c1417">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItOC0xLTEtMA_7866271c-efd3-4d20-8bc6-7df3e735f10c">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtMi0xLTEtMA_dc1221fb-0570-454f-82f7-a73b0dab8cf7">59,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtNC0xLTEtMA_67c3df88-0d59-43bb-9909-09e5001a848c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtNi0xLTEtMA_a02e6151-2d1e-46dd-bb8d-9713ddecfb05">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtOC0xLTEtMA_4022611a-1731-4563-b973-da741007533d">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4760033181744f46bfacb2148a09aa31_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtMS0xLTEtMTkxOA_19e5be69-5837-4098-8232-58f41d520fdb">17,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4760033181744f46bfacb2148a09aa31_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtMy0xLTEtMTkxOA_45eb8a94-93e3-4f55-aaaf-077449eb70f3">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4760033181744f46bfacb2148a09aa31_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtNS0xLTEtMTkxOA_c54cfec3-73c9-448e-ac25-d31193776a50">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4760033181744f46bfacb2148a09aa31_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtNy0xLTEtMTkxOA_f78a4a8c-eae5-49b0-95b9-a91d7f639e5a">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtMi0xLTEtMA_68a6db66-294e-4e49-9b01-7e8547c0babc">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtNC0xLTEtMA_795272d7-04cc-4ba2-92eb-763ee01506cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtNi0xLTEtMA_681d7044-301e-475e-ad2c-4df0d5ea37f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtOC0xLTEtMA_1f0edffa-887b-477e-8a76-21aeffc011c8">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctMi0xLTEtMA_8916563a-ccc7-47ed-8271-5f388f57fb23">560,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctNC0xLTEtMA_281fc9d4-4bbd-4369-8dc0-f36e92c29c20">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctNi0xLTEtMA_4b362369-26c8-4aa0-8f6c-d82b74d26685">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctOC0xLTEtMA_11a83c91-8146-4be9-b2ac-82d5ba213174">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtMi0xLTEtMA_d14ac960-8fb3-4076-ab26-f6d6fb0d6c72">613,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtNC0xLTEtMA_53bc23b1-d19d-4407-bba8-13cc29edf3c3">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtNi0xLTEtMA_0c0800b7-f301-4679-b0c5-69519894e713">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtOC0xLTEtMA_fb9f1faf-e0c8-49bb-bc3a-64764b2039e3">613,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk1OQ_6871e6f2-4590-4e32-86c1-7bc88ea6654d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.496%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMS0yLTEtMS0w_6c356b37-befb-4467-8c20-74ac1e5e68d9">359,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMS00LTEtMS0w_17c85cfa-9430-4e4b-8e9c-964ca4de0296">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMi0yLTEtMS0w_905f8e1d-4e48-4ef2-99d7-3ac5ca44d3da">49,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMi00LTEtMS0w_aad328f7-e54c-48ce-90fb-77c4c5f46434">50,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMy0yLTEtMS0w_3cb90d4d-3b76-461a-b0d0-bffa35cf726d">408,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMy00LTEtMS0w_64a8964b-1ab1-4dbd-b233-8129fe36d78b">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did <ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_02d67287-d78d-4483-8b9d-5877382e8a3f"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_0bf20720-26f5-40b9-9356-2dd5940ea62e"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_1f85eebe-2765-416e-b339-dd51d73330ee"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_2c374a95-95bd-462f-a6cc-958c2a10e4f8"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_6ab4aca8-9704-4799-9866-2a6cc02a6acd"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_96ba8c91-ef6e-47b5-b0a4-75d580a070ab"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_a983d3d5-0d64-4c72-9eee-dc698171b1b0"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_fc60bd72-93f2-44c4-90f4-22f4bf5a820a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc28105b4ea2434a9f02bf0e67dc46df">to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were <ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTg3Mg_198b8df6-06c1-464a-8400-e81703c58b65"><ix:nonFraction unitRef="usd" contextRef="i6ad6e61fa5a14049a4a165e22c9557b6_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTg3Mg_9b2b9188-2a47-4dd2-a08d-46566a8a13c1">no</ix:nonFraction></ix:nonFraction> other-than-temporary impairments for these marketable securities at either June&#160;30, 2021 or December&#160;31, 2020.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA3NA_3ee11b0b-49f6-4144-bce5-00a9a5024858" continuedAt="i537189747bcc41cc9d20de8e75cb3188" escape="true">BASIC AND DILUTED NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i537189747bcc41cc9d20de8e75cb3188"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2021 and 2020 totaled <ix:nonFraction unitRef="shares" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA1MA_760718cf-4e1d-4fdd-b656-ef91655954ca">16,978,884</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA1Nw_2ace78a7-1200-43b1-8be4-f35c2ca22d9a">14,964,567</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="i88a2484078e34264a08acc98742bbce0_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MTk_6e8cf694-75dc-4845-bee0-9f0173099c9c" continuedAt="i9d5ca3ba7b354fc3aca8eeff7f230810" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i9d5ca3ba7b354fc3aca8eeff7f230810" continuedAt="i3b885356bd024c04865938e14b8cfd03"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $<ix:nonFraction unitRef="usd" contextRef="ie97ab57d631741109dd7c1a32d722ecf_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTc4Nw_e4d5abd6-b133-4995-bc3b-62dc6826db15">75.0</ix:nonFraction>&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $<ix:nonFraction unitRef="usd" contextRef="i16b4febff3d343589497559b4dbc5f8b_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2MQ_62ef347f-4ac2-42f5-b332-5b55bdd86390">420.0</ix:nonFraction>&#160;million in development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i8b84cec3c18f41669b32e9a32a83d4da_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjAwMA_ec2b0e05-a3c8-4117-8e98-7df9896c9dfe">300.0</ix:nonFraction>&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjk0Mw_f91d4add-20dc-4740-822d-fa81bbeeede9">95.1</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjk4Mg_88916afd-464f-441a-905e-b1872a5452bb">75.0</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzAxNw_cf1d5141-29d9-469b-95cb-487d0e4056f3">20.1</ix:nonFraction>&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i8586e51ff5384c2b9ada2a4f735e3e0f_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDYzOA_76e6fda7-a975-47c3-b3e0-397cccc36356">57.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2e4879cf2b1844a59c47a50b6bf44286_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDY0NQ_b2a6dc1c-39c3-4aba-97dd-7cddf63a3b6e">70.9</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i3b885356bd024c04865938e14b8cfd03" continuedAt="i66b7301188b64525a84fd6dae7bf522a"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNg_7ffc78d1-5f12-4671-90a0-6ce1108d5223" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fbe30a7032d47a7a786786e1076584a_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy0xLTEtMS04MTM_c4274b51-5793-480c-9bf3-565327d39d36">7,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cff57d2627245a98dea197fe78cc195_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy0zLTEtMS04MTM_4dde5efe-ae08-45c0-a471-ac392921d233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic486fd39de0248c3bf81822737de9125_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy01LTEtMS04MTM_09dacb8a-9bce-415e-9e86-078593faebe8">13,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib688d56d6edc44adbe31811d44707d1b_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy03LTEtMS04MTM_cd03198f-b9c8-49fa-bbc7-7ad425f91dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835ea8e2ca074d12bcb1b9c6349fbd74_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC0xLTEtMS04MTM_e9905eb3-2f50-42e5-be82-ee006d278645">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9188107d02544fb9b95edda10fc6daf_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC0zLTEtMS04MTM_101a78df-c133-45a3-87e1-3b27af7901c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d858ffe5d284f3fb40b15c110d4d661_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC01LTEtMS04MTM_03263c49-656f-4203-b2dc-50fbabc2ba06">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0a358e8ea34e7d96de8f674d8a0733_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC03LTEtMS04MTM_5ac53571-8fde-451a-90d1-cbc73d2e4bc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf78996e51842fd8c577ced5c319f9e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS0xLTEtMS04MTM_ed233868-ab5e-4e16-96b4-b5f789456826">9,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c078f8f84f44092b1c987d2f9ba3780_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS0zLTEtMS04MTM_09b23eb7-59c3-486d-bae3-0ada75aeffb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS01LTEtMS04MTM_3a1a8069-3f0c-442b-80ec-fb864c9894c7">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd324fe4f6a48e79647a1e6e13a939d_D20200101-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS03LTEtMS04MTM_7264d21b-ce73-4854-ac1e-006540b07c55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDk2NQ_c83a1094-4a12-458c-90ba-4636b71a8254">1.5</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTA0Ng_aa8277b7-672e-487d-b3eb-6b172f6274e0">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTA1Mg_81c85185-1faa-4c7f-bd14-bf6b8ec9bd45">75.0</ix:nonFraction>&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTE4MQ_c83a1094-4a12-458c-90ba-4636b71a8254">1.5</ix:nonFraction>&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i4f0fa707fab440019c997c6ac3943ca0_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTUxNg_56c2052a-3605-468f-bd49-6e3a677ecce5">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5850fbbe650b4f7ca149d58bba066b5b_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4ODc5Nw_cebe9b89-08dc-4286-9840-269778d57607">0.3</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2021, respectively. No amounts were amortized during the three and six months ended June&#160;30, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjIyNA_974bda9a-9af5-4e96-bdf6-89c3d5864709">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6d9cb92b6b80443c83fcad54e2dcea08_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjMxMQ_b159519a-c61f-48fd-9143-4c2bb816d215">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjM2NA_838c47e2-9d64-4450-9a0f-46680f45c2ba">225.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjYzMg_58d77c2d-94fa-4ea4-9f1b-06a1fc49007b">225.0</ix:nonFraction>&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ibee042a0e57b44b08fcec9b88eb3ff1b_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjc1OQ_2f0f9042-c12c-453c-9e13-2efa92933ae2">125.0</ix:nonFraction>&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjkyMA_337915e1-0d64-4538-a93e-eb7c73888d38">2.37</ix:nonFraction>&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="i80a6feacaa574ddd9bd1767b41d0d48e_I20200229" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzA4Mw_1302361a-f170-4e21-bb9b-83afdbaf97e8">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="ie7c1b1cdac1240e2ab1190ed09b03af4_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzEzMQ_95d276bf-7ba4-4bc8-b289-fef62ba1778f">1.45</ix:nonFraction>&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzg0Mg_d83a98d5-cf0d-4556-8d20-348dad085259">12</ix:nonFraction>&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, a neuromuscular disease target and a fourth neurological disease gene target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODE1NA_a7a7d232-0167-4310-b473-1c8343b50906">nine</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationAgreementTargetSelectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODIxMA_c4e8fcc6-e832-4cc3-a33f-8229931a8f4e">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODc5Ng_0a12768c-dfed-42cc-9936-8ef8e377a0e8">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTA0Nw_33bae89f-f976-43af-914d-4097734ca679">three</ix:nonFraction> products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed <ix:nonNumeric contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationArrangementResearchPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTE1OA_11ce890f-ed19-4c6e-8f4d-3f6c6f184ee7">seven years</ix:nonNumeric> from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to <ix:nonFraction unitRef="product_target" contextRef="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTc4Nw_5bb51c63-e1bd-4440-9a14-7b3b49e8b528">ten</ix:nonFraction> targets. Each party has the right to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i66b7301188b64525a84fd6dae7bf522a" continuedAt="i8f01a5154aed408cb68ee46853b5990f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <ix:nonNumeric contextRef="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjA_1271ac46-e2cc-4479-a992-f3c936485c0e">three-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229" decimals="INF" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA3NTE_c28bbd66-9ce1-4ca5-9bfc-daa6bbb4fe39">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least <ix:nonFraction unitRef="number" contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229" decimals="INF" name="sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA5ODQ_256eef1b-3360-469c-89ef-45f98368a9ca">50</ix:nonFraction>% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the <ix:nonNumeric contextRef="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjE_76283eba-66cd-4b85-994a-cef8690e54d8">two-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229" decimals="INF" name="sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTE4Nzk_340a5058-94fb-4e0c-ba23-3b25142efb49">5</ix:nonFraction>% of the Company&#8217;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIyODc_37806157-c79f-414b-a5cf-26141eda7db0">204.6</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIzMjY_ced2a0de-a7bc-41f2-a53c-57b476f274ec">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIzODU_94c72905-dcc5-4d05-ac2c-585b00098335">79.6</ix:nonFraction>&#160;million, which represents the difference between the $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTI0MzM_9885d0fc-6984-45be-89ca-34e7ab9afbbe">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTI0OTE_e5b0d257-222f-4155-be25-619a79281394">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i2feef78f3b79481c95ab041ca41b6d27_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ1MTI_7673c660-2860-4a8f-b28d-8513314a423b">168.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i91eecccd242942a7817f59f45d876655_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ1MTk_15569c67-0252-4f99-8275-32221e012987">183.2</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><ix:nonNumeric contextRef="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNQ_562df54e-44b5-4e45-ba27-7758e916389c" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6aabab5ee264688a6d71a905f925e4b_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy0xLTEtMS0yMjc3_43db914f-4b30-4ce0-95a9-f364bf56cd36">7,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc2dd941800420886a2af2fa1765639_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy0zLTEtMS0yMjc3_7ece8952-7ee0-403e-9471-d996b81888c1">6,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbabaf0c6e544c5696a66609bb1a32f2_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy01LTEtMS0yMjc3_0219833c-354b-4e1a-bf48-6e463420d8de">14,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d932e2741554bd4a83bff4554127b46_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy03LTEtMS0yMjc3_3f521514-543d-448b-a6f8-2705741cd831">6,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45f3ae8095146d9b1f030e6d1b3c45e_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC0xLTEtMS0yMjc3_59f89659-def0-49fb-adf8-f4367beaf1ea">3,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd23694ec1c40ae9f6a4c23849d8ab3_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC0zLTEtMS0yMjc3_be335b59-b071-4f85-be64-8704973d6e4b">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03284b31d89d49b79fcb22265c258ce9_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC01LTEtMS0yMjc3_be2cccb0-36e6-48a1-82a6-4bdc394471f6">6,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic897ac864eec4950857bfb672f25b043_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC03LTEtMS0yMjc3_3842ff19-bee3-4ca7-9505-fc784645d58b">1,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4323b438c56c49ddbd9f8c4452cc5cbb_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS0xLTEtMS0yMjc3_4913e5f3-1e3e-4712-8d9d-ba9ea50fe1e3">10,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64d854a46e26420aba7a79befd4d3e77_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS0zLTEtMS0yMjc3_813d85e9-6fe6-4117-8cac-aebd23085708">8,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS01LTEtMS0yMjc3_45d08d5f-5c5a-4307-804c-12e71e51d7f9">21,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633a41af52284d31bdc9e6504274de2c_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS03LTEtMS0yMjc3_101eb56a-fa50-472b-88dc-c8ee43e398b8">8,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ4ODc_d390fd27-fb43-48b0-8c25-c8c833fbd0a0">7.0</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ5Njg_0e8c2669-63a8-44c5-b539-8ee4d4eaa599">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ5NzQ_9885d0fc-6984-45be-89ca-34e7ab9afbbe">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUwMTM_28f2851c-1115-46e9-850e-3161aa23dff1">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUwMTk_ced2a0de-a7bc-41f2-a53c-57b476f274ec">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i8f01a5154aed408cb68ee46853b5990f" continuedAt="i98d01ee9456644fb91e6a746bb7fa647"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i3572522eb86c427da2f7e25c65c67b1b_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzMzE_615c7b16-868b-46c7-be80-ab52cad26801">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzNTI_9e29e81d-6a4d-4c15-9ec5-1a0038b77302">2</ix:nonFraction>% of the transaction price of $<ix:nonFraction unitRef="usd" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzODM_2d211192-3136-446f-b6e1-ffcbab9324e6">204.6</ix:nonFraction>&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i03b2f05be78a47058af5e123836007ae_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU2NTc_8d94cbdb-e93e-4a97-8f6e-19f044a0cda2">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjE5OTAyMzMwMzI5OA_875e3a17-32e2-4641-a70d-b2f805a7ee76">0.3</ix:nonFraction>&#160;million during the three and six months ended June&#160;30, 2021, respectively. <ix:nonFraction unitRef="usd" contextRef="ie0d564efa3a54efdbab0331632c968f5_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjU0Ng_99a20fe9-4462-4d9e-bc47-aedbf24dafc1"><ix:nonFraction unitRef="usd" contextRef="id7b52cec79ab48a2ba640cefacfbece0_D20200401-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjU0Ng_ea6a8783-3e34-4b4f-b488-e701ed4f73b7">No</ix:nonFraction></ix:nonFraction> amounts were amortized during the three and six months ended June&#160;30, 2020. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NDU_c27be853-968f-463a-a595-d3cfc2ff9f27">2.9</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NjY_f05e32d8-be4b-44df-a2d1-6cb26b4607a6">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NzY_e5b0d257-222f-4155-be25-619a79281394">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead company, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTgxMDE_179baaa8-2bb9-4aaa-bc94-059a7bc0409c">150.0</ix:nonFraction>&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTgzMzE_eac698c1-a8c3-4428-bf64-2a6d9997dae2">3.01</ix:nonFraction>&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="ib8501312825a4e209788ef85d358bc38_D20180401-20180430" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTg0NDE_d11a87c4-49bd-49ea-aa5f-ebd2cba2d6bd">1.26</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTg1ODM_5ae8ad58-5163-4168-91f1-94d1123cc12d">1.75</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first <ix:nonFraction unitRef="milestone" contextRef="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430" decimals="INF" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1NTMzNQ_b0c41390-f270-43cf-b8fb-c8438f67f1bd">10</ix:nonFraction> times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is <ix:nonNumeric contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk1Mzc_9e9a540a-54f7-4403-9acc-7674d6bf2555">six years</ix:nonNumeric>. Kite has an option to extend the research term of the agreement for up to <ix:nonFraction unitRef="option" contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2MTU_053796e8-e0a8-454c-879b-affe3c608961">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630" format="ixt-sec:durwordsen" name="sgmo:ExtendedResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjQ_eb291d05-c331-4d08-904d-56f010d2c5e7">one-year</ix:nonNumeric> periods for a separate upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SeparateUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2NzU_89010291-417e-4de1-959b-919b9012c035">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $<ix:nonFraction unitRef="usd" contextRef="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk5ODg_11aebab2-59aa-4fc8-a3d0-e18a49c76240">3.4</ix:nonFraction>&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA5OTUxMTY4Mzg3Mw_554509ca-76fa-4dff-80b1-89af2762ddd2">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM5ODA0NjU2NTU2MA_9aa913e0-65c0-4da2-8e75-3e303fad72c2">150.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjUwMQ_91cc9951-54eb-4a09-beb8-5e64c554b5ef">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i98d01ee9456644fb91e6a746bb7fa647" continuedAt="i520e9525d27f4b3fb6c55e5f95fbe912"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i96eec01b5a724940ba35b94c5052e547_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjI2ODI_10a2429c-3948-49f4-a0bd-746906a51d49">69.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i513cb6fdd03a4af6a95f35c66fa0287f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjI2ODk_d016d190-2b3b-42c9-b649-055c12389ef1">81.4</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjI_e6930f25-424d-4d5d-a412-bb42373212fb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d915090bdc4052aaca779390bc0142_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS03OTc_f07c23e7-7f40-42b3-92c4-b0b8a5900645">6,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieee2cbdd740b48d58e90428fd2477bdb_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0zLTEtMS03OTc_cc4da144-7e85-43d6-b3ea-d2fb1d58169d">6,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80babf04d54545919679cc087e35d0f7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS0w_8a832201-bbea-4ec2-a2d8-0661e3925621"><ix:nonFraction unitRef="usd" contextRef="i80babf04d54545919679cc087e35d0f7_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS0w_9c4de449-d07e-4a77-b1b9-73b99e16bb93">12,386</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30a3cd7910e54e3ba3fb080b6faa69ac_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0zLTEtMS0w_db978b11-e311-4723-b35b-219b58b19688">12,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d5461382a74ce0b82725ff6d4dffd8_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0xLTEtMS03OTc_672055d8-84ec-42f8-81f1-2e8916da1f08">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb3c41b97bcb4c6893772a2384819bbd_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0zLTEtMS03OTc_7b889e1f-32e7-4fec-a7a6-5d2a1ed4fbd7">1,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cc29534661e4306917bc72380c1ea3d_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0xLTEtMS0w_9f2d5dc8-6aa0-4175-b0b6-ebb3c48bd999">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i972f741b215341248c20287be9d34ec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0zLTEtMS0w_a60813b3-881e-45eb-a34c-841b8e0db2b1">2,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f6b10a317f4701aac7778e60fc00f1_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0xLTEtMS03OTc_8ffde39f-7ad5-460c-bc92-63261e7a5ace">6,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc812ad521304f0ab6d3a2b04029f0f8_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0zLTEtMS03OTc_7513b544-54e9-4a85-a13e-f4075a04bf64">7,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0xLTEtMS0w_908af429-0469-4927-b0dc-f5d364380702">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654a42c3511c4a73913c506f1153cab0_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0zLTEtMS0w_dadb9974-aa6c-4690-8cbe-9430b6e0dbf6">14,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase&#160;1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;<ix:nonNumeric contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630" format="ixt-sec:durwordsen" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjQ3ODE_b938b65d-04fa-4115-a7bb-6c5e7c36dae1">fifteen years</ix:nonNumeric> after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i284384bda5c84aba85f546f831ef8980_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU3MDI_643cfd6d-3122-42cf-860c-02165b57df49">70.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i59545cce221e43deb1db8aa0c8c8619f_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU3Mzg_e01e4c8c-a58d-4b45-a2c3-8c39f390557e">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i284384bda5c84aba85f546f831ef8980_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU4Njc_5dc11811-7f2b-433b-a524-2d4bf9cd3797">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="i4902644de3a643778c13659e688fac50_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYxOTY_c29a107c-4fab-4ca8-81f5-6135ab2a09d4">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="iaf27be7caa634555848e2064b64db08a_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYyMjE_9ad24984-61fd-475e-8c4d-ca0aa9b33036">300.0</ix:nonFraction>&#160;million for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="i1599f0d2349045a39ceba19a613ae914_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYyNjY_a87c9b0e-c1a5-47cf-97a7-124c0634173c">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i520e9525d27f4b3fb6c55e5f95fbe912" continuedAt="i17a1b3e6f7df4631a5747730b7be2b40"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, <ix:nonFraction unitRef="milestone" contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY4NDU_9aaa52e0-dd2e-459e-916e-50254fb86831">two</ix:nonFraction> milestones of $<ix:nonFraction unitRef="usd" contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY4NjI_ddd72c48-a465-460f-a1ff-9867223ed628">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i75557659a8d24752a662921819a09f1c_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY5MTU_7597924b-b7cb-495a-9e3c-21cfc5a841d9">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="royaltyfee" contextRef="i75557659a8d24752a662921819a09f1c_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY5NjA_5b683190-acdf-495b-bb88-ddf66a33bb5e">no</ix:nonFraction> royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcxODc_8977d847-8340-4b47-b348-eaa7db7b69bb">134.0</ix:nonFraction>&#160;million, which represents the upfront fee and research services fees of $<ix:nonFraction unitRef="usd" contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementResearchServiceFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcyNTQ_dd7174e2-a22f-43c5-a944-2a1c7a1930fc">79.0</ix:nonFraction>&#160;million and fees related to <ix:nonFraction unitRef="milestone" contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfMilestonesAchieved" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcyNjE_eb53699f-43fe-4e67-9f78-02675c19340c">two</ix:nonFraction> achieved milestones in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjczMjQ_2b0fb607-e134-4cd9-a88b-b616943ade85">55.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and <ix:nonFraction unitRef="usd" contextRef="icafc6c9e5da64fc39cba314fee725d9a_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNw_8e80661a-1943-4f02-809a-5b06af833d32"><ix:nonFraction unitRef="usd" contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNw_8fc50228-8ec4-4464-98aa-c22d0b24a886">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i29f42ad77a67406fbca238b8af8a5ff2_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4OTgyMA_a83f149f-d320-4f92-abc8-06465a427444">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4b2ac5d2705044b993a63db847d92bd0_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzA2NTg_1a5ee442-c49d-4e41-88aa-418b0dd63549">2.5</ix:nonFraction>&#160;million of upfront license fee and research services revenue during the three and six months ended June&#160;30, 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iedd52702a7604029a53060995365270a_D20200401-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4OTg0OQ_0eae51db-f228-4210-b900-b1d26f32f231">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i02d5cb930a144a9cbb549d7b9e0cb689_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzA3MTA_14e69a85-69bf-41a2-ae04-2968fced32a5">1.1</ix:nonFraction>&#160;million milestone achievement revenue during the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;<ix:nonNumeric contextRef="i123d6bac6b904da084b4648b22e9cceb_D20210101-20210630" format="ixt-sec:duryear" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzIyNDU_63ef95f3-fef7-40a7-a3bd-f1ab16589591">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i17a1b3e6f7df4631a5747730b7be2b40" continuedAt="i00ea92af0fdc496a8a92b23171e837a8"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="if1d3391092d7417eac346ff77c7d0fcc_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzM5NDE_68c1a8e8-b6fd-437b-80c2-432a733e88dc">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ifc852cf62580436a97598e1e2e7bf50b_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQwMDU_8181eff1-77f9-4e85-b991-63ba74d83acb">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i78f2298db25940a68086c2f2eb497a03_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQxOTE_2f954a09-3a84-442b-941b-6947c1d7c510">90.0</ix:nonFraction>&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQ5Mzg_bcea8242-e267-4a79-9c67-fe9201d26966">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQ5Nzc_dc2a5c69-7f3a-4470-8b14-2dd931130f4b">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUwMjI_3da2e48b-4bfc-4e65-98f0-a0b3aec10a33">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUyODY_385d5e36-b751-444d-aa54-8ba4a86a9d4d">17.0</ix:nonFraction>&#160;million, which represents the upfront fees of $<ix:nonFraction unitRef="usd" contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUzMjc_daab53dc-d7c2-4e50-b0e2-b03e75daa750">12.0</ix:nonFraction>&#160;million and fees related to achievement of one milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUzNzk_dd0cd9f6-d64e-4fdf-a9ee-6e490671c5ec">5.0</ix:nonFraction>&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $<ix:nonFraction unitRef="usd" contextRef="i4dff6bb9876a41ea8f14c14d974128b0_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzY5MzM_da49f467-c083-4a92-b216-a8e49416302a">5.0</ix:nonFraction>&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and <ix:nonFraction unitRef="usd" contextRef="i816dc751251a43bc8a0c475d4f25692d_D20210401-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEzNg_b9f08757-3060-4395-a33d-6807d3cab0f8"><ix:nonFraction unitRef="usd" contextRef="ifd8b8b826b1842fc8ed899c4dbf877d6_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEzNg_fd69f02e-85fb-4119-bd66-dfc10df51710">no</ix:nonFraction></ix:nonFraction> revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="id4750f84c1fc4cd28df96b044fc89692_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjE5OTAyMzMwMzQzNQ_5b2007df-41af-4a77-bac4-d6e12ff48bda">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id613ed24d16b4765acccce91ced04655_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzcyNDM_221fc00b-639c-436f-ad10-fc1c554011a8">3.8</ix:nonFraction>&#160;million of upfront license fee and research services as revenue related to this agreement during the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting <ix:nonFraction unitRef="program" contextRef="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfResearchProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzc3NzE_606898ad-2a4a-4e34-b3e9-b20b9e0b9ee9">two</ix:nonFraction> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon <ix:nonNumeric contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzk3OTU_0583df08-5e6b-4871-8969-4f20eb84cc43">180</ix:nonNumeric> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i00ea92af0fdc496a8a92b23171e837a8" continuedAt="i78bf4938867e43449db575c771869b5e"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAxMTI_b047c47b-e448-4574-9b03-6abd109cd2fa">20.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i265ca64c9422418893702f8fafcef2d2_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAxNDg_40b2a1ca-d5c9-43a1-b78c-569ed933083c">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i4e4aeedad67245b6b57656cba94ee249_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAyNjI_18d93d6c-c5e9-4242-b7df-cc1120f86c4c">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA1MDI_8f9eff02-1638-4425-abeb-1a49a2814387">276.3</ix:nonFraction>&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="iae65106e3a964b398c60b12ac672bd06_I20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA4MTE_0d855564-3061-49a3-a090-188ec5b57b63">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="i5b2e93e3f8e44d4f8070ca3215e04801_I20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA4OTM_df580fe9-eec5-4a45-b256-4b436bab8c0d">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA5NDg_fad3add4-3f42-432e-b892-8260efed196b">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA5OTM_7003a1be-259e-4736-894e-c53e4aa5efb2">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDExODA_e90d044e-2da0-4661-8114-2e76a3e564f1">93.3</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEyMTk_9fa5931c-2f65-4d48-bf59-f14c4f31aa94">20.0</ix:nonFraction>&#160;million, two unconstrained milestones in the amount of $<ix:nonFraction unitRef="usd" contextRef="i65fc4f7975b44d38bd7edb0af5fa7902_I20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEyNjk_c494a921-e03e-4c6d-9eb1-921e6453441e">13.5</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEzMDQ_9bc32eb5-4bdd-40c0-9c07-3f9a963ebcb6">59.8</ix:nonFraction>&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i4f67506e89ce44568390610e8d2b4c62_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMxMzc_33c28f1e-88c0-4a8b-904c-fb655157d6fe">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i89c77516ab934aaaa96b5a86b02b8088_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMxNDQ_889bc54f-7b4f-45c1-95c0-bf7543507429">1.2</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ie375b8492a12465a99eabff9410bf3a4_D20190801-20190831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMyMjg_9ae2554b-83cf-46d9-b320-411c872d6a8a">6.0</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the third subject in the ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0Mjc_5016273b-9e6e-4948-96a6-1dcb7181f88c">5.9</ix:nonFraction>&#160;million as of June&#160;30, 2021 and included $<ix:nonFraction unitRef="usd" contextRef="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0NTI_28a122c0-d79c-4e3d-b70a-4eb94d257dc2"><ix:nonFraction unitRef="usd" contextRef="id1512a9ddf574d86903b981a4ce57329_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0NTI_f675a17d-704b-421f-bfb8-979059fdd105">0.1</ix:nonFraction></ix:nonFraction>&#160;million recognized in each of the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i585d0b863b2e455eb3b8ea38806281f2_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM1Mzg_ebfbb3da-6228-49aa-a351-c38a9f9d39ad">7.5</ix:nonFraction>&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementCumulativeMilestoneAchieved" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM3MTc_fb397782-dba9-4376-91e3-19343d67eb79">7.4</ix:nonFraction>&#160;million as of June&#160;30, 2021 and included $<ix:nonFraction unitRef="usd" contextRef="i5b7cd206e83e4758904b5e5fc3f1286e_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM3NDI_13f115b7-2c86-44ee-9036-0b1460732cad">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i710717b98c6d41c0b46518ae1f4899ff_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMilestoneRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ5MTQ2Mw_f9c633e4-9a11-490b-890b-1a5d25829e48">0.2</ix:nonFraction>&#160;million recognized during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjM_d7b24d6b-9754-4a06-b3c2-f8ed786bb237" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18d41eac62204415b943de1ef2ecb501_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0xLTEtMS05NTk_007cf8c2-7cb8-452e-afc8-1ef22000834f">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05b743385b4d48ca9fe7791ecbb5bb8f_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0zLTEtMS05NTY_39e5a360-bd78-4411-af47-e63a92a00744">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6900d77cd9b42d4b868148dfc43e2dd_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0xLTEtMS0w_75542865-d962-4611-81c2-43e76281ebdd">433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ac0654b4e2f48dbaec56149181d417a_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0zLTEtMS0w_60db08b3-e6f7-4c0b-bba3-b7ac935d1eff">349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5cd1c78eb547b6a7cf66897094551c_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0xLTEtMS05NTk_d0cfed88-5441-44ad-9b23-2811d166473e">613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8f6533454f547909bd615768ac32c21_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0zLTEtMS05NTY_c9bb4df2-20ae-4992-847d-27b931991ee1">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8302d557aa5476eb1873deb8ef6875d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0xLTEtMS0w_e0b67b98-27f6-438c-a833-1dbaca27918e">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bbca3607d7f4b9dbfe618a574b3cf7f_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0zLTEtMS0w_6a692d46-c972-4c72-91b5-e3ec6e4bdb93">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38026dfb9ff54ab38444e2c29717dc5d_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0xLTEtMS05NTk_cfb8b4bf-99b6-400b-985f-7b9e7bb0086f">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8627855bb84142d381d3d87efbd3557b_D20200401-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0zLTEtMS05NTY_da7536e6-b13a-4cd8-b81c-ca2207a27cad">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3deb558477ad44f6a2d0a235b31ff428_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0xLTEtMS0w_c45356d8-42c3-444c-9cd8-962d6932c17f">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i703707af95494f1883c80ff59a982ada_D20200101-20200630" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0zLTEtMS0w_34735fff-6a62-41f7-b96d-c7791817dfc3">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1f96a8d30f2472682f523526a58819b_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0xLTEtMS05NTk_c70a9b17-9522-4beb-8e49-2cc63b3e81aa">957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbaf08395b3f410388bfae8549a7f1ec_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0zLTEtMS05NTY_d3aaa9a2-ac23-4fab-8d61-0565f491cfe2">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0xLTEtMS0w_c8d6ae22-70ec-4918-b8fe-153e26a9e653">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaafcd0ad264e48e3aa1e5d6b42480cf1_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0zLTEtMS0w_5f4bc596-eaaa-4172-aceb-66cba3bd5cf1">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $<ix:nonFraction unitRef="usd" contextRef="i7d369449f64a4fe9802fbfa50d7c5894_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:GrantFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDQ1OTY_9918b029-0f38-4c0c-9e07-71ce9c35dd34">8.0</ix:nonFraction>&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2021, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i486e45b737f34ead89ccdfd67614cc80_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDUwMDg_1f2cd8dd-84d1-47de-81df-caf830f6a7d5">5.2</ix:nonFraction>&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i78bf4938867e43449db575c771869b5e">option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2021 and December&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="if65442cfd04e40d3ae655da86b882810_I20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU2NTY_a777afcb-4195-4a36-abd5-28199b58d951">6.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id6a2fee8655546779fce8418e68deeb6_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU2NjM_b1253fdb-35b6-468d-9077-25b32daa38d9">6.4</ix:nonFraction>&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</ix:continuation></span></div><div id="i88a2484078e34264a08acc98742bbce0_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfODcx_5b4d8c82-22b6-4362-8043-74876fe6b365" continuedAt="i6e75e1cc55cc4d21947b6255dbe45ee4" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6e75e1cc55cc4d21947b6255dbe45ee4">The Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. In the six months ended June&#160;30, 2021, the Company recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfNDM5ODA0NjUxMjQxMg_10a58fe8-d3ad-4a28-acf1-79fb299bd053">0.3</ix:nonFraction>&#160;million, and <ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfMzg0ODI5MDY5ODUzMQ_d75e24ba-3a5b-4c88-9796-8c5f14f6c671">no</ix:nonFraction> such expense was recorded in the six&#160;months ended June&#160;30, 2020. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three and six months ended June&#160;30, 2021 was due to foreign income tax expense.</ix:continuation></span></div><div id="i88a2484078e34264a08acc98742bbce0_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyNQ_fcdce8d7-6bba-412d-8c4e-03c69924a29b" continuedAt="iad3c2febfd9f4a259029cb09a711087b" escape="true">COMMITMENTS</ix:nonNumeric></span></div><ix:continuation id="iad3c2febfd9f4a259029cb09a711087b" continuedAt="i3870261660494d82a051f72ec710b987"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately <ix:nonFraction unitRef="sqft" contextRef="ia382d9bdbbdf435a8b54bc9a6f870e20_I20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjI_748824ff-1331-407f-9187-f55b4903fde5">87,700</ix:nonFraction> square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately <ix:nonFraction unitRef="sqft" contextRef="idf88ce12a67f455e9a78d4bf52333bd6_I20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjM5_0f4db11e-ced3-4a85-be81-690ae172b24a">59,200</ix:nonFraction> square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i77ccec543f23406c8dce0f2a0b6c2285_I20210630" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDAx_9ee4683c-8efe-4496-ab65-13db6078579d">25,600</ix:nonFraction> square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjc3_08762a14-8ec2-41bb-9293-f9377bdafc34">five</span> to <ix:nonNumeric contextRef="i54bc17f50cf74a93848b137afc7fba91_I20210630" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjgz_695770e6-9df2-4a74-8582-4af81cc02e08">ten years</ix:nonNumeric>. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzg0ODI5MDcwMjAyNA_76535701-da1f-44d6-a68d-d0bc4e5e1730" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. Components of operating leases were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi0xLTEtMS0xNjAz_189dbf53-9be6-402c-8e90-978130852c11">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi0zLTEtMS0xNjAz_daa4f581-be3b-4ff1-aa2e-2e7cffd0d209">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi01LTEtMS0xNjAz_e850da92-83a9-4d2d-86a8-f78f10b0ba4e">5,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi03LTEtMS0xNjAz_6215dd2e-ccf3-442b-b5fb-11f567036e80">5,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy0xLTEtMS0xNjAz_b276100a-0284-4945-9005-f145debf2800">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy0zLTEtMS0xNjAz_0643b62d-ad2d-4ca4-92df-697aa288d356">552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy01LTEtMS0xNjAz_1d35278a-bcce-4699-a81b-d03cbbe52cd3">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy03LTEtMS0xNjAz_74a3dd90-dc1e-4689-9704-090fd90c616f">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC0xLTEtMS0xNjAz_cb0e5e87-16f6-479f-9ca7-be0401e90a67">3,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC0zLTEtMS0xNjAz_a79e3ad2-a115-4d0d-b81f-71b0bf5b5085">3,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC01LTEtMS0xNjAz_cde30828-4769-42c4-b414-8a1e4e16d8ac">6,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC03LTEtMS0xNjAz_0f343bb1-aeb3-40ec-9969-c627f36b9489">6,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expenses were not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE5OTAyMzI2MDE5Mw_32ab3615-f562-4e4d-8802-a37ddf1511dd">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE5OTAyMzI2MDE4Nw_5166cf13-2781-4571-a105-9f5e19baf488">3.1</ix:nonFraction>&#160;million, respectively, and was included in net cash (used in) provided by operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><ix:continuation id="i3870261660494d82a051f72ec710b987"><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyMg_dc88b19b-7688-4fcc-b5f1-25c46e3b7d45" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:87.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMS0xLTEtMS0w_5a078451-79cf-418a-9e1e-84afcce20afb">2,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMi0xLTEtMS0w_40905fc7-f896-4d19-9fe9-973183e4b84f">6,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMy0xLTEtMS0w_fa9bca85-08fe-4580-bb4b-cbdde2912c63">7,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNC0xLTEtMS0w_40929149-a3f6-4be2-9b7f-a6eabc59de3b">7,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNS0xLTEtMS0w_de711f84-1e71-42e5-be50-9a8b92891b21">7,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNi0xLTEtMS0w_88d6b5da-8cdd-4c5e-b28c-5ea8a6a439ea">20,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNy0xLTEtMS0w_7858d3e6-9274-4e5e-af6b-e244952832a4">51,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfOS0xLTEtMS0w_e91f6d58-e6ab-46f0-b98c-e492052c5f56">10,331</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTEtMS0xLTEtMA_ecd88dea-691a-4bcd-a353-cc7044a4d8f2">41,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of June 30, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTQtMS0xLTEtMA_6364d61f-8215-4eb8-bd02-72552e6f8003">3,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTUtMS0xLTEtMA_29d07455-5537-44c4-90dc-b4b14eda7d37">37,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTYtMS0xLTEtMA_8aafcf1f-f097-40c8-8370-27da7270bacd">41,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the weighted-average remaining lease term is <ix:nonNumeric contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE0Mw_cbc2d74d-ea15-4352-b977-10b3dbe75530">7.3</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjI1MA_2ca2003b-d57d-4658-a22f-64adea7ebd7f">6.2</ix:nonFraction>% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment to an existing lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjM5MA_286d17c2-c211-4573-a0e0-1e02fc217958">5,000</ix:nonFraction>&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $<ix:nonFraction unitRef="usd" contextRef="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkxNw_6e0a83c7-2b50-4293-99fc-12e376d5b96e">0.9</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="ie759a817c5c842dc869ef8337be7e5b5_I20210201" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkzMA_39dbf189-5df4-4996-a67d-4fad802b9800">0.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company also entered into a new lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzAwNQ_fe156fb2-2c4d-47de-845f-a9202c192230">5,800</ix:nonFraction>&#160;square feet of research and office space in Valbonne, France, which expires in January 2030. Total lease payments over the life of this amended lease are approximately $<ix:nonFraction unitRef="usd" contextRef="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkzOA_63b1b328-8dcd-4990-a35c-cda9a3aa8a2e">0.8</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="ic293643aa8de4967836920062840361b_I20210129" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTk0Ng_10e15307-a084-4de8-8d4b-529c940179b6">0.6</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:OtherCommitmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyMw_0b0c57e7-0a72-4e06-b9c9-97c8bb79c67b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib32b37dab57243ff923131f59634e7db_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMS0yLTEtMS0w_246e7f1e-7349-4e91-8d74-bc4f1d8957d3">4,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4481f3dcb92a483898be17cb32b7bf7f_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMi0yLTEtMS0w_cd77f6bb-c7f4-4107-9c04-819ea0c477cd">9,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMy0yLTEtMS0w_64cef207-faf2-412f-b674-0b036b84a68c">14,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $<ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LicenseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzc1MQ_b91e08ae-4ee6-455a-a387-6ddf31440fe5">0.9</ix:nonFraction>&#160;million of license obligations related to its intellectual property as of June&#160;30, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RleHRyZWdpb246NTU0ZjIwYjlmYmU0NDU2NTliYThlYjNkYTYzZjY4NTlfMjE4_2d8e8f13-2287-4a29-9b20-1b07de6efc9b" continuedAt="i519e76d119cc4092b01a3ffaaa5f9428" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i519e76d119cc4092b01a3ffaaa5f9428"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RleHRyZWdpb246NTU0ZjIwYjlmYmU0NDU2NTliYThlYjNkYTYzZjY4NTlfMjE5_55d6b343-dd75-4d94-9f4d-60cc4c389150" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"></td><td style="width:50.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id91afce1bd2045ce87ebb34073d3ebb3_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0xLTEtMS0xMDEx_9ecfbd3b-3688-4e9d-bc0b-80adf591d36d">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dbf6eee474c485286ce46451d007985_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0zLTEtMS0xMDEx_94d7aa0a-70cd-47ff-b57e-507946d64ab0">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9b0b01e53e4cc1ad161df3748b4306_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0xLTEtMS0w_261a3882-7a78-442c-a2d0-a89fafd414b9">9,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2337f42bb8a494cb58c83594f9439eb_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0zLTEtMS0w_64bd8262-3d64-4f57-a3c5-71de44d65311">6,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife2d5e93bac84cb9b315459ace950026_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0xLTEtMS0xMDEx_a2c3c841-ff98-420a-8963-452a1b165eb8">4,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c0de19663e46b5a34f83368fe2a0c0_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0zLTEtMS0xMDEx_95b5b694-3db6-422d-ab6d-2907c44d0935">3,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193dfd8314f24ec6b3d6b58709ed8e14_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0xLTEtMS0w_424814e2-355c-4224-ac49-b3d421e9e2c8">7,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e988a6d8f274d49aef75fec334e2456_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0zLTEtMS0w_0b6f7563-d135-4a93-aeed-40970121157f">5,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0xLTEtMS0xMDEx_9fa2c58d-02a0-42ef-8314-38efe1e277dd">9,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0zLTEtMS0xMDEx_617b700e-940b-4ccc-818c-e022f5eab570">6,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0xLTEtMS0w_c52831f0-d7b1-4b95-a62f-06ade86ae9f9">17,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0zLTEtMS0w_56cb2d5d-45fa-41ae-b807-387d7e64a59c">12,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div id="i88a2484078e34264a08acc98742bbce0_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNjQ4_32e71c21-1454-48d1-a573-93c86733a04f" continuedAt="i44180c10a7ee4092ad1a959fb87af382" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i44180c10a7ee4092ad1a959fb87af382"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i287279db3cc248a09fec60c8d435c802_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:StockOfferingProgramMaximumValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfMzg4_af744bab-99a3-47e2-b735-0e5c60b2b786">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three and six months ended June&#160;30, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNTc1_3b4dc875-b79e-4081-9fb4-e48c54ce365a">770,465</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNDM5ODA0NjUxMTc3NA_7c8fca83-a051-46ba-967f-b4f925ac35a7">1,805,227</ix:nonFraction> shares of its common stock for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNjQ0_06a55e1a-958f-46e7-8847-0f70cf35c8e3">9.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNDM5ODA0NjUxMTc5MA_ae7d2162-481c-448c-8e65-eef8b0a18fc0">24.7</ix:nonFraction>&#160;million, respectively, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i68bfdf24a47d45d792d479c5f84033cb_D20210701-20210731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfMzg0ODI5MDY5ODE4Ng_2f589031-e39b-4289-b548-b75c769953e9">2.5</ix:nonFraction>&#160;million was received in July 2021 and recorded within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div id="i88a2484078e34264a08acc98742bbce0_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10&#8212;<ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjAxMQ_27977090-c38a-454c-a157-52a53cb50e0d" continuedAt="i27a8adce6d894cfca090f612b8c8ccbc" escape="true">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ix:nonNumeric></span></div><ix:continuation id="i27a8adce6d894cfca090f612b8c8ccbc"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Sangamo entered into various agreements with the goal of eventually acquiring <ix:nonFraction unitRef="number" contextRef="i5ced8520ef3f4fabbda53a780b5dc09d_I20181231" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTUw_4a4d30c9-2385-4908-8814-2d62f0798362">100</ix:nonFraction>% of Sangamo France&#8217;s share capital, including arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjQ1_c48f3d9a-9426-47f5-b430-c556f521c972">477,000</ix:nonFraction> free shares of Sangamo France pursuant to which the Company had the right to purchase such shares from the holders, and such holders had the right to sell to the Company such shares from time to time through mid-2021. As of June&#160;30, 2021, the Company acquired all of the <ix:nonFraction unitRef="shares" contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfNDM5ODA0NjUxMzU4NA_9e130e04-62d7-4a55-b8db-ab733b68064d">477,000</ix:nonFraction> free shares, resulting in <ix:nonFraction unitRef="number" contextRef="icc3d33b771494438a51064004b2d92d3_I20210630" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfNDM5ODA0NjUxNzA4OQ_e6104301-18d8-49bb-90c2-5c35b832e710">100</ix:nonFraction>% ownership of Sangamo France.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i192244a99ff14df4a634c33f2294f707_D20181001-20181031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTAyNw_2c23817a-cdaa-4fce-bd31-dfb4eafeab30">45.9</ix:nonFraction>&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i302cfc143c434200849acab7c19e79ec_D20200101-20200630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTI0NA_92d02dc5-f4c1-445d-bdf3-be8feee99188"><ix:nonFraction unitRef="usd" contextRef="i9d0d661e140c49a08925fdca70921940_D20210101-20210630" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTI0NA_cd1596a0-3594-4977-948e-e3f176e22268">no</ix:nonFraction></ix:nonFraction> goodwill impairment during any of the periods presented and, as noted below, all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of all the free shares, the fair value of the remaining non-controlling interest was determined based on the number of outstanding free shares comprising the non-controlling interest and the $<ix:nonFraction unitRef="usdPerShare" contextRef="iaedb801aae5d487896c33c8747f89875_I20181001" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTczNA_c853598d-fd66-464b-9e1d-b546c99309b3">2.99</ix:nonFraction> acquisition price per share as of the October 2018 acquisition date. The non-controlling interest was presented as a component of stockholders&#8217; equity on the Company&#8217;s Condensed Consolidated Balance Sheets. As of June&#160;30, 2021, upon acquisition of <ix:nonFraction unitRef="number" contextRef="icc3d33b771494438a51064004b2d92d3_I20210630" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMzg0ODI5MDcwNDIxNQ_ec53b3c8-d08d-4927-b6db-5db2175ed8d8">100</ix:nonFraction>% of ordinary shares of Sangamo France, the carrying amount of the non-controlling interest was recorded as additional paid-in capital on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><ix:nonNumeric contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" name="sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjAxMA_464a0845-a86d-4d35-a639-45a2a4178f25" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of June&#160;30, 2021 was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMS0xLTEtMS0w_e7fdb784-f152-4c0b-a760-866a9d36d5d1">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMi0xLTEtMS0w_8c07bee9-1739-4640-82cc-6e6f9be1e89b">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMy0xLTEtMS0w_9bdfb284-114e-4945-83cf-78c3f747bb32">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-out of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfNC0xLTEtMS0zMjUw_b5e44fbd-142f-4413-9d98-b3f1ebd7e7aa">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45a1fa516b24d509732822dedf80969_I20210630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfNC0xLTEtMS0w_f9310eb0-2dab-4bd9-be13-56ec9a2feb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect our current views with respect to future events, are based on assumptions and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that could impact our business. In particular, we encourage you to review the risks and uncertainties summarized under &#8220;Special Note Regarding Forward-Looking Statements&#8221; that appears in the forepart of this report and as discussed in more detail under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on February&#160;24, 2021, or the 2020 Annual Report, as supplemented by the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report. You should also read the following discussion and analysis in conjunction with our Condensed Consolidated Financial Statements and accompanying notes included in this report and the Consolidated Financial Statements and accompanying notes thereto included in our 2020 Annual Report.</span></div><div id="i88a2484078e34264a08acc98742bbce0_76"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases. We plan to deliver on this mission through development of our clinical and preclinical product candidates based on&#160;our novel science and our in-house manufacturing capabilities.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are:</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec, also known as SB-525, our lead product candidate, is a gene therapy for the treatment of hemophilia&#160;A and is currently being evaluated in the registrational Phase&#160;3 AFFINE clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase&#160;1/2 STAAR clinical study;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SAR445136, formerly known as BIVV003, our cell therapy product candidate for the treatment of sickle cell disease, is currently being evaluated in our Phase&#160;1/2 PRECIZN-1 clinical study. We are developing SAR445136 with our collaborator Sanofi S.A., or Sanofi;</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.37pt">ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400, our cell therapy product candidate for the treatment of transfusion dependent beta thalassemia, is currently being evaluated in our Phase&#160;1/2 Thales clinical study. We are developing ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400 with our collaborator Sanofi; and</span></div><div style="margin-top:6pt;padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection is currently being evaluated in our Phase&#160;1/2 STEADFAST clinical study. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are focusing our preclinical development in two priority areas: (i)&#160;CAR-Treg cell therapies for autoimmune disorders such as inflammatory bowel disease and multiple sclerosis, and (ii)&#160;genome engineering therapies for central nervous system, or CNS, diseases such as Alzheimer&#8217;s, autism spectrum disorder and amyotrophic lateral sclerosis, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Novartis Institutes for BioMedical Research, Inc., or Novartis, and Pfizer.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger protein, or ZFP, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect of the value of our ZFP technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0&#160;million in upfront licensing fees, milestone payments, and proceeds from sale of our common stock to collaborators, and we are eligible to earn up to $7.0&#160;billion in future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current and future in-house manufacturing capacity provides us a competitive advantage. We currently operate an in-house adeno-associated virus, or AAV, manufacturing facility in our Brisbane, California headquarters, and are building cell therapy manufacturing facilities in Brisbane, California and Valbonne, France, both of which we expect to be operational by the end of 2021. We believe our manufacturing strategy, which leverages in-house manufacturing and the resources of our contracting manufacturing organizations, or CMOs, provides us flexibility, quality, control and the necessary capacity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recently dosed the fourth patient in our Phase&#160;1/2 STAAR clinical study of ST&#8209;920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease. Based on initial safety data from the patients dosed to date, the Safety Monitoring Committee recommended dose escalating to the third dose as planned under the study protocol. We are currently screening patients for the third dose cohort, and we expect to dose the first two patients in this third cohort by the end of this year. We will make a decision on when to first present the initial data from this study depending on clinical timelines and will publicly announce our plans when available.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biogen recently selected a fourth neurological disease gene target under our collaboration agreement, and we have begun early research activities on therapies addressing this target.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In order to focus resources on preclinical programs in our two priority areas of CAR-Treg cell therapies for autoimmune disorders and genome engineering therapies for CNS diseases, we recently made the business decision to discontinue our phenylketonuria gene therapy research program.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We appointed Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June&#160;1, 2021. Ms. Duraibabu has served as our Principal Financial Officer since March 2021 and Principal Accounting Officer since June 2019.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We appointed Scott Willoughby as Senior Vice President, General Counsel &amp; Corporate Secretary, effective August 2, 2021. Mr. Willoughby has served as our Vice President, Corporate Law since March 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Impacts of Evolving COVID-19 Pandemic</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and continue to experience impacts from the evolving COVID-19 pandemic on our business and operations and could continue to experience these or potentially more severe impacts for the rest of the 2021 as the pandemic evolves in the United States, France, United Kingdom and locations of our clinical studies and trials. We continue to conduct business operations pursuant to a modified operating plan that includes enhanced workplace safety protocols and modified working schedules in our laboratories. Employees who are able to fulfill their job duties working from home are required to work from home, and have been doing so since March 2020, although we are currently planning a phased return to the office for most employees. These protocols and modifications have slowed our productivity and disrupted our business to a moderate degree and are likely to continue doing so through 2021. For example, we have experienced periodic short-term disruptions to our onsite laboratory and manufacturing operations while addressing positive cases of COVID-19 by onsite workers, and our laboratory and manufacturing operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers. Moreover, from time to time, we have been required to reorganize and prioritize our research resources to mitigate moderate COVID-19 impacts arising from travel restrictions, laboratory density restrictions and laboratory supply constraints. If our research programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our research timelines, although we do not believe that the short-term disruptions to date have resulted in any such impacts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase&#160;1/2 STAAR clinical study evaluating ST-920 has experienced and continues to experience delays in its timeline due in part to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, we estimate that the opening of the first clinical trial site in the United Kingdom for this study experienced a delay of approximately one year due to the significant prevalence of COVID-19 in the United Kingdom. Additionally, we have experienced delays in recruiting, enrolling and dosing patients for this study at our U.S. trial sites, due in part to the hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and also due in part to trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. The study has also experienced delays when certain patients have decided to take the COVID-19 vaccine prior to enrollment or dosing in the study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines three to six months. Clinical timelines for this study could be revised again if COVID-19 impacts to our recruitment, screening, enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs. We estimate that these challenges set back our clinical study timeline by approximately three months. While we have now initiated this clinical study and expect to enroll the first patient in this study by the end of 2021, this timeline could be revised if COVID-19 impacts result in additional delays.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced and continue to experience in our STAAR and STEADFAST studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. The magnitude of these impacts will depend, in part, on the length and severity of the COVID-19 pandemic and related government orders and restrictions, and how the pandemic limits the ability of us and our business partners to operate business in the ordinary course. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate any material negative impact on our financial condition in 2021 as a result of the COVID-19 pandemic. We believe we are well positioned financially in the near term to execute on our wholly-owned and partnered research and clinical programs. As of June&#160;30, 2021, we had $578.9&#160;million in cash, cash equivalents and marketable securities. Although we believe we are well capitalized currently, the effects of the evolving pandemic could result in disruption of global financial markets, impairing our ability to access capital, which could negatively affect our liquidity in the future. We do not currently anticipate any material impairments to the valuation of the financial assets or goodwill on our balance sheet as a result of the COVID-19 pandemic. We do not believe that the remote workplace arrangements we have implemented for our office-based employees have affected our financial reporting or control systems.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. These developments include the ultimate duration and severity of the pandemic, the impacts of new COVID-19 variants, travel restrictions, new public health restrictions in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs. The surge of new variants of the virus has resulted and may in the future result in the return of prior orders and restrictions or new quarantine and shelter-in-place orders or other restrictions. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestone achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials. Pursuant to the terms of our agreements with Biogen, Kite Pharma, Inc., or Kite, Novartis and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Biogen, Kite, Novartis and Sanofi will be recognized as revenue as the related costs are incurred and collection is reasonably assured.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying management&#8217;s discussion and analysis of our financial condition and results of operations are based upon our Condensed Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these Condensed Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Condensed Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition and valuation of long-lived assets including goodwill and intangible assets are the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the three and six months ended June&#160;30, 2021, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our 2020 Annual Report.</span></div><div id="i88a2484078e34264a08acc98742bbce0_79"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Three and Six Months Ended June&#160;30, 2021 and 2020</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,523&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Kite, Novartis, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $6.3&#160;million in revenues for the three months ended June&#160;30, 2021, compared to the same period in 2020, was primarily due to the recognition of upfront license fees and research revenue of $9.6&#160;million under our collaboration agreement with Novartis, which became effective in July 2020, and an increase of $2.6&#160;million in revenue related to our collaboration agreement with Biogen. These increases were partially offset by a decrease of $3.8&#160;million in revenue related to our giroctocogene fitelparvovec and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreements with Pfizer driven by completion of activities under these collaborations as of December&#160;31, 2020, a decrease of $1.1&#160;million in revenue related to our collaboration agreement with Kite, and a decrease of $0.9&#160;million in revenue related to our collaboration agreement with Sanofi.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $19.5&#160;million in revenues for the six months ended June&#160;30, 2021, compared to the same period in 2020, was primarily due to the recognition of upfront license fees and research revenue of $13.0&#160;million and $17.4&#160;million under our collaboration agreements with Biogen and Novartis, respectively. These increases were partially offset by a decrease of $7.4&#160;million in revenue related to our giroctocogene fitelparvovec and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreements with Pfizer driven by completion of activities under these collaborations as of December&#160;31, 2020, and a decrease of $2.0&#160;million in revenue related to our collaboration agreement with Kite.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:24.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,927&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,046&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,572&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,450&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,048&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,106&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, allocated facilities and information technology expenses.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $18.6&#160;million in research and development expenses for the three months ended June&#160;30, 2021, compared to the same period in 2020, was primarily driven by an $8.6&#160;million increase in preclinical, clinical and lab supply expenses due to the timing of our trials and increased activity attributed to our new collaborations, a $5.0&#160;million increase in compensation expense as a result of increased headcount to support our programs, clinical trials and start-up of our manufacturing operations, and a $4.0&#160;million increase in manufacturing and overhead costs as we ramp up our internal manufacturing operations. Stock-based compensation expense included in research and development expenses was $5.5&#160;million and $3.6&#160;million for the three months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $33.5&#160;million in research and development expenses for the six months ended June&#160;30, 2021, compared to the same period in 2020, was primarily driven by a $13.8&#160;million increase in preclinical, clinical and lab supply expenses due to the timing of our trials and increased activity attributed to our new collaborations, an $11.8&#160;million increase in compensation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense as a result of increased headcount to support our programs, clinical trials and start-up of our manufacturing operations, and an $8.0&#160;million increase in manufacturing and overhead costs as we ramp up our internal manufacturing operations. Stock-based compensation expense included in research and development expenses was $9.7&#160;million and $6.4&#160;million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our clinical programs and if we are able to progress our earlier stage product candidates into clinical trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. The full extent of the impact of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may not be able to accurately predict. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of the 2020 Annual Report, as supplemented by the risks and uncertainties described under &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation related expenses including stock-based compensation for executive, legal, finance and administrative personnel, professional fees, allocated facilities and information technology expenses, and other general corporate expenses.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $1.4&#160;million in general and administrative expenses for the three months ended June&#160;30, 2021, compared to the same period in 2020, was primarily due to a $1.7&#160;million decrease in legal and professional fees. Stock-based compensation expense included in general and administrative expenses was $4.0&#160;million and $3.2&#160;million for the three months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $1.4&#160;million in general and administrative expenses for the six months ended June&#160;30, 2021, compared to the same period in 2020, was primarily due to a $1.6&#160;million decrease in legal and professional fees. Stock-based compensation expense included in general and administrative expenses was $7.3&#160;million and $6.0&#160;million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to build out our product portfolio and advance our product candidates into the clinic, we expect higher general and administrative expenses to support the growth of the business.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net, decreased by $0.4&#160;million for the three months ended June&#160;30, 2021, compared to the same period in 2020, primarily due to a decrease of $1.1&#160;million in interest income reflecting the decline in market interest rates, partially offset by an increase of $0.7&#160;million in research tax credits earned by Sangamo France.</span></div><div style="margin-top:6pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income, net, decreased by $1.3&#160;million for the six months ended June&#160;30, 2021, compared to the same period in 2020, primarily due to a decrease of $2.5&#160;million in interest income reflecting the decline in market interest rates, partially offset by an increase of $1.4&#160;million in research tax credits earned by Sangamo France.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had cash, cash equivalents, and marketable securities totaling $578.9&#160;million compared to $692.0&#160;million as of December&#160;31, 2020. Our most significant use of capital was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including U.S. government-sponsored entity debt securities, commercial paper, money market funds, corporate debt securities, asset-backed securities and certificates of deposit. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement, or the sales agreement, with Jefferies LLC, or Jefferies, providing for the sale of up to $150.0&#160;million of our common stock from time to time in &#8220;at-the-market&#8221; offerings under an existing shelf registration statement. During the six months ended June&#160;30, 2021, we sold 1,805,227 shares of our common stock under the sales agreement for net proceeds of approximately $24.7&#160;million, of which approximately $2.5&#160;million was received in July 2021 and recorded within prepaid expenses and other current assets on our Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents and marketable securities and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund our currently planned operations through at least the next 12&#160;months from the date the Condensed Consolidated Financial Statements are issued. During this period of uncertainty and volatility related to the COVID-19 pandemic, we will continue to monitor our liquidity.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $121.1&#160;million for the six months ended June&#160;30, 2021, primarily reflecting our net loss of $93.1&#160;million and a decrease in deferred revenues of $41.5&#160;million. These decreases were partially offset by $21.1&#160;million of non-cash expenses related to stock-based compensation and depreciation and amortization and an increase in prepaid expenses and other assets by $4.4&#160;million. Net cash provided by operating activities was $141.1&#160;million for the six months ended June&#160;30, 2020, primarily reflecting an increase in deferred revenues of $178.9&#160;million driven by cash received in connection with the Biogen collaboration agreement, a decrease in accounts receivable of $31.3&#160;million and stock-based compensation of $12.4&#160;million and other activities, partially offset by our net loss of $78.9&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $134.6&#160;million for the six months ended June&#160;30, 2021, mostly related to net maturities, sales and purchases of marketable securities, partially offset by $15.2&#160;million purchases of property and equipment. The increase in cash provided by investing activities during the six months ended June&#160;30, 2021, compared to the same period in 2020, was mostly due to an increase in net maturities, sales and purchases of marketable securities, partially offset by purchases of property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $25.3&#160;million for the six months ended June&#160;30, 2021, mostly related to $22.9&#160;million of proceeds from the at-the-market offering, net of offering expenses of $0.7&#160;million. The decrease of $119.3&#160;million in cash provided in financing activities during the six months ended June&#160;30, 2021 compared to the same period in 2020, was mostly due to the proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs, in April 2020, of $142.6&#160;million, partially offset by the net proceeds from our at-the-market offering of $22.2&#160;million in the six months ended June&#160;30, 2021.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents and marketable securities and expected revenues from collaborations, strategic partners and research grants, will be adequate to fund our currently planned operations through at least the next 12&#160;months from the date the Condensed Consolidated Financial Statements are issued. Although we believe we are well capitalized currently, the effects of the ongoing COVID-19 pandemic could result in significant disruption of global financial markets, impairing our ability to access capital, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could in the future negatively affect our liquidity. Future capital requirements beyond the next 12&#160;months will be substantial, and we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek United States Food and Drug Administration, or </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We regularly consider fund-raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including sales pursuant to our at-the-market offering program, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div id="i88a2484078e34264a08acc98742bbce0_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Item&#160;303(a)(4)(ii) of Regulation S-K.</span></div><div id="i88a2484078e34264a08acc98742bbce0_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future minimum contractual obligations as of December&#160;31, 2020 were reported in the 2020 Annual Report. Other than as described below, during the six months ended June&#160;30, 2021, there have been no other material changes outside the ordinary course of our business from the contractual obligations previously disclosed in our 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. The contractual obligations during the lease term are approximately $0.9&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France that expires in January 2030. The contractual obligations during the lease term are approximately $0.8&#160;million.</span></div><div id="i88a2484078e34264a08acc98742bbce0_91"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of U.S. government-sponsored entity debt securities, commercial paper, corporate debt securities, asset-backed securities and certificates of deposit. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio. Our market risks at June&#160;30, 2021 have not changed materially from those discussed in Item&#160;7A of our 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatile market conditions arising from the evolving COVID-19 pandemic may result in significant changes to exchange rates relative to the U.S. dollar and may affect our operating results as expressed in U.S. dollars.</span></div><div id="i88a2484078e34264a08acc98742bbce0_94"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of June&#160;30, 2021. Based on that evaluation, as of June&#160;30, 2021, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting that occurred during the quarter ended June&#160;30, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i88a2484078e34264a08acc98742bbce0_100"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any material pending legal proceedings. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_103"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below we are providing, in supplemental form, changes to our risk factors from those previously disclosed in Part&#160;I, Item&#160;1A of the 2020 Annual Report. Our risk factors disclosed in Part&#160;I, Item&#160;1A of the 2020 Annual Report provide additional discussion about these supplemental risks and we encourage you to read and carefully consider the risk factors disclosed in Part&#160;I, Item&#160;1A of the 2020 Annual Report for a more complete understanding of the risks and uncertainties material to our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conducting clinical trials and obtaining regulatory approvals is complex and exposes our business to numerous risks, including potential unexpected costs and delays.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities in order to obtain regulatory approvals necessary for commercialization. We have limited experience in conducting later stage clinical trials and may not possess the necessary resources and expertise to complete such trials. Clinical trials are expensive, lengthy and unpredictable. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage. Events that may prevent successful or timely completion of clinical development and regulatory approval include, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory authorities on clinical trial design;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent ethics committee approval at each clinical trial site, such as the delays we have experienced opening the clinical trial sites in the United Kingdom for our Phase&#160;1/2 STAAR clinical study evaluating ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, due to the diversion of healthcare resources to address the evolving COVID-19 pandemic;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting, screening and enrolling suitable patients to participate in our clinical trials and dosing enrolled patients, such as the delays we have recently experienced and continue to experience in recruiting, screening, enrolling and dosing patients for our Phase 1/2 STAAR clinical study evaluating ST-920 due to challenges related to the COVID-19 pandemic and Brexit, patients reconsidering their participation in the study and the limited number of screening sites, among other reasons;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical trial activities due to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic, such as the delays that have previously impacted clinical trial timelines for our Fabry and TX200 programs and delays associated with certain patients deciding to take COVID-19 vaccines prior to enrollment or dosing in the study;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of clinical holds by regulatory authorities as a result of serious adverse events or after an inspection of clinical trial operations or trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with the Good Clinical Practice regulations of the FDA, or applicable regulatory guidelines in the EU and other countries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions, or as a result of manufacturing or formulation changes to our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites or patients dropping out of a trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selections of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrences of serious adverse events or other safety concerns associated with product candidates that are viewed to outweigh their potential benefits, result in approval delays or other regulatory restrictions, or harm our reputation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrences of serious adverse events or other safety concerns in clinical trials of the same class of agents conducted by other sponsors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failures to demonstrate that product candidates are safe and effective for their proposed indication;</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected costs and expenses and lack of sufficient funding to develop our product candidates; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">losses of licenses to critical intellectual properties.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet reached agreement with regulatory authorities on the complete development pathway for certain product candidates, and such authorities have the ability to change decisions or guidance with respect to approvable endpoints, particularly as the technology continues to develop in these areas. For example, we are aware of another company developing a gene therapy to treat hemophilia&#160;A that the FDA recommended complete its Phase&#160;3 study and submit two-year follow-up safety and efficacy data on all study participants notwithstanding the company&#8217;s contention that it and the FDA had previously agreed on the extent of data necessary to support a biologics license application.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the novelty of certain product candidates and their technologies, the endpoints needed to support regulatory approvals will likely be different from those originally anticipated. Any inability to successfully complete preclinical and clinical development of our product candidates, or complete such trials in the time frames anticipated, could result in additional costs to us or impair our ability to generate revenues from product sales or achieve regulatory and commercialization milestones and royalties, or shorten any periods during which we may have exclusivity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate successfully obtains approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our product candidates, once obtained, may be withdrawn. If we are unable to obtain and maintain regulatory approvals for our product candidates in one or more jurisdictions, or if any approval contains significant limitations, we would not be able to generate anticipated revenues and may struggle to become profitable, which would have an adverse effect on our business operations and financial conditions</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to identify, qualify and enroll sufficient patients for our clinical trials or complete our clinical trials in a timely manner, which could delay or prevent us from proceeding with the development of our product candidates.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying, qualifying and enrolling patients in clinical trials of our product candidates, and completing these clinical trials, is critical to our success. Patient enrollment and trial completion is affected by factors including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population and process for identifying patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design of the trial protocol;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility and exclusion criteria;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of genomic approaches to treatment of diseases;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of competing therapies and clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential delays related to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic, including the decision of certain patients to take COVID-19 vaccines prior to enrolling or dosing in the study;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of genetic testing for potential patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required and desired characteristics of patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to obtain and maintain patient consent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that enrolled patients will drop out before completion of the trial;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to monitor patients adequately during and after treatment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. There are also a number of other product candidates in development by our competitors, who compete for the same limited patient populations. If we are not able to enroll the necessary number of patients in a timely </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manner, we may not be able to complete our clinical trials on our desired timelines or at all. For example, we have experienced delays and challenges in recruiting, screening, enrolling and dosing patients for our Phase&#160;1/2 STAAR clinical study evaluating ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, due to challenges related to the  COVID-19 pandemic and Brexit, patients reconsidering their participation in the study and the limited number of screening sites, among other reasons.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if fewer patients are willing to participate in our clinical trials because of negative publicity from adverse events related to genomic medicines, competitive clinical trials for similar patient populations or for other reasons, the timelines for conducting clinical trials of our product candidates may be delayed. These delays could result in increased costs, limitation or termination of clinical trials, and delays in product development timelines. If we are forced to expand to additional jurisdictions to address these challenges, it could impose additional costs, delays and risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The evolving COVID-19 pandemic has adversely impacted and could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and continue to experience impacts from the evolving COVID-19 pandemic on our business and operations and could continue to experience these or potentially more severe impacts for the rest of the 2021 as the pandemic evolves in the United States, France, United Kingdom and locations of our clinical studies and trials. We continue to conduct business operations pursuant to a modified operating plan that includes enhanced workplace safety protocols and modified working schedules in our laboratories. Employees who are able to fulfill their job duties working from home are required to work from home, and have been doing so since March 2020, although we are currently planning a phased return to the office for most employees. These protocols and modifications have slowed our productivity and disrupted our business to a moderate degree and are likely to continue doing so through 2021. For example, we have experienced periodic short-term disruptions to our onsite laboratory and manufacturing operations while addressing positive cases of COVID-19 by onsite workers, and our laboratory and manufacturing operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers. Moreover, from time to time, we have been required to reorganize and prioritize our research resources to mitigate moderate COVID-19 impacts arising from travel restrictions, laboratory density restrictions and laboratory supply constraints. If our research programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our research timelines, although we do not believe that the short-term disruptions to date have resulted in any such impacts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase&#160;1/2 STAAR clinical study evaluating ST-920 has experienced delays in its timeline due in part to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, we estimate that the opening of the clinical trial site in the United Kingdom for this study experienced a delay of approximately one year due to the significant prevalence of COVID-19 in the United Kingdom. Additionally, we have experienced delays in recruiting, screening, enrolling and dosing patients for this study at our U.S. trial sites, due in part to the hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and also due in part to trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines three to six months. Clinical timelines for this study could be revised again if COVID-19 impacts to our recruitment, screening, enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs. We estimate that these challenges set back our clinical study timeline by approximately three months. While we have now initiated this clinical study and expect to enroll the first patient in this study by the end of 2021, this timeline could be revised if COVID-19 impacts result in additional delays.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced in our STAAR and STEADFAST studies.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. The magnitude of these impacts will depend, in part, on the length and severity of the COVID-19 pandemic and related government orders and restrictions, and how the pandemic </span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">limits the ability of us and our business partners to operate business in the ordinary course. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. These developments include the ultimate duration and severity of the pandemic, the impacts of new COVID-19 variants, travel restrictions, any new public health restrictions in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs. The surge of new variants of the virus has resulted and may in the future result in the return of prior orders and restrictions or new quarantine and shelter-in-place orders or other restrictions. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it could continue to result in significant disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent the evolving COVID-19 pandemic continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section and in the risk factors disclosed in Part&#160;I, Item&#160;1A of the 2020 Annual Report.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the process of growing the size of our organization globally, and we have experienced and may continue to experience difficulties in hiring, integrating and retaining qualified skilled employees.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth and stability of our organization is critical to our ability to successfully achieve our strategic objectives. We may not be able to hire, integrate and retain a sufficient number of qualified employees with the appropriate levels of experience and skills to accomplish our growth objectives.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There currently is a shortage of skilled individuals with substantial experienc</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e discovering, developing and manufacturing genomic medicines, which is likely to continue. As a result, competition for these individuals is intense and the turnover rate can be high. We may not be able to hire, integrate and retain employees with these skills on acceptable terms given the competition among numerous biopharmaceutical companies and academic institutions for individuals with these skills. In addition, any negative or unexpected results in our preclinical or clinical trials or applications for marketing approval would make it more challenging to hire and retain qualified skilled employees. Moreover, the evolving COVID-19 pandemic has further challenged our ability to hire skilled employees. If we do not achieve our growth objectives, the progress of our research, development, manufacturing and regulatory efforts will slow down, which will adversely impact our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on certain key members of our executive team and certain of our scientific, clinical development and manufacturing personnel, the loss of whose services may impede the progress of our research, development, manufacturing and regulatory efforts. For example, in 2021, our former Chief Financial Officer and our former General Counsel, as well as several other senior finance and legal employees, resigned from Sangamo to pursue opportunities at various other biotechnology companies. We could experience resignations of other executives and employees in the future given the intensity of the competition for talent in the biotechnology industry, particularly in the San Francisco Bay Area. Additional resignations could result in more significant disruptions and threats to our growth and stability. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not have &#8220;key person&#8221; insurance on any of our employees.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_106"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i88a2484078e34264a08acc98742bbce0_109"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i88a2484078e34264a08acc98742bbce0_112"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i88a2484078e34264a08acc98742bbce0_115"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i88a2484078e34264a08acc98742bbce0_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160; 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:11.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.801%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.522%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 22, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">Fourth Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 15, 2020).</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">Letter Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">Prathyusha Duraibabu </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">May 21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:87%;text-decoration:underline" href="sgmo-20210631xex101_employ.htm"> </a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210631xex311.htm">Rule 13a &#8212; 14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210630xex312.htm">Rule 13a &#8212; 14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20210630xex321.htm">Certifications Pursuant to 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from Sangamo&#8217;s Quarterly Report on Form 10-Q for the three months ended June&#160;30, 2021 is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;The certifications attached as Exhibit&#160;32.1 accompany this Quarterly Report on Form&#160;10-Q pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Registrant for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">#&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Indicates management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">+&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Table of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i88a2484078e34264a08acc98742bbce0_7">Contents</a></span></div></div><div><span><br/></span></div><div id="i88a2484078e34264a08acc98742bbce0_121"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: August&#160;5, 2021 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALEXANDER D. MACRAE</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Alexander D. Macrae</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Duly Authorized Officer and Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ PRATHYUSHA DURAIBABU</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>sgmo-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20210630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20210630">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
        <link:definition>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail">
        <link:definition>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
        <link:definition>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSNarrativeDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail">
        <link:definition>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
        <link:definition>2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIES" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES">
        <link:definition>2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESTables" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables">
        <link:definition>2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails">
        <link:definition>2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail">
        <link:definition>2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHARE" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE">
        <link:definition>2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail">
        <link:definition>2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES">
        <link:definition>2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
        <link:definition>2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
        <link:definition>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
        <link:definition>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sangamo.com/role/INCOMETAXES">
        <link:definition>2123106 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://www.sangamo.com/role/INCOMETAXESDetails">
        <link:definition>2424413 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTS" roleURI="http://www.sangamo.com/role/COMMITMENTS">
        <link:definition>2125107 - Disclosure - COMMITMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSTables" roleURI="http://www.sangamo.com/role/COMMITMENTSTables">
        <link:definition>2326305 - Disclosure - COMMITMENTS - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail">
        <link:definition>2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSComponentsofOperatingLeasesDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail">
        <link:definition>2428415 - Disclosure - COMMITMENTS - Components of Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail">
        <link:definition>2429416 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1">
        <link:definition>2429416 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail">
        <link:definition>2430417 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2131108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2332306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
        <link:definition>2433418 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2134109 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetail" roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail">
        <link:definition>2435419 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS">
        <link:definition>2136110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables">
        <link:definition>2337307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
        <link:definition>2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail">
        <link:definition>2439421 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NetProceedsFromAtTheMarketOffering" abstract="false" name="NetProceedsFromAtTheMarketOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" abstract="true" name="ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseAreaOfRealEstate" abstract="false" name="LesseeOperatingLeaseAreaOfRealEstate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sgmo_LonzaNetherlandsBVMember" abstract="true" name="LonzaNetherlandsBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMilestoneRevenueRecognized" abstract="false" name="CollaborativeArrangementMilestoneRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ChangeInCollaborationAgreementScopeMember" abstract="true" name="ChangeInCollaborationAgreementScopeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveMember" abstract="true" name="SBFiveTwoFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" abstract="false" name="CollaborativeArrangementCumulativeMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborationArrangementResearchPeriod" abstract="false" name="CollaborationArrangementResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_GainLossOnFreeShares" abstract="false" name="GainLossOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MeasurementInputStockPriceCorrelationMember" abstract="true" name="MeasurementInputStockPriceCorrelationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" abstract="false" name="CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SBFiveTwoFiveAndOtherProductsMember" abstract="true" name="SBFiveTwoFiveAndOtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" abstract="false" name="CollaborativeArrangementNumberOfMilestonesAchieved" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" abstract="false" name="ScheduleOfNoncontrollingInterestTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" abstract="false" name="CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_BrammerBioMAMember" abstract="true" name="BrammerBioMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseAmount" abstract="false" name="LesseeOperatingLeaseAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" abstract="false" name="CollaborativeArrangementVotingProvisionsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_FreeSharesAssetMember" abstract="true" name="FreeSharesAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" abstract="false" name="BusinessAcquisitionsFairValueOfFreeSharesAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_MeasurementInputExchangeRateMember" abstract="true" name="MeasurementInputExchangeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" abstract="false" name="CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_PropertySubjectToOperatingLeaseOneMember" abstract="true" name="PropertySubjectToOperatingLeaseOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>3
<FILENAME>sgmo-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5919b209-a421-4481-822f-1c894f2074da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_72ba817a-0f16-458d-80c4-d24faa5273ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5919b209-a421-4481-822f-1c894f2074da" xlink:to="loc_us-gaap_Liabilities_72ba817a-0f16-458d-80c4-d24faa5273ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_402cc948-9513-4544-867b-a5402979e8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5919b209-a421-4481-822f-1c894f2074da" xlink:to="loc_us-gaap_CommitmentsAndContingencies_402cc948-9513-4544-867b-a5402979e8dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b2ceb0ba-bc4a-4932-a3d0-d624a74477fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5919b209-a421-4481-822f-1c894f2074da" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b2ceb0ba-bc4a-4932-a3d0-d624a74477fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c7898f7-454a-4334-b53e-36e33fd379b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_69e989cb-f9cc-4594-ae8d-034c49a75e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c7898f7-454a-4334-b53e-36e33fd379b7" xlink:to="loc_us-gaap_AccountsPayableCurrent_69e989cb-f9cc-4594-ae8d-034c49a75e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ea9990b6-e8ea-4fae-b1d0-6f7e9141c596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c7898f7-454a-4334-b53e-36e33fd379b7" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ea9990b6-e8ea-4fae-b1d0-6f7e9141c596" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae65e8c0-afa1-43ec-90dd-e37762d31958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c7898f7-454a-4334-b53e-36e33fd379b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ae65e8c0-afa1-43ec-90dd-e37762d31958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7976e7af-b3b6-4b79-8455-8266d314933a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3c7898f7-454a-4334-b53e-36e33fd379b7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7976e7af-b3b6-4b79-8455-8266d314933a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd5ecf43-d005-4199-a66a-9ff6e81f5336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd5ecf43-d005-4199-a66a-9ff6e81f5336" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bc07764b-5ebe-46b0-a5d4-e24e48ea5128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_bc07764b-5ebe-46b0-a5d4-e24e48ea5128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_151f5c65-eb02-478d-b249-c08f1c527f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_151f5c65-eb02-478d-b249-c08f1c527f29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e241236f-9dcf-4b54-8dc6-d95c02193f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e241236f-9dcf-4b54-8dc6-d95c02193f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_629c6fe4-a6b5-45ed-a961-784395e4473a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_11de0064-31b7-4171-b303-f28a3e56c960" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_629c6fe4-a6b5-45ed-a961-784395e4473a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4c20abf2-cecb-431d-b403-d00be445bcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:to="loc_us-gaap_PreferredStockValue_4c20abf2-cecb-431d-b403-d00be445bcc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_449d7286-c6f9-48b3-b666-689365e628b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:to="loc_us-gaap_CommonStockValue_449d7286-c6f9-48b3-b666-689365e628b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32c5f838-7c2c-4e4a-8894-fd2815a74049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_32c5f838-7c2c-4e4a-8894-fd2815a74049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5752b866-c11b-4c27-891b-5af299a7c7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5752b866-c11b-4c27-891b-5af299a7c7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b8cbee7-51d2-486c-9e44-1360c2d61d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d60c0899-78c9-4503-8af1-979067fa175f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1b8cbee7-51d2-486c-9e44-1360c2d61d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d64b6fc2-3b94-4623-a0ca-daf9cc10b164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d64b6fc2-3b94-4623-a0ca-daf9cc10b164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b10319ef-5ece-464a-baf6-815f5606a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b10319ef-5ece-464a-baf6-815f5606a687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_a1057559-57da-4cbb-962f-f3b2f7cc49ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:to="loc_us-gaap_InterestReceivableCurrent_a1057559-57da-4cbb-962f-f3b2f7cc49ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_54324a9c-1dbe-41eb-a97e-ff86a964a3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_54324a9c-1dbe-41eb-a97e-ff86a964a3a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4f9222c8-505f-4c76-aa19-89c0a9153bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_53a223f8-4d6a-4c86-af51-76c308158554" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4f9222c8-505f-4c76-aa19-89c0a9153bcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4bc84dca-42ec-4a50-a410-f72e1081428c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_503cea24-efcc-42a7-b4bf-ee111b4d4510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4bc84dca-42ec-4a50-a410-f72e1081428c" xlink:to="loc_us-gaap_StockholdersEquity_503cea24-efcc-42a7-b4bf-ee111b4d4510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8089622d-8112-4439-93d5-d9931b7ba556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4bc84dca-42ec-4a50-a410-f72e1081428c" xlink:to="loc_us-gaap_MinorityInterest_8089622d-8112-4439-93d5-d9931b7ba556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b64822d1-bd75-4fc2-a4e1-4421013031a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_AssetsCurrent_b64822d1-bd75-4fc2-a4e1-4421013031a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c1e81eb9-b25a-4445-838f-eb3fbef41559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_c1e81eb9-b25a-4445-838f-eb3fbef41559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59da8c26-ab06-4e8f-9939-5d8120871783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_59da8c26-ab06-4e8f-9939-5d8120871783" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d25467ec-f0c7-486a-8276-3bbc0050d261" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d25467ec-f0c7-486a-8276-3bbc0050d261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b2587ad2-7b00-4f14-bde3-19af16d8fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_Goodwill_b2587ad2-7b00-4f14-bde3-19af16d8fbe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9b56440-93de-44de-8e8c-69ecd0839253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d9b56440-93de-44de-8e8c-69ecd0839253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_035247f0-52d8-4ac1-8154-4072075d30bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_035247f0-52d8-4ac1-8154-4072075d30bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7f24523d-b691-4694-bb3b-8bd80898c1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_270b8199-1568-490a-b9c7-75963c2afc3c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7f24523d-b691-4694-bb3b-8bd80898c1bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_0a5b3e3b-1347-4146-9508-f357d5dab11d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34cd1b73-2ab1-48b3-97e6-6583fc1dad59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_0a5b3e3b-1347-4146-9508-f357d5dab11d" xlink:to="loc_us-gaap_OperatingIncomeLoss_34cd1b73-2ab1-48b3-97e6-6583fc1dad59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_1bb77d3e-8b55-40c6-975e-ba772ceacf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_0a5b3e3b-1347-4146-9508-f357d5dab11d" xlink:to="loc_us-gaap_InterestAndOtherIncome_1bb77d3e-8b55-40c6-975e-ba772ceacf70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_36a34add-e378-4edb-a9e6-4ca3ba2eea99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_2fec1c57-8e09-46ae-b751-ce9119353ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_36a34add-e378-4edb-a9e6-4ca3ba2eea99" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_2fec1c57-8e09-46ae-b751-ce9119353ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6e0304c5-c466-47ea-93f4-e85250efb555" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_36a34add-e378-4edb-a9e6-4ca3ba2eea99" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6e0304c5-c466-47ea-93f4-e85250efb555" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cfeb5bbc-7f65-47c4-b6ff-211e98c488f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_35b13242-06a3-4342-82c6-a3c0be4c1fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cfeb5bbc-7f65-47c4-b6ff-211e98c488f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_35b13242-06a3-4342-82c6-a3c0be4c1fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_71f0bf6b-790b-4352-918b-4635bbc0f539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cfeb5bbc-7f65-47c4-b6ff-211e98c488f4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_71f0bf6b-790b-4352-918b-4635bbc0f539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_90ea19ab-5b81-4209-bdd5-cb34f3f0b7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aa12d86-a0c4-40c4-aa91-5447ced1491c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_90ea19ab-5b81-4209-bdd5-cb34f3f0b7e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8aa12d86-a0c4-40c4-aa91-5447ced1491c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e03b513b-26b0-45ca-b179-140ad0da75bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_90ea19ab-5b81-4209-bdd5-cb34f3f0b7e5" xlink:to="loc_us-gaap_OperatingExpenses_e03b513b-26b0-45ca-b179-140ad0da75bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d2d54ca-7494-47a4-878d-efb1fd244130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6fd1a0f0-c281-4fae-a884-895cf3cc487c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4d2d54ca-7494-47a4-878d-efb1fd244130" xlink:to="loc_us-gaap_ProfitLoss_6fd1a0f0-c281-4fae-a884-895cf3cc487c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ca570d71-b266-4285-a176-88d5bb397745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4d2d54ca-7494-47a4-878d-efb1fd244130" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_ca570d71-b266-4285-a176-88d5bb397745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c173eee5-892b-49c9-9de7-08aad799b54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eaa40b7d-0829-402c-9c47-5df2b1737661" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c173eee5-892b-49c9-9de7-08aad799b54c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_eaa40b7d-0829-402c-9c47-5df2b1737661" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_624db5a8-e988-4569-87e6-8076ff0442a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c173eee5-892b-49c9-9de7-08aad799b54c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_624db5a8-e988-4569-87e6-8076ff0442a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e6c72bf-225a-4ce1-ae9b-29275a86d0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_83f4faea-f884-495a-88d4-737b1e9f1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e6c72bf-225a-4ce1-ae9b-29275a86d0d8" xlink:to="loc_us-gaap_ProfitLoss_83f4faea-f884-495a-88d4-737b1e9f1ff1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92392d42-2165-4d7b-8df5-c30e72789716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e6c72bf-225a-4ce1-ae9b-29275a86d0d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92392d42-2165-4d7b-8df5-c30e72789716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1cd7e03a-07ff-44c9-bb47-ef35c4df0d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1e6c72bf-225a-4ce1-ae9b-29275a86d0d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1cd7e03a-07ff-44c9-bb47-ef35c4df0d22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9ad4c477-feec-452e-bfe1-c085fd2e8dac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9ad4c477-feec-452e-bfe1-c085fd2e8dac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromAtTheMarketOffering_02fb305e-e67a-4d29-8a4d-5eb2321405a6" xlink:href="sgmo-20210630.xsd#sgmo_NetProceedsFromAtTheMarketOffering"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:to="loc_sgmo_NetProceedsFromAtTheMarketOffering_02fb305e-e67a-4d29-8a4d-5eb2321405a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_84ca4cd5-3a77-4b8f-ad4b-9e06d2693b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_84ca4cd5-3a77-4b8f-ad4b-9e06d2693b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1657d778-664a-4c32-bfe9-bec11837838a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1657d778-664a-4c32-bfe9-bec11837838a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_69e4db03-97d5-4558-a91c-1c8baab74a95" xlink:href="sgmo-20210630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7ed9cf6-2491-4cf2-ac29-d19efb1b5e83" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_69e4db03-97d5-4558-a91c-1c8baab74a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3a095309-310e-47c3-9b46-54659d9b0cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3a095309-310e-47c3-9b46-54659d9b0cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8266a9b9-05ee-4f9d-be8a-52750c867d89" xlink:href="sgmo-20210630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_8266a9b9-05ee-4f9d-be8a-52750c867d89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_99910506-7ee4-4867-9845-7046ce093de5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_99910506-7ee4-4867-9845-7046ce093de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a973b788-f8fb-42f7-b520-acb4300b6724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_ShareBasedCompensation_a973b788-f8fb-42f7-b520-acb4300b6724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_dad61082-7e49-4448-ad6f-1db608dda164" xlink:href="sgmo-20210630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_sgmo_GainLossOnFreeShares_dad61082-7e49-4448-ad6f-1db608dda164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06b40c1a-6f97-419b-b378-baa9168d35c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_06b40c1a-6f97-419b-b378-baa9168d35c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2bfdbef8-fa9d-477e-842f-60d370014971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2bfdbef8-fa9d-477e-842f-60d370014971" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ba123478-3b0e-4819-a382-36cedb35883e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ba123478-3b0e-4819-a382-36cedb35883e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_4e60ee90-5084-43bc-8a36-f2ba226f35cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_4e60ee90-5084-43bc-8a36-f2ba226f35cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_aed543fa-0cbb-416a-92bc-9118834e3747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_aed543fa-0cbb-416a-92bc-9118834e3747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_62b96aca-5d72-40f5-8413-a8f92ae224c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_ProfitLoss_62b96aca-5d72-40f5-8413-a8f92ae224c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_9bbb17b8-5014-4b4d-bf43-bf057ff10a86" xlink:href="sgmo-20210630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_9bbb17b8-5014-4b4d-bf43-bf057ff10a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_15fc1f5f-697a-4f56-b50d-8d4c8bd28602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_15fc1f5f-697a-4f56-b50d-8d4c8bd28602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1cfb0132-d2ad-4642-b79c-769c90398ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_da8d28b5-0021-447d-957c-632e84a928f9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1cfb0132-d2ad-4642-b79c-769c90398ef0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a69f9eb7-77a7-415f-8522-00ba58c250cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec837460-b5ea-49b4-bf6d-29eeb5960472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a69f9eb7-77a7-415f-8522-00ba58c250cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ec837460-b5ea-49b4-bf6d-29eeb5960472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57f55fe-96c5-47df-92de-7d5abd197641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a69f9eb7-77a7-415f-8522-00ba58c250cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a57f55fe-96c5-47df-92de-7d5abd197641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0bd3406-c33d-40ac-865e-ec6e65d5f918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a69f9eb7-77a7-415f-8522-00ba58c250cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0bd3406-c33d-40ac-865e-ec6e65d5f918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_420a03a0-cfae-4c30-b636-5e56a86310ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a69f9eb7-77a7-415f-8522-00ba58c250cf" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_420a03a0-cfae-4c30-b636-5e56a86310ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d657c25a-7b26-40a7-af30-39f4f5993a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d657c25a-7b26-40a7-af30-39f4f5993a1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_dae44103-e729-4fe5-884f-ba49bfc5224e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_dae44103-e729-4fe5-884f-ba49bfc5224e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_431c0660-d907-4f8a-b1f5-f5364eff3e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_431c0660-d907-4f8a-b1f5-f5364eff3e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_bd0970ad-6f2d-47c9-9b93-4676dbca27bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_bd0970ad-6f2d-47c9-9b93-4676dbca27bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_b76fbfbb-c71f-473e-82e3-1852a7a1d636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee9bc902-b12f-4d35-89ca-0e75f6752824" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_b76fbfbb-c71f-473e-82e3-1852a7a1d636" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_936486e4-b678-4dcc-a9b4-c5350b0c582a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e1139be-c8d8-4ce6-af54-e4aafe1a76b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_936486e4-b678-4dcc-a9b4-c5350b0c582a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3e1139be-c8d8-4ce6-af54-e4aafe1a76b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9763c154-325d-42ec-a2eb-7f6db11eb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_936486e4-b678-4dcc-a9b4-c5350b0c582a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9763c154-325d-42ec-a2eb-7f6db11eb3fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_87cd4621-13b3-4e19-8c60-be235e4469d7" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_98bfba2a-5dcf-4eb5-8ac5-98fa72a8d7f0" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_87cd4621-13b3-4e19-8c60-be235e4469d7" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_98bfba2a-5dcf-4eb5-8ac5-98fa72a8d7f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02c634b4-6538-4ab8-9361-1798851675e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_87cd4621-13b3-4e19-8c60-be235e4469d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_02c634b4-6538-4ab8-9361-1798851675e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_e506be25-6b87-4e57-a206-1efa62808969" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c6b7caf7-a5c8-4041-b3bc-1d76a82b782b" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_e506be25-6b87-4e57-a206-1efa62808969" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_c6b7caf7-a5c8-4041-b3bc-1d76a82b782b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_56b3e91c-43d5-4eed-b2bc-b1120e9d0e19" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_e506be25-6b87-4e57-a206-1efa62808969" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_56b3e91c-43d5-4eed-b2bc-b1120e9d0e19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3350dd36-e81a-464a-a242-fd994abe03b5" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_e506be25-6b87-4e57-a206-1efa62808969" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_3350dd36-e81a-464a-a242-fd994abe03b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_2907a434-e010-404f-a4ca-48cea2957b70" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cdf51eb-5254-4720-91c8-6240b82c4360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_2907a434-e010-404f-a4ca-48cea2957b70" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4cdf51eb-5254-4720-91c8-6240b82c4360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8c990c84-51dc-4629-92ae-c97d35145a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_2907a434-e010-404f-a4ca-48cea2957b70" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8c990c84-51dc-4629-92ae-c97d35145a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_6519e43f-e4eb-49cc-9dfc-91835fc92995" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_764fee23-e3f0-42bd-9b72-80785bbfa59c" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_6519e43f-e4eb-49cc-9dfc-91835fc92995" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_764fee23-e3f0-42bd-9b72-80785bbfa59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d2785d9-c181-4dbe-804d-da199485b4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_6519e43f-e4eb-49cc-9dfc-91835fc92995" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3d2785d9-c181-4dbe-804d-da199485b4d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6cdb7b1-e097-45a5-9af8-84448c55e363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ede89c49-4bd7-4ea8-801d-7b7def5987ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6cdb7b1-e097-45a5-9af8-84448c55e363" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ede89c49-4bd7-4ea8-801d-7b7def5987ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fdd9479e-0ed1-4222-ac73-f1487ed96087" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6cdb7b1-e097-45a5-9af8-84448c55e363" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fdd9479e-0ed1-4222-ac73-f1487ed96087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_feb95891-b7a4-499c-bf40-4574c042af10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e6cdb7b1-e097-45a5-9af8-84448c55e363" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_feb95891-b7a4-499c-bf40-4574c042af10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_979deb2d-830b-4afd-b3fb-4cc9b61365e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_859f668a-270e-453c-8ba0-b475dbfc8bef" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_979deb2d-830b-4afd-b3fb-4cc9b61365e7" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_859f668a-270e-453c-8ba0-b475dbfc8bef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6df549af-a074-40df-8197-c0c284660e20" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_979deb2d-830b-4afd-b3fb-4cc9b61365e7" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6df549af-a074-40df-8197-c0c284660e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1653ccd5-20ca-41ec-a530-86460bfa8296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_979deb2d-830b-4afd-b3fb-4cc9b61365e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1653ccd5-20ca-41ec-a530-86460bfa8296" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ca5fb3da-1d13-4f24-9d80-aab76d36c8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dc46b076-accd-49f0-8a20-61a0fec679d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ca5fb3da-1d13-4f24-9d80-aab76d36c8d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dc46b076-accd-49f0-8a20-61a0fec679d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6e949dc0-c481-43f6-8d6a-330b5194ccc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ca5fb3da-1d13-4f24-9d80-aab76d36c8d6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_6e949dc0-c481-43f6-8d6a-330b5194ccc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSComponentsofOperatingLeasesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_26cd4f4f-4d9a-4bb4-93fc-1fce152fa872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_92eebec3-5705-4d30-b458-b6506ffa0634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_26cd4f4f-4d9a-4bb4-93fc-1fce152fa872" xlink:to="loc_us-gaap_OperatingLeaseCost_92eebec3-5705-4d30-b458-b6506ffa0634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b8b6e079-216b-4dbd-aa15-dfcd0527d85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_26cd4f4f-4d9a-4bb4-93fc-1fce152fa872" xlink:to="loc_us-gaap_VariableLeaseCost_b8b6e079-216b-4dbd-aa15-dfcd0527d85d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9823a3ee-a1ec-4539-a9ec-76b4f7671215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9823a3ee-a1ec-4539-a9ec-76b4f7671215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3fcc38b0-5ab6-498f-b3ad-a07e7b147c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3fcc38b0-5ab6-498f-b3ad-a07e7b147c9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0fb9dbc9-7730-49d9-9ea6-91754bda96c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0fb9dbc9-7730-49d9-9ea6-91754bda96c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5043a5c6-7807-484f-9dc8-dd7ab932916f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5043a5c6-7807-484f-9dc8-dd7ab932916f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6de707e5-f12e-4c2f-aaf3-ec224e9e4247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6de707e5-f12e-4c2f-aaf3-ec224e9e4247" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_de9a0c6e-a3d6-4083-ae27-596fd8824fe5" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_698c9d42-c573-469a-b459-bc4c12d62db4" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_de9a0c6e-a3d6-4083-ae27-596fd8824fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cea67503-269e-4d2d-bd92-f9646a6166dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_471e83ca-338b-4f16-9089-114a9b1521ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cea67503-269e-4d2d-bd92-f9646a6166dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_471e83ca-338b-4f16-9089-114a9b1521ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abef8483-77a8-4ed7-8a00-f52a2cb0c759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_cea67503-269e-4d2d-bd92-f9646a6166dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_abef8483-77a8-4ed7-8a00-f52a2cb0c759" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be0313bb-110b-4661-b05e-79f0590b4538" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a191ff3e-3ae6-4864-87d5-ff74e44d33fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be0313bb-110b-4661-b05e-79f0590b4538" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a191ff3e-3ae6-4864-87d5-ff74e44d33fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_333e210f-8188-4631-9ce2-2bfe2ed6a493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_be0313bb-110b-4661-b05e-79f0590b4538" xlink:to="loc_us-gaap_OperatingLeaseLiability_333e210f-8188-4631-9ce2-2bfe2ed6a493" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>sgmo-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i6819fb81760342da9c25f81e28cd1d86_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_46fd9205-94ab-495c-8ae0-d77814687edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_CommonStockSharesIssued_46fd9205-94ab-495c-8ae0-d77814687edc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f523f5f3-f206-4599-9696-15faff9d803a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f523f5f3-f206-4599-9696-15faff9d803a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_303733ee-3db1-48fa-b2b5-3d38d5f0ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_303733ee-3db1-48fa-b2b5-3d38d5f0ec19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5fb0990-88a9-4107-8e95-440d3aac5dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5fb0990-88a9-4107-8e95-440d3aac5dc3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2de78502-62e7-460b-ae3a-2548a07e0be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2de78502-62e7-460b-ae3a-2548a07e0be7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cceb0c3b-aaed-4cb2-aeeb-edf9d6fc8563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cceb0c3b-aaed-4cb2-aeeb-edf9d6fc8563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_103aa891-854c-4360-bac4-bd07022b7506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_103aa891-854c-4360-bac4-bd07022b7506" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d2f67e3e-76eb-4c10-bc44-0d2cf85154b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d2f67e3e-76eb-4c10-bc44-0d2cf85154b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8f925810-61fc-4f85-b778-6b9f3a10ac66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8f925810-61fc-4f85-b778-6b9f3a10ac66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_2840dbad-12c1-48b8-acfd-a5b2d36cd5be" xlink:href="sgmo-20210630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_2840dbad-12c1-48b8-acfd-a5b2d36cd5be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cce313df-659b-45ef-8ffc-23c67442439e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cce313df-659b-45ef-8ffc-23c67442439e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_40f9af20-c070-46ee-a948-bbef88595dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_40f9af20-c070-46ee-a948-bbef88595dae" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_87e0f008-966e-483c-b0cc-14713b0313ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_87e0f008-966e-483c-b0cc-14713b0313ba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e84b5c7-f179-439d-85ba-5b5c58cd4fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_ProfitLoss_4e84b5c7-f179-439d-85ba-5b5c58cd4fac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_910bacbc-6e3d-4a00-ab3a-1bd5d183b8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59f86f7d-053b-4a8c-9cc5-c66849a32ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:to="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_551895a8-8b89-4b5a-847f-038bce983730_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:to="loc_us-gaap_EquityComponentDomain_551895a8-8b89-4b5a-847f-038bce983730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:to="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b1c8231-7eb0-4fe6-af8e-3dccdf247b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_CommonStockMember_0b1c8231-7eb0-4fe6-af8e-3dccdf247b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7458f5fe-9bf0-4888-9146-d450a5f0f448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7458f5fe-9bf0-4888-9146-d450a5f0f448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_370ff02f-87a6-482d-a02d-5b51bacb2b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_RetainedEarningsMember_370ff02f-87a6-482d-a02d-5b51bacb2b22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181acc-c1f2-4ba2-9f55-d91a8550c42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181acc-c1f2-4ba2-9f55-d91a8550c42b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7304e122-d665-4c82-b3d6-8bc949f6497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7304e122-d665-4c82-b3d6-8bc949f6497a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended" id="i13f8feb12429495eae59f757c8ca16d3_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_53ad60aa-e4ed-4ffc-8fbf-4e93be08ebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_53ad60aa-e4ed-4ffc-8fbf-4e93be08ebfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:to="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_657c52f0-6005-4bcb-bcae-4b2c9a45fce4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_657c52f0-6005-4bcb-bcae-4b2c9a45fce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_32759412-da91-465c-94ad-2cbde930b5cf" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_BiogenMAIncMember_32759412-da91-465c-94ad-2cbde930b5cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a5abe495-bae0-4ff9-b82e-6051959086c5" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a5abe495-bae0-4ff9-b82e-6051959086c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_cf0da4e4-4fc3-4a8c-b644-6c68a0568d25" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_KitePharmaIncMember_cf0da4e4-4fc3-4a8c-b644-6c68a0568d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_196f19e7-39d3-4e72-b23b-ce602c92874a" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_SanofiMember_196f19e7-39d3-4e72-b23b-ce602c92874a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_7585a187-e371-4182-8781-f2553589179a" xlink:href="sgmo-20210630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_PfizerMember_7585a187-e371-4182-8781-f2553589179a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7ee0e52b-0e6c-476d-829a-d99d39d09d63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7ee0e52b-0e6c-476d-829a-d99d39d09d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_52ef9499-b259-43dd-8e3d-96c3724f21b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_52ef9499-b259-43dd-8e3d-96c3724f21b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2c68ab27-2098-4007-9eed-db1e6b46bafa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2c68ab27-2098-4007-9eed-db1e6b46bafa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_9ea6bf77-da2d-4a21-bba4-f58dcf77b7d3" xlink:href="sgmo-20210630.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_9ea6bf77-da2d-4a21-bba4-f58dcf77b7d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended" id="i9883869bbc3841f79bd33963af9b1662_ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a27e0965-16ac-432c-8711-fe0ca04edf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a27e0965-16ac-432c-8711-fe0ca04edf22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2b3c7af7-884e-4b96-aa8b-567eb704e7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_ProfitLoss_2b3c7af7-884e-4b96-aa8b-567eb704e7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_10db8b19-e3f0-4727-ac02-7b89de12995f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_EarningsPerShareBasic_10db8b19-e3f0-4727-ac02-7b89de12995f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e23dc94e-ab08-4c4f-952e-60d2c3cb852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e23dc94e-ab08-4c4f-952e-60d2c3cb852f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cab28229-2d91-4db6-88c8-d5709e92138c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cab28229-2d91-4db6-88c8-d5709e92138c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8d2788d2-047f-48d1-be33-24b59e8c1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8d2788d2-047f-48d1-be33-24b59e8c1d75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_217b2c42-873c-480f-80a4-5ad0c53a52df" xlink:href="sgmo-20210630.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:to="loc_sgmo_PfizerSB525Member_217b2c42-873c-480f-80a4-5ad0c53a52df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5fc56e15-972c-4593-984b-251395ee3214" xlink:href="sgmo-20210630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5fc56e15-972c-4593-984b-251395ee3214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15053376-109d-451a-be0f-84fec8bad7a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15053376-109d-451a-be0f-84fec8bad7a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0297cece-7fce-4d40-a2ef-9d9b11792b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0297cece-7fce-4d40-a2ef-9d9b11792b67" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended" id="i492adb9b6a7641e5bf2a808fbe799658_FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f97feae8-87b8-4cd0-89d3-815926210697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f97feae8-87b8-4cd0-89d3-815926210697" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07a22dd9-867c-48b7-936c-12fdb1ec1138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07a22dd9-867c-48b7-936c-12fdb1ec1138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8631378c-0e08-4c6a-a275-aba1533bd378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8631378c-0e08-4c6a-a275-aba1533bd378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b4f6a34a-ee23-4751-8285-3dd53e4bff59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b4f6a34a-ee23-4751-8285-3dd53e4bff59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b438bf97-1793-4366-90fb-46538cc7b920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b438bf97-1793-4366-90fb-46538cc7b920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa4427d-4660-4a10-82e9-9f6a687c708f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaa4427d-4660-4a10-82e9-9f6a687c708f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bc0f8909-a3e5-4489-a4e6-c747801db65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bc0f8909-a3e5-4489-a4e6-c747801db65f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_896dbea0-2073-4d9a-8ea0-71629959b943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_896dbea0-2073-4d9a-8ea0-71629959b943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6701eacc-c789-453b-8884-cf0f819ca2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6701eacc-c789-453b-8884-cf0f819ca2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd2c357c-5ab2-4b2e-a811-c14d8f06746c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd2c357c-5ab2-4b2e-a811-c14d8f06746c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b3e4cf28-289d-4fb0-92f7-6e040822b96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b3e4cf28-289d-4fb0-92f7-6e040822b96b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6b80a42e-b072-4043-8823-51d4eb5a640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6b80a42e-b072-4043-8823-51d4eb5a640c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f66a3f67-6891-492e-8b33-1064e7384cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CommercialPaperMember_f66a3f67-6891-492e-8b33-1064e7384cdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_20c68519-f861-4257-b168-6cc4c7aad9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_20c68519-f861-4257-b168-6cc4c7aad9c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2a60dba-7a24-42a7-a452-7af38fbee1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2a60dba-7a24-42a7-a452-7af38fbee1e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7f07c495-b6ea-4a3e-9841-0c0b3a834cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7f07c495-b6ea-4a3e-9841-0c0b3a834cd8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_611a8037-9c34-498a-8216-ec58d5ac8e09" xlink:href="sgmo-20210630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_sgmo_FreeSharesAssetMember_611a8037-9c34-498a-8216-ec58d5ac8e09" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended" id="i21f532f75ae04d759d2feeb5152a00ad_FAIRVALUEMEASUREMENTSNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_27a6fa8c-a818-4dd6-936f-c218af2dbbbb" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_27a6fa8c-a818-4dd6-936f-c218af2dbbbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_eb49e261-6a8d-445f-a9c0-9042f43cf5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_eb49e261-6a8d-445f-a9c0-9042f43cf5bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_76456d30-b87b-4ffa-8ffb-945e649d549a" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_76456d30-b87b-4ffa-8ffb-945e649d549a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_ed454d55-5db5-431e-827d-dd1371355c0f" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_ed454d55-5db5-431e-827d-dd1371355c0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_190f7d60-4a17-4631-a39c-f765e4a5c5f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_190f7d60-4a17-4631-a39c-f765e4a5c5f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_9b5c3a83-5f78-4f17-aff8-946d263d2115" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:to="loc_sgmo_SangamoFranceMember_9b5c3a83-5f78-4f17-aff8-946d263d2115" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c83d539-9401-43db-9df1-cab2620e3c9f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c83d539-9401-43db-9df1-cab2620e3c9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_4698f5c2-af30-4cdb-933e-d2921838b3d6" xlink:href="sgmo-20210630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_4698f5c2-af30-4cdb-933e-d2921838b3d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended" id="i6170df4f3ca4445f970f5a77a7a37051_FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_866388ec-f790-49a1-92e2-f3158dd723e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_SharePrice_866388ec-f790-49a1-92e2-f3158dd723e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_72710416-e364-408c-88f8-9008e6d812ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_72710416-e364-408c-88f8-9008e6d812ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_daa6e0b1-c964-48dc-bf0f-90dbace78cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_daa6e0b1-c964-48dc-bf0f-90dbace78cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_82fa6080-6ae0-4aa2-98b2-4ec3c48df2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_82fa6080-6ae0-4aa2-98b2-4ec3c48df2bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2be28856-41b9-4afc-bde0-9b935452910c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2be28856-41b9-4afc-bde0-9b935452910c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04b730ac-3051-4c0a-a736-612d60b31a5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04b730ac-3051-4c0a-a736-612d60b31a5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_8b80b1e6-92e6-4d43-99b8-5073cc948adb" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:to="loc_sgmo_SangamoFranceMember_8b80b1e6-92e6-4d43-99b8-5073cc948adb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_bce93245-442d-47ae-afdf-5bec464156c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_bce93245-442d-47ae-afdf-5bec464156c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_3599b985-52b5-4679-bcca-243ff272c4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_3599b985-52b5-4679-bcca-243ff272c4f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_0048af1f-8c69-4e1c-883b-70862740a454" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_0048af1f-8c69-4e1c-883b-70862740a454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ec96451b-e989-490c-b423-57d8fea469d1" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ec96451b-e989-490c-b423-57d8fea469d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_4bede3e4-e4d7-42ae-987e-cd49254630c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_4bede3e4-e4d7-42ae-987e-cd49254630c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_465440ac-bafb-4bc9-922e-2e1519d9a73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_465440ac-bafb-4bc9-922e-2e1519d9a73f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="ie76141e09adb481f8ab2c4ddb7481741_CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c892edab-80ec-443c-be15-780330eb9e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c892edab-80ec-443c-be15-780330eb9e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e4644d6c-f1c0-46c1-9843-a9bc58f0ef4e" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e4644d6c-f1c0-46c1-9843-a9bc58f0ef4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6902a826-396c-4601-8b85-937718c1e643" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6902a826-396c-4601-8b85-937718c1e643" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f19017-146e-45dd-8822-3b12aa2c3b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f19017-146e-45dd-8822-3b12aa2c3b12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8514bb25-09b9-4861-be54-4846b43b89c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8514bb25-09b9-4861-be54-4846b43b89c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11c0bcc4-e304-4ab0-a791-a810464e4340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11c0bcc4-e304-4ab0-a791-a810464e4340" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5a328e4-cded-4fce-9b79-5765e7ebd999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5a328e4-cded-4fce-9b79-5765e7ebd999" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_589e83e4-b3a7-4cdd-bbdb-5f02f2cf21cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_589e83e4-b3a7-4cdd-bbdb-5f02f2cf21cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_a68a2204-360e-4172-b1be-27901f58091a" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_a68a2204-360e-4172-b1be-27901f58091a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8e095d31-74fa-42d9-861d-64d0ddb08a10" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8e095d31-74fa-42d9-861d-64d0ddb08a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2bca07d0-7659-4938-8f69-eeff0c88a23c" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2bca07d0-7659-4938-8f69-eeff0c88a23c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_18143e1a-0cfd-4e82-a991-89de94da9ac5" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_18143e1a-0cfd-4e82-a991-89de94da9ac5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e251c8e8-7316-4e82-b277-9c0ce1efd0dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e251c8e8-7316-4e82-b277-9c0ce1efd0dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5056dc07-b7a2-4889-b4e3-89e7f5568c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5056dc07-b7a2-4889-b4e3-89e7f5568c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_a42d5c39-a441-497a-900d-dfead2e21c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CashEquivalentsMember_a42d5c39-a441-497a-900d-dfead2e21c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c85f4d68-bcd5-4ca1-8880-122cdc9028ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c85f4d68-bcd5-4ca1-8880-122cdc9028ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_18c09472-00fc-4f85-8e5f-9630db825606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CommercialPaperMember_18c09472-00fc-4f85-8e5f-9630db825606" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a4ade550-6767-4d3e-9ba6-0bc51627fb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a4ade550-6767-4d3e-9ba6-0bc51627fb0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c2550e63-e2e6-467f-9261-efc9a1937b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c2550e63-e2e6-467f-9261-efc9a1937b53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a9efce9a-e73b-4f81-80d2-e81ac6c81869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a9efce9a-e73b-4f81-80d2-e81ac6c81869" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended" id="i597ed1175e834124b3a7cdcbbed40dbd_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_58a50f0c-48eb-4fd4-8f21-b7293530f572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_58a50f0c-48eb-4fd4-8f21-b7293530f572" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:to="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_053e81f9-b2ce-4c4c-8785-01da7519d88b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_053e81f9-b2ce-4c4c-8785-01da7519d88b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6176e7ea-a245-48bb-a135-198f969da840" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6176e7ea-a245-48bb-a135-198f969da840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_0a130d7e-ba74-494d-9091-bf41163d3dff" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_BiogenMAIncMember_0a130d7e-ba74-494d-9091-bf41163d3dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_c0b19632-430b-45d1-a03c-a72258e8263b" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_KitePharmaIncMember_c0b19632-430b-45d1-a03c-a72258e8263b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cc8dc5f0-85a9-45ce-bc13-7fbf9bf082a4" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_SanofiMember_cc8dc5f0-85a9-45ce-bc13-7fbf9bf082a4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended" id="iefee07ed41d64976a11b53c758a0553e_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7391196e-0537-4894-bd7e-6c269d64a357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7391196e-0537-4894-bd7e-6c269d64a357" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_ebbe02fc-746f-4fd8-838b-a2c3b24edfcd" xlink:href="sgmo-20210630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_ebbe02fc-746f-4fd8-838b-a2c3b24edfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_46ce2343-e4d1-42e6-9a47-484fde972241" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_46ce2343-e4d1-42e6-9a47-484fde972241" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_0cff1c64-eb54-4a19-a017-caa8afd03cb1" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_0cff1c64-eb54-4a19-a017-caa8afd03cb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_4ed52888-c920-497d-8224-91e4cf6ddbdc" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_4ed52888-c920-497d-8224-91e4cf6ddbdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_17dd1d16-bb9b-40bc-a4f5-0e584c03c6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_17dd1d16-bb9b-40bc-a4f5-0e584c03c6dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_80204def-b90f-42f5-8d02-53227ee3a8be" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_80204def-b90f-42f5-8d02-53227ee3a8be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1c92bbf4-20c8-4d84-8fbe-ea2411cfc45b" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1c92bbf4-20c8-4d84-8fbe-ea2411cfc45b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_72577f7e-0273-4c90-b9ad-5a7c86339441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_72577f7e-0273-4c90-b9ad-5a7c86339441" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c474fcc6-e7c3-4248-86f0-aa78665feec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c474fcc6-e7c3-4248-86f0-aa78665feec2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f4bd6331-8ceb-4efc-b6df-16a9fb304470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f4bd6331-8ceb-4efc-b6df-16a9fb304470" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_6266cbe1-aa4f-499c-8bc0-d0573a3d0bb0" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_6266cbe1-aa4f-499c-8bc0-d0573a3d0bb0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_cbbc5b82-3e57-4e01-ba0c-0814327e3500" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_cbbc5b82-3e57-4e01-ba0c-0814327e3500" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_0f63440a-8c50-4a2e-bc54-895f68c1bcf6" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_0f63440a-8c50-4a2e-bc54-895f68c1bcf6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_bce1ddee-d101-424f-8715-cf70f03a0203" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_bce1ddee-d101-424f-8715-cf70f03a0203" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_abf44e98-e27e-4f87-b56d-f74a225414bc" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_abf44e98-e27e-4f87-b56d-f74a225414bc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_881efb16-92dc-4f6b-ad2a-f900b7454435" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_881efb16-92dc-4f6b-ad2a-f900b7454435" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_8a9b2caf-c231-4c4e-84a2-3b0150cc1a48" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_8a9b2caf-c231-4c4e-84a2-3b0150cc1a48" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_fe706923-cfe0-4ecd-b992-009b7daccac7" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_fe706923-cfe0-4ecd-b992-009b7daccac7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_7d825e4a-4dc0-4572-8a22-4ef67342a384" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_7d825e4a-4dc0-4572-8a22-4ef67342a384" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_197ada14-d2f6-478a-b4a5-2857213383d8" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_197ada14-d2f6-478a-b4a5-2857213383d8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_d83119ab-02be-4d61-89ac-dfe9e09d1f24" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_d83119ab-02be-4d61-89ac-dfe9e09d1f24" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_499eec4f-485e-4bd0-a365-b0c75be0a769" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_499eec4f-485e-4bd0-a365-b0c75be0a769" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_dcc4904c-7a3e-4e14-82ea-937451496188" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_dcc4904c-7a3e-4e14-82ea-937451496188" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_7670dc96-8d6f-4fb7-b1b1-f6a4129ad352" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_7670dc96-8d6f-4fb7-b1b1-f6a4129ad352" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_6c7f98f3-f60e-4e28-9658-1b9a9184b844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_6c7f98f3-f60e-4e28-9658-1b9a9184b844" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c61c92-3f9e-4cf7-98a0-b40cdc43fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c61c92-3f9e-4cf7-98a0-b40cdc43fcb4" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fe05c813-3eff-4210-98f9-685d46a9d630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fe05c813-3eff-4210-98f9-685d46a9d630" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_41f9eda0-d39b-4874-b303-5e9077033f6b" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_41f9eda0-d39b-4874-b303-5e9077033f6b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_682bae73-958c-4a31-8cbf-f032a870bb71" xlink:href="sgmo-20210630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_MilestonePaymentsReceived_682bae73-958c-4a31-8cbf-f032a870bb71" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_53230472-3e71-4c13-ba2d-7436505987f4" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_53230472-3e71-4c13-ba2d-7436505987f4" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_50b9fd66-0be5-42f3-8370-7708b9182805" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_50b9fd66-0be5-42f3-8370-7708b9182805" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_e718f7ad-4975-413f-bef2-f1f3d2417cc3" xlink:href="sgmo-20210630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_e718f7ad-4975-413f-bef2-f1f3d2417cc3" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_380580c1-6298-4255-9769-7c59d620b267" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_380580c1-6298-4255-9769-7c59d620b267" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_ed931e29-7c22-4193-9cca-0c7ad74b646d" xlink:href="sgmo-20210630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_ed931e29-7c22-4193-9cca-0c7ad74b646d" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_bac9263d-9415-43c7-9676-2e20db93cc95" xlink:href="sgmo-20210630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SeparateUpfrontFee_bac9263d-9415-43c7-9676-2e20db93cc95" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_439aea69-5fb1-47b8-9de5-8985f179207a" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_439aea69-5fb1-47b8-9de5-8985f179207a" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c075a763-82eb-496a-ac70-e7f697657522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c075a763-82eb-496a-ac70-e7f697657522" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_f6581b8c-397c-4338-8d05-e603cd960fb0" xlink:href="sgmo-20210630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_AgreementTerminationTerm_f6581b8c-397c-4338-8d05-e603cd960fb0" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_ff53f61a-0e90-441d-89cc-213de7cb77be" xlink:href="sgmo-20210630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_ff53f61a-0e90-441d-89cc-213de7cb77be" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_323680e4-6b81-4f2a-b359-808da9927737" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_MilestoneRevenueReceivable_323680e4-6b81-4f2a-b359-808da9927737" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_016e7e4b-9a15-456c-ba91-49591e895168" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_016e7e4b-9a15-456c-ba91-49591e895168" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_d5ca8857-7195-4d58-be25-e44673eb411c" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_d5ca8857-7195-4d58-be25-e44673eb411c" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_13ed053a-5f08-4f94-8e2a-56b6852ded0a" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_13ed053a-5f08-4f94-8e2a-56b6852ded0a" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_ed4e80a2-49cc-4c6f-a563-e61b23eeda50" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_ed4e80a2-49cc-4c6f-a563-e61b23eeda50" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177f65d3-0dc6-4533-b56f-e3fe6a97f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177f65d3-0dc6-4533-b56f-e3fe6a97f3a0" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_c567786a-d80b-489b-80fe-a007d13be0ac" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfResearchProgram_c567786a-d80b-489b-80fe-a007d13be0ac" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_8f202088-f05d-44f5-a03b-cc2fc7d4f45a" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_8f202088-f05d-44f5-a03b-cc2fc7d4f45a" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_bd08b38a-c1a3-4e41-b9b4-ecd943f3ff67" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_bd08b38a-c1a3-4e41-b9b4-ecd943f3ff67" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_2225ecda-a0e2-4e0f-b701-df5eef52ac49" xlink:href="sgmo-20210630.xsd#sgmo_GrantFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_GrantFundingAmount_2225ecda-a0e2-4e0f-b701-df5eef52ac49" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7c42bb3a-8418-4b14-830f-dab97e673749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7c42bb3a-8418-4b14-830f-dab97e673749" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5577f5e-ea63-478d-b6c2-2fbd53e66c33_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a5577f5e-ea63-478d-b6c2-2fbd53e66c33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ec09b055-8d25-4ca8-81c2-c3845873d1d4" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ec09b055-8d25-4ca8-81c2-c3845873d1d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_1d9f3598-d32d-43d6-9de5-7f8b20c6c76e" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_BiogenMAIncMember_1d9f3598-d32d-43d6-9de5-7f8b20c6c76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_5aff8b74-bdaa-42c2-beea-2415c32079b7" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_KitePharmaIncMember_5aff8b74-bdaa-42c2-beea-2415c32079b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_03dc267c-29d8-4c3f-b84e-f376eb9cf7f1" xlink:href="sgmo-20210630.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_PfizerMember_03dc267c-29d8-4c3f-b84e-f376eb9cf7f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_93b233ba-7b6f-4f70-b95c-ff779dc4c217" xlink:href="sgmo-20210630.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_PfizerSB525Member_93b233ba-7b6f-4f70-b95c-ff779dc4c217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_d0854e06-90d7-4d6b-b8bd-b1ffec83646c" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_SanofiMember_d0854e06-90d7-4d6b-b8bd-b1ffec83646c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3e4ff508-0864-4466-a9b3-62084d66a873_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3e4ff508-0864-4466-a9b3-62084d66a873_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_18581f10-ae13-434c-ae2e-e3e09a614829" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_18581f10-ae13-434c-ae2e-e3e09a614829" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_b5facdaf-604f-45d0-b8d7-d1946e25a781" xlink:href="sgmo-20210630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:to="loc_sgmo_StockPurchaseAgreementMember_b5facdaf-604f-45d0-b8d7-d1946e25a781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02fabfbd-d549-4175-b277-8c2a2a6e057a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02fabfbd-d549-4175-b277-8c2a2a6e057a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_aee99c00-2c68-4730-a16e-228a1c80e87a" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_aee99c00-2c68-4730-a16e-228a1c80e87a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_1f8c2495-3622-465a-90b4-2999a2649f6b" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_1f8c2495-3622-465a-90b4-2999a2649f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8db82aa8-7e5d-48da-9595-67c60d9ba524" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8db82aa8-7e5d-48da-9595-67c60d9ba524" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_4dca5b23-e27f-4395-9d84-d7f62517973d" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_4dca5b23-e27f-4395-9d84-d7f62517973d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_275d9732-68da-46fd-ae0c-7a02762aea4c" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_275d9732-68da-46fd-ae0c-7a02762aea4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_4c99c35d-8f2b-4eee-951b-d78951be6434" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_4c99c35d-8f2b-4eee-951b-d78951be6434" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_c2875659-9688-4705-8871-426ce3a8dd84" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_c2875659-9688-4705-8871-426ce3a8dd84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_c58d059a-f487-483b-8db1-d24f4cd97d1d" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_c58d059a-f487-483b-8db1-d24f4cd97d1d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_73a2ce5e-f065-4419-9395-970a4070c8d3" xlink:href="sgmo-20210630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_73a2ce5e-f065-4419-9395-970a4070c8d3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_76edb866-0a2e-4860-9dae-04d2624dbb22_default" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_76edb866-0a2e-4860-9dae-04d2624dbb22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_d651376b-f78a-4cb8-8425-3d2741d0edd2" xlink:href="sgmo-20210630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_PreApprovalMilestoneMember_d651376b-f78a-4cb8-8425-3d2741d0edd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_441bc7e9-0458-42eb-a0f6-66f9a91b2af8" xlink:href="sgmo-20210630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_SalesBasedMilestoneMember_441bc7e9-0458-42eb-a0f6-66f9a91b2af8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_c8c9a3d1-2b1f-43a1-bcae-7d641c8fe424" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_MilestoneTwoMember_c8c9a3d1-2b1f-43a1-bcae-7d641c8fe424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_e37f01de-a890-4bd2-9954-4c4aed57f956" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_MilestoneThreeMember_e37f01de-a890-4bd2-9954-4c4aed57f956" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_52d7f645-cd39-4291-a353-67d6ad0807ad" xlink:href="sgmo-20210630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_52d7f645-cd39-4291-a353-67d6ad0807ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e7725c82-131d-4449-9a3a-c8a8cddb3ae3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:to="loc_srt_ProductsAndServicesDomain_e7725c82-131d-4449-9a3a-c8a8cddb3ae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:to="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_b00eb2c5-b14e-4637-b7d2-9a2154a99461" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_b00eb2c5-b14e-4637-b7d2-9a2154a99461" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_12618b6b-fb07-4998-a3df-7f3a46646503" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_SBFiveTwoFiveMember_12618b6b-fb07-4998-a3df-7f3a46646503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_467ff84f-f2c6-496c-a243-371b989a7cec" xlink:href="sgmo-20210630.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_OtherProductsMember_467ff84f-f2c6-496c-a243-371b989a7cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_41a476fe-5325-4b26-b697-7fe1612b3311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_us-gaap_LicenseAndServiceMember_41a476fe-5325-4b26-b697-7fe1612b3311" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_da95425b-4537-407b-943c-e01692e8ffec" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_MilestoneAchievementMember_da95425b-4537-407b-943c-e01692e8ffec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_f28756f3-3685-461c-abd3-9c763520ada0" xlink:href="sgmo-20210630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_CNineORFSevenTwoMember_f28756f3-3685-461c-abd3-9c763520ada0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_011bca4a-9ae5-4d0e-b3c7-749c2dc4de85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_us-gaap_GrantMember_011bca4a-9ae5-4d0e-b3c7-749c2dc4de85" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="if451df23b66048cfa13d736f1bac6a59_MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_604151d5-9756-42b1-84c8-6193c38b7ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_604151d5-9756-42b1-84c8-6193c38b7ab9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:to="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18245c24-13a4-4fea-89c9-2f85521ea8a9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18245c24-13a4-4fea-89c9-2f85521ea8a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_13d098f9-96e5-4224-be7a-24662e670f24" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_13d098f9-96e5-4224-be7a-24662e670f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_de25991f-a46d-46f7-9d3d-2474098830a8" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_BiogenMAIncMember_de25991f-a46d-46f7-9d3d-2474098830a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_9d8cbad7-04e5-45d5-9520-f5674aed00f7" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_KitePharmaIncMember_9d8cbad7-04e5-45d5-9520-f5674aed00f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_39ff24dd-e1f4-4d9b-b9c5-63738c67985b" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_SanofiMember_39ff24dd-e1f4-4d9b-b9c5-63738c67985b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:to="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b25a67e2-e20e-4de4-8db5-50a204e6c3e7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:to="loc_srt_ProductsAndServicesDomain_b25a67e2-e20e-4de4-8db5-50a204e6c3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:to="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_2fa40e3b-1f83-4c38-86b7-aa7eb627f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_us-gaap_LicenseAndServiceMember_2fa40e3b-1f83-4c38-86b7-aa7eb627f994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_de990568-8398-4ec7-ab03-5b90dbb66e2c" xlink:href="sgmo-20210630.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_sgmo_ResearchServicesMember_de990568-8398-4ec7-ab03-5b90dbb66e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_7d0723da-0a80-49ad-8349-e94d07dc83d1" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_sgmo_MilestoneAchievementMember_7d0723da-0a80-49ad-8349-e94d07dc83d1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="extended" id="idd1f274ee60546dca50ad5c5cd2517e4_COMMITMENTSAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_88bfb628-7a01-4fb7-81c1-4a31b4f01c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_88bfb628-7a01-4fb7-81c1-4a31b4f01c71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ea04b3d-14be-4489-bec9-f169da17413d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ea04b3d-14be-4489-bec9-f169da17413d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3ce84293-29fe-4133-bddf-00f8cf22ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeasePayments_3ce84293-29fe-4133-bddf-00f8cf22ca27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a4625af8-dcfb-4913-b0e2-8d545d96f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a4625af8-dcfb-4913-b0e2-8d545d96f9ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_31ee457e-4993-4415-9acc-779ff7d3817f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_31ee457e-4993-4415-9acc-779ff7d3817f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_44b07c91-9a62-4c43-a114-77c4fbdc512a" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_44b07c91-9a62-4c43-a114-77c4fbdc512a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount_5ac9c167-55e5-49ab-a1b9-d2693f9715bc" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LesseeOperatingLeaseAmount_5ac9c167-55e5-49ab-a1b9-d2693f9715bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_f05576d1-a9d1-4fa4-9473-395fc8943318" xlink:href="sgmo-20210630.xsd#sgmo_LicenseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LicenseObligations_f05576d1-a9d1-4fa4-9473-395fc8943318" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_9c56f906-0161-4998-aa79-2e032f4404d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_9c56f906-0161-4998-aa79-2e032f4404d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_8185745a-798f-40c1-8d1a-6f54653860c2" xlink:href="sgmo-20210630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_8185745a-798f-40c1-8d1a-6f54653860c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ad7afd8-0661-46d6-a2ba-efc8fc691d67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ad7afd8-0661-46d6-a2ba-efc8fc691d67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_4ff808a9-1438-476f-9c2b-c5cd6eebc103" xlink:href="sgmo-20210630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_4ff808a9-1438-476f-9c2b-c5cd6eebc103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_3e38392d-e4fe-4a6a-8234-ec605001102c" xlink:href="sgmo-20210630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_3e38392d-e4fe-4a6a-8234-ec605001102c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5cd9e040-23ac-4e62-8df8-345e5e6be46d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:to="loc_srt_SegmentGeographicalDomain_5cd9e040-23ac-4e62-8df8-345e5e6be46d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:to="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_2e54a96f-8118-4c93-9a07-9336f4e7a99d" xlink:href="sgmo-20210630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_2e54a96f-8118-4c93-9a07-9336f4e7a99d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_cd42a72f-afdb-4b42-8a09-2cd38fe61f69" xlink:href="sgmo-20210630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_RichmondCaliforniaMember_cd42a72f-afdb-4b42-8a09-2cd38fe61f69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_b559ba6c-6842-4733-8c59-749da06083c3" xlink:href="sgmo-20210630.xsd#sgmo_ValbonneFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_ValbonneFranceMember_b559ba6c-6842-4733-8c59-749da06083c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_931e55c4-6754-4aac-8f7a-307f95318136_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:to="loc_srt_RangeMember_931e55c4-6754-4aac-8f7a-307f95318136_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:to="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ecda6d5d-8c5f-4b1b-9eea-1dfcb28ab133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:to="loc_srt_MinimumMember_ecda6d5d-8c5f-4b1b-9eea-1dfcb28ab133" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b464f9ac-bf43-4bd8-b046-32f00d24ba79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:to="loc_srt_MaximumMember_b464f9ac-bf43-4bd8-b046-32f00d24ba79" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended" id="i1b9c7ccb85284d3c9cd3ea2c6fb564fc_COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_e357372c-df7d-49f4-8f93-8329e51be864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:to="loc_us-gaap_ContractualObligation_e357372c-df7d-49f4-8f93-8329e51be864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:to="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:to="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36a70598-7c68-47bc-b031-5b5a90526aac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36a70598-7c68-47bc-b031-5b5a90526aac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_8ee50850-5f84-42cd-8ecf-a34dccd050a9" xlink:href="sgmo-20210630.xsd#sgmo_BrammerBioMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:to="loc_sgmo_BrammerBioMAMember_8ee50850-5f84-42cd-8ecf-a34dccd050a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_a5396daa-7f90-49f0-a606-434b162af34f" xlink:href="sgmo-20210630.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_a5396daa-7f90-49f0-a606-434b162af34f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended" id="ie8daedb28d5042fab9f6d2ac683cf07b_STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc713ea2-8f6f-4d99-8764-6244d0917efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc713ea2-8f6f-4d99-8764-6244d0917efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_554cd4f0-2dc9-47d0-901c-84d3bc1330d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_554cd4f0-2dc9-47d0-901c-84d3bc1330d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f803194d-baff-49fe-b77c-9390b64bfaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f803194d-baff-49fe-b77c-9390b64bfaf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6b1d858-4ef5-4a7c-8279-6bbd6a8c8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6b1d858-4ef5-4a7c-8279-6bbd6a8c8b6d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended" id="ic0a8c308d9564ac486fa322bb9d0f1b8_STOCKHOLDERSEQUITYNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_b913e221-9885-4f1e-ab49-d57503a908b2" xlink:href="sgmo-20210630.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_b913e221-9885-4f1e-ab49-d57503a908b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4e3161b-26cb-4c49-8497-704f08b34356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4e3161b-26cb-4c49-8497-704f08b34356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a45d4ffe-96f8-4583-8c4e-03302b075c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a45d4ffe-96f8-4583-8c4e-03302b075c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_31e2e02e-ba8c-4217-81c7-94262509fc24" xlink:href="sgmo-20210630.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:to="loc_sgmo_JefferiesLLCMember_31e2e02e-ba8c-4217-81c7-94262509fc24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fa77139-936d-4622-ae45-dc9f324a4c5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1fa77139-936d-4622-ae45-dc9f324a4c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_901d28ef-f585-4284-8d8d-d25019a81026" xlink:href="sgmo-20210630.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_901d28ef-f585-4284-8d8d-d25019a81026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1b638c33-00fe-4225-a06d-b5fc5ec648d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1b638c33-00fe-4225-a06d-b5fc5ec648d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_db516608-b3f8-44ef-915a-1b57303fe91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_db516608-b3f8-44ef-915a-1b57303fe91f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1798c263-e407-424b-9132-e24b036d5099_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1798c263-e407-424b-9132-e24b036d5099_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9c693034-ebe7-457d-aa72-531fedcfb3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:to="loc_us-gaap_SubsequentEventMember_9c693034-ebe7-457d-aa72-531fedcfb3d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended" id="ib1ff31287a174565a373d8f98a0610c2_ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_66386feb-9f60-40fb-855f-4a889fcfa8c4" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_66386feb-9f60-40fb-855f-4a889fcfa8c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_879a6981-02e3-44c7-8dfc-d5a8b18b5e48" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_879a6981-02e3-44c7-8dfc-d5a8b18b5e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8b8d2fc9-335a-4687-903e-8b17cf93c441" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8b8d2fc9-335a-4687-903e-8b17cf93c441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fd29f7ab-31f1-4a56-ad41-200352a0b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fd29f7ab-31f1-4a56-ad41-200352a0b32f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a5c185c3-11fa-4dbf-8a82-f0b23cfc8b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a5c185c3-11fa-4dbf-8a82-f0b23cfc8b48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_b471d2e1-350e-4e25-aea1-b8a94fedac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_b471d2e1-350e-4e25-aea1-b8a94fedac98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f59353a-f858-4bdb-8f61-b3adc5677afb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0f59353a-f858-4bdb-8f61-b3adc5677afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_2f2bc288-be6f-4bcd-8c2d-c3a5672481e3" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:to="loc_sgmo_SangamoFranceMember_2f2bc288-be6f-4bcd-8c2d-c3a5672481e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_4a398b65-7e6e-49e7-b378-92e4a09d85fc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:to="loc_srt_OwnershipDomain_4a398b65-7e6e-49e7-b378-92e4a09d85fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:to="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_5a9faf52-92ea-43a1-94e9-1d82db6ced36" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:to="loc_sgmo_SangamoFranceMember_5a9faf52-92ea-43a1-94e9-1d82db6ced36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3773e47b-b063-4214-849f-3aceceb78d2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3773e47b-b063-4214-849f-3aceceb78d2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_8d576148-4d7e-4493-8173-03179979e6b4" xlink:href="sgmo-20210630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_8d576148-4d7e-4493-8173-03179979e6b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>sgmo-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_6374ebf1-52f1-454b-9ec1-1a25e7a2a85f_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6bdccbbc-1a63-473a-87cc-ebb101932edc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2ff1fa06-395c-48ae-b27b-b53eb8e70a02_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3f528180-96dc-405f-afd7-5d5451a8d24c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_30eb0d5d-aad6-4ae8-8f46-f96dba7222f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_764243bb-aa08-4196-b01b-8ac62cd76e5b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_ce003508-b1a5-473a-b9f5-360d0cefee4a_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions, Fair Value of Free Shares' Asset</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions, Fair Value of Free Shares' Asset</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions, Fair Value of Free Shares' Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:to="lab_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2b251951-f433-4407-8fa2-e55cb6e8e25e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_b28a431e-9468-4b30-87ad-17a174c29041_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_34ce2190-85d5-4e47-b1af-11461f3ae368_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_18ab6377-bdbb-49d2-a894-3bb7019e514b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR / USD exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_14d8b8bf-4102-4228-98a8-02408394639b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_b9966d92-2fe9-47bd-8ba2-9f7b093bb730_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Stock Price Correlation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_72c32b6f-706d-4b2e-a4a3-4e66f857d885_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20210630.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_0c389b59-2400-4b90-b323-52014531d88f_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20210630.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_b255717d-084e-492d-b6de-9c5fe8f5d84f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other impairment charges related to marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_6a7b2c25-a119-49ba-b1a5-05202156c9dc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_696c455c-1207-48d8-917f-6baeb8fa12c8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5424f141-37ca-43d3-8599-5b4bb0bd065c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_41de969e-baa7-4537-946e-391194f79c2f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_58ac3e86-f606-4dd5-ac75-040a9c50405a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_44abbd6d-758f-45ee-97e2-c64ada0c7314_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0bb1c7c6-ce0c-4bb7-8fb7-1cfbf9473593_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_12c53060-9bc8-4eb6-9f3e-afe358fbb600_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_bfbc1936-b2b5-479d-a7a9-69a4400b01ba_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Genzyme</link:label>
    <link:label id="lab_sgmo_SanofiMember_c0e69f5a-171c-425a-81b6-93d3d1da2576_verboseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ca2a5093-d3bc-46e3-bb0d-fa00f4773684_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e633c67b-e407-4aa2-9e10-3600c7604759_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a1c1475b-a86a-41de-b558-62a5207b5db1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_221e09fa-37c3-4945-a726-c51bb4ef6429_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_582b1539-57db-423b-8b2c-beb33e780c13_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_aa61294a-5708-4565-9852-75efdcf3e3f0_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments Due After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="lab_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_29b3b124-bc3f-42f7-9305-5c7f1915e53c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_d9d82e04-299e-4ef9-90cc-ef7e4d89bf2c_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20210630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_26e40bff-9b35-4a93-bafd-1c463d2244e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_575182f3-c57a-454c-949d-474f421c0f3c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_08f6a281-aba0-4117-8273-e708a75c8147_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_e9dc51ec-ea64-4635-94d6-34d8e94cb2d5_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2afd63b8-b6e3-4f27-ac60-ed24d28b0c79_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_ee91a2ac-9b50-4c17-be56-32cc43516b96_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_bdf8c7fe-33ee-4da8-ad2a-1469057505ea_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_3cb0da86-3498-49a6-8f78-7700dadaaecb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_0646ee35-3865-406a-980a-6cb86e172d19_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20210630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0834c4da-3e04-4a4a-946f-250bcbf8ecef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b252360d-6967-4ed9-bd04-a9bb6f4635f5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_6edb0fc3-92a2-43f3-9982-d670d0caf2cd_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20210630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_eec04e55-1283-4280-bac3-7e0beccecd5f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_2d8ce275-cfd5-4c57-b784-448318809625_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill or indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_d72d5e12-dd95-478b-a57a-aef01848134f_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e132d599-8e13-4df0-acda-d6530ecaf690_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_af8bf08d-e20d-4418-b378-0fdaf8fbe895_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_6a0e24c4-360e-49ac-a0e5-9710500e258f_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_580a641b-4d2e-4063-9ea9-8ce1329365ef_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_dc158bde-c64a-4b16-bf14-1db8956b30b1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_4bd46863-fd42-4b92-a1fa-18702dad0f92_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange rate</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputExchangeRateMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputExchangeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Exchange Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputExchangeRateMember" xlink:to="lab_sgmo_MeasurementInputExchangeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_89d4ddcc-7983-4607-a4f7-12232cf38371_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_33d9bc41-d5e5-471e-a0d3-4fba2147eafb_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:href="sgmo-20210630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_b51fc645-d4b2-4e13-979a-17dadb4fba9c_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_d966e997-2c82-4c15-9f4f-19410cadf110_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e7b0dbda-876d-4f19-bf40-6bee59e400c5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_03d23474-54a4-4dae-8714-2bcdfc68c725_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_4753b1f1-c926-4e57-9603-aef18e8399ae_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_82814c54-0cc9-4a17-8a47-2f298f9dacd3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_679a9e68-623f-4841-aab4-af0b9c62f2d0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_bfc68553-e4c3-48c7-9408-47da00e9640d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ddd6149-21a6-4fc0-b766-4bf43152ab00_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_898597b5-8f7b-4664-b253-5d5371cc4539_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_a1bd3f8f-b055-4295-bb8a-311f78e57029_negatedTotalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_b2dae3dd-6695-453f-be8e-b9ca099ff2de_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_a4f55a82-c1cc-46d0-b2fd-111b2f3c114d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_f6b33023-25e5-4d77-9593-f4049a19be41_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_166b1965-e687-4dd5-817d-197a54d4531c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_58211217-7b46-4c2d-8357-6ae125357864_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c0e7c817-14b3-4563-bc74-c37a132f3e61_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2259c279-d5bd-433b-bcc4-6972b9316014_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f8b2dbf4-04bb-4480-af57-9d046455ae9e_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a0e787c6-e5e9-4343-a6c7-24d33317ddb9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb0465b0-c14f-4b8a-ac4b-b22bf75e0225_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_77fc778f-2485-4503-811d-f4c0b9f610e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_bc1858cc-7135-47cc-bcfc-dee609c35cf7_terseLabel_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_label_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V. [Member]</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_documentation_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember" xlink:href="sgmo-20210630.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LonzaNetherlandsBVMember" xlink:to="lab_sgmo_LonzaNetherlandsBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d9694df0-5666-45d5-933a-cea099ac6b26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_31972717-002a-48fe-9419-9b909cbb9808_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2ee169fe-1e5f-4cf4-94c2-a56290648698_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_22cfa613-a104-4d1c-a5b2-af28fc61242b_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Milestones Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_e61f3726-63c4-463d-8508-fbac5f733c9b_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20210630.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_362a7e39-e063-4c62-b55b-1905b1a77db9_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_096d5045-a7f1-4219-ac43-461bb1991a76_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4b368984-46bd-40c1-a132-ebe4e0a65046_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_d623f6b6-5264-4a9f-a379-fc23c171235e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper securities</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_838114b0-2914-4851-8897-069d41b517a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease liabilities included net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b6bf514c-10fc-44c9-949a-da9aaeb0f748_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_341cef43-ff8a-4e0c-bd8e-b18c5b256735_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5b3630b1-1e2a-43a0-9792-eb48fa4c5c91_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities and free shares asset</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a4abc3ed-fc93-4ad8-9d84-021fd4e5bc63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c8de954f-f66b-49d9-9c03-edbbcedadf3e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_ec843180-0e7c-4ea2-8bea-3098b5287f1e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_342bb039-9708-47b7-b618-c410f4f7ca25_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a121eadb-8e23-42ca-bfb4-010a615274dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_56cea9cb-9af4-4291-8429-5205df7b3b61_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fa3536c8-e494-41e9-ae91-db0b62563ad0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ff63ac77-4ab6-4197-93d8-e90ce537d306_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_c3be12c1-0b42-4839-b6e2-773a3e692282_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_595d14b6-3a3d-47cf-8998-d26d9d2584df_terseLabel_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease one</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_label_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject To Operating Lease One [Member]</link:label>
    <link:label id="lab_sgmo_PropertySubjectToOperatingLeaseOneMember_documentation_en-US" xlink:label="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property subject to operating lease one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:href="sgmo-20210630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:to="lab_sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_9fcb1b4f-305d-49d0-9297-e2686555a0d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e5caa678-d8b2-48ef-b88b-d8d7899f7388_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a02f08a4-15f7-48cc-92f9-6088902d15d1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3ccf6c2f-4c16-4f4e-8487-53407de77856_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_12482a7c-4404-43c5-aeb5-ea9f65f5984b_terseLabel_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 clinical trial milestone</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_label_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]</link:label>
    <link:label id="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:href="sgmo-20210630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:to="lab_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_43c25a70-af1d-436f-a7b8-9af54938519f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_130b2304-daef-4a9b-9e86-3d3c887fafcc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8084c4c-56ee-423f-8f6f-b91709887248_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_b21d0536-44d6-461c-a55e-7434920434ca_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9865cc78-dfe9-4d91-be10-c6c50626cc57_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3cb005b3-38a8-4f08-b351-3af2010c1aef_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b62b7375-b200-4d07-9be2-22184c0de7d2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_98814117-0f86-4099-9b69-3e95f507e4e7_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes for BioMedical Research, Inc.</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc. [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For BioMedical Research Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_f327fe95-bac4-4995-b31a-cb8cf1f2c86e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9e7883c9-db2a-4682-b5d8-734fb8ac4c3c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_19d0a09a-18e7-4e38-b414-58a4368b549e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b3a12368-e200-4e7c-8031-af97f8c59023_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_645a9cac-363f-4fc8-a859-d4ca5abef5bf_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_7482d757-7b47-41fa-885c-712cff1aff0c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional product targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_72e9c1f8-7764-47b4-95c3-8834d89552a1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_733a4c55-4190-4b24-b423-5c162d3b4077_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f84c7391-11cb-446b-98ca-e3a2aa031642_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_1baae8eb-5362-441b-b4c6-546224391b79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_82b105bf-e978-4d0e-9196-1408a7430c19_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_4944669e-c3de-4e61-8265-4d5e9487cf80_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_b006343d-29ff-467f-885d-d47a5cd4e0ef_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions, ownership threshold percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85e96b96-eb8b-4838-8d6a-10ba8761b16e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c39e03ee-e50d-4690-ac07-977c8165348c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NetProceedsFromAtTheMarketOffering_1866ef2e-7f52-485d-874b-e884fc981534_terseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromAtTheMarketOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from at-the-market offering, net of offering expenses</link:label>
    <link:label id="lab_sgmo_NetProceedsFromAtTheMarketOffering_label_en-US" xlink:label="lab_sgmo_NetProceedsFromAtTheMarketOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From At-The-Market Offering</link:label>
    <link:label id="lab_sgmo_NetProceedsFromAtTheMarketOffering_documentation_en-US" xlink:label="lab_sgmo_NetProceedsFromAtTheMarketOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From At-The-Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromAtTheMarketOffering" xlink:href="sgmo-20210630.xsd#sgmo_NetProceedsFromAtTheMarketOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetProceedsFromAtTheMarketOffering" xlink:to="lab_sgmo_NetProceedsFromAtTheMarketOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_df487b62-3cf0-41bd-ae62-6119337e8259_negatedLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in operating lease right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20210630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b96e6365-345c-4d84-b732-a1e0d3aa14a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_19f50134-e0a0-4422-8e4f-30c6658df456_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_b9e476d5-09a6-48b7-b748-3a8697a19acc_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit established as a deposit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4dca0193-85a0-4821-9b1c-34324060d498_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_178bfe2d-f84a-479e-8cbe-24d535e3099e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_569d0ee0-891c-4d39-aa9d-f30c0309e989_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_b45f8a06-a9e9-44e8-90d5-08a03450d033_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office and laboratory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember" xlink:href="sgmo-20210630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember" xlink:to="lab_sgmo_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d77db27b-b4ad-4395-97ec-324e583e069f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_6cf78233-f3c3-4bac-a318-ec366094f774_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_2123824b-6d38-4c95-9cf4-89747862f01f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial advisory fees</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e4d25206-3207-4116-8eec-86c6db4e6d30_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six months ending December 31, 2021:</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_b4ac2327-8b11-4a16-9fd6-cc760e2d035b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_b9b988cc-8c99-4d4b-a342-2cf58fb87876_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue reversal</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Recognized</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Milestone Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:to="lab_sgmo_CollaborativeArrangementMilestoneRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_8de4d1da-9366-48ac-b74c-454385394fa1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_a67957bd-389d-4f3a-84f8-c0f5d07365ed_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_e8f5380c-2498-403d-bc84-68b510677c35_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_e435dfd7-1768-4b7e-97d2-e38c8ad54edc_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting provisions expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b1760316-3fd9-4e4a-a9f8-2648a03e0c5e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_f7814d3a-9ec4-4982-9db8-ed8634d2edc9_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20210630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_06b7d68a-c5a6-46f6-ae2c-01c73d931858_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_2785c505-02c7-4d25-bd5e-7fed1f3d578b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH EQUIVALENTS AND MARKETABLE SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_6e9f6fc1-8816-4cb0-b48b-cebc27a84b21_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20210630.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_025c09d4-966b-412c-83cd-9553199d3fef_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_245893cf-d7d2-4608-bd7d-69450d177047_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_5e8d4623-7b5a-4074-acc4-0aafb9e403dc_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-The-Market Offering Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20210630.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6ad59945-1945-401a-950e-36f1893991eb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_62f6c451-df04-4606-a415-dcdff6baddc2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_1e462a2d-3ca4-40ec-bbe1-fe1fcc42ddd3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_5049bd29-9099-4477-bd4f-dad4f3d4023a_verboseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_41a37d6d-549c-41c9-a72b-de026bd828f8_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_16e1170f-aa62-4efc-b837-95fe35dbe73e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_05a0effa-368e-41c5-aeb7-e429c1c6a7b4_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesAssetMember_35683452-d4dc-4188-b069-a5f1ad5edffd_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember" xlink:href="sgmo-20210630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember" xlink:to="lab_sgmo_FreeSharesAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0193a1c1-a623-49c8-add3-3e14ccd23f63_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_50ced669-e645-48be-8cf2-6c6f8a5a619f_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_99045fc6-dc3c-40dc-801d-b122d6c73959_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_be0765b9-e1b7-4746-b681-fd1f369f9e19_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_2cb93d92-ad34-4e42-8d95-b32d270a9d31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_78d62521-e6d3-47d4-871d-25f646dfa545_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized portion of equity issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_5f9de88d-36c5-41c0-ab35-1a27585a3e2f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1359513-cc79-4f4b-850c-1f9b1ce89384_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_b6caa9d7-bddc-412f-acfa-32afbef9565a_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20210630.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_506f1c56-83e4-4943-8370-c2070db21b6a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_4a08c8f6-3542-40ac-82f5-6ace4563a10c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ec30bc02-ac90-46e6-a20e-167411bab99d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_dfa5506f-4e9b-43fb-a40c-5f21e04154d6_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20210630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_80e8e5e7-22f9-40e8-b68a-8b890e55e840_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buy-out of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_04e63c8d-9d9f-4b15-b584-bb484ede1467_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_421dce12-9f33-4a9b-b6c8-0da0ab987981_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_97fd2d13-f6e8-4c4c-9cf1-44d74a6facd7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3bf8a6a2-3d72-4ab2-a8cc-528877382c88_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_b35813a0-9e51-4888-a37a-b1a623ebf685_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_673dce5c-4d56-4bba-a7b8-fa55100ebad7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_1f4f922d-14ab-4661-afaa-45002421ca41_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:href="sgmo-20210630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f62605a6-43d7-4f23-8faf-cb4338910c9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_79954d54-061f-4673-91d6-7d23e22c81ed_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_80b9327a-2c2c-4e9e-9c78-8744ec14d684_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ad49ac10-fd49-4861-8675-536714c73257_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d19522b9-d40b-4616-8e7f-8a1c30e030f6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7bde233d-cd8d-4966-b651-6d0fee781006_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_03fa0c0c-d202-43dc-b21a-7b91a8f392ab_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development And regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_89d72a0f-ddfc-433e-a919-06637f951f89_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_8ee6d238-b37e-4b00-8fbe-27440a1a8537_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_fc968577-4f7e-43ec-9cfb-ecfa220c9fec_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, percentage of shares held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:to="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3898d13f-3508-44ca-b0e0-4a77e58abfaf_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_23510bf0-61d4-42e2-ab30-264a8a35da42_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc. [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a944aae8-6a9d-46ee-9dd0-3ae5b2f69a6e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce4d5e99-9d68-4ff8-8ac0-3088c3e1b963_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_790ef5a2-7181-4d97-bc97-3113fc3fe89f_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20210630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_86c4fd3b-b32a-490d-8aa1-d46d68b5ce65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Recognized under Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d20c77a7-b65c-4d4b-ab35-44a71d5551d2_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_ab6a7156-8daa-4107-8495-82c12cd3a7bd_terseLabel_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="sgmo-20210630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef21616b-b86f-4b68-bdca-57818bc1d563_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_7f494962-6d68-4e5d-95dd-54370f7fadaf_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares outstanding subject to purchase (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_65a67045-0723-4f93-81df-126667f55ecf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3d96250e-2121-4e31-9551-bd598dec13ca_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4f4a27f5-c3f5-4893-99a8-3b8255c23763_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_14a17871-f659-4e96-8193-14ff692f46db_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price volatility estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b9db67cf-1eb7-42a6-ba3c-7bcdf9dcd0fa_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8e3bec1c-4c30-45be-8434-4a26b222e9d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainLossOnFreeShares_4fee3d43-c945-4c8e-b35f-3735b726a2d6_negatedLabel_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on free shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Free Shares</link:label>
    <link:label id="lab_sgmo_GainLossOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainLossOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on free shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares" xlink:href="sgmo-20210630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainLossOnFreeShares" xlink:to="lab_sgmo_GainLossOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_06d05c4f-ca40-430e-9833-e5c21595a519_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_a291f4b0-9204-42f9-8dd8-8973258afee6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease</link:label>
    <link:label id="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_label_en-US" xlink:label="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Subject to or Available for Operating Lease [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="lab_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_82a0aa2a-a17c-4087-aca6-52dc4367cc7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_5bfff6c0-721a-47ca-9149-1b6cab9b596e_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_7a71df9e-7ba5-408e-84ac-fbdf84f2c4ff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France stock price (EUR) (in euros per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_3e4c9f01-b98b-48ea-9269-3a8d37426741_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_f33289d8-6420-4e6f-8138-b50b37c78caa_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_aa5f853f-ef1a-4386-9dde-2c535a205931_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9d272b4f-e689-4ba3-b76f-78194bc40d9b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1bbdb90b-5775-496d-ba19-54f4c362f4f5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ea4cd4c1-7a6a-4562-a8fc-4cba8bcfab95_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2bc7988c-d91e-4f44-8534-4173923d89b9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3e576868-ff2c-49ef-bde7-41d7c8186c15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3a0e047d-6749-4b35-b0bd-12b632aa55d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_903b1fd4-c8f2-454a-a1a5-fbb3a50b8346_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_44bd4383-9c96-49ad-a1c6-dbc73439d395_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo stock price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_81bdfc29-8efa-4fc0-890d-2d013b3a2c0f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrammerBioMAMember_010d92a7-9121-4e77-ad1b-339d2607c760_terseLabel_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_label_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA [Member]</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_documentation_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember" xlink:href="sgmo-20210630.xsd#sgmo_BrammerBioMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrammerBioMAMember" xlink:to="lab_sgmo_BrammerBioMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_91dd56c6-291b-4bf1-ba9a-a15cb55ab7a1_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20210630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_80a11fbd-404e-46f4-8152-0d5aac6e48bf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7089dab7-e55f-4275-8f24-63c8c72c0df1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_2e020896-b7e0-4342-9cbb-bbcb1cfd67fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_b442576e-495a-48fc-b901-e074d100fb75_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_e4bc66d8-61f6-43c2-85ad-6514806a4b58_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_6a872ba7-7d33-4683-a4d8-1a8567520d5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporarily impaired investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f3da9292-9172-49fa-9f7c-cb0bc9e299e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4e250c1f-52ff-460d-86a8-006e913e9907_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5b7756a8-882d-48a9-ac63-1a59b4b68638_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_d96e4a8a-6bfb-45c0-ae1e-de9bef0e4d5f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_6316779d-f08e-480f-9a5e-f2c012dd9e10_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_ba4e8a4f-5c6a-4236-828e-2018a6959113_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_786f9724-778b-4e89-86c7-88558e6d9bca_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20210630.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f114da4a-ba13-46dc-a5f9-96b432456750_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89871bc8-c0bd-4b43-8682-76c7ff7cf218_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_412306c6-65aa-441a-a3f4-1a18b1abf221_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e7213b01-a247-4957-9bf9-bc23d1a90ef0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e9c27097-45c7-40c6-b8c1-1403f4a8ff55_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_9dae30ef-5143-46ed-8127-a8917484ea5a_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative milestone achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cumulative Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:to="lab_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fb55bd7f-1ed3-43f4-b761-826ee0991ab6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_6470e2da-7815-454d-9563-264a63123245_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standstill restriction, ownership threshold percentage ownership percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_069f0bd6-4c1a-421b-a313-8dcec5695029_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e5bbdd14-842c-43df-872b-ca09215b75b6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_47683ce9-58d4-41b2-b83b-d88e979c5139_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e9f09ef2-91a3-4735-b0e6-cdc7391d2bc7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3ad298ae-1bce-4902-adae-d16765c82b99_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_5eef7e24-1081-4f8d-97b5-ee5f3b4a5a93_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_21b9fcf1-684d-4d31-b187-9a7e1043ebd8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_a17ef6e4-03af-429e-b7cc-6d5fc6f74202_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525 and other products</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five And Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:to="lab_sgmo_SBFiveTwoFiveAndOtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2a9075e6-9923-45dc-8b75-e2f3bec1053c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c9b2cdad-c10a-4ddd-8e01-dd090c38c9bd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_29a61e4a-cd4a-4697-b22f-9061e01ce58b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility estimate</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_4602eea0-2eb4-4b72-bb44-78295e6ee1ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional shares acquired</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_633a2ede-0f8b-44e6-a3a7-9d2fcbe17652_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_30dd0cb7-0156-4858-a27d-9276d935b5e9_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e5711e18-a668-497c-92d6-d59a5ac81c49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aba05c25-9916-4b47-8080-a3c8b5116b9c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2d948dbf-f12c-4182-a4b2-eda6bd22da65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4f942b3e-a82d-4cdc-958b-398e70d050a0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_c02da184-c1e9-4141-9989-66b2f4ad382e_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc.</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_48d64ec3-90ba-4d1f-92e4-7892924cfe9a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_87086ed7-9bc0-4ccb-a98a-179a18edb0d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9437b142-6a1e-4b8f-8fc6-a1239be9dfce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c42e81b6-df02-4533-ac8e-d053cd6512bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_37285ea0-5b4d-499c-a835-9da01f0c6677_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1b4f7d47-e4d5-43b6-b634-d4c112b4cb37_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f9f72321-5703-41c7-bcc7-5250586c6726_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1fb1ece6-3447-4c0b-884d-b1ca32b0e26b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_9f92113e-926c-48e0-808b-4fb33fb5b300_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_e39e3819-4215-4fcf-8088-c68a3f1bb24b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_de277831-7874-4f58-996c-197061d1ae2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_12a159d0-488d-4634-9b0d-67e3c53378bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_41cdeb81-e9b3-42c1-a127-07759dd2a51d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3b6cd9c-496c-4ac1-b459-f031a40e5626_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_af3c94e0-4dd1-468d-98c4-c6597ab5db09_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18a3c576-7e6d-41ca-b7c1-8d0e6836d7d2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_081f4bc2-98a5-43d2-91fa-90fba2a024c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7e161603-1567-4e00-99ef-c1ba8fc7b418_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9786052c-496c-4db8-b6e8-af20746fa95f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_44bb080f-9fea-4b15-9b8c-c7685d58a727_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7a306658-bcff-4bdb-ba5d-299677d7de36_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f912b69d-ee21-4e64-8c3c-93458924ef71_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d49a141e-45f1-48ae-bae6-2cf1f35698a8_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_87f03d1d-304a-4b64-9303-4d4f1d35cdc9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_883736f5-a61d-45b2-a6b6-7f96fccc2c0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bb5d8772-6df8-4fb0-9c33-a1cb9d950686_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d81c2c3a-308e-4486-8395-f400f70dd9fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_79d7ac88-c1b0-4bc1-9840-902efd9f15e9_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8f6e82f5-28a8-4be5-86d6-6885ee5f458d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_e13b4b65-1ebc-40c1-95c8-65756037f414_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_43c88cf8-5910-4e66-b0c3-460f95f7f021_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:href="sgmo-20210630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseObligations_7b1eef55-4362-4ef0-9d94-c7d5ad51354e_terseLabel_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_label_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_documentation_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations" xlink:href="sgmo-20210630.xsd#sgmo_LicenseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseObligations" xlink:to="lab_sgmo_LicenseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_b1d143b2-7183-450a-ba06-eaaee4125ff4_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20210630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6e8d9433-5b15-4302-9ef8-929f24758d94_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_212b4134-11a5-42cb-b8c8-eb87d494bafe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_909afdf8-f8fc-49f1-b2c6-b60bab756147_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_78019e70-082f-402f-98a4-05624ed9d374_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_b2727ba6-ff6b-43cc-88cc-d18e41269556_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_45fe80a9-1faf-4259-8360-3e1dcd631886_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_9058dbf5-cdf2-4415-837d-26bf4db4c206_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c56830bc-5eee-478b-8226-24571e701632_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_70c5e1a9-1e31-4fde-b432-275b004e6f96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_4acf1ff8-ea4c-41d2-b2a2-0b5a770fe761_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a9c3a519-10ec-4a34-a76b-847c9ac24c22_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_4144cc70-b468-406a-98d8-9040d59eba03_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_label_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received On Transaction, Net Of Adjustments</link:label>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received On Transaction, Net Of Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:to="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_1bacc89b-1133-474b-b11d-f85c46c286ce_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c860b877-6f1f-4634-8490-1f8b6931cbd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_40465137-1eac-4d71-85ef-480ab85d242c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Operating Leases</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_41da02d7-e84c-4fdc-91ca-7481534b2f13_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_98585e55-da11-4903-b3b5-f9dbf9a73b1f_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c21dbfb0-caa4-4807-be71-a78afdb8a534_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_fe61bd6c-e1b1-42da-87bc-4f309dc66465_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ValbonneFranceMember_e666d879-f234-4fcf-bb12-3e9b9a154aac_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_label_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_documentation_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember" xlink:href="sgmo-20210630.xsd#sgmo_ValbonneFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneFranceMember" xlink:to="lab_sgmo_ValbonneFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bea4656c-18ab-43cf-8b5c-c2eb10de972d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_79793349-a562-478f-a66a-4f840de1181e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_d3035f74-d665-47d1-9d59-288a4f02b355_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of license and stand-ready fee</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_07eca073-1d8a-49d3-b689-d03b1b59c9d4_verboseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of commercial milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5045d666-ef9c-4f66-a8be-28efda39f433_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a9efbd6b-e392-4ee5-9955-75eaed8e5d4a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_245777fb-36c5-44e3-a12c-a3c9ebc37e15_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f219717c-e9e2-4452-8346-3bed1351cab2_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_7b263b2d-2082-4b17-8c76-ac531a3facc9_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Inc.</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20210630.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_29630e8c-6cb0-4ec9-b47c-faebbfd1037e_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_62351e6e-4a47-4796-b8fb-c7a95c9e1e66_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_237678e6-810c-4c91-8d2c-0395d0fb2507_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SangamoFranceMember_6e4cda2b-1910-4b64-9bc0-b56ca016ab0a_terseLabel_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_label_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SangamoFranceMember" xlink:to="lab_sgmo_SangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_67a165fd-c460-4993-9db1-b44f30465fd0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_a9162c8c-3b2f-47b7-a998-1652ee208188_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:href="sgmo-20210630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_70ab9157-a7e4-4a6d-b39b-33fbb938e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_88c4e840-26fb-4678-82e6-c19af8dbe07a_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_label_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember" xlink:href="sgmo-20210630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneCaliforniaMember" xlink:to="lab_sgmo_BrisbaneCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_c35d07b4-4111-4dae-bca4-624863e028cd_verboseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20210630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_96accfcd-077a-4da1-a7b2-a279a670f8bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_de1a069b-7dd9-4d07-8ad5-31146338ff15_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_379eb51c-1b08-4ea4-b0cf-d79c9c6a9448_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_62a95d62-e07a-418c-a5c9-48cceae2dcd4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9b21c740-14ee-412f-b0e3-d41ffbd1bd3b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_eb46b6cc-796e-4dc7-a936-85d8582d8592_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in collaboration agreement scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:href="sgmo-20210630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_1820e683-fdab-4501-8853-11bdc450f6ae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bc568f21-48e6-434d-b970-67d11fd10592_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_ce853b0d-f676-4893-afc5-6fc72675a4e3_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_b34b6a66-f9e8-4d2f-b642-52d14a15f06d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of contract asset recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_59627979-f856-408f-a2e3-6336af2099af_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_d2c06abe-820a-4f8c-9408-b0885509a9fc_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:to="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_b44297bb-50d4-406f-8501-8e8c27eb8398_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development - and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_35e12f5b-b4dd-4948-8a9b-e6facd846018_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_7edeb974-4432-4471-9803-3723ff30493d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional shares of Sangamo France</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_a1e9c506-f3b2-41a7-8343-de8b79f44f34_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_4652d978-309d-42da-8741-515ae6eef757_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a949a0ee-04b6-45e8-b46d-9a0b2a93609f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GrantFundingAmount_da05232f-5f16-43ff-be12-96f5ecca7665_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount" xlink:href="sgmo-20210630.xsd#sgmo_GrantFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount" xlink:to="lab_sgmo_GrantFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_146de6ad-9fa0-438b-a614-0791754095d5_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_125e56e3-7e32-415f-ad2d-849624716cee_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_17545224-e8f6-4c29-9648-31a321c8e0ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_64376860-43b4-487f-88dd-b78202801e8b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bfa31f28-a1ed-4f12-9929-bbd0361151af_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_948657d2-7629-4ee7-a511-3a1dc14eaf13_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eb0ae159-75a1-4e00-a399-1ddb9d720ab6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3166ac7b-6e7a-426f-a0f5-ababf84548ab_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_6f6dff11-42f5-4d6c-a96f-9a09c36ace56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3c9a9149-9a62-4d87-97e6-ba33ee6ebeeb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_065ba3b7-8e13-4110-9470-e41f544daa88_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_2b0fc9c6-b00f-46e7-82fe-4cd079d78573_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc38e8f9-16e9-46e8-9d73-2d70bac55fe3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a065dd53-886e-4373-ac83-9ed1bb5e6eac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_0105f988-1717-476d-9698-8280762aa957_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in long-term portion of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20210630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_b2d34e05-48e3-46cd-ad7a-7b0f59ee1cdc_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_1146e9f9-ff28-4da8-888c-6c0cd8967d32_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of real estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area Of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:to="lab_sgmo_LesseeOperatingLeaseAreaOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_8299a555-f348-4a0e-8c5e-0a73f9c29d5a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_168355fc-ab9c-46cb-8ff4-8a225872fa18_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_e8ddda90-14c3-4b5b-ad62-8c2c247e0d66_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_1090c885-d673-4c53-ae8e-15b4eb8b90fb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_eed8de1e-f978-41fe-a6bc-e70468cd598a_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e3e8925c-41e6-4cc0-8fb0-891b3cde48a7_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_f7c24902-c016-483d-9bc5-d3f04d73ee17_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20210630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_d6d4a633-ff28-430b-9b24-34aa2e0b1285_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_932f0d82-5229-42b5-9b84-1b2873262d3e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_902f69dd-ca94-4a17-a3fc-ead817af4775_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_e08aadf5-708f-4ab5-bafb-cf5ee2018b3a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8567b250-5a52-457e-b5b1-28b0e4fd3e9c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium (discount) on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c779e66a-02ac-44d7-97bc-302e62ebf546_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_befce2bf-4a22-4606-9f7b-7388275bf21a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_8d272e92-68a3-48bd-8430-2fc19ef19692_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:to="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_c7579831-d8e2-44c2-8fec-07d8722f8575_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_955f8d4e-5555-45e8-b3bb-26e233046362_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_288ff7a4-f646-414e-82f0-de1319085250_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c3989ba7-47ba-41e2-8a48-c37462f8bd90_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d651fe83-89f9-4273-9830-ed49bca1c67f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_4b1a1153-52a8-41b4-a26a-84a0c3a9e514_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_41096438-c3fd-493a-b974-44e9399ad4fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d320e8a3-a26c-4aee-9835-3ef9fea7728e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_8f8f3c58-3d8e-42d1-95e8-cfacf43ad366_verboseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_00060c54-0e82-4058-a6fe-f1cd770b26fa_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_adf03590-ddac-4b1e-86a8-2fb2914515cc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b465e30c-96cf-4fff-ad64-8ce85a3124e4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f268ee90-3296-4c6d-8767-17a68a3cd235_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_396a51cc-c3d0-486c-9171-e949de4b60cf_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4f67241-2b86-4b37-8331-e32bae4fe939_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5f9782dc-c3fc-4666-be86-87b3bd8172e8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dc515c6d-04d1-4e19-8345-20d316ec8483_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bc84bef5-b076-4146-956c-4c3b9806270d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7d50d06e-1a0e-4ed1-8371-85f8b2df3ea6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_dd448eb3-79fe-4189-9a99-118eeb93ce25_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payment amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not Yet Commenced, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseAmount" xlink:to="lab_sgmo_LesseeOperatingLeaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_014b5e81-aa4f-4b33-a41d-7a250ba9e6b1_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of product targets replaced</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:to="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_35512694-1951-42b6-aef3-13e98c1dd8f4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_4720a560-88fb-4300-95c8-db7a63c36ff6_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_71cfb328-8175-4631-850f-94504f98ec4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_c9460188-c70f-4904-a017-e12cc004a716_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_9ba0374e-41a8-422a-968c-0b0095f00868_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of achieved milestones to receive payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Receive Payment</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_7453e008-9999-4143-b75f-d3ade053fb87_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20210630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_af33a7aa-541a-4e04-b3cc-fa2d0a350f4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_7b43808f-673a-4c20-bbd3-d676ee2b2f19_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20210630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b46ddec-6ff3-48cd-b0fd-3e0c0aa7f0c6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_defc8515-ee34-4f7a-bd19-1f59d60b3d9a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7bd5347b-f7ac-4b32-abbe-7105ec018096_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9c819d3c-24d6-447b-85fb-d95af7bdcf4e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_07d41f08-4edb-4f9b-999f-6d33aef08f61_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_adc6f710-a6e4-49c8-94a5-6f0571189604_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_740b4d4a-9db4-4b1e-9b99-0392371f3128_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d95b0aa0-2297-488d-80c0-b6dc891fd676_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_a71b665e-cab3-4598-a315-c03bb40ecb6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:to="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9837cfb4-ca33-407b-a268-864d72beb27e_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_c1805488-e288-4d75-9fc4-035cf0148654_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2f027c66-b716-40b7-ac99-87629a659d45_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_08715d94-f9b6-4f21-a98a-ad61527bb7e1_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_f3f60880-065b-4da6-a6f1-be5d472cf467_terseLabel_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB-525</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_label_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S B Five Two Five [Member]</link:label>
    <link:label id="lab_sgmo_SBFiveTwoFiveMember_documentation_en-US" xlink:label="lab_sgmo_SBFiveTwoFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SB five two five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SBFiveTwoFiveMember" xlink:to="lab_sgmo_SBFiveTwoFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_919a621c-1cff-477a-a4f6-74c96845c536_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_bde994cf-66e2-4bd6-966d-cba57593fcdd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_a6f9fc1d-2109-40e9-bc71-5036079449b7_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7e1c6765-c15f-4b78-9d5c-370a945c9dd5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_d3b8cd63-50fb-4f3a-8de6-8fbacda8fea8_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, Gross Unrealized (Losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_c8ad9a32-2ca9-4ba4-baf4-db08b799c5c1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5f5a06c6-ab6d-46c7-8987-c5fa67e57706_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_ad2ea5b2-e273-4f17-a424-13a8fa161801_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_5d2cbd60-4f33-4839-8d4d-ec5648199a19_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3dfe3996-4ebc-4ffd-9902-cb90ba062f57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8bbc836a-55a9-426e-a397-68e011ea04b9_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_c0ca4a12-28c5-4f77-b1a4-2d366870a8cb_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20210630.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_c9e296bc-1819-4bb9-8a5b-c00242e61d54_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_42e7233b-3426-4397-a6dc-e3cba428d54d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_efb1fb28-9cf1-4cd0-b122-8a835b117ec9_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December 31, 2020</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_adc30d0a-5594-49aa-8347-973f8eddd08f_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June 30, 2021</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_a6ef52fa-3fe8-48c6-825d-1735ee517dc3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_8b0f3ea4-5d5e-4852-a7a8-11eed9f16d5b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_b2d386bb-4b7e-466d-bc3c-3fdfd35b8578_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_371dce91-20c3-4391-ad31-7465f2eab654_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated correlation between Sangamo and Sangamo France stock prices</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_5291ae28-33a8-487e-98b8-b1b06bfc48bc_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4f1b2dca-304c-4525-bddf-01624e91b66d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7791b4c0-f61e-40b8-a40a-cfaa7ce18b99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_9b350fbd-249b-4a8e-9672-10471eae4a1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_9cae6500-1413-41af-a818-7af9015db342_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20210630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_b62dc8dc-1097-4231-9ce1-c2a931b0ade7_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_3e08bd27-8ad4-4b64-98d4-d4108168014a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_b9ebcf2a-8dba-452a-b400-57534a6c3ea2_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>sgmo-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:2f9f5f51-e4f0-4167-bcfd-7f037d3e4640,g:f62f6950-7bc9-4d58-b99c-2ff6ec68cec0-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20210630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3a64b25a-1cf2-4453-9792-cb62616b8af1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentType_3a64b25a-1cf2-4453-9792-cb62616b8af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_cf72b415-a1d5-4d00-bf31-1de2e54497c5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentQuarterlyReport_cf72b415-a1d5-4d00-bf31-1de2e54497c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9dde53aa-1756-464c-8823-e2673b5a904b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentPeriodEndDate_9dde53aa-1756-464c-8823-e2673b5a904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7422e85d-b6ac-4368-af17-c1305633e0f0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentTransitionReport_7422e85d-b6ac-4368-af17-c1305633e0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_158b7f95-2802-42fc-a0a9-14189b721129" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityFileNumber_158b7f95-2802-42fc-a0a9-14189b721129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_84c98a67-792d-454a-a2f0-5f05603c2de3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityRegistrantName_84c98a67-792d-454a-a2f0-5f05603c2de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_807d7e3b-dde2-4480-a988-6af9e1d960f2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityIncorporationStateCountryCode_807d7e3b-dde2-4480-a988-6af9e1d960f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4aa029a2-012a-4e66-b6d8-fbbed3d2e78f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityTaxIdentificationNumber_4aa029a2-012a-4e66-b6d8-fbbed3d2e78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cdefe188-969a-43b3-8f92-4458bd8cd899" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityAddressAddressLine1_cdefe188-969a-43b3-8f92-4458bd8cd899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_222bc94c-854b-4689-b815-492684203453" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityAddressCityOrTown_222bc94c-854b-4689-b815-492684203453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3d8d463d-9e0c-4780-b354-bc18d326506d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityAddressStateOrProvince_3d8d463d-9e0c-4780-b354-bc18d326506d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_51594b29-2d66-4eec-a02b-5e2ed9370cb0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityAddressPostalZipCode_51594b29-2d66-4eec-a02b-5e2ed9370cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3e132ed7-8a47-425c-b343-ba976825f344" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_CityAreaCode_3e132ed7-8a47-425c-b343-ba976825f344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_96a6de6e-fa54-4e39-b0d3-dcd066d18e61" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_LocalPhoneNumber_96a6de6e-fa54-4e39-b0d3-dcd066d18e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_602260d3-2dc0-4539-bfea-ad89d9d36fc4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_Security12bTitle_602260d3-2dc0-4539-bfea-ad89d9d36fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4727497b-1057-4828-a025-748ef57f5b5d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_TradingSymbol_4727497b-1057-4828-a025-748ef57f5b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2305d1cf-c6c2-4c02-b0ec-c5a377582d8f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_SecurityExchangeName_2305d1cf-c6c2-4c02-b0ec-c5a377582d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_01ba19b4-8374-4ca6-bb61-b7b12980d87e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityCurrentReportingStatus_01ba19b4-8374-4ca6-bb61-b7b12980d87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e0fe18d8-a0a6-4884-8545-a39cfa5dca54" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityInteractiveDataCurrent_e0fe18d8-a0a6-4884-8545-a39cfa5dca54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_272631c7-c9cb-4c7d-8dd6-bde7f9e74027" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityFilerCategory_272631c7-c9cb-4c7d-8dd6-bde7f9e74027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1ee6c543-508b-4542-9104-92b9f4f33565" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntitySmallBusiness_1ee6c543-508b-4542-9104-92b9f4f33565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_830898df-6a26-4460-95e8-49841ea38382" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityEmergingGrowthCompany_830898df-6a26-4460-95e8-49841ea38382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d6cf6123-1ff5-40a8-a809-6b1f9b7c91f4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityShellCompany_d6cf6123-1ff5-40a8-a809-6b1f9b7c91f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ee9d8849-559b-44af-9ac7-0f1bcd858973" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ee9d8849-559b-44af-9ac7-0f1bcd858973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0872e41f-a188-411b-b156-8709c687baed" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_AmendmentFlag_0872e41f-a188-411b-b156-8709c687baed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e9dd8d8a-08bf-4b88-a0f3-e9ed31aa5fa5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentFiscalYearFocus_e9dd8d8a-08bf-4b88-a0f3-e9ed31aa5fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c2bd7f82-b813-4db7-9471-fe32acce97a6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c2bd7f82-b813-4db7-9471-fe32acce97a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4403e4c7-d67b-4db4-b92d-6f1c1d32020e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_EntityCentralIndexKey_4403e4c7-d67b-4db4-b92d-6f1c1d32020e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_af76fa5a-4f5b-44c1-a978-c63032037cac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_119d92db-f909-4864-adae-15383a040aaf" xlink:to="loc_dei_CurrentFiscalYearEndDate_af76fa5a-4f5b-44c1-a978-c63032037cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ac699a85-eae2-4cae-9827-77222d84c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ac699a85-eae2-4cae-9827-77222d84c1ab" xlink:to="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b3f411a-07c0-46c6-b7a0-6d71de143c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2b3f411a-07c0-46c6-b7a0-6d71de143c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_09f3b916-7975-4dce-afda-74c6b4a2227b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_09f3b916-7975-4dce-afda-74c6b4a2227b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_af367f65-bcda-4ea5-9b25-fe6855b7a5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_InterestReceivableCurrent_af367f65-bcda-4ea5-9b25-fe6855b7a5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d2d19d64-c1e1-4c98-83d8-ddf973293bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d2d19d64-c1e1-4c98-83d8-ddf973293bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d3fd9314-a077-444f-b41a-4402e7d67c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d3fd9314-a077-444f-b41a-4402e7d67c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f7861c43-8f40-43cd-b90d-8c35425dd85d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e1d1d860-7796-4d5b-888f-96c028f23fdf" xlink:to="loc_us-gaap_AssetsCurrent_f7861c43-8f40-43cd-b90d-8c35425dd85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d960ba65-f341-4ccc-ad5a-12717bf8185a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_d960ba65-f341-4ccc-ad5a-12717bf8185a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a3bce4d-ca3b-459c-8820-2e20e3b72196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5a3bce4d-ca3b-459c-8820-2e20e3b72196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b58ef9a0-333c-42e4-8182-111ca115fb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b58ef9a0-333c-42e4-8182-111ca115fb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_42b554ac-80d9-477d-845e-dc3c09c5b87b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_Goodwill_42b554ac-80d9-477d-845e-dc3c09c5b87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8f7825f-f16c-4f72-9c3d-16421e75c132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f8f7825f-f16c-4f72-9c3d-16421e75c132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_04cc490c-2ce6-4ff6-abbd-f70ffab3b250" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_04cc490c-2ce6-4ff6-abbd-f70ffab3b250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_cd605bb7-08ee-44ba-a14f-b9537b921285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_cd605bb7-08ee-44ba-a14f-b9537b921285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_387b280a-a145-4c10-b339-c0411f3dea9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d37f900d-d2c3-46c9-8a3d-a94c8b3a89e3" xlink:to="loc_us-gaap_Assets_387b280a-a145-4c10-b339-c0411f3dea9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ac699a85-eae2-4cae-9827-77222d84c1ab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_daed172e-86e7-42dc-8275-34ef6c2122e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:to="loc_us-gaap_AccountsPayableCurrent_daed172e-86e7-42dc-8275-34ef6c2122e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ece0d4b0-2dc3-4fe4-a11f-396b3675b617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_ece0d4b0-2dc3-4fe4-a11f-396b3675b617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d9f22d3f-ef2c-4e3f-93c2-fd4cf3164f69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d9f22d3f-ef2c-4e3f-93c2-fd4cf3164f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fdc765be-ff3e-4865-aba4-59c732038334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_fdc765be-ff3e-4865-aba4-59c732038334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_897424f8-4f68-4309-8e86-8e319bc76c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_759dcd9a-d5de-4bda-98f1-4b6c12d97e4d" xlink:to="loc_us-gaap_LiabilitiesCurrent_897424f8-4f68-4309-8e86-8e319bc76c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b656220b-c602-40a2-a3a2-538b4b67775f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b656220b-c602-40a2-a3a2-538b4b67775f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d65189bc-c336-4a0d-976c-2c70a63106fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d65189bc-c336-4a0d-976c-2c70a63106fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_84626099-87c0-4765-ad7d-c71df36f0b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_84626099-87c0-4765-ad7d-c71df36f0b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9c5d2329-79eb-4b37-988a-511cad5376c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9c5d2329-79eb-4b37-988a-511cad5376c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c57bfaf8-5917-4741-9530-6f70d8a18c80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_Liabilities_c57bfaf8-5917-4741-9530-6f70d8a18c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0c5c86c6-2624-4d25-9a15-09076da865f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0c5c86c6-2624-4d25-9a15-09076da865f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c122c5a7-4019-46bc-b5b3-03d546ee8858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_PreferredStockValue_c122c5a7-4019-46bc-b5b3-03d546ee8858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_23869e3b-06c2-450e-ab28-bebe73df0ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_CommonStockValue_23869e3b-06c2-450e-ab28-bebe73df0ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_164b7bf6-6101-4f0a-96d1-6f2fdb028153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_164b7bf6-6101-4f0a-96d1-6f2fdb028153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_917d19e5-4016-4664-9d89-2a115628d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_917d19e5-4016-4664-9d89-2a115628d0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e77bda70-2fb4-4798-9f2a-4c87499f51ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e77bda70-2fb4-4798-9f2a-4c87499f51ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_580ecae4-fe4b-42b8-ab8a-adec1243f6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_StockholdersEquity_580ecae4-fe4b-42b8-ab8a-adec1243f6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6654c3c1-8ebc-47d3-8328-643d9c0ff987" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_MinorityInterest_6654c3c1-8ebc-47d3-8328-643d9c0ff987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f3e7227-7d92-44ed-a6e4-7938af3550cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3f16c9e2-7c9e-4cf9-9ad3-00a32e14d4f5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0f3e7227-7d92-44ed-a6e4-7938af3550cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6393686d-de05-4300-8b02-adc0bda5da7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c478923-4468-46e2-be0d-111321b6b853" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6393686d-de05-4300-8b02-adc0bda5da7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5a840fc-5e30-4011-be8c-22e1bb92076e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a5a840fc-5e30-4011-be8c-22e1bb92076e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1ec04798-0f4b-4c16-b65a-a14956a6a677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1ec04798-0f4b-4c16-b65a-a14956a6a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ab3039f8-11fe-42ba-92f0-36197654f4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ec04798-0f4b-4c16-b65a-a14956a6a677" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ab3039f8-11fe-42ba-92f0-36197654f4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f70360ae-244d-4a16-8b9d-dbbd8242a966" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ec04798-0f4b-4c16-b65a-a14956a6a677" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f70360ae-244d-4a16-8b9d-dbbd8242a966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_09154752-6f4d-4d2d-abb8-2cc64edd5bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1ec04798-0f4b-4c16-b65a-a14956a6a677" xlink:to="loc_us-gaap_OperatingExpenses_09154752-6f4d-4d2d-abb8-2cc64edd5bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c5bc442-f5e0-4c94-b96d-475b2f471c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_OperatingIncomeLoss_4c5bc442-f5e0-4c94-b96d-475b2f471c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_342ef231-6687-4702-bdb1-022cd7305cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_InterestAndOtherIncome_342ef231-6687-4702-bdb1-022cd7305cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4b07fa66-19b5-483c-89b9-fea649619e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest_4b07fa66-19b5-483c-89b9-fea649619e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8cf3194f-d16b-4bff-9a9a-6d080e48a1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8cf3194f-d16b-4bff-9a9a-6d080e48a1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1366b6df-6edc-4a58-ab30-b1cdccad57d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_ProfitLoss_1366b6df-6edc-4a58-ab30-b1cdccad57d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e559c43b-9351-40a5-b104-c97366e782a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e559c43b-9351-40a5-b104-c97366e782a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7f62562d-9bed-4c2c-99b1-5330b475f99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_NetIncomeLoss_7f62562d-9bed-4c2c-99b1-5330b475f99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_762de3e4-bbc3-45c6-8383-f268aa5a9c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_EarningsPerShareBasic_762de3e4-bbc3-45c6-8383-f268aa5a9c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4994221e-7abf-4ddb-9e0c-4183f5be1ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4994221e-7abf-4ddb-9e0c-4183f5be1ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a50e3645-bb7f-4fa8-9988-fc7fbef0898c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a50e3645-bb7f-4fa8-9988-fc7fbef0898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0174db5-8352-48ce-8d2f-0d513e634f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9289ccf6-4f03-4928-a183-8f2b0e7e48a6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a0174db5-8352-48ce-8d2f-0d513e634f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_94d85603-22be-4c6b-917c-a2d6d1c2b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_ProfitLoss_94d85603-22be-4c6b-917c-a2d6d1c2b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85596abf-e3e9-4af3-a085-2224d55aac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_85596abf-e3e9-4af3-a085-2224d55aac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48db0c13-3858-4bca-8690-daf39376ea0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_48db0c13-3858-4bca-8690-daf39376ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d237587b-e12e-4055-935d-eeeba50ba121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d237587b-e12e-4055-935d-eeeba50ba121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3400234b-71ba-4663-897b-81b8f5aa5a12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_3400234b-71ba-4663-897b-81b8f5aa5a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_703bd81c-6214-4e66-a856-48d3c889ba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_e4f7c45b-d9e4-4ab5-94bb-bbe88224b36a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_703bd81c-6214-4e66-a856-48d3c889ba7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_643ac9c4-16cc-4bbe-8a99-a89ad2309c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_643ac9c4-16cc-4bbe-8a99-a89ad2309c03" xlink:to="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551895a8-8b89-4b5a-847f-038bce983730" xlink:to="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0b1c8231-7eb0-4fe6-af8e-3dccdf247b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_CommonStockMember_0b1c8231-7eb0-4fe6-af8e-3dccdf247b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7458f5fe-9bf0-4888-9146-d450a5f0f448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7458f5fe-9bf0-4888-9146-d450a5f0f448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_370ff02f-87a6-482d-a02d-5b51bacb2b22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_RetainedEarningsMember_370ff02f-87a6-482d-a02d-5b51bacb2b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181acc-c1f2-4ba2-9f55-d91a8550c42b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fb181acc-c1f2-4ba2-9f55-d91a8550c42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_7304e122-d665-4c82-b3d6-8bc949f6497a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f896170d-153d-4ca2-929b-f7a2ce8188ff" xlink:to="loc_us-gaap_NoncontrollingInterestMember_7304e122-d665-4c82-b3d6-8bc949f6497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8befa1db-ebc1-4169-9d0b-e5a9cbb14a81" xlink:to="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71a3c7c9-739b-4a7f-b665-cb4afc984b32" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_46fd9205-94ab-495c-8ae0-d77814687edc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_CommonStockSharesIssued_46fd9205-94ab-495c-8ae0-d77814687edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f523f5f3-f206-4599-9696-15faff9d803a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f523f5f3-f206-4599-9696-15faff9d803a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_303733ee-3db1-48fa-b2b5-3d38d5f0ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_303733ee-3db1-48fa-b2b5-3d38d5f0ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5fb0990-88a9-4107-8e95-440d3aac5dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d5fb0990-88a9-4107-8e95-440d3aac5dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2de78502-62e7-460b-ae3a-2548a07e0be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2de78502-62e7-460b-ae3a-2548a07e0be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cceb0c3b-aaed-4cb2-aeeb-edf9d6fc8563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cceb0c3b-aaed-4cb2-aeeb-edf9d6fc8563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_103aa891-854c-4360-bac4-bd07022b7506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_103aa891-854c-4360-bac4-bd07022b7506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d2f67e3e-76eb-4c10-bc44-0d2cf85154b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_d2f67e3e-76eb-4c10-bc44-0d2cf85154b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8f925810-61fc-4f85-b778-6b9f3a10ac66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8f925810-61fc-4f85-b778-6b9f3a10ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_2840dbad-12c1-48b8-acfd-a5b2d36cd5be" xlink:href="sgmo-20210630.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_2840dbad-12c1-48b8-acfd-a5b2d36cd5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cce313df-659b-45ef-8ffc-23c67442439e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_cce313df-659b-45ef-8ffc-23c67442439e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_40f9af20-c070-46ee-a948-bbef88595dae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_40f9af20-c070-46ee-a948-bbef88595dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_87e0f008-966e-483c-b0cc-14713b0313ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_87e0f008-966e-483c-b0cc-14713b0313ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4e84b5c7-f179-439d-85ba-5b5c58cd4fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_ProfitLoss_4e84b5c7-f179-439d-85ba-5b5c58cd4fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_910bacbc-6e3d-4a00-ab3a-1bd5d183b8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_CommonStockSharesIssued_910bacbc-6e3d-4a00-ab3a-1bd5d183b8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59f86f7d-053b-4a8c-9cc5-c66849a32ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_da41b353-2412-4643-babd-a222b26f910f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59f86f7d-053b-4a8c-9cc5-c66849a32ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c5880a98-0471-4abb-9446-c146037bfa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:to="loc_us-gaap_ProfitLoss_c5880a98-0471-4abb-9446-c146037bfa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92045c1c-0394-4579-90e4-3447c6731558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92045c1c-0394-4579-90e4-3447c6731558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_896f79d3-122a-4c3f-a341-39dfa1c1a2a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_896f79d3-122a-4c3f-a341-39dfa1c1a2a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_08c89d20-d0fe-4cd7-9773-69d863716fa6" xlink:href="sgmo-20210630.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_08c89d20-d0fe-4cd7-9773-69d863716fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainLossOnFreeShares_be181d30-609f-43a2-b2fb-fe4de1deeffb" xlink:href="sgmo-20210630.xsd#sgmo_GainLossOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:to="loc_sgmo_GainLossOnFreeShares_be181d30-609f-43a2-b2fb-fe4de1deeffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_23a6dee2-990c-4e2e-9162-65ef6307e3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b223ce98-e07b-43d9-b8e9-2852d8ff1047" xlink:to="loc_us-gaap_ShareBasedCompensation_23a6dee2-990c-4e2e-9162-65ef6307e3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_8e2fcb97-2826-4d7b-8f27-440018c56b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_8e2fcb97-2826-4d7b-8f27-440018c56b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc97867b-0467-4d2b-b3df-7eead546992f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dc97867b-0467-4d2b-b3df-7eead546992f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc5e18d8-352a-4f40-b86c-58a4745682a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc5e18d8-352a-4f40-b86c-58a4745682a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6d5f1252-9b07-4822-bf65-cf803d65d76a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_6d5f1252-9b07-4822-bf65-cf803d65d76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_562a43bf-2469-428b-9dd2-566b7473c7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_562a43bf-2469-428b-9dd2-566b7473c7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_42e45376-4277-41ab-a91c-5f0f6eab32d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_42e45376-4277-41ab-a91c-5f0f6eab32d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_67540936-165b-4684-91ed-b8a1644e61d2" xlink:href="sgmo-20210630.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_67540936-165b-4684-91ed-b8a1644e61d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fb6227c8-a959-4dda-875b-3e49a9909474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83a5a966-e259-4230-b69d-5f63af1754a3" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_fb6227c8-a959-4dda-875b-3e49a9909474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab52c1bd-e963-4e04-87e1-448cae89dadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40670914-70d4-4058-871f-1bb7865199cc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab52c1bd-e963-4e04-87e1-448cae89dadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a866b2fe-4ae1-4564-a4ac-3254d3c0057e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_a866b2fe-4ae1-4564-a4ac-3254d3c0057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0fc91091-972c-49db-8cfb-ca4781a6da43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities_0fc91091-972c-49db-8cfb-ca4781a6da43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ce949286-d3a1-4f5d-b6bf-492a8d8bd003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities_ce949286-d3a1-4f5d-b6bf-492a8d8bd003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_50c14cb6-bcf0-430a-aa89-db65a6a581fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_50c14cb6-bcf0-430a-aa89-db65a6a581fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ae3361dc-760f-4f29-a789-e8e05411598a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_ae3361dc-760f-4f29-a789-e8e05411598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_691590f9-a86f-4902-8736-34af5b1b935c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_cfdf5fa0-b475-43c4-84a1-6be755de4cb0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_691590f9-a86f-4902-8736-34af5b1b935c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromAtTheMarketOffering_b292418d-8028-4743-8ef6-362da9d9ab3a" xlink:href="sgmo-20210630.xsd#sgmo_NetProceedsFromAtTheMarketOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_sgmo_NetProceedsFromAtTheMarketOffering_b292418d-8028-4743-8ef6-362da9d9ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_eda7d51d-7e88-43d7-845a-fe8993af619e" xlink:href="sgmo-20210630.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_eda7d51d-7e88-43d7-845a-fe8993af619e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6cb5b18-6902-4a99-8f6c-285bd4038dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d6cb5b18-6902-4a99-8f6c-285bd4038dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_60e1e07a-7a3c-4dc7-a06a-5e250e82461d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_60e1e07a-7a3c-4dc7-a06a-5e250e82461d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_460ce4cd-472a-4902-8969-b5f0edfa75da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_460ce4cd-472a-4902-8969-b5f0edfa75da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc151782-a24e-4356-9419-49c3d6167cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40ce2d6f-e901-48af-a4ed-9f4198b4c6a9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cc151782-a24e-4356-9419-49c3d6167cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01c19efe-52f6-4b0f-ab98-0f6182e10a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_01c19efe-52f6-4b0f-ab98-0f6182e10a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_330f4e54-d9f5-43cd-b77d-3a4facecb707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_330f4e54-d9f5-43cd-b77d-3a4facecb707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daffd2e2-6b26-4e3b-9064-33c848f3275b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_daffd2e2-6b26-4e3b-9064-33c848f3275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a40072ea-c9b4-49ab-adff-0a320b13eaec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a40072ea-c9b4-49ab-adff-0a320b13eaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c840cf14-55c4-4518-84a3-ae44593c22c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1ca46571-5b22-4438-ab3a-35f20394fc31" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c840cf14-55c4-4518-84a3-ae44593c22c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0e116e45-674d-4a28-9ce1-ec627053a42a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c840cf14-55c4-4518-84a3-ae44593c22c2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0e116e45-674d-4a28-9ce1-ec627053a42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37ea88dd-fd2e-424d-aeb3-ba716296b29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c840cf14-55c4-4518-84a3-ae44593c22c2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_37ea88dd-fd2e-424d-aeb3-ba716296b29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_bbf38d98-5a95-47b0-9f11-e24bb9557487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_c840cf14-55c4-4518-84a3-ae44593c22c2" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_bbf38d98-5a95-47b0-9f11-e24bb9557487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fe129522-6be6-409a-9f14-c95513119727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4e6fbcdb-b2a6-445a-92f3-7bc4ec2c3625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fe129522-6be6-409a-9f14-c95513119727" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_4e6fbcdb-b2a6-445a-92f3-7bc4ec2c3625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cd848fc-4129-4ed4-b8dc-0aea53888211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0cd848fc-4129-4ed4-b8dc-0aea53888211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e06b16ee-a0c5-4313-8201-535550c8e9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_UseOfEstimates_e06b16ee-a0c5-4313-8201-535550c8e9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0b504c9e-aa6b-446e-9118-85a179f87462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0b504c9e-aa6b-446e-9118-85a179f87462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_b03eedeb-3645-46d9-8de6-318d82cf2b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_b03eedeb-3645-46d9-8de6-318d82cf2b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_846edf51-13ff-4518-979f-6160d0507ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_846edf51-13ff-4518-979f-6160d0507ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ab66e0c1-3e26-49b5-9293-87a2aed43122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ab66e0c1-3e26-49b5-9293-87a2aed43122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_795ecc90-9b87-47d7-be1b-33be2e7b09ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_795ecc90-9b87-47d7-be1b-33be2e7b09ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7d77b6d2-528b-48c8-bc0e-4f8bed748ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7d77b6d2-528b-48c8-bc0e-4f8bed748ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_0e7cbc23-e252-45ae-bc48-15e63c279763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_0e7cbc23-e252-45ae-bc48-15e63c279763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_17dde90f-b304-4dfd-a271-e02bd00e0b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_17dde90f-b304-4dfd-a271-e02bd00e0b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d7c43f14-6f9e-4dcb-babb-931df3dd8fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d7c43f14-6f9e-4dcb-babb-931df3dd8fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_abccb9d3-f50f-4020-af25-8e66e38802b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_abccb9d3-f50f-4020-af25-8e66e38802b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b2a8a7de-c6b1-4edb-8f7a-bd83c3bb7402" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30d9635b-d914-43ce-8941-e54cb04d3e1f" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b2a8a7de-c6b1-4edb-8f7a-bd83c3bb7402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_eced22f2-6353-4b2b-be95-dc01395d10a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_4eac71f4-e2c6-4129-95fb-eac30731dfa6" xlink:href="sgmo-20210630.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eced22f2-6353-4b2b-be95-dc01395d10a0" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_4eac71f4-e2c6-4129-95fb-eac30731dfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_21e06f0e-90dd-4a99-9531-cd6f47d29965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eced22f2-6353-4b2b-be95-dc01395d10a0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_21e06f0e-90dd-4a99-9531-cd6f47d29965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_41cc5b38-e030-49e0-b384-a2f99a3310dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_eced22f2-6353-4b2b-be95-dc01395d10a0" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_41cc5b38-e030-49e0-b384-a2f99a3310dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc3ec5df-7b99-4b88-a471-7cc58c520b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fc3ec5df-7b99-4b88-a471-7cc58c520b08" xlink:to="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_657c52f0-6005-4bcb-bcae-4b2c9a45fce4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_32759412-da91-465c-94ad-2cbde930b5cf" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_BiogenMAIncMember_32759412-da91-465c-94ad-2cbde930b5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a5abe495-bae0-4ff9-b82e-6051959086c5" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_a5abe495-bae0-4ff9-b82e-6051959086c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_cf0da4e4-4fc3-4a8c-b644-6c68a0568d25" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_KitePharmaIncMember_cf0da4e4-4fc3-4a8c-b644-6c68a0568d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_196f19e7-39d3-4e72-b23b-ce602c92874a" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_SanofiMember_196f19e7-39d3-4e72-b23b-ce602c92874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_7585a187-e371-4182-8781-f2553589179a" xlink:href="sgmo-20210630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc881ea-f4a5-4771-8af6-dc9775af79a2" xlink:to="loc_sgmo_PfizerMember_7585a187-e371-4182-8781-f2553589179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7ee0e52b-0e6c-476d-829a-d99d39d09d63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_52ef9499-b259-43dd-8e3d-96c3724f21b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5d1d166-c08e-4ddc-9e8c-5f0cc9cb16ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_52ef9499-b259-43dd-8e3d-96c3724f21b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2c68ab27-2098-4007-9eed-db1e6b46bafa" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_9ea6bf77-da2d-4a21-bba4-f58dcf77b7d3" xlink:href="sgmo-20210630.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f02ab74c-bd81-419b-883c-252f00d16e86" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_9ea6bf77-da2d-4a21-bba4-f58dcf77b7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_bdaf3f53-9368-4fc1-a8a2-02d58add2db7" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_53ad60aa-e4ed-4ffc-8fbf-4e93be08ebfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7a91ee2e-a890-48d6-b183-96d81a427d1e" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_53ad60aa-e4ed-4ffc-8fbf-4e93be08ebfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ca53306b-b6d7-4b5e-9875-902dc175f5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ca53306b-b6d7-4b5e-9875-902dc175f5fe" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_15dd3bd9-25a4-4fc0-b9f1-bca32ef56bf4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_217b2c42-873c-480f-80a4-5ad0c53a52df" xlink:href="sgmo-20210630.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e40f7d1f-47c8-4ca3-899d-414009f4e92c" xlink:to="loc_sgmo_PfizerSB525Member_217b2c42-873c-480f-80a4-5ad0c53a52df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_a942fad9-fb9c-48f3-aeaa-dde1d033cf1c" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5fc56e15-972c-4593-984b-251395ee3214" xlink:href="sgmo-20210630.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d253d4b4-a6a7-47ea-ba3c-0ff342de0eb3" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_5fc56e15-972c-4593-984b-251395ee3214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15053376-109d-451a-be0f-84fec8bad7a3" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_0297cece-7fce-4d40-a2ef-9d9b11792b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e00821f-12d2-44fc-9432-499c1361ec3b" xlink:to="loc_us-gaap_CollaborativeArrangementMember_0297cece-7fce-4d40-a2ef-9d9b11792b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_d3edf8fb-873b-426d-a119-b0ec5b9aefa1" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a27e0965-16ac-432c-8711-fe0ca04edf22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a27e0965-16ac-432c-8711-fe0ca04edf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2b3c7af7-884e-4b96-aa8b-567eb704e7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_ProfitLoss_2b3c7af7-884e-4b96-aa8b-567eb704e7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_10db8b19-e3f0-4727-ac02-7b89de12995f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_EarningsPerShareBasic_10db8b19-e3f0-4727-ac02-7b89de12995f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e23dc94e-ab08-4c4f-952e-60d2c3cb852f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_e23dc94e-ab08-4c4f-952e-60d2c3cb852f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cab28229-2d91-4db6-88c8-d5709e92138c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_cab28229-2d91-4db6-88c8-d5709e92138c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_8d2788d2-047f-48d1-be33-24b59e8c1d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_5874195c-f6c2-4a45-b703-8bfc7945ffe2" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_8d2788d2-047f-48d1-be33-24b59e8c1d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6371ec14-68bb-4136-8dbb-b3fae5250c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86c17af0-b4cb-4e5f-a7ee-e49b57f66728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6371ec14-68bb-4136-8dbb-b3fae5250c39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_86c17af0-b4cb-4e5f-a7ee-e49b57f66728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_24f2cbf5-c80f-4a7e-9b4e-3c8c888cbd20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6371ec14-68bb-4136-8dbb-b3fae5250c39" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_24f2cbf5-c80f-4a7e-9b4e-3c8c888cbd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcc76ab4-0115-42b2-95f0-f3acfa7a7a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6371ec14-68bb-4136-8dbb-b3fae5250c39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fcc76ab4-0115-42b2-95f0-f3acfa7a7a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f27b5b76-7046-45e4-8657-995e1c9ee054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1194efb2-a459-43b0-a06a-f0b42d504a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f27b5b76-7046-45e4-8657-995e1c9ee054" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1194efb2-a459-43b0-a06a-f0b42d504a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_65d33345-ec7c-425c-91cf-e7bfdc6123ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e143da72-a6e6-4dda-b51d-3c1fcbc13599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65d33345-ec7c-425c-91cf-e7bfdc6123ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_e143da72-a6e6-4dda-b51d-3c1fcbc13599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ad14e66f-90df-43d1-9acb-98e67cff8468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_65d33345-ec7c-425c-91cf-e7bfdc6123ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ad14e66f-90df-43d1-9acb-98e67cff8468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_04df3808-d1db-4000-82db-e08cecd0cb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_04df3808-d1db-4000-82db-e08cecd0cb40" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b4f6a34a-ee23-4751-8285-3dd53e4bff59" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b438bf97-1793-4366-90fb-46538cc7b920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af13f01b-329a-4095-85ad-165f960452cd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b438bf97-1793-4366-90fb-46538cc7b920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaa4427d-4660-4a10-82e9-9f6a687c708f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bc0f8909-a3e5-4489-a4e6-c747801db65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bc0f8909-a3e5-4489-a4e6-c747801db65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_896dbea0-2073-4d9a-8ea0-71629959b943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_896dbea0-2073-4d9a-8ea0-71629959b943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6701eacc-c789-453b-8884-cf0f819ca2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e1d00ca-1da3-4ba5-9d88-5e5be0e60cf4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6701eacc-c789-453b-8884-cf0f819ca2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_bd2c357c-5ab2-4b2e-a811-c14d8f06746c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b3e4cf28-289d-4fb0-92f7-6e040822b96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b3e4cf28-289d-4fb0-92f7-6e040822b96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6b80a42e-b072-4043-8823-51d4eb5a640c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_6b80a42e-b072-4043-8823-51d4eb5a640c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_f66a3f67-6891-492e-8b33-1064e7384cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CommercialPaperMember_f66a3f67-6891-492e-8b33-1064e7384cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_20c68519-f861-4257-b168-6cc4c7aad9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_20c68519-f861-4257-b168-6cc4c7aad9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_a2a60dba-7a24-42a7-a452-7af38fbee1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_a2a60dba-7a24-42a7-a452-7af38fbee1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_7f07c495-b6ea-4a3e-9841-0c0b3a834cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_us-gaap_CertificatesOfDepositMember_7f07c495-b6ea-4a3e-9841-0c0b3a834cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_611a8037-9c34-498a-8216-ec58d5ac8e09" xlink:href="sgmo-20210630.xsd#sgmo_FreeSharesAssetMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3efbc1a-589b-4272-8239-b9099a815968" xlink:to="loc_sgmo_FreeSharesAssetMember_611a8037-9c34-498a-8216-ec58d5ac8e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_93d2b248-56cf-40ae-971a-296c1c32437a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f97feae8-87b8-4cd0-89d3-815926210697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f97feae8-87b8-4cd0-89d3-815926210697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07a22dd9-867c-48b7-936c-12fdb1ec1138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_07a22dd9-867c-48b7-936c-12fdb1ec1138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8631378c-0e08-4c6a-a275-aba1533bd378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6560ecab-b8a0-4925-9e75-275ed224263f" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8631378c-0e08-4c6a-a275-aba1533bd378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_effd65e5-927d-4261-a355-814113378627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_effd65e5-927d-4261-a355-814113378627" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_190f7d60-4a17-4631-a39c-f765e4a5c5f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_9b5c3a83-5f78-4f17-aff8-946d263d2115" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2d6d13e2-78b2-4d0d-ae0b-fd7ce5ee5a91" xlink:to="loc_sgmo_SangamoFranceMember_9b5c3a83-5f78-4f17-aff8-946d263d2115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7c83d539-9401-43db-9df1-cab2620e3c9f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_4698f5c2-af30-4cdb-933e-d2921838b3d6" xlink:href="sgmo-20210630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0c97cebf-7ea4-4bec-b654-c6979c0d94ab" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_4698f5c2-af30-4cdb-933e-d2921838b3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_cc2ba4cf-a380-4a07-9158-a8426b6047bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_27a6fa8c-a818-4dd6-936f-c218af2dbbbb" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_27a6fa8c-a818-4dd6-936f-c218af2dbbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_eb49e261-6a8d-445f-a9c0-9042f43cf5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_eb49e261-6a8d-445f-a9c0-9042f43cf5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_76456d30-b87b-4ffa-8ffb-945e649d549a" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_76456d30-b87b-4ffa-8ffb-945e649d549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_ed454d55-5db5-431e-827d-dd1371355c0f" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_816fcef6-c70b-4c7e-b0bf-43a806a1bafc" xlink:to="loc_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset_ed454d55-5db5-431e-827d-dd1371355c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a5416a7-3159-4e53-9e36-bb2ff511c09c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a5416a7-3159-4e53-9e36-bb2ff511c09c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_04b730ac-3051-4c0a-a736-612d60b31a5a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_8b80b1e6-92e6-4d43-99b8-5073cc948adb" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6aa1b6b2-2b7f-49e2-ba64-ca73054a7f39" xlink:to="loc_sgmo_SangamoFranceMember_8b80b1e6-92e6-4d43-99b8-5073cc948adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_bce93245-442d-47ae-afdf-5bec464156c3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_3599b985-52b5-4679-bcca-243ff272c4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_3599b985-52b5-4679-bcca-243ff272c4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputExchangeRateMember_0048af1f-8c69-4e1c-883b-70862740a454" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputExchangeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_sgmo_MeasurementInputExchangeRateMember_0048af1f-8c69-4e1c-883b-70862740a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ec96451b-e989-490c-b423-57d8fea469d1" xlink:href="sgmo-20210630.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_ec96451b-e989-490c-b423-57d8fea469d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_4bede3e4-e4d7-42ae-987e-cd49254630c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_4bede3e4-e4d7-42ae-987e-cd49254630c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_465440ac-bafb-4bc9-922e-2e1519d9a73f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de5e3b9e-6dd9-4152-b463-d22dae9225de" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_465440ac-bafb-4bc9-922e-2e1519d9a73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_332e7de4-ae4c-407d-b95a-fa52f1c4b5b2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_866388ec-f790-49a1-92e2-f3158dd723e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_SharePrice_866388ec-f790-49a1-92e2-f3158dd723e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_72710416-e364-408c-88f8-9008e6d812ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_72710416-e364-408c-88f8-9008e6d812ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_daa6e0b1-c964-48dc-bf0f-90dbace78cef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_daa6e0b1-c964-48dc-bf0f-90dbace78cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_82fa6080-6ae0-4aa2-98b2-4ec3c48df2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_82fa6080-6ae0-4aa2-98b2-4ec3c48df2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_2be28856-41b9-4afc-bde0-9b935452910c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_d1c486a1-7c88-4b56-9063-42551f37b990" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_2be28856-41b9-4afc-bde0-9b935452910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6bfa4f9d-bddd-4873-aed4-7dbbb802c38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7461cb20-fc95-4e8b-b356-02d7b029ab12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6bfa4f9d-bddd-4873-aed4-7dbbb802c38b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_7461cb20-fc95-4e8b-b356-02d7b029ab12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea4c5079-454e-4b62-8ff6-1183d3bf5a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_0604b776-0b2e-4564-9e35-ade287547cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea4c5079-454e-4b62-8ff6-1183d3bf5a03" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_0604b776-0b2e-4564-9e35-ade287547cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a090f2f1-7e21-4e66-a318-5208951d792c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ea4c5079-454e-4b62-8ff6-1183d3bf5a03" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_a090f2f1-7e21-4e66-a318-5208951d792c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66cca5b9-f169-4d15-832a-9c4c7bd323d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_66cca5b9-f169-4d15-832a-9c4c7bd323d7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_e251c8e8-7316-4e82-b277-9c0ce1efd0dc" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5056dc07-b7a2-4889-b4e3-89e7f5568c25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5056dc07-b7a2-4889-b4e3-89e7f5568c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_a42d5c39-a441-497a-900d-dfead2e21c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CashEquivalentsMember_a42d5c39-a441-497a-900d-dfead2e21c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c85f4d68-bcd5-4ca1-8880-122cdc9028ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c85f4d68-bcd5-4ca1-8880-122cdc9028ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_18c09472-00fc-4f85-8e5f-9630db825606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CommercialPaperMember_18c09472-00fc-4f85-8e5f-9630db825606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_a4ade550-6767-4d3e-9ba6-0bc51627fb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_a4ade550-6767-4d3e-9ba6-0bc51627fb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c2550e63-e2e6-467f-9261-efc9a1937b53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c2550e63-e2e6-467f-9261-efc9a1937b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a9efce9a-e73b-4f81-80d2-e81ac6c81869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bd494142-3ea6-48df-b6fe-1b11fdeca5bd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a9efce9a-e73b-4f81-80d2-e81ac6c81869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_42eef427-623e-4341-9786-d6c1308b210f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c892edab-80ec-443c-be15-780330eb9e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c892edab-80ec-443c-be15-780330eb9e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e4644d6c-f1c0-46c1-9843-a9bc58f0ef4e" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax_e4644d6c-f1c0-46c1-9843-a9bc58f0ef4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6902a826-396c-4601-8b85-937718c1e643" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax_6902a826-396c-4601-8b85-937718c1e643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f19017-146e-45dd-8822-3b12aa2c3b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7f19017-146e-45dd-8822-3b12aa2c3b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8514bb25-09b9-4861-be54-4846b43b89c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8514bb25-09b9-4861-be54-4846b43b89c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11c0bcc4-e304-4ab0-a791-a810464e4340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_11c0bcc4-e304-4ab0-a791-a810464e4340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5a328e4-cded-4fce-9b79-5765e7ebd999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d5a328e4-cded-4fce-9b79-5765e7ebd999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_589e83e4-b3a7-4cdd-bbdb-5f02f2cf21cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_70d9b5ea-fee7-4a70-8d36-f2284a1a16fe" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_589e83e4-b3a7-4cdd-bbdb-5f02f2cf21cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_a68a2204-360e-4172-b1be-27901f58091a" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_a68a2204-360e-4172-b1be-27901f58091a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8e095d31-74fa-42d9-861d-64d0ddb08a10" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_8e095d31-74fa-42d9-861d-64d0ddb08a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2bca07d0-7659-4938-8f69-eeff0c88a23c" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_2bca07d0-7659-4938-8f69-eeff0c88a23c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_18143e1a-0cfd-4e82-a991-89de94da9ac5" xlink:href="sgmo-20210630.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c2184dea-f179-473a-a819-891dc274aec0" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_18143e1a-0cfd-4e82-a991-89de94da9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_147194f3-3366-4295-a00a-cdfdec847511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9f813f3e-95d1-4d57-8197-f6603209dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_147194f3-3366-4295-a00a-cdfdec847511" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9f813f3e-95d1-4d57-8197-f6603209dee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_772aabbe-f234-4b73-ad9b-775462c0deb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_147194f3-3366-4295-a00a-cdfdec847511" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_772aabbe-f234-4b73-ad9b-775462c0deb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a66f3f46-04f0-4eff-bcaf-6a476c7bad02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_147194f3-3366-4295-a00a-cdfdec847511" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a66f3f46-04f0-4eff-bcaf-6a476c7bad02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e9b359e-6f15-444d-86e9-8e66076e1f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_ebc896d0-6a33-481a-a42c-8810b3b81acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e9b359e-6f15-444d-86e9-8e66076e1f2a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded_ebc896d0-6a33-481a-a42c-8810b3b81acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_8f5ed81b-a556-42b7-b93a-378816a7ffe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e9b359e-6f15-444d-86e9-8e66076e1f2a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_8f5ed81b-a556-42b7-b93a-378816a7ffe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_8900ed61-6f77-4177-ab99-df089a849ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e9b359e-6f15-444d-86e9-8e66076e1f2a" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_8900ed61-6f77-4177-ab99-df089a849ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="simple" xlink:href="sgmo-20210630.xsd#BASICANDDILUTEDNETLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2f21cb27-6784-4fe7-90f6-6b9615c9a581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4c025d71-b6d9-45ee-8af1-3e917626742b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2f21cb27-6784-4fe7-90f6-6b9615c9a581" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4c025d71-b6d9-45ee-8af1-3e917626742b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7f268900-da71-48ce-966d-1b622b492a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1fd0ecf6-3fca-4437-848e-22089823bd11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7f268900-da71-48ce-966d-1b622b492a52" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1fd0ecf6-3fca-4437-848e-22089823bd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7bb65ff-2a3e-4235-aa02-c069d55f36f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c641afad-6500-4d27-b833-13681ef288c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a7bb65ff-2a3e-4235-aa02-c069d55f36f7" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c641afad-6500-4d27-b833-13681ef288c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3cc46cb2-39b0-4328-8407-da6c7dc71e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3cc46cb2-39b0-4328-8407-da6c7dc71e5d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:to="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_053e81f9-b2ce-4c4c-8785-01da7519d88b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6176e7ea-a245-48bb-a135-198f969da840" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_6176e7ea-a245-48bb-a135-198f969da840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_0a130d7e-ba74-494d-9091-bf41163d3dff" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_BiogenMAIncMember_0a130d7e-ba74-494d-9091-bf41163d3dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_c0b19632-430b-45d1-a03c-a72258e8263b" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_KitePharmaIncMember_c0b19632-430b-45d1-a03c-a72258e8263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_cc8dc5f0-85a9-45ce-bc13-7fbf9bf082a4" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_296a7359-a945-4e73-8035-df9f137d5853" xlink:to="loc_sgmo_SanofiMember_cc8dc5f0-85a9-45ce-bc13-7fbf9bf082a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76d406eb-3481-453a-bac4-69622628fe5d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_58a50f0c-48eb-4fd4-8f21-b7293530f572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d342daed-0886-45c5-98c4-200ce6068351" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_58a50f0c-48eb-4fd4-8f21-b7293530f572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c1f2b23-641d-4f21-becb-7663b8b8d30c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8c1f2b23-641d-4f21-becb-7663b8b8d30c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a5577f5e-ea63-478d-b6c2-2fbd53e66c33" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ec09b055-8d25-4ca8-81c2-c3845873d1d4" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ec09b055-8d25-4ca8-81c2-c3845873d1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_1d9f3598-d32d-43d6-9de5-7f8b20c6c76e" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_BiogenMAIncMember_1d9f3598-d32d-43d6-9de5-7f8b20c6c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_5aff8b74-bdaa-42c2-beea-2415c32079b7" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_KitePharmaIncMember_5aff8b74-bdaa-42c2-beea-2415c32079b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_03dc267c-29d8-4c3f-b84e-f376eb9cf7f1" xlink:href="sgmo-20210630.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_PfizerMember_03dc267c-29d8-4c3f-b84e-f376eb9cf7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_93b233ba-7b6f-4f70-b95c-ff779dc4c217" xlink:href="sgmo-20210630.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_PfizerSB525Member_93b233ba-7b6f-4f70-b95c-ff779dc4c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_d0854e06-90d7-4d6b-b8bd-b1ffec83646c" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0863fbbf-646a-4631-941c-19551f52a6f9" xlink:to="loc_sgmo_SanofiMember_d0854e06-90d7-4d6b-b8bd-b1ffec83646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3e4ff508-0864-4466-a9b3-62084d66a873" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_18581f10-ae13-434c-ae2e-e3e09a614829" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_18581f10-ae13-434c-ae2e-e3e09a614829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_b5facdaf-604f-45d0-b8d7-d1946e25a781" xlink:href="sgmo-20210630.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_77ee2e91-db17-400d-af3a-893efbe2d35e" xlink:to="loc_sgmo_StockPurchaseAgreementMember_b5facdaf-604f-45d0-b8d7-d1946e25a781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02fabfbd-d549-4175-b277-8c2a2a6e057a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_aee99c00-2c68-4730-a16e-228a1c80e87a" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_aee99c00-2c68-4730-a16e-228a1c80e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_1f8c2495-3622-465a-90b4-2999a2649f6b" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_1f8c2495-3622-465a-90b4-2999a2649f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8db82aa8-7e5d-48da-9595-67c60d9ba524" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_8db82aa8-7e5d-48da-9595-67c60d9ba524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_4dca5b23-e27f-4395-9d84-d7f62517973d" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_4dca5b23-e27f-4395-9d84-d7f62517973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_275d9732-68da-46fd-ae0c-7a02762aea4c" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_275d9732-68da-46fd-ae0c-7a02762aea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_4c99c35d-8f2b-4eee-951b-d78951be6434" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_4c99c35d-8f2b-4eee-951b-d78951be6434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_c2875659-9688-4705-8871-426ce3a8dd84" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_c2875659-9688-4705-8871-426ce3a8dd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_c58d059a-f487-483b-8db1-d24f4cd97d1d" xlink:href="sgmo-20210630.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_c58d059a-f487-483b-8db1-d24f4cd97d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_73a2ce5e-f065-4419-9395-970a4070c8d3" xlink:href="sgmo-20210630.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_9e4609e6-8422-4e72-bac5-52492a127ac5" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_73a2ce5e-f065-4419-9395-970a4070c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_76edb866-0a2e-4860-9dae-04d2624dbb22" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_d651376b-f78a-4cb8-8425-3d2741d0edd2" xlink:href="sgmo-20210630.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_PreApprovalMilestoneMember_d651376b-f78a-4cb8-8425-3d2741d0edd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_441bc7e9-0458-42eb-a0f6-66f9a91b2af8" xlink:href="sgmo-20210630.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_SalesBasedMilestoneMember_441bc7e9-0458-42eb-a0f6-66f9a91b2af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_c8c9a3d1-2b1f-43a1-bcae-7d641c8fe424" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_MilestoneTwoMember_c8c9a3d1-2b1f-43a1-bcae-7d641c8fe424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_e37f01de-a890-4bd2-9954-4c4aed57f956" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_MilestoneThreeMember_e37f01de-a890-4bd2-9954-4c4aed57f956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_52d7f645-cd39-4291-a353-67d6ad0807ad" xlink:href="sgmo-20210630.xsd#sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_e92142f0-0a58-4b22-9345-20a425937cda" xlink:to="loc_sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember_52d7f645-cd39-4291-a353-67d6ad0807ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e7725c82-131d-4449-9a3a-c8a8cddb3ae3" xlink:to="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_b00eb2c5-b14e-4637-b7d2-9a2154a99461" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveAndOtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_SBFiveTwoFiveAndOtherProductsMember_b00eb2c5-b14e-4637-b7d2-9a2154a99461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SBFiveTwoFiveMember_12618b6b-fb07-4998-a3df-7f3a46646503" xlink:href="sgmo-20210630.xsd#sgmo_SBFiveTwoFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_SBFiveTwoFiveMember_12618b6b-fb07-4998-a3df-7f3a46646503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_467ff84f-f2c6-496c-a243-371b989a7cec" xlink:href="sgmo-20210630.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_OtherProductsMember_467ff84f-f2c6-496c-a243-371b989a7cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_41a476fe-5325-4b26-b697-7fe1612b3311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_us-gaap_LicenseAndServiceMember_41a476fe-5325-4b26-b697-7fe1612b3311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_da95425b-4537-407b-943c-e01692e8ffec" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_MilestoneAchievementMember_da95425b-4537-407b-943c-e01692e8ffec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_f28756f3-3685-461c-abd3-9c763520ada0" xlink:href="sgmo-20210630.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_sgmo_CNineORFSevenTwoMember_f28756f3-3685-461c-abd3-9c763520ada0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_011bca4a-9ae5-4d0e-b3c7-749c2dc4de85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e57e4247-fc0c-482d-bd66-8dbe49eb4bc2" xlink:to="loc_us-gaap_GrantMember_011bca4a-9ae5-4d0e-b3c7-749c2dc4de85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_fd2c18bf-96c0-4be2-a01c-0266c32e509a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_7391196e-0537-4894-bd7e-6c269d64a357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ProceedsFromCollaborators_7391196e-0537-4894-bd7e-6c269d64a357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_ebbe02fc-746f-4fd8-838b-a2c3b24edfcd" xlink:href="sgmo-20210630.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_ebbe02fc-746f-4fd8-838b-a2c3b24edfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_46ce2343-e4d1-42e6-9a47-484fde972241" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_46ce2343-e4d1-42e6-9a47-484fde972241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_0cff1c64-eb54-4a19-a017-caa8afd03cb1" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_0cff1c64-eb54-4a19-a017-caa8afd03cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_4ed52888-c920-497d-8224-91e4cf6ddbdc" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_4ed52888-c920-497d-8224-91e4cf6ddbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_17dd1d16-bb9b-40bc-a4f5-0e584c03c6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_17dd1d16-bb9b-40bc-a4f5-0e584c03c6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_80204def-b90f-42f5-8d02-53227ee3a8be" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_80204def-b90f-42f5-8d02-53227ee3a8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1c92bbf4-20c8-4d84-8fbe-ea2411cfc45b" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_1c92bbf4-20c8-4d84-8fbe-ea2411cfc45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_72577f7e-0273-4c90-b9ad-5a7c86339441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_72577f7e-0273-4c90-b9ad-5a7c86339441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c474fcc6-e7c3-4248-86f0-aa78665feec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c474fcc6-e7c3-4248-86f0-aa78665feec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f4bd6331-8ceb-4efc-b6df-16a9fb304470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f4bd6331-8ceb-4efc-b6df-16a9fb304470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_6266cbe1-aa4f-499c-8bc0-d0573a3d0bb0" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments_6266cbe1-aa4f-499c-8bc0-d0573a3d0bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_cbbc5b82-3e57-4e01-ba0c-0814327e3500" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_cbbc5b82-3e57-4e01-ba0c-0814327e3500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_0f63440a-8c50-4a2e-bc54-895f68c1bcf6" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_0f63440a-8c50-4a2e-bc54-895f68c1bcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_bce1ddee-d101-424f-8715-cf70f03a0203" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_bce1ddee-d101-424f-8715-cf70f03a0203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_abf44e98-e27e-4f87-b56d-f74a225414bc" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_abf44e98-e27e-4f87-b56d-f74a225414bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_881efb16-92dc-4f6b-ad2a-f900b7454435" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_881efb16-92dc-4f6b-ad2a-f900b7454435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_8a9b2caf-c231-4c4e-84a2-3b0150cc1a48" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_8a9b2caf-c231-4c4e-84a2-3b0150cc1a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_fe706923-cfe0-4ecd-b992-009b7daccac7" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_fe706923-cfe0-4ecd-b992-009b7daccac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_7d825e4a-4dc0-4572-8a22-4ef67342a384" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_7d825e4a-4dc0-4572-8a22-4ef67342a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_197ada14-d2f6-478a-b4a5-2857213383d8" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_197ada14-d2f6-478a-b4a5-2857213383d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_d83119ab-02be-4d61-89ac-dfe9e09d1f24" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_d83119ab-02be-4d61-89ac-dfe9e09d1f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_499eec4f-485e-4bd0-a365-b0c75be0a769" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_499eec4f-485e-4bd0-a365-b0c75be0a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_dcc4904c-7a3e-4e14-82ea-937451496188" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_dcc4904c-7a3e-4e14-82ea-937451496188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_7670dc96-8d6f-4fb7-b1b1-f6a4129ad352" xlink:href="sgmo-20210630.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_7670dc96-8d6f-4fb7-b1b1-f6a4129ad352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_6c7f98f3-f60e-4e28-9658-1b9a9184b844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_6c7f98f3-f60e-4e28-9658-1b9a9184b844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c61c92-3f9e-4cf7-98a0-b40cdc43fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_53c61c92-3f9e-4cf7-98a0-b40cdc43fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fe05c813-3eff-4210-98f9-685d46a9d630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_fe05c813-3eff-4210-98f9-685d46a9d630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_41f9eda0-d39b-4874-b303-5e9077033f6b" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_41f9eda0-d39b-4874-b303-5e9077033f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_682bae73-958c-4a31-8cbf-f032a870bb71" xlink:href="sgmo-20210630.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_MilestonePaymentsReceived_682bae73-958c-4a31-8cbf-f032a870bb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_53230472-3e71-4c13-ba2d-7436505987f4" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_53230472-3e71-4c13-ba2d-7436505987f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_50b9fd66-0be5-42f3-8370-7708b9182805" xlink:href="sgmo-20210630.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment_50b9fd66-0be5-42f3-8370-7708b9182805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_e718f7ad-4975-413f-bef2-f1f3d2417cc3" xlink:href="sgmo-20210630.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_e718f7ad-4975-413f-bef2-f1f3d2417cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_380580c1-6298-4255-9769-7c59d620b267" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_380580c1-6298-4255-9769-7c59d620b267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_ed931e29-7c22-4193-9cca-0c7ad74b646d" xlink:href="sgmo-20210630.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_ed931e29-7c22-4193-9cca-0c7ad74b646d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_bac9263d-9415-43c7-9676-2e20db93cc95" xlink:href="sgmo-20210630.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_SeparateUpfrontFee_bac9263d-9415-43c7-9676-2e20db93cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_439aea69-5fb1-47b8-9de5-8985f179207a" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_439aea69-5fb1-47b8-9de5-8985f179207a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c075a763-82eb-496a-ac70-e7f697657522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c075a763-82eb-496a-ac70-e7f697657522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_f6581b8c-397c-4338-8d05-e603cd960fb0" xlink:href="sgmo-20210630.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_AgreementTerminationTerm_f6581b8c-397c-4338-8d05-e603cd960fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_ff53f61a-0e90-441d-89cc-213de7cb77be" xlink:href="sgmo-20210630.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_ff53f61a-0e90-441d-89cc-213de7cb77be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_323680e4-6b81-4f2a-b359-808da9927737" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_MilestoneRevenueReceivable_323680e4-6b81-4f2a-b359-808da9927737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_016e7e4b-9a15-456c-ba91-49591e895168" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementNumberOfMilestonesAchieved"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved_016e7e4b-9a15-456c-ba91-49591e895168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_d5ca8857-7195-4d58-be25-e44673eb411c" xlink:href="sgmo-20210630.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_d5ca8857-7195-4d58-be25-e44673eb411c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_13ed053a-5f08-4f94-8e2a-56b6852ded0a" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_13ed053a-5f08-4f94-8e2a-56b6852ded0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_ed4e80a2-49cc-4c6f-a563-e61b23eeda50" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_ed4e80a2-49cc-4c6f-a563-e61b23eeda50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177f65d3-0dc6-4533-b56f-e3fe6a97f3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_177f65d3-0dc6-4533-b56f-e3fe6a97f3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_c567786a-d80b-489b-80fe-a007d13be0ac" xlink:href="sgmo-20210630.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_NumberOfResearchProgram_c567786a-d80b-489b-80fe-a007d13be0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_8f202088-f05d-44f5-a03b-cc2fc7d4f45a" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementCumulativeMilestoneAchieved"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved_8f202088-f05d-44f5-a03b-cc2fc7d4f45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_bd08b38a-c1a3-4e41-b9b4-ecd943f3ff67" xlink:href="sgmo-20210630.xsd#sgmo_CollaborativeArrangementMilestoneRevenueRecognized"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_CollaborativeArrangementMilestoneRevenueRecognized_bd08b38a-c1a3-4e41-b9b4-ecd943f3ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_2225ecda-a0e2-4e0f-b701-df5eef52ac49" xlink:href="sgmo-20210630.xsd#sgmo_GrantFundingAmount"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_sgmo_GrantFundingAmount_2225ecda-a0e2-4e0f-b701-df5eef52ac49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7c42bb3a-8418-4b14-830f-dab97e673749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_aa606df2-42df-440f-934d-316218fd60c4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7c42bb3a-8418-4b14-830f-dab97e673749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9324d58a-0d0e-4e0a-b819-7c0de34e5848" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9324d58a-0d0e-4e0a-b819-7c0de34e5848" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:to="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_18245c24-13a4-4fea-89c9-2f85521ea8a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_13d098f9-96e5-4224-be7a-24662e670f24" xlink:href="sgmo-20210630.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_13d098f9-96e5-4224-be7a-24662e670f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_de25991f-a46d-46f7-9d3d-2474098830a8" xlink:href="sgmo-20210630.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_BiogenMAIncMember_de25991f-a46d-46f7-9d3d-2474098830a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_9d8cbad7-04e5-45d5-9520-f5674aed00f7" xlink:href="sgmo-20210630.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_KitePharmaIncMember_9d8cbad7-04e5-45d5-9520-f5674aed00f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_39ff24dd-e1f4-4d9b-b9c5-63738c67985b" xlink:href="sgmo-20210630.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f2f8e61-5789-4525-96ec-ecb1ef3c28cd" xlink:to="loc_sgmo_SanofiMember_39ff24dd-e1f4-4d9b-b9c5-63738c67985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:to="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b25a67e2-e20e-4de4-8db5-50a204e6c3e7" xlink:to="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_2fa40e3b-1f83-4c38-86b7-aa7eb627f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_us-gaap_LicenseAndServiceMember_2fa40e3b-1f83-4c38-86b7-aa7eb627f994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_de990568-8398-4ec7-ab03-5b90dbb66e2c" xlink:href="sgmo-20210630.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_sgmo_ResearchServicesMember_de990568-8398-4ec7-ab03-5b90dbb66e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_7d0723da-0a80-49ad-8349-e94d07dc83d1" xlink:href="sgmo-20210630.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_639f5211-807a-48af-aeac-8c24a62c81e9" xlink:to="loc_sgmo_MilestoneAchievementMember_7d0723da-0a80-49ad-8349-e94d07dc83d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_93ae7d8e-38ba-4b71-9f13-330e59b35745" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_604151d5-9756-42b1-84c8-6193c38b7ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_85c11271-bc7e-4762-92e1-b9a414b81b90" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_604151d5-9756-42b1-84c8-6193c38b7ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sgmo-20210630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b31833e0-28ec-4a43-8db1-b2757f606858" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2df9f962-17ee-4d28-b87b-81cf9e7dfa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b31833e0-28ec-4a43-8db1-b2757f606858" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2df9f962-17ee-4d28-b87b-81cf9e7dfa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sgmo-20210630.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_57328004-7967-4880-a040-68e8a823b98b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4b58d0c7-3c8d-464d-9aa6-b2d758fbd687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_57328004-7967-4880-a040-68e8a823b98b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4b58d0c7-3c8d-464d-9aa6-b2d758fbd687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_490e1a3f-2094-4c0e-89c3-d78e9236b644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_29d4f3bf-d073-43fb-a2f3-df7fb4c6228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_490e1a3f-2094-4c0e-89c3-d78e9236b644" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_29d4f3bf-d073-43fb-a2f3-df7fb4c6228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6549e1bf-9f6e-45fe-bdef-4509445a6ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_66beb10c-ef74-46ac-90e8-937867a21308" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6549e1bf-9f6e-45fe-bdef-4509445a6ac6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_66beb10c-ef74-46ac-90e8-937867a21308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b627e70-4c04-486c-af19-b6fc0be2dcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6549e1bf-9f6e-45fe-bdef-4509445a6ac6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b627e70-4c04-486c-af19-b6fc0be2dcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock_2cd6ede3-535d-45ea-8f18-952e1d376ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6549e1bf-9f6e-45fe-bdef-4509445a6ac6" xlink:to="loc_us-gaap_OtherCommitmentsTableTextBlock_2cd6ede3-535d-45ea-8f18-952e1d376ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca70ecc-b6c1-4201-a8c2-dadd2a96a371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca70ecc-b6c1-4201-a8c2-dadd2a96a371" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_9c56f906-0161-4998-aa79-2e032f4404d0" xlink:to="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_8185745a-798f-40c1-8d1a-6f54653860c2" xlink:href="sgmo-20210630.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_dcf8313c-0546-4fa3-8254-76bdd4e2b973" xlink:to="loc_sgmo_PropertySubjectToOperatingLeaseOneMember_8185745a-798f-40c1-8d1a-6f54653860c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_3ad7afd8-0661-46d6-a2ba-efc8fc691d67" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_4ff808a9-1438-476f-9c2b-c5cd6eebc103" xlink:href="sgmo-20210630.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_4ff808a9-1438-476f-9c2b-c5cd6eebc103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_3e38392d-e4fe-4a6a-8234-ec605001102c" xlink:href="sgmo-20210630.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a0e29e21-b509-4c4f-a3c4-7751b07c4b10" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_3e38392d-e4fe-4a6a-8234-ec605001102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5cd9e040-23ac-4e62-8df8-345e5e6be46d" xlink:to="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_2e54a96f-8118-4c93-9a07-9336f4e7a99d" xlink:href="sgmo-20210630.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_2e54a96f-8118-4c93-9a07-9336f4e7a99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_cd42a72f-afdb-4b42-8a09-2cd38fe61f69" xlink:href="sgmo-20210630.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_RichmondCaliforniaMember_cd42a72f-afdb-4b42-8a09-2cd38fe61f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_b559ba6c-6842-4733-8c59-749da06083c3" xlink:href="sgmo-20210630.xsd#sgmo_ValbonneFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b60018cc-da2f-4700-905f-d019d5ce8dcc" xlink:to="loc_sgmo_ValbonneFranceMember_b559ba6c-6842-4733-8c59-749da06083c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_931e55c4-6754-4aac-8f7a-307f95318136" xlink:to="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ecda6d5d-8c5f-4b1b-9eea-1dfcb28ab133" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:to="loc_srt_MinimumMember_ecda6d5d-8c5f-4b1b-9eea-1dfcb28ab133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b464f9ac-bf43-4bd8-b046-32f00d24ba79" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4dbfdf88-c6d7-4561-84d8-e78deba9f06c" xlink:to="loc_srt_MaximumMember_b464f9ac-bf43-4bd8-b046-32f00d24ba79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:href="sgmo-20210630.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_9f230718-e014-4375-9ea1-0cfc96e1809a" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_88bfb628-7a01-4fb7-81c1-4a31b4f01c71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_88bfb628-7a01-4fb7-81c1-4a31b4f01c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ea04b3d-14be-4489-bec9-f169da17413d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ea04b3d-14be-4489-bec9-f169da17413d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3ce84293-29fe-4133-bddf-00f8cf22ca27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeasePayments_3ce84293-29fe-4133-bddf-00f8cf22ca27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a4625af8-dcfb-4913-b0e2-8d545d96f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a4625af8-dcfb-4913-b0e2-8d545d96f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_31ee457e-4993-4415-9acc-779ff7d3817f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_31ee457e-4993-4415-9acc-779ff7d3817f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_44b07c91-9a62-4c43-a114-77c4fbdc512a" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAreaOfRealEstate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LesseeOperatingLeaseAreaOfRealEstate_44b07c91-9a62-4c43-a114-77c4fbdc512a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseAmount_5ac9c167-55e5-49ab-a1b9-d2693f9715bc" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LesseeOperatingLeaseAmount_5ac9c167-55e5-49ab-a1b9-d2693f9715bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_f05576d1-a9d1-4fa4-9473-395fc8943318" xlink:href="sgmo-20210630.xsd#sgmo_LicenseObligations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_f7936614-d8f7-46bf-9217-e2e90444093e" xlink:to="loc_sgmo_LicenseObligations_f05576d1-a9d1-4fa4-9473-395fc8943318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSComponentsofOperatingLeasesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5974be20-c0ca-4b70-b306-d93b1a79aa5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d361b640-8dec-47d8-a94e-ab8c8e9bbd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5974be20-c0ca-4b70-b306-d93b1a79aa5b" xlink:to="loc_us-gaap_OperatingLeaseCost_d361b640-8dec-47d8-a94e-ab8c8e9bbd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_edfefa89-45ae-476a-863f-f536e2eab27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5974be20-c0ca-4b70-b306-d93b1a79aa5b" xlink:to="loc_us-gaap_VariableLeaseCost_edfefa89-45ae-476a-863f-f536e2eab27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1f5c9db0-65e0-4979-845f-6e32e1ee0293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5974be20-c0ca-4b70-b306-d93b1a79aa5b" xlink:to="loc_us-gaap_LeaseCost_1f5c9db0-65e0-4979-845f-6e32e1ee0293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51e8a0e2-6c07-400d-93b2-1b931b7cdee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_51e8a0e2-6c07-400d-93b2-1b931b7cdee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78b14ed9-169e-4cca-b41b-4bfeb06aefd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_78b14ed9-169e-4cca-b41b-4bfeb06aefd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b0dfa53d-29d8-4b7a-99d3-0be0d0ece6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b0dfa53d-29d8-4b7a-99d3-0be0d0ece6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc886835-bf13-4242-ac89-a22e58b15d19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_bc886835-bf13-4242-ac89-a22e58b15d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_af6510f0-66ae-41c6-b1df-5c2e69c1282a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_af6510f0-66ae-41c6-b1df-5c2e69c1282a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5e4e2944-eb2c-4d9e-b778-bd3bc68837fc" xlink:href="sgmo-20210630.xsd#sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_5e4e2944-eb2c-4d9e-b778-bd3bc68837fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_608227c1-0296-4bcb-84b5-7253ff67c500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_608227c1-0296-4bcb-84b5-7253ff67c500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_96e4473a-f6a0-4960-b589-22178ae452be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_96e4473a-f6a0-4960-b589-22178ae452be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_62b3ebef-471c-40fe-acce-f5b8ef983983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_OperatingLeaseLiability_62b3ebef-471c-40fe-acce-f5b8ef983983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_71f26497-2caa-4844-a48e-0d3be9c79e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_71f26497-2caa-4844-a48e-0d3be9c79e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46ea64fc-bbe4-4a5d-b1f6-27e6bc2b76e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_46ea64fc-bbe4-4a5d-b1f6-27e6bc2b76e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_19241b6f-947f-4d8d-8318-59594d0afc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5f0cd4ce-28ac-44ed-9302-a18ea3c481b1" xlink:to="loc_us-gaap_OperatingLeaseLiability_19241b6f-947f-4d8d-8318-59594d0afc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60931bb7-b569-4431-b7bf-49717d07ebf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_60931bb7-b569-4431-b7bf-49717d07ebf0" xlink:to="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:to="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_36a70598-7c68-47bc-b031-5b5a90526aac" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_8ee50850-5f84-42cd-8ecf-a34dccd050a9" xlink:href="sgmo-20210630.xsd#sgmo_BrammerBioMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:to="loc_sgmo_BrammerBioMAMember_8ee50850-5f84-42cd-8ecf-a34dccd050a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_a5396daa-7f90-49f0-a606-434b162af34f" xlink:href="sgmo-20210630.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a3351505-94a9-4bce-ae32-d0c3534f7891" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_a5396daa-7f90-49f0-a606-434b162af34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_9d2ef4e6-2718-405f-8c1e-a0dd6bb7f51e" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_e357372c-df7d-49f4-8f93-8329e51be864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_a38ca06d-e7b6-452d-b8a7-92a12237c734" xlink:to="loc_us-gaap_ContractualObligation_e357372c-df7d-49f4-8f93-8329e51be864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b42f6e28-cb60-47c4-a752-542748103650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60e29504-79a9-4b27-ba88-e600e8b1d6ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b42f6e28-cb60-47c4-a752-542748103650" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_60e29504-79a9-4b27-ba88-e600e8b1d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92d47d20-09a8-48a4-b14b-7ab75b6d1907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b4bc6ab-dcca-4e4d-bbc8-175e8e282913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92d47d20-09a8-48a4-b14b-7ab75b6d1907" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4b4bc6ab-dcca-4e4d-bbc8-175e8e282913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_660f764c-8c5e-48cb-b5df-f7f2d336dae0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_660f764c-8c5e-48cb-b5df-f7f2d336dae0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_554cd4f0-2dc9-47d0-901c-84d3bc1330d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f803194d-baff-49fe-b77c-9390b64bfaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f803194d-baff-49fe-b77c-9390b64bfaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6b1d858-4ef5-4a7c-8279-6bbd6a8c8b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_170f4bd4-ab04-48cb-acda-5070834f4f2d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6b1d858-4ef5-4a7c-8279-6bbd6a8c8b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64dbdee4-887a-4246-93cf-a8118c1b291e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc713ea2-8f6f-4d99-8764-6244d0917efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9851674f-6865-4630-8b51-1dd1b44a69f3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc713ea2-8f6f-4d99-8764-6244d0917efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_88ba5304-268d-43bb-85fa-624223113609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_970940d4-a12e-4468-830b-26ddfbdce850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88ba5304-268d-43bb-85fa-624223113609" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_970940d4-a12e-4468-830b-26ddfbdce850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#STOCKHOLDERSEQUITYNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5982ec8c-d653-48ba-bb8c-d6005cdbb680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5982ec8c-d653-48ba-bb8c-d6005cdbb680" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7824b6a8-2fb0-47fb-bc94-7c3ea3a4d591" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_31e2e02e-ba8c-4217-81c7-94262509fc24" xlink:href="sgmo-20210630.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36ffda41-2990-4bad-a868-7377a9d22261" xlink:to="loc_sgmo_JefferiesLLCMember_31e2e02e-ba8c-4217-81c7-94262509fc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1fa77139-936d-4622-ae45-dc9f324a4c5b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_901d28ef-f585-4284-8d8d-d25019a81026" xlink:href="sgmo-20210630.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f9b60672-bc00-473e-843a-b5b7654c820b" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_901d28ef-f585-4284-8d8d-d25019a81026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1b638c33-00fe-4225-a06d-b5fc5ec648d8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_db516608-b3f8-44ef-915a-1b57303fe91f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f7a06d02-13e5-4615-b543-1c381fbc4c12" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_db516608-b3f8-44ef-915a-1b57303fe91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1798c263-e407-424b-9132-e24b036d5099" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9c693034-ebe7-457d-aa72-531fedcfb3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7473ca84-808d-424c-8f34-d10eecdfd8d5" xlink:to="loc_us-gaap_SubsequentEventMember_9c693034-ebe7-457d-aa72-531fedcfb3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acc4a291-5713-4642-b082-633567cd61e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_b913e221-9885-4f1e-ab49-d57503a908b2" xlink:href="sgmo-20210630.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_b913e221-9885-4f1e-ab49-d57503a908b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4e3161b-26cb-4c49-8497-704f08b34356" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d4e3161b-26cb-4c49-8497-704f08b34356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a45d4ffe-96f8-4583-8c4e-03302b075c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_29dda43f-bbc8-440a-8526-2729ddb3c658" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a45d4ffe-96f8-4583-8c4e-03302b075c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ac49c18d-f7a7-4f9a-8448-f80182f267b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9ce81603-c979-4e7d-9d0a-eda560b47a57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ac49c18d-f7a7-4f9a-8448-f80182f267b6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_9ce81603-c979-4e7d-9d0a-eda560b47a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a2371ec1-819d-4a2f-9eca-98c328bb015d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_d2d6249e-5e11-4125-a484-0900b25162f0" xlink:href="sgmo-20210630.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a2371ec1-819d-4a2f-9eca-98c328bb015d" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock_d2d6249e-5e11-4125-a484-0900b25162f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33344fa1-1f67-41bd-953b-e729829344a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_33344fa1-1f67-41bd-953b-e729829344a1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0f59353a-f858-4bdb-8f61-b3adc5677afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_2f2bc288-be6f-4bcd-8c2d-c3a5672481e3" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c4b293d-23fb-4249-917d-f103b1697806" xlink:to="loc_sgmo_SangamoFranceMember_2f2bc288-be6f-4bcd-8c2d-c3a5672481e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4a398b65-7e6e-49e7-b378-92e4a09d85fc" xlink:to="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_5a9faf52-92ea-43a1-94e9-1d82db6ced36" xlink:href="sgmo-20210630.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_92c25e4b-0a7b-4ea4-ae61-92ee03f6fda8" xlink:to="loc_sgmo_SangamoFranceMember_5a9faf52-92ea-43a1-94e9-1d82db6ced36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3773e47b-b063-4214-849f-3aceceb78d2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_8d576148-4d7e-4493-8173-03179979e6b4" xlink:href="sgmo-20210630.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84ef0ed2-9ad3-4880-9a87-63a1a8137c58" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_8d576148-4d7e-4493-8173-03179979e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d5502b04-e96e-4918-a157-8b6e14717977" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_66386feb-9f60-40fb-855f-4a889fcfa8c4" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_66386feb-9f60-40fb-855f-4a889fcfa8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_879a6981-02e3-44c7-8dfc-d5a8b18b5e48" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_879a6981-02e3-44c7-8dfc-d5a8b18b5e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8b8d2fc9-335a-4687-903e-8b17cf93c441" xlink:href="sgmo-20210630.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_8b8d2fc9-335a-4687-903e-8b17cf93c441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fd29f7ab-31f1-4a56-ad41-200352a0b32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fd29f7ab-31f1-4a56-ad41-200352a0b32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_a5c185c3-11fa-4dbf-8a82-f0b23cfc8b48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_a5c185c3-11fa-4dbf-8a82-f0b23cfc8b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_b471d2e1-350e-4e25-aea1-b8a94fedac98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e9e5da7-8b5d-46c4-83b4-2b9510a6e595" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_b471d2e1-350e-4e25-aea1-b8a94fedac98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20210630.xsd#ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_57925e12-cc1d-4f29-9bc2-16bfc754b473" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_57925e12-cc1d-4f29-9bc2-16bfc754b473" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_b674d1a6-7275-4ee8-ae37-bd4dcad73ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:to="loc_us-gaap_MinorityInterest_b674d1a6-7275-4ee8-ae37-bd4dcad73ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_4659e581-98f8-431a-be35-f6c157fef272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_4659e581-98f8-431a-be35-f6c157fef272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b1122d6c-3ec3-4288-81a0-027571c446e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b1122d6c-3ec3-4288-81a0-027571c446e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_896938b4-ed63-414e-ad18-b69914c8560b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_896938b4-ed63-414e-ad18-b69914c8560b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f889cf83-2657-4ebd-976f-fb3709c54216" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_f0495822-c892-4374-b5d2-ce81267c6e58" xlink:to="loc_us-gaap_MinorityInterest_f889cf83-2657-4ebd-976f-fb3709c54216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>sgmo-20210630xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib210644702454412b6e5479a79d0446e_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Prathyusha Duraibabu, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>sgmo-20210630xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i259e6159c8654005b078d64f29cf2aa5_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), each of the undersigned hereby certifies in his or her capacity as an officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), that, to the best of his or her knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Quarterly Report on Form 10-Q for the period ended June 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prathyusha Duraibabu</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>9
<FILENAME>sgmo-20210631xex101_employ.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if7e2de1dc2b44b62befe436138735c95_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.1</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employment Agreement (&#8220;Agreement&#8221;) made as of the 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of May 2021 by and between Sangamo Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Prathyusha Duraibabu (&#8220;Executive&#8221;) (collectively, the &#8220;Parties&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">R E C I T A L S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, the Company desires to promote Ms. Duraibabu to Executive, and Executive desires to be promoted by the Company, on the terms and conditions set forth in this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, in consideration of the mutual promises set forth herein, the Parties agree follows&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company hereby agrees to employ Executive and Executive hereby agrees to accept such employment, on the terms and conditions set forth in this Agreement, with a start date of  June 1, 2021  (the &#8220;Effective Date&#8221;).  To the extent of any inconsistency with Ms. Duraibabu&#8217;s prior employment agreements with the Company, this Agreement shall supersede such prior agreements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:30pt">Executive shall be employed on an at-will basis.  Either Executive or the Company may terminate employment at any time, with or without cause, and with or without advance notice.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Position, Duties and Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive shall be appointed as the Senior Vice President, Chief Financial Officer and shall serve in such position, and in such other positions as the Board and the Company may from time to time reasonably determine, subject at all times to the direction, supervision and authority of the Chief Executive Officer (collectively, your &#8220;Duties&#8221;).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">During Executive&#8217;s employment, Executive shall perform Executive&#8217;s Duties faithfully and to the best of Executive&#8217;s ability, and shall devote substantially all of Executive&#8217;s business time, attention, knowledge, skills and interests to the business of the Company (and its affiliates or subsidiaries).  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">During Executive&#8217;s employment, Executive shall not, whether directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation or otherwise, without the prior written consent of the Chief Executive Officer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">The foregoing in this Section 3 shall not preclude Executive from serving on any corporate, civic or charitable boards or committees on which Executive is serving as of the Effective Date and discloses to the Chief Executive Officer prior to the Effective Date or on which Executive commences service following such date with the Chief Executive Officer&#8217;s prior written approval, so long as such activities do not interfere with the performance of Executive&#8217;s responsibilities hereunder.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Executive&#8217;s principal place of business will be located in Brisbane,  California.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Executive represents that Executive may enter into this Agreement, and as of the Effective Date, 1) accept employment with the Company under the terms of this Agreement, and 2) perform the Duties and responsibilities contemplated by this Agreement without violating any other agreement or agreements with other parties including but not limited to and any prior employers.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Compensation and Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall pay to Executive an annual base salary of $400,000 Dollars, prorated for any partial employment period and payable in equal monthly installments in accordance with the Company&#8217;s payroll schedule.  The Compensation Committee of the Board shall annually review the then-current level of Executive&#8217;s base salary (for increase only) to determine the amount, if any, of change to such salary.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Annual Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive is eligible to earn an annual performance bonus commencing with the 2021 calendar year performance period.  The target amount of Executive&#8217;s annual cash bonus shall be 35% percent of Executive&#8217;s annual base salary.  Your new bonus target will be pro-rated accordingly for the remainder of 2021. The Board shall have sole discretion to determine whether any annual cash bonus will be paid based upon achievement of both corporate objectives and Executive&#8217;s personal objectives, and the reasonable discretion to determine that actual amount of any such bonus.  Executive must be an employee in good standing on the date that the Board makes such determination in order to earn any such bonus, which determination shall be made by the Board no later than March 31 of the calendar year first following the performance period calendar year.  The actual bonus may be more or less than the target amount based upon the Company&#8217;s achievement over the year.  Any bonus to which Executive becomes entitled for a particular calendar year shall be paid in accordance with the terms of the applicable bonus plan, but in no event later than the second payroll period following such Board determination.  The Compensation Committee of the Board shall annually review Executive&#8217;s then target amount for the annual cash bonus (for increase only) to determine the amount, if any, of change to such target amount.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Executive Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be deemed an Eligible Employee and an Executive Officer and entitled to receive certain severance benefits under the Sangamo Therapeutics, Inc. Executive Severance Plan dated February 6, 2019 (the &#8220;Severance Plan&#8221;) subject to the terms and conditions of the Severance Plan.  A copy of the Severance Plan has been provided to Executive concurrently with this Agreement.  Notwithstanding the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">foregoing, in the event that the Company withdraws this offer after it is signed by Executive or terminates this Agreement prior to the Effective Date for any reason other than Executive&#8217;s failure to successfully pass the requirements for a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States required under Section 8(a) herein, then Executive shall be entitled to severance under the Severance Plan as though his employment was terminated by the Company other than for Cause to the same extent as he would otherwise be entitled had such termination occurred after the Effective Date&#59; provided, however, that Executive shall not be entitled to such severance if he has not notified his current employer of his intent to resign his employment at the time the Company informs him of the withdrawal or termination of this Agreement.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive will be entitled to the employee benefits generally provided to other executive officers of the Company pursuant to the terms of the applicable benefit plans.  Executive will not be subject to a formal paid time off program.  Executive is free to take paid time off from work for vacation, medical appointments, and other short-term absences due to illnesses or other personal reasons.  If Executive desires to take time off for a duration longer than two (2) weeks manager approval is required.  Unlimited paid time off is available from the first day of employment.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Effective on the second Friday of the month, or if not a trading day, the trading day prior (the &#8220;Grant Date&#8221;) in which the Executive commences her new role, as long as the first day of employment with Sangamo occurs between the prior Grant Date and the day preceding the Grant Date, the Compensation Committee of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shall grant you non-statutory stock options to purchase up to  15,000 shares of the Company&#8217;s Common Stock subject to the terms and conditions of the Company&#8217;s 2018 Equity Incentive Plan (the &#8220;Plan&#8221;),with an exercise price per share equal to the fair market value of the Company&#8217;s Common Stock on the Grant Date (the &#8220;Option&#8221;).  The Option will be evidenced by the standard stock option agreement under the Plan and will be subject to the terms and conditions of that agreement and the Plan&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9679; 1&#47;4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (one-fourth) of the Option shares will vest on the first-year anniversary of the Grant Date, and </font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9679; 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (one forty-eighth) of the Option shares will vest in equal monthly installments for thirty-six (36) months thereafter, </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided Executive remains a full-time employee through each such vesting date.  Vesting of the Option and any subsequent equity grants will cease upon termination of Executive&#8217;s service by either party for any reason.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt">Also, subject to approval by the Compensation Committee of the Board, we intend to grant you 7,500 restricted stock units (&#34;Restricted Stock Units&#34;) under the Plan. Each Restricted Stock Unit represents the right to receive one share of the Company's common stock upon the specified issuance date following vesting. Your Restricted Stock Units will vest in a series of three (3) successive equal annual installments upon your completion of each year of service to the Company measured from the Vesting Commencement Date. The issuance of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">underlying shares of common stock in settlement of vested Restricted Stock Units will be subject to the Company's collection of all applicable withholding taxes. The Restricted Stock Units will be evidenced by the Plan's form of Restricted Stock Unit Issuance Agreement and will be subject to its terms and conditions and the Plan.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Clawback</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary in this Agreement, all compensation paid to Executive by the Company (whether payable pursuant to this Agreement or otherwise) will be subject to reduction, recovery and&#47;or recoupment to the extent required by any present or future law, government regulation or stock exchange listing requirement (or any policy adopted by the Company which ensures compliance with the requirements of any such law, government regulation or stock exchange listing requirement).</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Resignation from Positions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of this Agreement to the contrary, upon any termination of employment (whether voluntary or involuntary), Executive, upon written request from the Board, shall immediately resign from any positions Executive has with the Company (or any subsidiary), whether as an executive, officer, employee, consultant, director, trustee, fiduciary or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive agrees to continue to abide by the terms and conditions of the Employee Confidential Information and Invention Assignment Agreement between Executive and the Company, a copy of which has previously been execute and is attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive further agrees that at all times both during Executive&#8217;s employment by the Company and after Executive&#8217;s employment ends, Executive will keep in confidence and trust, and will not use or disclose, except as directed by the Company, any confidential or proprietary information of the Company.  </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Tax Withholdings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any and all cash compensation and other benefits (including without limitation, base salary, annual bonus and sign-on bonus) paid to Executive under this Agreement shall be subject to all applicable tax withholding requirements, and the Company shall make such other deductions as may be required and&#47;or allowed by applicable law and&#47;or as authorized in writing by Executive.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any dispute, controversy, or claim, whether contractual or non-contractual, between Executive and the Company shall be resolved by binding arbitration before the Judicial Arbitration and Mediation Service (the &#8220;JAMS&#8221;), in accordance with the JAMS Employment Arbitration Rules and Procedures, available at www.jamsadr.com.  Executive and the Company each agree that before proceeding to arbitration, they will mediate disputes before the JAMS by a mediator approved by the JAMS.  If mediation fails to resolve the matter, any subsequent arbitration shall be conducted by an arbitrator approved by the JAMS and mutually acceptable to Executive and the Company.  All disputes, controversies, and claims shall be conducted by a single arbitrator, who shall&#58; (i) allow discovery authorized by California Code of Civil Procedure Section 1282, et seq., or any other discovery required by applicable law&#59; and (ii) issue a written award that sets forth the essential findings of fact and conclusions of law on which the award is based.  The arbitrator shall have the authority to award any relief authorized by law in connection with the asserted claims or disputes.   Judgment upon the arbitrator&#8217;s award may be entered in any court having jurisdiction thereof.  If Executive and the Company are unable to agree on the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">mediator or the arbitrator, then the JAMS shall select the mediator&#47;arbitrator.  The resolution of the dispute by the arbitrator shall be final, binding, non-appealable, and fully enforceable by a court of competent jurisdiction under the Federal Arbitration Act.  The arbitration award shall be in writing and shall include a statement of the reasons for the award.  The arbitration shall be held in San Francisco, California.  The Company shall pay all JAMS, mediation, and arbitrator&#8217;s fees and costs, irrespective of who raised the claim and the outcome of arbitration.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Conditions to Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement is contingent upon a background check clearance, satisfactory reference check, and satisfactory proof of Executive&#8217;s legal right to work in the United States.  Executive agrees to provide any documentation or information at the Company&#8217;s request to facilitate these processes.  </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of California.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of any controversy, claim or dispute between the parties, arising out of or relating to this Agreement or the breach hereof, or the interpretation hereof, each party shall bear its own legal fees and expenses.  Notwithstanding the foregoing, in the event of a finding by any court having jurisdiction over such matter that any party initiating an action under this Agreement failed to have a reasonable prospect of prevailing on its claim, the arbitrator shall have discretion to award the prevailing party attorneys&#8217; fees and costs incurred by it with respect to such claim or action.  The &#34;prevailing party&#34; means the party determined by the arbitrator to have most nearly prevailed, even if such party did not prevail in all matters, not necessarily the one in whose favor a judgment is rendered.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the Parties hereto.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.7pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any provision of this Agreement as applied to any party or to any circumstance should be adjudged by a court of competent jurisdiction (or determined by the arbitrator) to be void or unenforceable for any reason, the invalidity of that provision shall in no way affect (to the maximum extent permissible by law) the application of such provision under circumstances different from those adjudicated by the court or determined by the arbitrator, the application of any other provision of this Agreement, or the enforceability or invalidity of this Agreement as a whole.  Should any provision of this Agreement become or be deemed invalid, illegal or unenforceable in any jurisdiction by reason of the scope, extent or duration of its coverage, then such provision shall be deemed amended to the extent necessary to conform to applicable law so as to be valid and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision will be stricken, and the remainder of this Agreement shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.03pt">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The rights and obligations of the Company under this Agreement shall inure to the benefit of and shall be binding upon the successors and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">assigns of the Company.  Executive shall not be entitled to assign any of Executive&#8217;s rights or obligations under this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.02pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, along with any other agreements set forth herein, including without limitation, the Proprietary Information and Inventions Agreement, constitutes the entire agreement between the parties with respect to the employment of Executive.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:216.9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:48.717%"><tr><td style="width:1.0%"></td><td style="width:12.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.873%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:25pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Whitney B. Jones</font></div><div style="margin-bottom:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58; Senior Vice President, Chief People Officer</font></div></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRATHYUSHA DURAIBABU</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:41pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if7e2de1dc2b44b62befe436138735c95_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;padding-left:43.2pt;padding-right:43.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:50.4pt"><font><br></font></div><div><font><br></font></div><div style="height:82pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_1a.jpg" src="image_1a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:83%"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>sgmo-20210631xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i8592ab1d0c654c04af3ac2296473f4e3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this quarterly report on Form 10-Q of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;padding-left:144pt;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 5, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_1a.jpg
<TEXT>
begin 644 image_1a.jpg
MB5!.1PT*&@H    -24A$4@  !7D   "," 8    I\JJA    "7!(67,  $SE
M  !,Y0%USO"5   $6$E$051XG.W8,0T , S L/(GW7+8,T6R$>3.+
M6?,[      " =R8O     $"8R0L     $&;R @    "$F;P      &$F+P
M  ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P     09O("
M     (29O       828O     $"8R0L     $&;R @    "$F;P      &$F
M+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P     0
M9O("     (29O       828O     $"8R0L     $&;R @    "$F;P
M &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P
M   09O("     (29O       828O     $"8R0L     $&;R @    "$F;P
M     &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)
M"P     09O("     (29O       828O     $"8R0L     $&;R @    "$
MF;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\
M0)C)"P     09O("     (29O       828O     $"8R0L     $&;R @
M  "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\
M    0)C)"P     09O("     (29O       828O     $"8R0L     $&;R
M @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A
M)B\     0)C)"P     09O("     (29O       828O     $"8R0L
M$&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\
M  !A)B\     0)C)"P     09O("     (29O       828O     $"8R0L
M    $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\
M      !A)B\     0)C)"P     09O("     (29O       828O     $"8
MR0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(
MA)F\      !A)B\     0)C)"P     09O("     (29O       828O
M $"8R0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(
M    A)F\      !A)B\     0)C)"P     09O("     (29O       828O
M     $"8R0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!V
4_&MJ-&BCO]4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>sgmo-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20210630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20210630.xsd" xlink:type="simple"/>
    <context id="ic8ea400821bf458997c74f535136745d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8bcb1501dfde480bb4a686c561586117_I20210802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="ia45a1fa516b24d509732822dedf80969_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if338f7d54d3a4f0cbc40c646455f0cca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if53d95c4f09b452589c92741496adec4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id509e95c58494ac8b19b3740eed626fa_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i451bb316444e433b8be0465675c9e502_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie0fbd6f12c9b40f7abf2b4e635ce09f8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib2532553bed14edca6798c93d083aa90_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie634578fb36048be98621104559edee6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9f40f023c8ff401bbb0eea92048c2752_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6818cea0cc0b4106acfd0ca299befb47_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i76400ba7a5394ae4bc48e57baf0b6966_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4050e8c74a1147cc858267b0e1b8c758_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic4d7313265bb442da33ae6f84d7c4862_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6c7f4351eee949c28a8776c4fe2c8654_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad53a190fa514e688060deebfd68d2e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8378ff7fc294b15a732b761ec44147c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6eb4957d21874146891b6c52f9a92192_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a8701b92bee4274ac683fe19bd1cfb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0cf2619b93af4c25a04727500e864515_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if136e6082b014302baf06eb9f33155bf_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i97c17820b63e4da5941380170aa10773_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3b9e78a2e83c4087b0d4cbfa66208b48_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iafb3ae2aae5a4f0da0dca70b744f197b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i91aa883725fe42df83a8efd02d7c81ac_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i381ca00d71c943629317c963c76a5403_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i7187c32f2e32406b93490265952a56f2_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie6222a8ff3b04b6a8b4ecb256e9b6bdc_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i93b4beb7f3064e62bae7ad43156944d3_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i799d8cc66f694906a0ab37290354d60d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i34c9bc741cc74c3f88015c7a849b517b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i12281bdefbdf476c8cfaf9303e3c4896_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ieb82e1104246402e998da7e18d3ac175_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1a22c45761394b75af4d6906696260fb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if5d851e70bb94ec78db2876e006a48d5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i18bb63471d3c4a7ba84788fd8f7005ad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1885d06587d454d8be9824fa3e6e68f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5e35e880a7ba447eb1db041c02cd0fc8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4afcf835853b4cad93648a7670596835_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3e76a7f09ff044139311009878988bb1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i18d94baa04ca43eb8d75f34105ed0623_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6df4f65d331a42e78e2fa83fb2c3971e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i43fb5fc4bec0489486d7be362a594089_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i160cf032b081413bb08a84005c04a475_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0dcbc0880e6f4929a436952cda81d81b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i826478ddac2547de9623bc77195eae38_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i06147cd0f2824f5c829d965b134af50c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i977b331cae2c44558ac4d8807d9beb5e_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i24e0372fb79547c0ab5707e59b555660_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id7cdf486da744840ae163e4c93082f83_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id443d9ba83d14bce9aa23f4e3906af56_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3900ce573569432e830a630426d6a8c7_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if3993368d6f34912853e783bfc42062f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46690bda004c48dc8fe1a34394fe2539_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id650bde047e54d44a28d7f3cf2147fba_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb3e1f0817d14b5082132f338ddf990a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i44f8df10acdf47de8be2793787e32c3f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6273dd375cbe431e851bf02f766c7d30_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3713011fcaf74d139f418e2d8b93a054_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id56b04a6fd3d4593b0228bf4b5070845_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if7f9b84d68624a3d8da6266d4a51b5f0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2323e4b2ca47436ab949fc5059e374c8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id901d356b1b34e939be8837407f81c5e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iede1b461482d4aed82d73d8a69942f6c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1cc0cd49c9d441feab4a2812269fe281_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i077c5113d6c84b65a3cd01c8c474aebf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifd9e21d00fd54ff8a09781d3bb15014b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i24d0b873fa0149c8b7057a9015e35d00_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id562a87f24e64a2389a1d8d8af690954_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib805bf377aca43d18a31ed9b25cbd937_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if450e0b0e1ee4143a860c134efa23684_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0349e23895b7421f8e06a6dbc6671d20_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8183472477d84945864fdedade5b202f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib5414aecb9154731b24f5050b5dbda09_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8db22379ed084ff283dba3989fe52b6e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib5029632c41647f2876db827348be963_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7def2ac71bde401591646c0426604256_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i68379fd4ffaf45be8859410fd6c6d092_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i64b7b79fb378470c800337959c76517b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i505b398cb72a4af8af945f5b2a8a5a17_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2f8eb9c45d4c408ba0e7213a7b21a8e3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia4e0c6ce0cdc4cdc85330469e1cebf83_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i02b46bcd8bc6494a8ffa054541480b01_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i720ec452f326424cae2d555e85cbe793_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i63e206d594384d51a4a4ea755c3ecac8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iecdcf307636f43bea5bac2dc2e4668ea_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic12cf9801c6e4bbd868ce62fb93d0483_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1309e7273bd24e24a45b18f385fbd498_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92fba028dc354b2eb96680caecf3f6e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i362bde0e7ad9484fb5748204542558d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i908904f75ecc47cca4d8fca5927696db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98e5bee530c449aaba799aaeba075e38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibaa17aef4be24c9488134ae6b2d112e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ec88d85ad284f01bb0601faca0f26d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11554ac8395246c1b797508e7c8e254a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifca71a895253445d9bab2b29a4f24697_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6afbf16e0ce49a4bbc2a2f2ca704329_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2d98818a61914dc19882f4a5fe585eef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i303ee2bb6e9a4ebaa06e5883c4402433_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4c30dc9b677a4b0ca056c73e4e52b5c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib77476f69b30416498dda50883c18ac1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7061108114744e25af56d34f408d6462_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d79151e513b4079a0407f83cc2655fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbaf1eb6abc0483f8d83c17330ca0080_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8bb3dfe79994423bbacf9f8d84283e72_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i13dbd67b064846a580f0e2753a85487c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0ad85f098bcf421c8794add0b139710b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1617c6130bb4fcd814b7b116daca30e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8a854ccb6ff4f32aff9c08dace430ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ce000386f6f43ecb585bb2bddba79ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic22c7a6ee30f40759935f2f2d7d05834_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i963546ecd5104507ad517a04791a50c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i706c0c1baf274bb08c2015e44b1886de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i58a9adeab28a45ad91025a9d341cc25a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1328c5aeb1034e05853f1890344e7e0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32c8d36f055d46c0bbb5f38ae8ded7f8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7dad1abe8fca4c9dabb1a22b9f475901_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="i381be31f4a96421eaace1530a63600f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc3d33b771494438a51064004b2d92d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6117a419ac54480ab8e969b26e8ae160_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie3ba6686f885449fbf9782164f707326_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide00909279d94c5a9ba8d214c592b3ff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputExchangeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i81061d827331480d88e9dc8cbe6d82cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if916a4018cf94a308d569e7cc671aeb8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4194918b5c8f4b7b829c28cf27413388_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c37f58da8234bf5b594e14ec1be3875_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1418093930b2494c9efc86566330110c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i22e9e7ac993e4ab7b129b505e24d788f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i36c99173dbfe418bab2ee3066dfea7db_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8ce71d590cc54013935014a27b276620_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8e6ef0b9d424f72856f86ece181ec9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib92334fc47614d2ab175150cbbea1d90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe7231be7af84f809a1dd4836d13b306_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4760033181744f46bfacb2148a09aa31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2b87a7579154dcb87d6a2eacbe03968_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ad6e61fa5a14049a4a165e22c9557b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie97ab57d631741109dd7c1a32d722ecf_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i16b4febff3d343589497559b4dbc5f8b_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i8b84cec3c18f41669b32e9a32a83d4da_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i8586e51ff5384c2b9ada2a4f735e3e0f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2e4879cf2b1844a59c47a50b6bf44286_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1fbe30a7032d47a7a786786e1076584a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4cff57d2627245a98dea197fe78cc195_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic486fd39de0248c3bf81822737de9125_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib688d56d6edc44adbe31811d44707d1b_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i835ea8e2ca074d12bcb1b9c6349fbd74_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic9188107d02544fb9b95edda10fc6daf_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2d858ffe5d284f3fb40b15c110d4d661_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc0a358e8ea34e7d96de8f674d8a0733_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1bf78996e51842fd8c577ced5c319f9e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2c078f8f84f44092b1c987d2f9ba3780_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4cd324fe4f6a48e79647a1e6e13a939d_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f0fa707fab440019c997c6ac3943ca0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5850fbbe650b4f7ca149d58bba066b5b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6d9cb92b6b80443c83fcad54e2dcea08_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibee042a0e57b44b08fcec9b88eb3ff1b_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ia808be1f58f54cccaab1ff5dea2e968c_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i80a6feacaa574ddd9bd1767b41d0d48e_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ie7c1b1cdac1240e2ab1190ed09b03af4_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="iee0d594216f84c7c8299b126f82ebab2_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2feef78f3b79481c95ab041ca41b6d27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i91eecccd242942a7817f59f45d876655_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie6aabab5ee264688a6d71a905f925e4b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idcc2dd941800420886a2af2fa1765639_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibbabaf0c6e544c5696a66609bb1a32f2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5d932e2741554bd4a83bff4554127b46_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia45f3ae8095146d9b1f030e6d1b3c45e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icfd23694ec1c40ae9f6a4c23849d8ab3_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i03284b31d89d49b79fcb22265c258ce9_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic897ac864eec4950857bfb672f25b043_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4323b438c56c49ddbd9f8c4452cc5cbb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64d854a46e26420aba7a79befd4d3e77_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i633a41af52284d31bdc9e6504274de2c_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3572522eb86c427da2f7e25c65c67b1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03b2f05be78a47058af5e123836007ae_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie0d564efa3a54efdbab0331632c968f5_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id7b52cec79ab48a2ba640cefacfbece0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ib8501312825a4e209788ef85d358bc38_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i96eec01b5a724940ba35b94c5052e547_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i513cb6fdd03a4af6a95f35c66fa0287f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib0d915090bdc4052aaca779390bc0142_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieee2cbdd740b48d58e90428fd2477bdb_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i80babf04d54545919679cc087e35d0f7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30a3cd7910e54e3ba3fb080b6faa69ac_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id0d5461382a74ce0b82725ff6d4dffd8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ieb3c41b97bcb4c6893772a2384819bbd_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3cc29534661e4306917bc72380c1ea3d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i972f741b215341248c20287be9d34ec4_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie2f6b10a317f4701aac7778e60fc00f1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icc812ad521304f0ab6d3a2b04029f0f8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i654a42c3511c4a73913c506f1153cab0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i284384bda5c84aba85f546f831ef8980_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i59545cce221e43deb1db8aa0c8c8619f_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i4902644de3a643778c13659e688fac50_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="iaf27be7caa634555848e2064b64db08a_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i1599f0d2349045a39ceba19a613ae914_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75557659a8d24752a662921819a09f1c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:SBFiveTwoFiveAndOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icafc6c9e5da64fc39cba314fee725d9a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i29f42ad77a67406fbca238b8af8a5ff2_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4b2ac5d2705044b993a63db847d92bd0_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iedd52702a7604029a53060995365270a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i02d5cb930a144a9cbb549d7b9e0cb689_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i123d6bac6b904da084b4648b22e9cceb_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if1d3391092d7417eac346ff77c7d0fcc_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ifc852cf62580436a97598e1e2e7bf50b_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i78f2298db25940a68086c2f2eb497a03_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i4dff6bb9876a41ea8f14c14d974128b0_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i816dc751251a43bc8a0c475d4f25692d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifd8b8b826b1842fc8ed899c4dbf877d6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id4750f84c1fc4cd28df96b044fc89692_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id613ed24d16b4765acccce91ced04655_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i265ca64c9422418893702f8fafcef2d2_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i4e4aeedad67245b6b57656cba94ee249_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="iae65106e3a964b398c60b12ac672bd06_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5b2e93e3f8e44d4f8070ca3215e04801_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i65fc4f7975b44d38bd7edb0af5fa7902_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4f67506e89ce44568390610e8d2b4c62_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89c77516ab934aaaa96b5a86b02b8088_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie375b8492a12465a99eabff9410bf3a4_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1512a9ddf574d86903b981a4ce57329_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i585d0b863b2e455eb3b8ea38806281f2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5b7cd206e83e4758904b5e5fc3f1286e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i710717b98c6d41c0b46518ae1f4899ff_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i18d41eac62204415b943de1ef2ecb501_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i05b743385b4d48ca9fe7791ecbb5bb8f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id6900d77cd9b42d4b868148dfc43e2dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ac0654b4e2f48dbaec56149181d417a_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6b5cd1c78eb547b6a7cf66897094551c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8f6533454f547909bd615768ac32c21_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8302d557aa5476eb1873deb8ef6875d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1bbca3607d7f4b9dbfe618a574b3cf7f_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i38026dfb9ff54ab38444e2c29717dc5d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8627855bb84142d381d3d87efbd3557b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3deb558477ad44f6a2d0a235b31ff428_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i703707af95494f1883c80ff59a982ada_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia1f96a8d30f2472682f523526a58819b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idbaf08395b3f410388bfae8549a7f1ec_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iaafcd0ad264e48e3aa1e5d6b42480cf1_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7d369449f64a4fe9802fbfa50d7c5894_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i486e45b737f34ead89ccdfd67614cc80_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if65442cfd04e40d3ae655da86b882810_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id6a2fee8655546779fce8418e68deeb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia382d9bdbbdf435a8b54bc9a6f870e20_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idf88ce12a67f455e9a78d4bf52333bd6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i77ccec543f23406c8dce0f2a0b6c2285_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia0480773874148cfac5726298c1d7995_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i54bc17f50cf74a93848b137afc7fba91_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ie759a817c5c842dc869ef8337be7e5b5_I20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-01</instant>
        </period>
    </context>
    <context id="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="ic293643aa8de4967836920062840361b_I20210129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="ib32b37dab57243ff923131f59634e7db_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4481f3dcb92a483898be17cb32b7bf7f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id91afce1bd2045ce87ebb34073d3ebb3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dbf6eee474c485286ce46451d007985_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5e9b0b01e53e4cc1ad161df3748b4306_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib2337f42bb8a494cb58c83594f9439eb_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ife2d5e93bac84cb9b315459ace950026_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64c0de19663e46b5a34f83368fe2a0c0_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i193dfd8314f24ec6b3d6b58709ed8e14_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e988a6d8f274d49aef75fec334e2456_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i287279db3cc248a09fec60c8d435c802_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68bfdf24a47d45d792d479c5f84033cb_D20210701-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i5ced8520ef3f4fabbda53a780b5dc09d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i192244a99ff14df4a634c33f2294f707_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i302cfc143c434200849acab7c19e79ec_D20200101-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9d0d661e140c49a08925fdca70921940_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iaedb801aae5d487896c33c8747f89875_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="royaltyfee">
        <measure>sgmo:royaltyFee</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV8yLTEtMS0xLTA_e0c28a91-06b5-4d41-aced-9ee912d48ca1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV8zLTEtMS0xLTA_d7f97516-b100-4979-a0ed-a956045ba09b">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV80LTEtMS0xLTA_79439e88-38ab-42c1-afa4-f01c460352f6">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV81LTEtMS0xLTA_577edadb-48fe-4f2b-8fe6-5cc49e44c1e1">0001001233</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80L2ZyYWc6NTA3M2E3NTNhOWEzNGQ1OGE2NzViNjgxNTMzMWNhN2YvdGFibGU6Y2U4YjMyYjAyYjEyNDZkZTk3ZDcyNjhjYTA0Njg2NzkvdGFibGVyYW5nZTpjZThiMzJiMDJiMTI0NmRlOTdkNzI2OGNhMDQ2ODY3OV82LTEtMS0xLTA_033e1896-7a70-4b09-8741-3cb6f3d79d25">--12-31</dei:CurrentFiscalYearEndDate>
    <sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset
      contextRef="i1418093930b2494c9efc86566330110c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xMzEwL2ZyYWc6NWJkZTgxYmM3Y2I2NDg2ZjllZjIxNjBiY2NlMzRkYzIvdGV4dHJlZ2lvbjo1YmRlODFiYzdjYjY0ODZmOWVmMjE2MGJjY2UzNGRjMl8zODQ4MjkwNjk3Mzc2_cf548017-480d-4395-91d7-dd1254b1f172"
      unitRef="usd">0</sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ia0480773874148cfac5726298c1d7995_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjc3_08762a14-8ec2-41bb-9293-f9377bdafc34">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcw_6b25b739-e76e-4500-aff4-f2d95998f2ca">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6YzU0YWFmODQ4ZWJmNDgyOGFkZTA1N2UzZGQ3ZDc2NGMvdGFibGVyYW5nZTpjNTRhYWY4NDhlYmY0ODI4YWRlMDU3ZTNkZDdkNzY0Y18wLTAtMS0xLTA_9c1f1c3c-1ab8-48a3-b31a-56d2f333fc3d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMzM_64bfb901-361a-4259-84f2-45746e1209ca">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MTI0YjRjYTU3MGIyNGRiNGJiMDRiNzM1ZjY3YWRkMDAvdGFibGVyYW5nZToxMjRiNGNhNTcwYjI0ZGI0YmIwNGI3MzVmNjdhZGQwMF8wLTAtMS0xLTA_1c67944c-8548-45cc-8f5d-c94f1fdeab99">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc1_388d6c0c-6264-4554-8e1d-a26be19dce98">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcx_77f0ce96-efad-4932-a6d3-93335c63b308">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18wLTAtMS0xLTA_88d99557-23c9-4715-aa06-7b812fb35445">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18wLTQtMS0xLTA_d44bcf5d-be5a-4a2d-aef5-8bc18a8b51dc">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN180_c0bd870d-a582-4c8e-9e55-70daa0c5bdf1">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN184_61d34e23-4099-4a64-bab9-ba3ee5228d95">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN18xMg_c704a47f-6dbd-4ce5-b358-3b0d79899ddc">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmUzZTM1MTBmMjMwNGY0MGI5YWM3YjczODU2Mjk0M2MvdGFibGVyYW5nZTpmZTNlMzUxMGYyMzA0ZjQwYjlhYzdiNzM4NTYyOTQzY18zLTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZDlmOTM2NzQ4ZDY0Y2Y1ODA2YmY4OGRlMjI0MTQwN18xNg_26c74176-1fbc-4373-8a10-bebd1a0dd93b">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcy_00582d55-10b7-4812-a2e5-c2f5e80b0fd7">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc3_6f30b53b-e0e3-43c4-b1be-884a4852bdf0">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTAtMS0xLTA_f8d34911-0889-482d-be39-449773a11b86">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTItMS0xLTA_58fd0fa6-454c-4118-944d-9216934a681f">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6ZmQ1YWRiZWZlOWJlNDcxYjkxZjAyNGRhMWY0NWNhMjgvdGFibGVyYW5nZTpmZDVhZGJlZmU5YmU0NzFiOTFmMDI0ZGExZjQ1Y2EyOF8xLTQtMS0xLTA_9b38c973-52ce-422d-a613-349db8e614d5">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjY5_548420df-5dba-4562-b48d-fd8b199ff2d8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjcz_400cc6dd-836d-43fa-9a6e-6e6580d84c55">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8wLTAtMS0xLTA_0d298b53-6498-4c01-b9f0-e8d302b16123">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8xLTQtMS0xLTA_0643d76a-7871-4043-aceb-3390db004637">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGFibGU6MDA5ZTNiYTExYmZjNDBiMjg4MGI1YTljNmU0MDA2ZmEvdGFibGVyYW5nZTowMDllM2JhMTFiZmM0MGIyODgwYjVhOWM2ZTQwMDZmYV8yLTQtMS0xLTA_d7a86d91-7459-4ae0-95d4-1853d529841e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMjc0_fe57dfc0-1df5-4ab9-bd59-81836498d081">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8bcb1501dfde480bb4a686c561586117_I20210802"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8xL2ZyYWc6NTMwMGE1M2I1MTY0NGZkODhjOTA1ZmYyM2RjYjRjNjYvdGV4dHJlZ2lvbjo1MzAwYTUzYjUxNjQ0ZmQ4OGM5MDVmZjIzZGNiNGM2Nl8yMTgz_00feb054-7951-47ea-8446-236e7a1e0401"
      unitRef="shares">145337046</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMy0xLTEtMS0w_8c3b2185-f69a-4c26-8e00-cb6f501407f3"
      unitRef="usd">169878000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMy0zLTEtMS0w_2a393978-ad35-44b7-ad97-43e8b9bdcfad"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNC0xLTEtMS0w_cacd96ae-e9c3-4019-b1c2-7987abeccee4"
      unitRef="usd">359775000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNC0zLTEtMS0w_22474d78-111d-4822-a812-a43a943988aa"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNS0xLTEtMS0w_04f15e30-c508-4dbd-9648-c479a5bffc49"
      unitRef="usd">807000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNS0zLTEtMS0w_8259b61b-0a18-487b-aba5-fc6e834dc912"
      unitRef="usd">1035000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNi0xLTEtMS0w_91528e66-e1d7-4ff1-9a9e-08658ff8dcab"
      unitRef="usd">6882000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNi0zLTEtMS0w_89804a65-a0bc-4f49-9a39-0b6a0bbbd901"
      unitRef="usd">5224000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNy0xLTEtMS0w_76463c2e-56d4-4c86-9387-bb6a02cae626"
      unitRef="usd">16722000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfNy0zLTEtMS0w_e68d8e95-e0db-4a29-8dc9-c8b15aaaffc0"
      unitRef="usd">11986000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOC0xLTEtMS0w_17af1ff9-0ce7-46bb-a9ed-eecfce9c8fbb"
      unitRef="usd">554064000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOC0zLTEtMS0w_ad5d5178-e2d1-4be9-8f0b-ddfa1f76c74f"
      unitRef="usd">659668000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOS0xLTEtMS0w_81e94bb4-bc6a-4cb1-8a62-039c72bddf4b"
      unitRef="usd">49205000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfOS0zLTEtMS0w_84c48610-99b1-471a-bfba-e34122b06d86"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTAtMS0xLTEtMA_b39131d9-a279-44f1-814f-5530fe70e5c8"
      unitRef="usd">49588000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTAtMy0xLTEtMA_f3daf367-62c7-4217-b3a4-22a60307e731"
      unitRef="usd">41324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTEtMS0xLTEtMA_2c00994d-12f9-4864-8b6a-eb7648890fe1"
      unitRef="usd">56298000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTEtMy0xLTEtMA_61a2ecf7-ccc9-49ec-81df-093aba91b607"
      unitRef="usd">58128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTItMS0xLTEtMA_3b357f8d-5e81-4110-b880-c5a5309d436c"
      unitRef="usd">41501000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTItMy0xLTEtMA_ef862ef6-d394-4fee-a99e-6f38a22cbec5"
      unitRef="usd">42798000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTMtMS0xLTEtMA_46b74521-59e7-4e46-87f4-0d91943757ff"
      unitRef="usd">68304000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTMtMy0xLTEtMA_01c7bad8-e697-4e30-8363-4a2ef25db786"
      unitRef="usd">71045000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTQtMS0xLTEtMA_58021c51-9cb3-4fc8-9784-d2a1e7099c38"
      unitRef="usd">14903000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTQtMy0xLTEtMA_e4e3a20a-dcf5-4f80-83d2-5466ce5a75c1"
      unitRef="usd">13557000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTUtMS0xLTEtMA_846a0478-5baf-4f21-b24f-20a764f4797a"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTUtMy0xLTEtMA_0b969638-2f22-47fb-a132-94f92c3ad81e"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTYtMS0xLTEtMA_2dd2f4db-8fbb-4607-a7c9-ebee22a8d263"
      unitRef="usd">835363000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTYtMy0xLTEtMA_b09e79f2-5c05-4e30-a10c-ecfa02ac00cf"
      unitRef="usd">938550000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTktMS0xLTEtMA_cce96a49-cf19-448d-a661-73695d4cb4dd"
      unitRef="usd">10132000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMTktMy0xLTEtMA_812943dd-60b5-4d5d-bac0-09242000bd4e"
      unitRef="usd">12553000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjAtMS0xLTEtMA_18e8844d-2b01-498a-93b5-045951092515"
      unitRef="usd">17406000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjAtMy0xLTEtMA_8707a518-c3a9-4c3d-9c01-a2fdc84d49a0"
      unitRef="usd">20738000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjEtMS0xLTEtMA_53bc3724-d2ba-4305-9210-175276e6abbd"
      unitRef="usd">15448000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjEtMy0xLTEtMA_fccc50b2-6c87-495b-8594-95a252e70e93"
      unitRef="usd">18612000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjItMS0xLTEtMA_2938cc41-d4a1-4cbf-8e03-18962ecd4c85"
      unitRef="usd">93957000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjItMy0xLTEtMA_24959f5f-b2fe-428b-862c-ab6284001ba2"
      unitRef="usd">91644000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjMtMS0xLTEtMA_44d3c75a-7f29-409f-9e4d-2c31cb05467d"
      unitRef="usd">136943000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjMtMy0xLTEtMA_bd8ab807-b29f-4d6d-8eba-2c389bff8a81"
      unitRef="usd">143547000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjQtMS0xLTEtMA_d6e5cd51-0f90-49a8-9df5-ebda86db30c5"
      unitRef="usd">201251000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjQtMy0xLTEtMA_5e27b232-895b-4da7-947c-e889512b99a2"
      unitRef="usd">245045000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjUtMS0xLTEtMA_a81c7a50-3022-4d21-821e-30d7b0037421"
      unitRef="usd">37328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjUtMy0xLTEtMA_4c6a1e47-9dd9-44fc-a4c7-14304cc1f318"
      unitRef="usd">38396000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjYtMS0xLTEtMA_cff707ef-d90a-4f34-9be8-f33af1764d21"
      unitRef="usd">6959000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjYtMy0xLTEtMA_01ea0df1-a9fa-48e9-bc18-976b8e6764a6"
      unitRef="usd">7185000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjctMS0xLTEtMA_12f559b8-e131-4a26-85fd-c29233908759"
      unitRef="usd">7425000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjctMy0xLTEtMA_2c29edaf-6254-4e9e-bee9-a705cb96ad18"
      unitRef="usd">7011000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjgtMS0xLTEtMA_d66dc86a-fdd3-46b3-816f-ff6c62916d55"
      unitRef="usd">389906000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjgtMy0xLTEtMA_9c079daf-6170-48b9-acd7-7f2abe8311e7"
      unitRef="usd">441184000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjktMS0xLTEtMA_b05f4a30-a1fd-49b3-8097-3563f2d921cb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMjktMy0xLTEtMA_fa38cd96-c9c8-4e7f-ac34-2ef437bd1636"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzEtMS0xLTEtMA_1df77f95-053a-4d79-bfe9-a7d03a6fdd34"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzEtMy0xLTEtMA_79472aa5-db15-443d-bfef-6117a337ef3e"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzItMS0xLTEtMA_d5a98df0-5e51-4428-95c4-b5e16e7e8fc1"
      unitRef="usd">1451000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzItMy0xLTEtMA_bdaa3f78-3ce4-43ce-b0a6-031e47c2dab3"
      unitRef="usd">1421000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzMtMS0xLTEtMA_26351cb3-6c54-494a-8d16-6bd009209eb3"
      unitRef="usd">1313102000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzMtMy0xLTEtMA_2603151a-9d09-47a2-aff7-6a0c9ff3f144"
      unitRef="usd">1269375000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzQtMS0xLTEtMA_a7595f52-321b-41ac-92ac-8088cb713f9f"
      unitRef="usd">-871083000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzQtMy0xLTEtMA_95e8de4b-1a00-4612-bcfd-80e0e102eb0d"
      unitRef="usd">-777981000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzUtMS0xLTEtMA_23c47656-b28e-4732-ac91-6286c1091667"
      unitRef="usd">1987000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzUtMy0xLTEtMA_3dea4416-5d27-4361-be58-d5bf4d15ca72"
      unitRef="usd">5419000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzYtMS0xLTEtMA_7b7ad35a-bc58-462b-92f1-37c62897f269"
      unitRef="usd">445457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzYtMy0xLTEtMA_daf34205-a28b-4762-9f43-c591fea4cf1d"
      unitRef="usd">498234000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzctMS0xLTEtMA_fa2271fd-d19b-4a55-94ce-ff518fbb2abf"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzctMy0xLTEtMA_bb9f27f1-7972-4f69-aa0a-0de9d5234f4d"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzgtMS0xLTEtMA_c6c4c503-a56b-4fb3-8309-60744bc329da"
      unitRef="usd">445457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzgtMy0xLTEtMA_ff94a03d-9d32-4d92-bfa6-841e3bea7752"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzktMS0xLTEtMA_c214a8f7-d3e8-482a-a7be-907afb1032db"
      unitRef="usd">835363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yMi9mcmFnOjY4ZGRmODU5YzI3NzRjN2RiYzRhMDU4MWZhZTQ0ZWMyL3RhYmxlOmUwZDc0OTlhZmQwMTQ3YmJhZWYxMWE0OWU1YTllYTdiL3RhYmxlcmFuZ2U6ZTBkNzQ5OWFmZDAxNDdiYmFlZjExYTQ5ZTVhOWVhN2JfMzktMy0xLTEtMA_ee850870-0540-4508-a5b9-dd4efc7c2626"
      unitRef="usd">938550000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0xLTEtMS04MQ_6e6d520b-c0db-4aae-82bc-e29b622474d1"
      unitRef="usd">27872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0zLTEtMS03OA_43566cbf-29d4-44e4-bed7-896754d15858"
      unitRef="usd">21553000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi0yLTEtMS0w_a272ce4a-1acb-480d-a974-dc58ebf3a28f"
      unitRef="usd">54152000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMi00LTEtMS0w_b5159c3d-1c44-493a-8b1b-13e980fb7ba9"
      unitRef="usd">34629000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0xLTEtMS04MQ_c9e2b12d-e9b5-40a6-97c5-8d4e4637db08"
      unitRef="usd">60086000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0zLTEtMS03OA_4c2c20b2-ae80-4628-8456-00a8350102f1"
      unitRef="usd">41523000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC0yLTEtMS0w_e15592d7-ad29-4c11-b5de-66fd15f55e7c"
      unitRef="usd">116520000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNC00LTEtMS0w_d871f443-1ab7-417d-a77a-aa9cfc4ca7b7"
      unitRef="usd">83002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0xLTEtMS04MQ_58138e7c-be89-4de4-8647-46960d9beafc"
      unitRef="usd">16486000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0zLTEtMS03OA_55f8381a-8b40-43aa-911d-a66a03cdd1ec"
      unitRef="usd">17927000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS0yLTEtMS0w_6da1220e-0f47-431a-aec4-45ac7ce1c121"
      unitRef="usd">32634000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNS00LTEtMS0w_8d5c4336-688b-4acd-b6ec-2321b39bcf22"
      unitRef="usd">34046000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0xLTEtMS04MQ_77296df1-6e44-4bb3-9178-d3184d3a7b2d"
      unitRef="usd">76572000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0zLTEtMS03OA_cf53dc7d-ca48-429f-95eb-873520b6720e"
      unitRef="usd">59450000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi0yLTEtMS0w_81f38c47-8490-4318-a2a0-d306322115aa"
      unitRef="usd">149154000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNi00LTEtMS0w_bd849a11-40da-4de8-bbae-fab83a1d981a"
      unitRef="usd">117048000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0xLTEtMS04MQ_23d43f78-4a20-409e-b5f1-f1d5ef3024d1"
      unitRef="usd">-48700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0zLTEtMS03OA_8b69f69f-63a0-421e-b0e0-755882ea76f5"
      unitRef="usd">-37897000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy0yLTEtMS0w_7c0a74d9-5fe2-4f07-909b-796e995ee7bd"
      unitRef="usd">-95002000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfNy00LTEtMS0w_a3bed0fa-8730-459f-8a93-a3bc6b4f83a1"
      unitRef="usd">-82419000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0xLTEtMS04MQ_25c90d7e-ce68-4524-a7ec-f0b0e52503b3"
      unitRef="usd">1550000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0zLTEtMS03OA_ceab933d-b458-411f-9194-95e5c6dad1d8"
      unitRef="usd">1932000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC0yLTEtMS0w_610f6384-a648-4a75-9c6d-bab831d3e3dd"
      unitRef="usd">2176000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOC00LTEtMS0w_7ccd0f19-df0c-4e9d-8012-e469f4edd871"
      unitRef="usd">3480000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0xLTEtMS04MQ_0c137bdd-a361-45d0-9b3f-16aff842c1fc"
      unitRef="usd">-47150000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0zLTEtMS03OA_ad0e4223-0745-4eb3-9764-f794def4373f"
      unitRef="usd">-35965000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS0yLTEtMS0w_0c8a0ed3-6f9c-4769-ae3d-f154030fe325"
      unitRef="usd">-92826000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfOS00LTEtMS0w_c165f78f-4591-464c-be98-18c0390e4e5a"
      unitRef="usd">-78939000</us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMS0xLTEtODE_bd274728-8be3-4e1f-8cd7-8c0575a44394"
      unitRef="usd">24000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMy0xLTEtNzg_14645e47-e2f7-4bf7-b589-8461e1bb1417"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtMi0xLTEtMA_b695d366-6e2b-428a-8a43-f17d354ebc5a"
      unitRef="usd">287000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTAtNC0xLTEtMA_79c7fac7-9cf6-4977-9a8b-3eccd089086a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMS0xLTEtODE_3660158b-9be7-44a6-ab71-206209c8f7f9"
      unitRef="usd">-47174000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMy0xLTEtNzg_050f5c98-6a10-4aa3-9124-8fa128a38cc9"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtMi0xLTEtMA_1b2aba0e-a5b7-4b97-81ce-349a9b21fc5f"
      unitRef="usd">-93113000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTEtNC0xLTEtMA_e3b5a7bb-25a5-4192-953a-70f06880bc55"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMS0xLTEtODE_ff89a354-aef9-4ae8-8ff5-ad6e402e42ee"
      unitRef="usd">-5000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMy0xLTEtNzg_332a95c5-f055-4aaf-897b-7d82ca6b7c8d"
      unitRef="usd">-36000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItMi0xLTEtMA_0a6e379c-4987-4614-b640-2f8b506882a0"
      unitRef="usd">-11000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTItNC0xLTEtMA_dcd00b86-3eb0-4775-9a9d-2ba5a6b2be2e"
      unitRef="usd">-97000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMS0xLTEtODE_2e6c3b2d-ee16-4970-a493-2b6a47591c99"
      unitRef="usd">-47169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMy0xLTEtNzg_cfce3b55-9ebd-4227-9f47-3d8f5ccb686d"
      unitRef="usd">-35929000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtMi0xLTEtMA_fd6de286-15a3-4b33-9b35-17c3d66ef0d5"
      unitRef="usd">-93102000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTMtNC0xLTEtMA_b0b2cb29-0a9f-4b92-a01d-89421eb0970c"
      unitRef="usd">-78842000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMS0xLTEtODE_21d1a89c-e3b6-4b18-9d9c-fb97cd1acc51"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMS0xLTEtODE_34db838d-c729-4cb1-ba62-d159926a403e"
      unitRef="usdPerShare">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMy0xLTEtNzg_1ef7312b-95c5-43d0-b047-a847bc552e93"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMy0xLTEtNzg_8bba98ee-98df-4030-93fe-f4eee92e280c"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMi0xLTEtMA_d9fa1e63-238c-46ed-8fc5-51eb8356f175"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtMi0xLTEtMA_ed36776d-c2d5-468e-a29c-945409cdab9f"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtNC0xLTEtMA_9da5364d-4ed3-4d4c-9fd7-3fce3c0c4bb0"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTQtNC0xLTEtMA_f14fe437-e3ea-43b9-b57b-da9bcef5967d"
      unitRef="usdPerShare">-0.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMS0xLTEtODE_47c37ac2-f3cd-403d-a992-38f7f995c4c9"
      unitRef="shares">143984000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMS0xLTEtODE_fd963f12-1fab-4acd-aea2-79cbe38a7435"
      unitRef="shares">143984000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMy0xLTEtNzg_9655f77e-2a36-4178-8a04-4b58b0408770"
      unitRef="shares">138977000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMy0xLTEtNzg_9fd5db31-8d1d-48b0-aa62-f05645eddaca"
      unitRef="shares">138977000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMi0xLTEtMA_318fa5d5-abf3-4245-b3d6-3ce83e0c08f4"
      unitRef="shares">143550000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtMi0xLTEtMA_45c5b2b7-ed2d-4b24-9e13-95f2511668fa"
      unitRef="shares">143550000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtNC0xLTEtMA_0f8dafcd-29cb-4ef0-9ffd-a595d18bc7e6"
      unitRef="shares">127519000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yNS9mcmFnOjNmNTk0MzE4ZTQ2OTQzNzY4YjNkZjgzNTVhOTRiM2M5L3RhYmxlOjAyNTJlODY5NmI4OTQ4ZmQ5Mjg1ZDJiZGQ1NDYzY2U3L3RhYmxlcmFuZ2U6MDI1MmU4Njk2Yjg5NDhmZDkyODVkMmJkZDU0NjNjZTdfMTUtNC0xLTEtMA_9a110d55-7f9b-4fa9-9750-dc33b36a842d"
      unitRef="shares">127519000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0xLTEtMS0xMDU_b26f6fc2-5a71-4af0-9926-98ae994e48fc"
      unitRef="usd">-47174000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0zLTEtMS0xMTY_72dbd736-bfcd-4c46-9809-45751dd0bb51"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi0yLTEtMS0w_1b2aba0e-a5b7-4b97-81ce-349a9b21fc5f"
      unitRef="usd">-93113000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMi00LTEtMS0w_808cd9f7-3c0a-44d3-b38a-de09b4e7f4e7"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0xLTEtMS0xMDU_f67ab08f-490d-4a88-bbf9-a2075fb55d3c"
      unitRef="usd">1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0zLTEtMS0xMTY_e07dcbb9-aaf3-4ebd-8864-f4e452599a52"
      unitRef="usd">1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy0yLTEtMS0w_3b2ea64e-067d-472f-93ff-f521be366b96"
      unitRef="usd">-3441000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfMy00LTEtMS0w_a9cfb806-f6ab-46d0-af94-7910a860655f"
      unitRef="usd">150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0xLTEtMS0xMDg_0c1834d5-3710-479e-80f2-0ab75de68cdf"
      unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0zLTEtMS0xMTk_415c294f-6119-4fc9-ad7f-d022cd32a8e8"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC0yLTEtMS0w_0c9849ab-3aa3-4e70-be99-bd0b78f31f57"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNC00LTEtMS0w_8cf6473e-74ce-4a35-ab2f-d56b16548dd5"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0xLTEtMS0xMTE_24f09e29-aa19-4210-b3a5-ecba3fb509cb"
      unitRef="usd">-45901000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0zLTEtMS0xMTE_bc5a6be2-232b-481c-8bab-5eab8b7e60db"
      unitRef="usd">-33790000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi0yLTEtMS0w_eacf00eb-4813-4949-92af-1e4245edd3e3"
      unitRef="usd">-96545000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNi00LTEtMS0w_66af0e0e-934a-41ff-830c-e11ab9b660af"
      unitRef="usd">-78143000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0xLTEtMS0xMTE_492688c1-e928-4566-ac8e-5c289664b864"
      unitRef="usd">-5000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0zLTEtMS0xMTE_6c636e8d-eb05-4433-ae14-84e78a7f8f89"
      unitRef="usd">-36000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy0yLTEtMS0w_9d734e38-f0a9-40ea-9253-9472772e5874"
      unitRef="usd">-11000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfNy00LTEtMS0w_bbe7f6ad-3fb6-4787-8e3f-24f17b1c32cc"
      unitRef="usd">-97000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0xLTEtMS0xMTE_dce693ee-3051-402d-b098-58388901b4ba"
      unitRef="usd">-45896000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0zLTEtMS0xMTE_f1b32dd3-7939-459d-9d60-cac9ebe9154a"
      unitRef="usd">-33754000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC0yLTEtMS0w_7fed8ede-3470-4105-8b9f-cbcbac5ba972"
      unitRef="usd">-96534000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8yOC9mcmFnOmJjNmM3MTgzNmU5ZjQwNmZiNGU2MmY5OGNlZDFjNWJjL3RhYmxlOmMzYzFhZTY3MTYwYzRhZmU5OGE5ZjNiOWFlZGI5M2E4L3RhYmxlcmFuZ2U6YzNjMWFlNjcxNjBjNGFmZTk4YTlmM2I5YWVkYjkzYThfOC00LTEtMS0w_96dca144-36f4-4c64-8d2a-23e8d285b8e8"
      unitRef="usd">-78046000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xLTEtMS0w_82748c47-452b-4d12-8bd0-3ad44013a480"
      unitRef="shares">143713765</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79e0ca759d1f41a3bf6e9cf3f2036171_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0zLTEtMS0w_a341b924-dcd2-4ca1-ae4e-6638a182f79c"
      unitRef="usd">1437000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id509e95c58494ac8b19b3740eed626fa_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy01LTEtMS0w_0a7c36fc-c5b9-462a-ba6d-69c4df0a965b"
      unitRef="usd">1292118000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i451bb316444e433b8be0465675c9e502_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy03LTEtMS0w_4e6461bc-c17c-42a6-ae07-5a1609d41cf0"
      unitRef="usd">-823914000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0fbd6f12c9b40f7abf2b4e635ce09f8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy05LTEtMS0w_7db8e842-0b66-4962-b3dd-0d5cc38c334d"
      unitRef="usd">714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib2532553bed14edca6798c93d083aa90_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xMS0xLTEtMA_e12424b0-da30-4cab-9fa6-059a63420651"
      unitRef="usd">-938000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie634578fb36048be98621104559edee6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMy0xMy0xLTEtMA_d09c4fef-a3d2-4f06-aec1-65d395bf10a0"
      unitRef="usd">469417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0xLTEtMS0w_49534776-2e42-4553-b82b-c55ec859a96b"
      unitRef="shares">770465</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0zLTEtMS0w_6d73ed85-4f03-474d-8742-af94038a30ca"
      unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC01LTEtMS0w_ab0f6121-a855-417f-ad8d-a4ed82b2c7d4"
      unitRef="usd">9073000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNC0xMy0xLTEtMA_f1e28f4d-5d92-421a-bf24-89e545740792"
      unitRef="usd">9081000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0xLTEtMS0w_b1440e50-858a-42bd-b42b-587bd0cbb72e"
      unitRef="shares">378101</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0zLTEtMS0w_4374f95a-d3a4-4e81-8849-c7a3ecc6686c"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS01LTEtMS0w_807ef63d-2c2f-4dc8-a822-214efdfe7cbf"
      unitRef="usd">1389000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNS0xMy0xLTEtMA_bb44719b-8223-4164-bf2a-c285781391df"
      unitRef="usd">1393000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0xLTEtMS0w_60ba53b5-d6a5-4981-bee4-fa722b3ad5b5"
      unitRef="shares">244570</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i04f51b2d4cfd4a09bec9bcd023e5025a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0zLTEtMS0w_0b05bc78-ee3f-41f6-824f-6aed565db0f6"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi01LTEtMS0w_3805072d-2c83-4764-9236-86b46f336112"
      unitRef="usd">2052000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNi0xMy0xLTEtMA_93f7eb7c-1837-4473-a1aa-22af2eac10f8"
      unitRef="usd">2054000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNy01LTEtMS0w_1bc729fd-a827-42ba-9813-637016c2b0a3"
      unitRef="usd">9483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfNy0xMy0xLTEtMA_33d2c4a3-8ef5-4cd5-a7b8-1ea4d3c17533"
      unitRef="usd">9483000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOC01LTEtMS0w_c50f10eb-14df-4648-b618-e20f1f19ee81"
      unitRef="usd">-70000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOC0xMy0xLTEtMA_faad1ea8-343a-44f5-b955-ebdb3ee82af1"
      unitRef="usd">-70000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOS05LTEtMS0w_1121e6b9-09e4-4a96-bc26-58da30bd48a6"
      unitRef="usd">-1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfOS0xMy0xLTEtMA_d0e59c9a-ed70-4e3c-852d-e66a63515638"
      unitRef="usd">-1308000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i63cbd74c34ab4515ba9e42558e99349c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTAtOS0xLTEtMA_fbc23fe8-50c7-46fc-b864-c6a790b7e37e"
      unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTAtMTMtMS0xLTA_ff91a1b9-b292-432d-b6d6-72dd65e6c8b8"
      unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i799f89a6ece24a3cb21cbc1203a96cd7_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItNS0xLTEtMzY4Nw_586b4c67-3af5-49b1-bf40-742ddf66679d"
      unitRef="usd">-943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTEtMS0xLTM2ODc_188e177e-e9f2-410c-8c9e-d8a12eb20b06"
      unitRef="usd">943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:ProfitLoss
      contextRef="i9f40f023c8ff401bbb0eea92048c2752_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItNy0xLTEtMA_d942f6fa-98fc-41f4-8c9f-48ef154708f9"
      unitRef="usd">-47169000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i572f450aa8494e2f9aa4872d5ad2a8cc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTEtMS0xLTA_8bcf7999-5dd8-44cc-9e40-9fa7e11281ee"
      unitRef="usd">-5000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTItMTMtMS0xLTA_2630edd3-2dc7-4d3c-a806-6a6251853f75"
      unitRef="usd">-47174000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMS0xLTEtMA_d6eb706d-849c-4b24-aab2-07c2ff5fd5e9"
      unitRef="shares">145106901</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMy0xLTEtMA_153cfc7f-e38b-4436-91a4-4fa840d0a9b7"
      unitRef="usd">1451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6818cea0cc0b4106acfd0ca299befb47_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtNS0xLTEtMA_e4cecd47-1a5c-428e-a862-dd49b57d86d8"
      unitRef="usd">1313102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76400ba7a5394ae4bc48e57baf0b6966_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtNy0xLTEtMA_08118841-8913-4f24-a763-80f403c18515"
      unitRef="usd">-871083000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4050e8c74a1147cc858267b0e1b8c758_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtOS0xLTEtMA_b662f1b7-2baa-44e9-bc6f-526d28d28de4"
      unitRef="usd">1987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4d7313265bb442da33ae6f84d7c4862_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMTEtMS0xLTA_aaceb23e-78a8-476a-a11a-9bc7b7149fcb"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjg0MzJhNDg3OTVkYTQ2NmNiZTJhMjc2ODBiYjdjMWU5L3RhYmxlcmFuZ2U6ODQzMmE0ODc5NWRhNDY2Y2JlMmEyNzY4MGJiN2MxZTlfMTMtMTMtMS0xLTA_6e3ce006-3dd8-4898-9c57-d512d685f929"
      unitRef="usd">445457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6c7f4351eee949c28a8776c4fe2c8654_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xLTEtMS0w_95d2a523-cd48-40ae-b475-b5b6b34d01f0"
      unitRef="shares">142063203</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c7f4351eee949c28a8776c4fe2c8654_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0zLTEtMS0w_9d361e64-c659-43c0-8466-0e86c085d207"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad53a190fa514e688060deebfd68d2e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy01LTEtMS0w_d80b5e9c-b723-4e7b-9016-ad4000ab2710"
      unitRef="usd">1269375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8378ff7fc294b15a732b761ec44147c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy03LTEtMS0w_a74f9298-9a93-4f82-94b0-96082703e9d3"
      unitRef="usd">-777981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6eb4957d21874146891b6c52f9a92192_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy05LTEtMS0w_b7dcd009-6d37-4bf3-b27f-77d5d430ef3f"
      unitRef="usd">5419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7a8701b92bee4274ac683fe19bd1cfb3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xMS0xLTEtMA_6510170f-0654-4118-a0c2-251801c703b4"
      unitRef="usd">-868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMy0xMy0xLTEtMA_feb4a750-a780-439f-9262-3728f7dd97e5"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xLTEtMS00NjA_3b736761-2fae-42bb-b3a5-c345b59d2d4c"
      unitRef="shares">1805227</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0zLTEtMS00NjA_44f35197-6697-46b6-8e6f-08f1cd950d2f"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC01LTEtMS00NjA_324648c2-d269-4f82-8ab4-1a7effda385f"
      unitRef="usd">24714000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xMy0xLTEtNDYw_46be2fd4-f720-4b2b-a0b6-96eb1feaa402"
      unitRef="usd">24732000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xLTEtMS0w_5195ffd5-5412-4a57-86cf-6ad97b445faf"
      unitRef="shares">993901</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0zLTEtMS0w_ba9a0aa1-f893-45f0-8193-8eb98db330ac"
      unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC01LTEtMS0w_d58ef121-3290-45a3-8856-06d026a6347e"
      unitRef="usd">967000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNC0xMy0xLTEtMA_0d040db7-85dc-4274-b5a4-80e2d6f10dc9"
      unitRef="usd">977000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xLTEtMS00NjA_8bfb7e50-e698-4235-bf27-907713dec139"
      unitRef="shares">244570</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if09d7bb5b44a4ff79f5202c0a8196fb8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0zLTEtMS00NjA_c26d98ab-a370-4712-afe9-66086f1da696"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi01LTEtMS00NjA_7295d88f-672f-44e4-b1a9-5b646a9a8f84"
      unitRef="usd">2052000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xMy0xLTEtNDYw_ab5d9453-4d37-4582-bbb5-27c35be3f87a"
      unitRef="usd">2054000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNS01LTEtMS0w_0322d353-284d-4bb0-8d19-be78fc3915da"
      unitRef="usd">17007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNS0xMy0xLTEtMA_e3c373f5-ccb6-46b7-b1b8-11d1747381ce"
      unitRef="usd">17007000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC01LTEtMS00NjA_3737dc30-f36b-4251-b011-aacc73c62f01"
      unitRef="usd">-70000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMS0xLTEtNDYw_716bbe90-4154-4625-b3ee-1009d860d3e1"
      unitRef="usd">-64000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMy0xLTEtNDYw_df2c7d75-f9a5-43fd-9ed8-2d108aaa9a72"
      unitRef="usd">-134000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if136e6082b014302baf06eb9f33155bf_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi05LTEtMS0w_3992130b-95fe-4603-9f0e-c9f47d97a511"
      unitRef="usd">3441000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNi0xMy0xLTEtMA_4fcf76b3-435e-4e26-80fe-b02680ffea2f"
      unitRef="usd">3441000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if136e6082b014302baf06eb9f33155bf_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNy05LTEtMS0w_a69b3ebe-5dbd-461a-bb68-770ac470aeb0"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfNy0xMy0xLTEtMA_7512ad8c-44e5-47f2-b634-237c7b8fa55a"
      unitRef="usd">9000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i0cf2619b93af4c25a04727500e864515_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTItNS0xLTEtMzk4MQ_16d9e4f8-cb8e-4c8d-8e02-72565a0a3797"
      unitRef="usd">-943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTItMTEtMS0xLTM5ODE_a2a0af7f-d0a6-4235-91b7-d2359ee280d3"
      unitRef="usd">943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:ProfitLoss
      contextRef="i97c17820b63e4da5941380170aa10773_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC03LTEtMS0w_f9bdad34-5808-4482-aaa7-59fbf0bcbe5c"
      unitRef="usd">-93102000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if02e977fba0844e697f155fd32f8ade4_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMS0xLTEtMA_4e555605-44b8-434d-a838-a69ae00163cb"
      unitRef="usd">-11000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfOC0xMy0xLTEtMA_8d9caa56-37c5-46c2-b354-9e8be496ff10"
      unitRef="usd">-93113000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMS0xLTEtMzcwNw_4354786b-7564-49d8-b36d-ae1279f79cac"
      unitRef="shares">145106901</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ab52c488ffc49ccbfd6c88b7c19a7a7_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMy0xLTEtMzcwNw_3ea85542-2fd0-4bfe-92cc-5d0173dd4df3"
      unitRef="usd">1451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6818cea0cc0b4106acfd0ca299befb47_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtNS0xLTEtMzcwMQ_def40d92-78c2-4be8-b39b-5ce522096a72"
      unitRef="usd">1313102000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76400ba7a5394ae4bc48e57baf0b6966_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtNy0xLTEtMzcwNw_0db8a476-df1a-4488-98c2-c0392fc6c28f"
      unitRef="usd">-871083000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4050e8c74a1147cc858267b0e1b8c758_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtOS0xLTEtMzcwNw_94796f71-15d9-4e48-a9bc-9a450dc31387"
      unitRef="usd">1987000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic4d7313265bb442da33ae6f84d7c4862_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMTEtMS0xLTM3MDE_3f801b04-aaaf-46d8-8562-131338b9d4c0"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjlhMDgzMjg3YjI0YTQyMmFhODcwODQ0YmNjZmFlMGVlL3RhYmxlcmFuZ2U6OWEwODMyODdiMjRhNDIyYWE4NzA4NDRiY2NmYWUwZWVfMTMtMTMtMS0xLTM3MDE_55e423cc-d75d-4116-967f-3c8f2f3fd70c"
      unitRef="usd">445457000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xLTEtMS0zNDA_95572606-1219-414f-bbb1-b3aab34e9378"
      unitRef="shares">116278553</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2700d5e8c81648b3b00cb3d8e2d708f1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0zLTEtMS0zNDA_511ced70-a275-4f57-bde9-973e5066d5c0"
      unitRef="usd">1163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b9e78a2e83c4087b0d4cbfa66208b48_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy01LTEtMS0zNDA_0ae8f49c-5c44-47ed-9cd0-1c6fa8d63369"
      unitRef="usd">1096854000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iafb3ae2aae5a4f0da0dca70b744f197b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy03LTEtMS0zNDA_02569a63-9d26-4bca-bb84-bf7e0253ea36"
      unitRef="usd">-699898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91aa883725fe42df83a8efd02d7c81ac_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy05LTEtMS0zNDA_f0973bda-d857-406b-81b1-616e9d97028f"
      unitRef="usd">-3828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i381ca00d71c943629317c963c76a5403_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xMS0xLTEtMzQw_ccdaee9f-8fa0-4110-bd4e-05ffa990a17a"
      unitRef="usd">124000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7187c32f2e32406b93490265952a56f2_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMy0xMy0xLTEtMzQw_7e4fc3cb-0de1-4e60-a48d-959885c44e76"
      unitRef="usd">394415000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0xLTEtMS0zNDA_566009ab-bbfc-465e-bfe8-191b20f439fc"
      unitRef="shares">103262</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0zLTEtMS0zNDA_e238c673-4537-4605-9c7f-fdc9e590c437"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS01LTEtMS0zNDA_60fbe962-df83-4ee2-99ce-73d59fc5b3b2"
      unitRef="usd">442000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNS0xMy0xLTEtMzQw_921b1e78-2ba7-4f25-b550-fb051ca9a67f"
      unitRef="usd">443000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xLTEtMS0zNDA_4770c4d7-0443-4bd9-9bf7-1313881b1934"
      unitRef="shares">171305</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0zLTEtMS0zNDA_1f0fb31d-9f44-4ce0-b547-13474fe559d2"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi01LTEtMS0zNDA_fcde1cd5-86c3-4c0e-be3c-8e1695a9eeb1"
      unitRef="usd">1185000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xMy0xLTEtMzQw_d9793a5e-c7d3-4c54-9485-dd2764effab0"
      unitRef="usd">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xLTEtMS0zNzM_d7a8660e-d8f0-43c4-a232-6bdc403a7ffd"
      unitRef="shares">24420157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ieeb736ca74b540338a231bd01c4ea7d0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0zLTEtMS0zNzM_a5936e52-015f-4389-8838-974c94ba5cdc"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi01LTEtMS0zNzM_df78ad57-a22d-415a-b6ca-c10399e17855"
      unitRef="usd">142282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNi0xMy0xLTEtMzcz_3fdaf981-4dc4-467f-a22a-498c695bab22"
      unitRef="usd">142526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iecf737a7ee2747c09d6fc9d7fcff6483_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNy01LTEtMS0zNDA_64528dbb-d91c-41a3-8b7a-8ad9c02e3e90"
      unitRef="usd">6764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfNy0xMy0xLTEtMzQw_87c3846d-a048-45e1-853a-b208eae92263"
      unitRef="usd">6764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOC0xMS0xLTEtMzQw_5d978101-67ae-4427-b748-b4397c16e943"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOC0xMy0xLTEtMzQw_f13a902d-6bcb-4596-89de-aa87ca2b3909"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOS05LTEtMS0zNDA_46ede9c7-f439-47e1-80d5-505dc5f5f298"
      unitRef="usd">-1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfOS0xMy0xLTEtMzQw_27e8d0d0-1f2e-455b-8ad7-17f15b16504d"
      unitRef="usd">-1783000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6d9eeb19436d44a4af46126070cd531e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTAtOS0xLTEtMzQw_9b1ae52f-ac3f-4640-817a-024ccdbfb1f9"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTAtMTMtMS0xLTM0MA_1b81a139-f2bc-4b26-8b50-d71363dc7994"
      unitRef="usd">392000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="ie6222a8ff3b04b6a8b4ecb256e9b6bdc_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItNy0xLTEtMzQw_5bf0c668-47d9-4bd7-9522-d74e7e506a9b"
      unitRef="usd">-35929000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8b3ff9dd853f4248bac7aa7b8b8ab26f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItMTEtMS0xLTM0MA_b441daa9-041d-4418-9efe-8b43f3b0b588"
      unitRef="usd">-36000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTItMTMtMS0xLTM0MA_a86ed5da-6fae-47f5-91d2-200225f45b2d"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMS0xLTEtMzQw_5d614941-7a89-4e3f-9230-58cbeacb33b2"
      unitRef="shares">140973277</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMy0xLTEtMzQw_a132a625-cba4-4855-b428-8250bce73966"
      unitRef="usd">1410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93b4beb7f3064e62bae7ad43156944d3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtNS0xLTEtMzQw_e770f3a1-12f2-4892-a197-fdb2b9fbdd71"
      unitRef="usd">1247527000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i799d8cc66f694906a0ab37290354d60d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtNy0xLTEtMzQw_f6c022d9-d544-4491-bd31-2828fe7be1b1"
      unitRef="usd">-735827000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34c9bc741cc74c3f88015c7a849b517b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtOS0xLTEtMzQw_4ef07222-88b4-402a-879e-4222bf6a6659"
      unitRef="usd">-1653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12281bdefbdf476c8cfaf9303e3c4896_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMTEtMS0xLTM0MA_b37f477f-d2ce-4b17-a008-f46561c9ac67"
      unitRef="usd">-251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjMwNDUxM2I5NmIyMjQwYWZiZTdhNjI5MDE4MzQ1MDEwL3RhYmxlcmFuZ2U6MzA0NTEzYjk2YjIyNDBhZmJlN2E2MjkwMTgzNDUwMTBfMTMtMTMtMS0xLTM0MA_7fa4f4fe-aeaf-4646-b0f8-9f0c5dc0127d"
      unitRef="usd">511206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1a22c45761394b75af4d6906696260fb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xLTEtMS0zODk_83040b14-3c50-4deb-9f71-71a6f36777ec"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a22c45761394b75af4d6906696260fb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0zLTEtMS0zODk_d8cb8418-638f-441f-abb3-01c2c6136f4c"
      unitRef="usd">1160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5d851e70bb94ec78db2876e006a48d5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy01LTEtMS0zODk_60482b6c-96ab-42d4-bdf3-39a538f9aea8"
      unitRef="usd">1090828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18bb63471d3c4a7ba84788fd8f7005ad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy03LTEtMS0zODk_dfed06d1-0eae-40cc-a113-8a4af938723c"
      unitRef="usd">-656985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1885d06587d454d8be9824fa3e6e68f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy05LTEtMS0zODk_4d2b10d3-4e1f-4565-a72d-a9c007ff19fe"
      unitRef="usd">-2449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e35e880a7ba447eb1db041c02cd0fc8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xMS0xLTEtMzg5_334d4b72-4441-418c-aa70-d4d0dd58c04a"
      unitRef="usd">185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4afcf835853b4cad93648a7670596835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMy0xMy0xLTEtMzg5_0fe4d208-da7c-48e2-b94a-90a16f421aa1"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0xLTEtMS0zODk_cb8d7b24-00e3-42f6-8fb0-46ec1b7889c1"
      unitRef="shares">409107</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0zLTEtMS0zODk_e7396693-7b3e-47ba-9373-28d55346f7ee"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC01LTEtMS0zODk_07ae9cd1-87d8-4a4e-b526-d68cf7e54cb4"
      unitRef="usd">848000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNC0xMy0xLTEtMzg5_e86073f0-8aa3-418b-a836-431d1894e9e4"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0xLTEtMS0zODk_255ea59e-0c27-4d93-adcb-eaae0a242e73"
      unitRef="shares">171305</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0zLTEtMS0zODk_395d6479-448c-49c9-9b2e-046256ab7e6e"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS01LTEtMS0zODk_0b34f73f-960d-497a-8001-8e413ad762e3"
      unitRef="usd">1185000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNS0xMy0xLTEtMzg5_946443d4-4474-4aca-9b39-421689f1248b"
      unitRef="usd">1187000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0xLTEtMS0zODk_fdb9b13c-2a14-4679-ba06-f9c677dea510"
      unitRef="shares">24420157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0a47b89f456b4d70b40efbd1fb140fd6_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0zLTEtMS0zODk_e466829f-d010-4432-be2e-bf08f4e022d4"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi01LTEtMS0zODk_ad308c11-c2f5-4895-b9a7-eb3a62a81796"
      unitRef="usd">142282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNi0xMy0xLTEtMzg5_d9a3b9ca-0d41-439d-b4f0-ac8d9a1c3c23"
      unitRef="usd">142526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id6d52d852ae147b6a65ba9f952725c46_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNy01LTEtMS0zODk_76f27c48-0d3b-41c2-b397-92c230bddf81"
      unitRef="usd">12384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfNy0xMy0xLTEtMzg5_2b534d34-20ab-4e13-863a-a51c159d4aae"
      unitRef="usd">12384000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOC0xMS0xLTEtMzg5_a0198be9-7e35-4348-b251-c80300644402"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOC0xMy0xLTEtMzg5_ccef869a-e2e0-4ac9-8704-30a810797125"
      unitRef="usd">-339000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i3e76a7f09ff044139311009878988bb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOS05LTEtMS0zODk_34d10f2d-ebfe-48ab-a1f5-44560219ed2b"
      unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfOS0xMy0xLTEtMzg5_0bc5f928-9205-4d0e-bdfb-8b0e28764757"
      unitRef="usd">-150000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i3e76a7f09ff044139311009878988bb1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTEtOS0xLTEtMzg5_b5fe9d47-aed7-4ff2-8306-4d85a7802d33"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTEtMTMtMS0xLTM4OQ_83893a34-1fb0-46f9-a5a4-2f013c4cd5f5"
      unitRef="usd">646000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i18d94baa04ca43eb8d75f34105ed0623_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItNy0xLTEtMzg5_d5599790-5ba3-461a-9390-f9c092f089e5"
      unitRef="usd">-78842000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2ba58a909dff436dbf22f98cce7fe836_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItMTEtMS0xLTM4OQ_e1f5a7bf-b6fb-4abc-a003-bbc9c47bf6de"
      unitRef="usd">-97000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTItMTMtMS0xLTM4OQ_64a774b3-9c02-48ea-9b01-0ed870c0ed1c"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMS0xLTEtMzg5_d43b0a0d-38b7-4708-a261-9165c9d15412"
      unitRef="shares">140973277</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id6ed42d296d64e07bdc98a8f3bd1000d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMy0xLTEtMzg5_f0c0c61c-1723-4eb6-9195-45862e899a06"
      unitRef="usd">1410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93b4beb7f3064e62bae7ad43156944d3_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtNS0xLTEtMzg5_2327ba5d-3151-47d7-9f1b-b18709e9bd6d"
      unitRef="usd">1247527000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i799d8cc66f694906a0ab37290354d60d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtNy0xLTEtMzg5_f55f988f-5369-43fe-8580-bccf49820df9"
      unitRef="usd">-735827000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i34c9bc741cc74c3f88015c7a849b517b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtOS0xLTEtMzg5_204feecd-ed10-4410-8961-df4fde1b0d6f"
      unitRef="usd">-1653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12281bdefbdf476c8cfaf9303e3c4896_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMTEtMS0xLTM4OQ_b3692fe0-13d9-4447-8b4d-aaeb1aa6f66b"
      unitRef="usd">-251000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zMS9mcmFnOjk0MWFjMzIzMmRkODQxYjE4ZGQxYmFiY2M2ZDZjN2Y4L3RhYmxlOjY0ZmIwNmEyMWZjNDQzMzFhNGM5ZDZmMDdmZWYzMmNiL3RhYmxlcmFuZ2U6NjRmYjA2YTIxZmM0NDMzMWE0YzlkNmYwN2ZlZjMyY2JfMTMtMTMtMS0xLTM4OQ_26a3e8c0-c94f-4b51-97b3-0c842c2f37c4"
      unitRef="usd">511206000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMy0xLTEtMS0w_e9f4250e-4b5c-4d1e-82d8-08ceba690fd1"
      unitRef="usd">-93113000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMy0zLTEtMS0w_d20f20ce-3362-4ab6-a386-65766bd5c284"
      unitRef="usd">-78939000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNS0xLTEtMS0w_bfd0613c-e86c-4093-bc64-8248952bb498"
      unitRef="usd">4120000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNS0zLTEtMS0w_a0975943-75d9-4c0d-ab1e-16f96c2f1958"
      unitRef="usd">2639000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNi0xLTEtMS0w_b2e210b6-7afb-4dcd-a6e4-a85f8f5afac7"
      unitRef="usd">-1733000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNi0zLTEtMS0w_7330ae69-d354-4b14-8c3c-98717648905a"
      unitRef="usd">1146000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNy0xLTEtMS0w_52aada19-234f-4252-bd93-2b8efd19bf97"
      unitRef="usd">-4067000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNy0zLTEtMS0w_1910dc28-7d24-45d3-906d-ff51ba5c9d70"
      unitRef="usd">-3788000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainLossOnFreeShares
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOC0xLTEtMS0w_be4372c4-a6d3-44de-a3df-52659b9975ce"
      unitRef="usd">18000</sgmo:GainLossOnFreeShares>
    <sgmo:GainLossOnFreeShares
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOC0zLTEtMS0w_63887a3a-2c35-4736-aeaf-986e1f79d31f"
      unitRef="usd">48000</sgmo:GainLossOnFreeShares>
    <us-gaap:ShareBasedCompensation
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOS0xLTEtMS0w_1e83f478-c89c-4602-a998-cc57f6edcd70"
      unitRef="usd">17007000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfOS0zLTEtMS0w_1d532e46-8d10-4e19-8f0e-0130c1cbd353"
      unitRef="usd">12384000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTItMS0xLTEtMA_6e8257f2-cb7f-4681-bbc4-12feecb745fe"
      unitRef="usd">-228000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTItMy0xLTEtMA_073d0123-6be8-4ab8-9175-655c0c3afdb6"
      unitRef="usd">-148000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTMtMS0xLTEtMA_3ae69a62-b305-4297-8355-305fb5a78237"
      unitRef="usd">1658000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTMtMy0xLTEtMA_b6592c91-085b-47d0-8a18-8d254c93986a"
      unitRef="usd">-31291000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTQtMS0xLTEtMA_93c23fa9-d5b6-4ac7-b7f1-433f61809a09"
      unitRef="usd">4441000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTQtMy0xLTEtMA_7bf894a9-1c74-4aff-b12d-0df4705fc779"
      unitRef="usd">7763000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTUtMS0xLTEtMA_8e688d7f-4a9b-4408-8007-03e4fa8bc74e"
      unitRef="usd">-3204000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTUtMy0xLTEtMA_ccb564a0-9745-4bac-9725-0cd749c6edc7"
      unitRef="usd">1559000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTYtMS0xLTEtMA_ebdb69d2-f01c-4b99-a258-93bd46a9ff92"
      unitRef="usd">-3253000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTYtMy0xLTEtMA_630575bb-3e81-4951-b045-60d71259d640"
      unitRef="usd">-248000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTctMS0xLTEtMA_5b40eaaa-69e7-495b-b385-b260509d8fc9"
      unitRef="usd">-41481000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTctMy0xLTEtMA_80ff0679-a932-4f25-815a-ef3ec63e2e2f"
      unitRef="usd">178890000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTgtMS0xLTEtMA_67113c75-2fda-4e5d-95c9-f0283a5368db"
      unitRef="usd">-2102000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTgtMy0xLTEtMA_92eb2619-f319-4ccc-86b9-0ffa28a99337"
      unitRef="usd">-1797000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTktMS0xLTEtMA_0b1ce357-7a1e-4345-82cb-6f9b65d6385a"
      unitRef="usd">998000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMTktMy0xLTEtMA_72094f6b-18de-482c-bf6b-856c9705b32b"
      unitRef="usd">345000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjAtMS0xLTEtMA_fccdc1d9-e50d-4a3b-9f95-11947a74a5ef"
      unitRef="usd">-121117000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjAtMy0xLTEtMA_f4514931-3357-4335-861c-531acd861453"
      unitRef="usd">141103000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjItMS0xLTEtMA_e0565b0e-2669-49f7-a580-cfeb15f98414"
      unitRef="usd">180049000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjItMy0xLTEtMA_216caf70-4534-443f-ab0a-7fe93f8d59d3"
      unitRef="usd">43580000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjMtMS0xLTEtMA_c9ebd480-10ee-4d4b-a3bf-a1b17b6b110e"
      unitRef="usd">323099000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjMtMy0xLTEtMA_286c4f71-291f-47b7-8c6c-a8c3cbb4fb50"
      unitRef="usd">151839000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjQtMS0xLTEtMA_c21f69aa-5a16-47ea-9db3-151e9d9a3fc1"
      unitRef="usd">6870000</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjQtMy0xLTEtMA_bd0649a3-794d-44a2-99d7-66b10a26e0ac"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjUtMS0xLTEtMA_9e20bf36-a7e4-4e3a-b61f-b54fa371b46b"
      unitRef="usd">15213000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjUtMy0xLTEtMA_8c29aa93-2d83-4a44-9a4c-2de7b45e3ae0"
      unitRef="usd">6694000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjYtMS0xLTEtMA_6869e3fd-682e-4dad-834e-aa1fe221ffe2"
      unitRef="usd">119000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjYtMy0xLTEtMA_4a1a9606-2731-4f47-8a86-803b2eb03bb4"
      unitRef="usd">237000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjgtMS0xLTEtMA_6152a804-9825-4089-b294-a0bddada0c00"
      unitRef="usd">134588000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMjgtMy0xLTEtMA_a72433b1-3c3f-4c29-9e81-54d2e094e789"
      unitRef="usd">101328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sgmo:NetProceedsFromAtTheMarketOffering
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzAtMS0xLTEtMA_44963642-05e2-4719-ba4e-a04afb5c38f6"
      unitRef="usd">22223000</sgmo:NetProceedsFromAtTheMarketOffering>
    <sgmo:NetProceedsFromAtTheMarketOffering
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzAtMy0xLTEtMA_ee4adf06-040e-42c3-b5ae-f9b46b771dc1"
      unitRef="usd">0</sgmo:NetProceedsFromAtTheMarketOffering>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMS0xLTEtMTcyOA_08b89630-43d1-4f2c-965a-212fc9279e89"
      unitRef="usd">0</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMy0xLTEtMTcyOA_17817573-3747-4899-adff-5e0505e1ebbf"
      unitRef="usd">142526000</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzEtMS0xLTEtMA_e4165b71-43f7-4250-bbc4-9350f67179d5"
      unitRef="usd">2725000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzEtMy0xLTEtMA_208d7a14-88de-48a9-a5ac-222272acc12d"
      unitRef="usd">455000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMS0xLTEtMA_ca034055-779c-4997-94fc-c2ed9374eb47"
      unitRef="usd">3702000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzItMy0xLTEtMA_ec43151b-6087-48dc-bc11-d239cd08ce4b"
      unitRef="usd">1307000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMS0xLTEtMTczOQ_813bb56c-9520-40c6-aa60-d97e8fb782e5"
      unitRef="usd">2054000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMy0xLTEtMTczOQ_86b76896-6443-4083-89ff-87e49c08b8b4"
      unitRef="usd">1187000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzQtMS0xLTEtMA_cf17fc69-8623-458e-ac3b-8be0eacc03a4"
      unitRef="usd">25254000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzQtMy0xLTEtMA_c532106c-be16-4a48-bc57-ff675f55bae7"
      unitRef="usd">144565000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMS0xLTEtMA_077b2922-3b4d-4bfe-8ad4-bb3adf6783e3"
      unitRef="usd">-176000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzUtMy0xLTEtMA_da00f033-6670-4e6d-a0e4-51e28b555abf"
      unitRef="usd">19000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzYtMS0xLTEtMA_4217072a-07dd-4428-8955-ee2708af8873"
      unitRef="usd">38549000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzYtMy0xLTEtMA_685f2473-b551-4971-852f-3f1ce5a976db"
      unitRef="usd">387015000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzctMS0xLTEtMA_0eb5201f-9f31-4522-8917-2d2a06678456"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4afcf835853b4cad93648a7670596835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzctMy0xLTEtMA_8f79697f-08e5-4e71-a098-29b17cfec406"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzgtMS0xLTEtMA_3a7cefb1-eb3c-4654-8a4d-338389d47464"
      unitRef="usd">171378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfMzgtMy0xLTEtMA_38b03d69-97d6-4ffd-9913-54763d17bb03"
      unitRef="usd">468943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDAtMS0xLTEtMA_7b1747c6-cb4a-4ffc-ab09-4bd14c6b953f"
      unitRef="usd">2267000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDAtMy0xLTEtMA_ccbe859e-02ef-447f-a3e5-d7067bffa8fd"
      unitRef="usd">1977000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDEtMS0xLTEtMA_5db0f0da-b96e-448f-9053-cd4e9c19f094"
      unitRef="usd">1364000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDEtMy0xLTEtMA_3b840532-35f7-4bfd-b867-01b3469b8626"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDQtMS0xLTEtMzg0OA_f68f5b94-d022-487f-8daf-1562558c47e0"
      unitRef="usd">943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF8zNC9mcmFnOjIyYmFlOTg1ZDA0YTQ0MzJiMDRiNGI3ZWRlMzYzNTQ4L3RhYmxlOjk5OWQ1Mzk1ZDIwNzQzOGI4ZjIxY2I3ZDMxYjMxOTk0L3RhYmxlcmFuZ2U6OTk5ZDUzOTVkMjA3NDM4YjhmMjFjYjdkMzFiMzE5OTRfNDQtMy0xLTEtMzg0OA_0c2ffe79-33d7-4f03-9067-99ca1c0cb470"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDU_88d9c88b-9958-4ab1-a9a5-9b66d3974ce9">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#x201c;2020 Annual Report&#x201d;) as filed with the SEC on February&#160;24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#x2019;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in estimates during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#x201c;Sanofi&#x201d;) and Pfizer Inc. (&#x201c;Pfizer&#x201d;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $3.1&#160;million, decreased net loss by $3.1&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2021, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of June&#160;30, 2021, no impairment of goodwill or indefinite-lived intangible assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of June&#160;30, 2021, no impairment of long-lived assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted as needed to approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions or issuers of investments holding its cash, cash equivalents and investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#x201c;IND&#x201d;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTY_63a87710-e549-4949-8f90-4198219bf338">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#x201c;2020 Annual Report&#x201d;) as filed with the SEC on February&#160;24, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#x2019;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDQ_ed888562-9723-492f-bdb8-c9aa5700d472">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the &lt;/span&gt;&lt;/div&gt;basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjI3NA_c0cbd8e4-03d0-4355-a48f-b163778e022b"
      unitRef="usd">3100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjI4OA_019d527a-069e-4787-93a4-a743d7360bac"
      unitRef="usd">3100000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9c97c3c2eb6c48558c61dd080096ad5b_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMzg0ODI5MDcyMjMwMg_0ab2a216-0a52-433b-b0a0-4dbf4d358d5f"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDI_80a7ee09-9829-498e-b491-331de6e15527">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic&#160;606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2021, the Company had not incurred any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjM_52637f40-af35-49be-9f19-98d2b5e1537e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi0xLTEtMS0w_6c655e2f-217c-4a83-8df5-b26e4c7b9089"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6df4f65d331a42e78e2fa83fb2c3971e_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi0zLTEtMS0w_d9a4faf0-b1cb-4a93-8206-79c499c2e242"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i43fb5fc4bec0489486d7be362a594089_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi01LTEtMS02ODU_76cf165a-de9f-491e-a1e7-9c75633a71ab"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i160cf032b081413bb08a84005c04a475_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMi03LTEtMS02Njg_75f66368-55c1-4e5e-a64b-3bf2ed41dcb5"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dcbc0880e6f4929a436952cda81d81b_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy0xLTEtMS0w_836f19bf-84b6-41f7-b5c4-44f3e6683100"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i826478ddac2547de9623bc77195eae38_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy0zLTEtMS0w_79fc200e-c24a-4741-883b-ce5070881bbc"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i06147cd0f2824f5c829d965b134af50c_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy01LTEtMS02ODI_63439180-9b0c-42fe-99b7-8f49305f541c"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i977b331cae2c44558ac4d8807d9beb5e_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfMy03LTEtMS02NzE_cd4f75eb-7fb5-42d8-a9d3-b48f3b8a16bd"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i24e0372fb79547c0ab5707e59b555660_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC0xLTEtMS0w_70adf803-9b65-4f44-9f79-f524e0d0ce00"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id7cdf486da744840ae163e4c93082f83_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC0zLTEtMS0w_2b087ef4-af57-4a59-94e8-e3a553834520"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id443d9ba83d14bce9aa23f4e3906af56_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC01LTEtMS02ODg_3cecd521-19b7-4540-9fb8-2f626b8e3d81"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3900ce573569432e830a630426d6a8c7_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNC03LTEtMS02NjY_09d6e442-cb61-43e2-aa1a-87f758e9048e"
      unitRef="number">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if3993368d6f34912853e783bfc42062f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS0xLTEtMS0w_6e1e3ca9-a265-452f-a695-e70036f526d7"
      unitRef="number">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i46690bda004c48dc8fe1a34394fe2539_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS0zLTEtMS0w_37627139-a4d5-45e3-89be-45cf8b002eeb"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id650bde047e54d44a28d7f3cf2147fba_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS01LTEtMS02Nzk_9e0028a7-7cb2-4fb8-a961-78b27a5b41f1"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb3e1f0817d14b5082132f338ddf990a_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNS03LTEtMS02NzQ_260e6b31-0156-4051-a322-16761b6da4f2"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i44f8df10acdf47de8be2793787e32c3f_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi0xLTEtMS0w_1e95b397-8c37-42b7-8522-b63491abf0ab"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6273dd375cbe431e851bf02f766c7d30_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi0zLTEtMS0w_a567da77-d14d-4dc0-88d2-dca7e28a703b"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3713011fcaf74d139f418e2d8b93a054_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi01LTEtMS02Nzc_044e2ede-fb08-46a8-add2-19f386985693"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id56b04a6fd3d4593b0228bf4b5070845_D20200101-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjVjMzJmMDVmM2U1YTRiOWNhZWMxYTgxYzNkMDBjODVhL3RhYmxlcmFuZ2U6NWMzMmYwNWYzZTVhNGI5Y2FlYzFhODFjM2QwMGM4NWFfNi03LTEtMS02NjQ_c92ce08c-378e-4078-9891-ce64e61e8db4"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTk_098948e5-996b-4e53-9aa8-41fa3679c132">&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTA_8f79c7d2-5404-44fb-a34c-3b9d3610d4c8">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTM2Mjg_f7504ba0-5de5-4419-8a38-23f0f83ad757"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjQ_1eb59497-dbbb-4cc1-b63d-763b8ab1f928">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTQzNzk_d676e89e-d640-44c8-8e5b-e16915fc84bc"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjA_e00d7a9b-7c5f-432d-a95c-99d663d888c3">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted as needed to approximate fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjU_fb3b1a70-06c5-47ef-b5de-d63c020a35a7">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMTUyMzg_664d949f-44ac-4e6c-b7b4-9738c3c9d5b1"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjY_056cdffb-30fe-42d1-b55c-493333428a90">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjY_98ee33cc-7877-44bc-b2f0-d3339f936811">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS0xLTEtMS0w_32dfad31-bf8c-4ad8-b23b-3e7261cd49bb"
      unitRef="usd">169878000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS0zLTEtMS0w_14f5fed1-3514-4fef-9ee8-7891c57fafe6"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS01LTEtMS0w_6b415e85-8116-476d-b95c-55061b2fc15a"
      unitRef="usd">467443000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4afcf835853b4cad93648a7670596835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMS03LTEtMS0w_c0447e2e-1edd-4081-aa17-2d0da7edf7db"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi0xLTEtMS0w_5037e816-e236-42ca-a5ea-e324b46c8f51"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi0zLTEtMS0w_811f97ad-43b7-4a66-93b3-7445ac6f5253"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi01LTEtMS0w_fc6e99a2-a367-4e83-a2d1-5c588963f8bb"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4afcf835853b4cad93648a7670596835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMi03LTEtMS0w_3a115be3-8a39-409c-b748-3c7bf35ef161"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy0xLTEtMS0w_894c81b7-7289-4223-80f1-2755dfef824c"
      unitRef="usd">171378000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy0zLTEtMS0w_c9c244a1-4dd6-4045-a908-c83ac493ff3b"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ieb82e1104246402e998da7e18d3ac175_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy01LTEtMS0w_29ed871a-1c1d-4103-930f-639de924421f"
      unitRef="usd">468943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4afcf835853b4cad93648a7670596835_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RhYmxlOjg2Y2MzZDQwNzBkNTQwMTJiNmUwZDQxMzUxOGIyMjA2L3RhYmxlcmFuZ2U6ODZjYzNkNDA3MGQ1NDAxMmI2ZTBkNDEzNTE4YjIyMDZfMy03LTEtMS0w_75ce7f14-0699-456c-a2eb-ec959a52bfb9"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNTg_96c3b6e9-18b7-478c-8acc-e8b6b7086926">&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjE_b3d2be71-9030-468f-af5f-2b80b536fbc7">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions or issuers of investments holding its cash, cash equivalents and investments to the extent recorded on the Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#x201c;IND&#x201d;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDc_f4360362-c0ee-4686-b20f-25e8a4782880">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNjI_7624ae1b-8fc1-4f5c-b925-e0c3b9d66663">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80MC9mcmFnOmYzMGFlNzc5YmRhNzQzNTI4OTdlMzJhMDUzOGI3ODJiL3RleHRyZWdpb246ZjMwYWU3NzliZGE3NDM1Mjg5N2UzMmEwNTM4Yjc4MmJfMjEyNDg_b49ff59d-583c-4c6e-a043-e4298706c9e3">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1NA_dc81bdd2-0ae3-4187-8b03-f2d438d523c5">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free Shares Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;Sangamo France SPA&#x201d;) to acquire Sangamo France (see Note 10 &#x2014; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;mid-2021 (a put option). As of June&#160;30, 2021, the Company had purchased all 477,000 free shares for an aggregate cash payment of approximately $1.1&#160;million, upon exercise of the put options. As of June&#160;30, 2021, there were no free shares outstanding subject to purchase by the Company. The fair value of the free shares&#x2019; asset was zero at June&#160;30, 2021 and immaterial at December&#160;31, 2020.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation between Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1Ng_95ea223d-c604-4b5a-a039-98bb76643676">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7f9b84d68624a3d8da6266d4a51b5f0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS0xLTEtMS0w_01825443-a056-4421-b609-5a8bcdcc1b51"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2323e4b2ca47436ab949fc5059e374c8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS0zLTEtMS0w_e34b2409-9468-4581-a474-c04a9907dce7"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id901d356b1b34e939be8837407f81c5e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS01LTEtMS0w_3b71d7f7-9f10-4da4-87d5-83865c0a8d07"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iede1b461482d4aed82d73d8a69942f6c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNS03LTEtMS0w_fabb763b-dbce-400b-b928-9364c4a15389"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy0xLTEtMS0w_a837b6c4-394f-4ef9-a713-c07ada9c6433"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy0zLTEtMS0w_30f21f7c-684f-49d6-82d8-fb761e47bfed"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy01LTEtMS0w_bd7fbb26-f1f7-456c-8734-c1dd53c3e690"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfNy03LTEtMS0w_470077ad-5d07-4e59-b940-25f6494077a6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd9e21d00fd54ff8a09781d3bb15014b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0xLTEtMS0xODM0_2d24276d-b177-40f2-be13-bcc90f215cde"
      unitRef="usd">160336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i24d0b873fa0149c8b7057a9015e35d00_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0zLTEtMS0xODM0_9e6286db-13d7-4aed-b433-070cd9716750"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id562a87f24e64a2389a1d8d8af690954_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS01LTEtMS0xODM0_1ba5bbf3-8f6c-403b-9650-23947b2b58cd"
      unitRef="usd">160336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib805bf377aca43d18a31ed9b25cbd937_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS03LTEtMS0xODM0_d85b4b40-16d7-4e12-ac6b-a09fa1e5726a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if450e0b0e1ee4143a860c134efa23684_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0xLTEtMS0w_37b451e4-6c4d-483c-a61c-03469bd1cdda"
      unitRef="usd">143465000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0349e23895b7421f8e06a6dbc6671d20_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS0zLTEtMS0w_d6e532f3-ff89-4baa-8f1b-550f2cca9c7a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8183472477d84945864fdedade5b202f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS01LTEtMS0w_56d6ac92-1254-4722-88be-4900864954c9"
      unitRef="usd">143465000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5414aecb9154731b24f5050b5dbda09_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfOS03LTEtMS0w_56328ef2-b968-4f63-8188-8224d67b8595"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8db22379ed084ff283dba3989fe52b6e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtMS0xLTEtMA_d12db64c-e91f-4277-8dc5-0aeafe6f4fd0"
      unitRef="usd">36938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5029632c41647f2876db827348be963_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtMy0xLTEtMA_d9f6c2c7-334e-480d-a479-db4ebd155ee3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7def2ac71bde401591646c0426604256_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtNS0xLTEtMA_bbc1a4f5-eb61-4734-9313-4de50ab31722"
      unitRef="usd">36938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68379fd4ffaf45be8859410fd6c6d092_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTAtNy0xLTEtMA_8027031b-f933-4e97-b36b-1a7d7f0b2b60"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i64b7b79fb378470c800337959c76517b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItMS0xLTEtMTg3Mg_5cf637f6-8983-43ce-ae17-e46dc2b87db8"
      unitRef="usd">45742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i505b398cb72a4af8af945f5b2a8a5a17_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItMy0xLTEtMTg3Mg_42605745-7296-4417-9498-6cb4ed4616ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2f8eb9c45d4c408ba0e7213a7b21a8e3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItNS0xLTEtMTg3Mg_f9326487-e35b-46a9-908c-43be96d97fed"
      unitRef="usd">45742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4e0c6ce0cdc4cdc85330469e1cebf83_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTItNy0xLTEtMTg3Mg_59d010fd-f45f-4e75-84eb-abd677ac04e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02b46bcd8bc6494a8ffa054541480b01_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtMS0xLTEtMA_6136d950-a1a4-4303-b0ad-cdf32d57f0d0"
      unitRef="usd">22499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i720ec452f326424cae2d555e85cbe793_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtMy0xLTEtMA_87e3e6cc-66b0-4df9-aba6-52434bf41c4a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i63e206d594384d51a4a4ea755c3ecac8_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtNS0xLTEtMA_c8ddf97a-3040-45fd-b88a-2b92aea89a12"
      unitRef="usd">22499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecdcf307636f43bea5bac2dc2e4668ea_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTEtNy0xLTEtMA_adaac5da-7c1c-46cf-af92-2c4002cc6c83"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtMS0xLTEtMA_6d9e528d-3eef-487c-a7ba-4667aa314da7"
      unitRef="usd">408980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtMy0xLTEtMA_93a2887b-be46-4493-bc99-47d7959cdcaf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtNS0xLTEtMA_f8c5e7e8-a2b9-4b57-8f11-a7bc0c5b2b8f"
      unitRef="usd">408980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTQtNy0xLTEtMA_26d25d6b-a901-4973-8ba0-d31e1804368f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1cc0cd49c9d441feab4a2812269fe281_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtMS0xLTEtMA_7154a8c7-f89f-40d9-81e4-719d8181f049"
      unitRef="usd">466351000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic8c4704ac0604965b5a89ba4a9d297d5_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtMy0xLTEtMA_e84e3100-67b5-46d7-a8d6-d179928ac6cb"
      unitRef="usd">57371000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20c3e9dbbc8b4ad5aa38289a8378eb05_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtNS0xLTEtMA_2be27da0-ad95-46c0-8f88-6f6a945cedeb"
      unitRef="usd">408980000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i077c5113d6c84b65a3cd01c8c474aebf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjU0ZjA1MDlmNGYyZjRjNDA4MzgwZTQ1MjNjYTE3ZmVjL3RhYmxlcmFuZ2U6NTRmMDUwOWY0ZjJmNGM0MDgzODBlNDUyM2NhMTdmZWNfMTUtNy0xLTEtMA_cd99467d-4a4f-4fde-bbcf-232676b4f8da"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic12cf9801c6e4bbd868ce62fb93d0483_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS0xLTEtMS0w_46990797-6a0b-4ec3-9356-edbd5232f038"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1309e7273bd24e24a45b18f385fbd498_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS0zLTEtMS0w_ddc9a98e-1941-40f9-933d-8d981608c774"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i92fba028dc354b2eb96680caecf3f6e7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS01LTEtMS0w_c348b80f-0a86-4cc8-89d9-570439d2663f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i362bde0e7ad9484fb5748204542558d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNS03LTEtMS0w_7e138160-3659-44c8-b7cb-a9537b71da1a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi0xLTEtMS0w_a60d8ad5-06db-4131-9e50-2875e432b339"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi0zLTEtMS0w_978d91f5-5d25-4861-8081-dfba8abebfdb"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi01LTEtMS0w_275d366b-a52c-42f2-978b-bf7701afd2a5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfNi03LTEtMS0w_a400a823-8ca4-4413-9f1c-ba64fd42b17a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ec88d85ad284f01bb0601faca0f26d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0xLTEtMS0xNzg3_3b7de7f5-6bde-4602-925a-c152e160fcc3"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11554ac8395246c1b797508e7c8e254a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0zLTEtMS0xNzg3_2646a6ae-f8aa-4363-9f44-1cbaade47a5d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifca71a895253445d9bab2b29a4f24697_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC01LTEtMS0xNzg3_86e246b4-56e1-46aa-8f0e-6873d6aa05c7"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic6afbf16e0ce49a4bbc2a2f2ca704329_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC03LTEtMS0xNzg3_db705134-907b-490b-bdb5-1f541215bf6f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2d98818a61914dc19882f4a5fe585eef_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0xLTEtMS0w_34a47f5b-8b98-469e-88c6-12c392058782"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i303ee2bb6e9a4ebaa06e5883c4402433_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC0zLTEtMS0w_760ee898-ffa7-40bd-ae7a-255a1e8b6155"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c30dc9b677a4b0ca056c73e4e52b5c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC01LTEtMS0w_0033b048-de44-4cd0-a39a-c93c25ae77ca"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib77476f69b30416498dda50883c18ac1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOC03LTEtMS0w_137be6ee-6618-48a3-ae38-e5ee071b7d4d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7061108114744e25af56d34f408d6462_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS0xLTEtMS0w_4c9f0889-f9e4-41a0-9dc8-b966613acd92"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d79151e513b4079a0407f83cc2655fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS0zLTEtMS0w_d9d888c9-2bd1-4461-8336-b25083f6b3d7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbaf1eb6abc0483f8d83c17330ca0080_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS01LTEtMS0w_0241f681-f04e-410a-bae3-deecd268b54e"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bb3dfe79994423bbacf9f8d84283e72_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfOS03LTEtMS0w_46686761-8c26-4175-93db-2c18663ebf82"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13dbd67b064846a580f0e2753a85487c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtMS0xLTEtMTgwNg_66037c52-b19a-4b70-ada1-9b4ec6234b53"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ad85f098bcf421c8794add0b139710b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtMy0xLTEtMTgwNg_ef207f52-2460-43cf-bd2e-05b8b89e69e3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1617c6130bb4fcd814b7b116daca30e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtNS0xLTEtMTgwNg_223b773d-71e2-45bb-a2a0-24ef6e40c0b5"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8a854ccb6ff4f32aff9c08dace430ff_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTEtNy0xLTEtMTgwNg_fd7d04fe-613d-42a1-9bd1-f8b8e7affcdd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ce000386f6f43ecb585bb2bddba79ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtMS0xLTEtMA_71333f46-fae3-4c7e-ae37-3cd5b4949d7f"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic22c7a6ee30f40759935f2f2d7d05834_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtMy0xLTEtMA_2f598514-1851-4b2a-ab96-e837d77ae930"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i963546ecd5104507ad517a04791a50c1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtNS0xLTEtMA_a6805b74-2d4b-4f22-b61d-4be25351a80f"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i706c0c1baf274bb08c2015e44b1886de_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTAtNy0xLTEtMA_078586c1-fd2c-44f8-bf8c-01cc537fc53f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtMS0xLTEtMA_d1c56a97-7e87-4a82-ba00-02745f08a86b"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtMy0xLTEtMA_e5ea3cfc-0f12-4e57-9a22-1b1e8c1c68bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtNS0xLTEtMA_de364d55-eb3c-4205-a855-566f400d00b6"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTMtNy0xLTEtMA_5e7c64f2-8328-4e1a-8479-2da59489e98c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia7181d2a95ce47b89c7f6fdf6047de11_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtMS0xLTEtMA_a7bd5c31-3de9-4b8f-904e-1e7f28bb856b"
      unitRef="usd">613789000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i908904f75ecc47cca4d8fca5927696db_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtMy0xLTEtMA_ca626a2a-4185-499e-9db1-2c5026140346"
      unitRef="usd">53165000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i98e5bee530c449aaba799aaeba075e38_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtNS0xLTEtMA_bd9cda98-a34f-4ce1-8f44-3e907673bc93"
      unitRef="usd">560624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibaa17aef4be24c9488134ae6b2d112e6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTQtNy0xLTEtMA_3f0489a4-5bda-489d-9fce-bc386273b387"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i58a9adeab28a45ad91025a9d341cc25a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtMS0xLTEtMA_33e4b783-5aba-409d-9568-aee253c247bc"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1328c5aeb1034e05853f1890344e7e0b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtMy0xLTEtMA_328e63ae-8463-4a19-8226-c0a4c4fcb377"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i32c8d36f055d46c0bbb5f38ae8ded7f8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtNS0xLTEtMA_8480d5a0-4b62-46b3-a761-188b1e5e5992"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7dad1abe8fca4c9dabb1a22b9f475901_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOjcxNGRjNzY5NWEyMDQwZjdhMGEzZDkxY2IxZWJjNGYyL3RhYmxlcmFuZ2U6NzE0ZGM3Njk1YTIwNDBmN2EwYTNkOTFjYjFlYmM0ZjJfMTYtNy0xLTEtMA_49755042-403c-4e15-8f53-60e77c5fe31c"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjU3MQ_9f5050b0-16fc-4345-adff-53c9f7797856"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjg4OA_9e130e04-62d7-4a55-b8db-ab733b68064d"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMjk0Ng_adf6bf4a-5198-496c-aac9-fa5fc5fbdad7"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase
      contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzg0ODI5MDcwMTYwMw_d753fca5-d460-405d-a7d8-1778cba3f1f6"
      unitRef="shares">0</sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase>
    <sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset
      contextRef="icc3d33b771494438a51064004b2d92d3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzg0ODI5MDcwMTYxMg_3e64b2c0-0755-4de3-a336-97c82af2b338"
      unitRef="usd">0</sgmo:BusinessAcquisitionsFairValueOfFreeSharesAsset>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RleHRyZWdpb246NzRmY2RkMWY4ZDYxNDNhMTg2NGY4ZGQ1M2U1YTYyZDdfMzE1Mw_334ce240-c727-4a62-ae95-c7e2c0be4e90">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation between Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR / USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="i6117a419ac54480ab8e969b26e8ae160_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMS00LTEtMS0w_40ff7f6e-6c71-419d-b324-4ac60bd81394"
      unitRef="usdPerShare">15.61</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ie3ba6686f885449fbf9782164f707326_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMi00LTEtMS0w_9191a06c-cfb0-46ae-9e0b-300aef4b0bb4"
      unitRef="eurPerShare">3.85</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ide00909279d94c5a9ba8d214c592b3ff_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfMy00LTEtMS0w_92cbc88c-6d48-48ae-b744-deab1e603b76"
      unitRef="number">0.82</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i81061d827331480d88e9dc8cbe6d82cd_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNC00LTEtMS0w_63aada21-e669-465c-a88c-12107555fbb3"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="if916a4018cf94a308d569e7cc671aeb8_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNS00LTEtMS0w_0c38dece-d8f5-4b5a-a4b2-043e1baadb83"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i4194918b5c8f4b7b829c28cf27413388_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNi00LTEtMS0w_58aa6144-72e5-49fb-8c2f-cadd70bcbdf7"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i6c37f58da8234bf5b594e14ec1be3875_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80My9mcmFnOjc0ZmNkZDFmOGQ2MTQzYTE4NjRmOGRkNTNlNWE2MmQ3L3RhYmxlOmI2ODUyZmMzYTk1ZTQ0ZjU4YjQ2ZTA4ZTY5OWM1NTU3L3RhYmxlcmFuZ2U6YjY4NTJmYzNhOTVlNDRmNThiNDZlMDhlNjk5YzU1NTdfNy00LTEtMS0w_beb3f80c-934d-40b0-97b1-4d8ff85f0f1d"
      unitRef="number">0.063</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk2MA_eaec5de9-b8df-4e9a-8b71-f031bdea6872">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had unrealized losses related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen &lt;/span&gt;&lt;/div&gt;to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#x2019;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at either June&#160;30, 2021 or December&#160;31, 2020.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk2Mw_06f4b63d-84cd-4a38-9887-8da8f0d26ff5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;(Losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC0yLTEtMS0w_80e98228-79a7-4f46-ae55-0de616be5622"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC00LTEtMS0w_98ad99d6-a940-4cf3-a0e0-a565e2039937"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC02LTEtMS0w_d070ed22-2244-42b1-af37-d725ae4272db"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i22e9e7ac993e4ab7b129b505e24d788f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNC04LTEtMS0w_cd43c8fb-9930-45f9-b1f6-bbacfe5bb54b"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi0yLTEtMS0w_2a29200a-ea95-4580-8861-1d396c1ee177"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi00LTEtMS0w_f2abbcdc-1017-4657-8b31-d0599563587f"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi02LTEtMS0w_c556d21a-62ca-43b8-84a0-3c00be1d13ef"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0af5ca91be0f4e55a8b4a8676a32527b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfNi04LTEtMS0w_71237b54-6f39-4b89-8cf5-26258b411644"
      unitRef="usd">57371000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0xLTEtMS0xOTQy_3b77282c-fde4-41b0-be7e-069e325233df"
      unitRef="usd">160310000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0zLTEtMS0xOTQy_7179812f-bbe8-4643-a8d5-64e34af9a271"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC01LTEtMS0xOTQy_d62c9bc8-7b2e-4db5-9035-4d19537d88fe"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i36c99173dbfe418bab2ee3066dfea7db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC03LTEtMS0xOTQy_fe98dfc5-5bea-40de-a847-a80679d78815"
      unitRef="usd">160336000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC0yLTEtMS0w_5dc036a8-a7b8-41c8-8507-aa658bf35625"
      unitRef="usd">143435000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC00LTEtMS0w_58918899-b4ee-46fe-8e72-b008b685591e"
      unitRef="usd">33000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC02LTEtMS0w_3ec30227-9c36-46b0-9b3c-2d93faad9cec"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ce9e8a4f4c84c95b8a034114fd5ad8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOC04LTEtMS0w_3becf26b-3805-4244-8e10-227727257f64"
      unitRef="usd">143465000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8ce71d590cc54013935014a27b276620_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS0yLTEtMS0w_b5acba09-3db7-43f6-ab77-cb401dc44e48"
      unitRef="usd">36942000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8ce71d590cc54013935014a27b276620_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS00LTEtMS0w_4115d21e-88d1-4675-b0e7-d69bfa6e3a2d"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8ce71d590cc54013935014a27b276620_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS02LTEtMS0w_32feddcc-dffe-494e-b6ec-0760660d1a7a"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ce71d590cc54013935014a27b276620_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfOS04LTEtMS0w_bd963541-7944-45ec-9598-f45212d513e4"
      unitRef="usd">36938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtMS0xLTEtMTk2Ng_628f44d2-1b1c-481a-9c23-4f2d932a163b"
      unitRef="usd">45743000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtMy0xLTEtMTk2Ng_27f56df5-0274-4f97-b414-28a0060596d0"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtNS0xLTEtMTk2Ng_9bb8fc4a-c20d-44c5-8344-e3304d1c54b1"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87323cf714eb4de6a0a1d5f70ffb1c93_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTEtNy0xLTEtMTk2Ng_59fa6554-29e1-4be8-90e8-436f95ed1c64"
      unitRef="usd">45742000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtMi0xLTEtMA_65967309-aae8-400f-abf8-9f61016ad16b"
      unitRef="usd">22492000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtNC0xLTEtMA_66d72104-98ab-42d7-a221-308b56dcceb5"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtNi0xLTEtMA_aee4cddd-68d2-4382-9e74-4c2688234981"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i136a3f20b3d644d68d50ee4ad3cb9b8b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTAtOC0xLTEtMA_a21f627f-5452-484b-a87e-ca9cc176b797"
      unitRef="usd">22499000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtMi0xLTEtMA_1e36a328-c321-465d-8037-e575ffec19f5"
      unitRef="usd">408922000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtNC0xLTEtMA_c403aa5a-2aaf-4745-adcf-7aa83af9b5bf"
      unitRef="usd">84000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtNi0xLTEtMA_1c269f4a-2f05-4a4e-a428-1ed901508184"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTMtOC0xLTEtMA_2bc11f36-c936-4ee1-b646-184ae8c30668"
      unitRef="usd">408980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtMi0xLTEtMA_b5f3c47c-0eea-4e9e-bae1-7f501fa315d5"
      unitRef="usd">466293000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtNC0xLTEtMA_fa7f8a26-167e-4dad-8a43-dadb1db2984d"
      unitRef="usd">84000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtNi0xLTEtMA_297ec28d-fade-4811-9d4c-35163c4f5b85"
      unitRef="usd">26000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTQtOC0xLTEtMA_b1682242-dd81-4f0e-97c1-0e278b99faa0"
      unitRef="usd">466351000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktMi0xLTEtMA_ec470d9d-c117-43c5-a828-4af829fa0beb"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktNC0xLTEtMA_5d24cfb0-2d36-4402-bd59-90091dadd9e4"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktNi0xLTEtMA_819abb69-91e5-4742-a84b-24d1be5fa2ae"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf2e92f60d1e4b6bb574ee3a90a34158_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMTktOC0xLTEtMA_6603518d-b878-42fb-930c-069621964baf"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtMi0xLTEtMA_1fbe1582-9276-4ca9-8daf-9afcd9ee454c"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax
      contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtNC0xLTEtMA_c5e9a77e-38fa-4c30-b189-9e29154bc916"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax
      contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtNi0xLTEtMA_d9fb43e4-cbd9-4a5f-8f8e-43f2cfd4f9db"
      unitRef="usd">0</sgmo:CashEquivalentsGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if8e6ef0b9d424f72856f86ece181ec9b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjAtOC0xLTEtMA_4755970b-5ce8-47a1-9765-5ecf9300066a"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMS0xLTEtMTkwMA_25b460aa-0957-43af-9f89-7d389d850c88"
      unitRef="usd">257284000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMy0xLTEtMTkwMA_a78c56f7-cbb1-43f5-84b9-dea6cf119bdb"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNS0xLTEtMTkwMA_d632b79b-2b04-4ed6-b8cb-bc2444a3dfa6"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c4d9bcf1e994baeb38642a3e110cf1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNy0xLTEtMTkwMA_a97b863c-afed-47bc-afee-28b9c2c15e25"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItMi0xLTEtMA_46a7843b-e673-49ea-afac-1c9dd166df7f"
      unitRef="usd">213500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNC0xLTEtMA_e08798bd-042d-4a6e-b490-727d4453462c"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItNi0xLTEtMA_a7744d92-7fe0-485d-8059-e644105c1417"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib92334fc47614d2ab175150cbbea1d90_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjItOC0xLTEtMA_7866271c-efd3-4d20-8bc6-7df3e735f10c"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtMi0xLTEtMA_dc1221fb-0570-454f-82f7-a73b0dab8cf7"
      unitRef="usd">59575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtNC0xLTEtMA_67c3df88-0d59-43bb-9909-09e5001a848c"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtNi0xLTEtMA_a02e6151-2d1e-46dd-bb8d-9713ddecfb05"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe7231be7af84f809a1dd4836d13b306_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjMtOC0xLTEtMA_4022611a-1731-4563-b973-da741007533d"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4760033181744f46bfacb2148a09aa31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtMS0xLTEtMTkxOA_19e5be69-5837-4098-8232-58f41d520fdb"
      unitRef="usd">17905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4760033181744f46bfacb2148a09aa31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtMy0xLTEtMTkxOA_45eb8a94-93e3-4f55-aaaf-077449eb70f3"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4760033181744f46bfacb2148a09aa31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtNS0xLTEtMTkxOA_c54cfec3-73c9-448e-ac25-d31193776a50"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4760033181744f46bfacb2148a09aa31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjUtNy0xLTEtMTkxOA_f78a4a8c-eae5-49b0-95b9-a91d7f639e5a"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtMi0xLTEtMA_68a6db66-294e-4e49-9b01-7e8547c0babc"
      unitRef="usd">12311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtNC0xLTEtMA_795272d7-04cc-4ba2-92eb-763ee01506cb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtNi0xLTEtMA_681d7044-301e-475e-ad2c-4df0d5ea37f6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2b87a7579154dcb87d6a2eacbe03968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjQtOC0xLTEtMA_1f0edffa-887b-477e-8a76-21aeffc011c8"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctMi0xLTEtMA_8916563a-ccc7-47ed-8271-5f388f57fb23"
      unitRef="usd">560575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctNC0xLTEtMA_281fc9d4-4bbd-4369-8dc0-f36e92c29c20"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctNi0xLTEtMA_4b362369-26c8-4aa0-8f6c-d82b74d26685"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjctOC0xLTEtMA_11a83c91-8146-4be9-b2ac-82d5ba213174"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtMi0xLTEtMA_d14ac960-8fb3-4076-ab26-f6d6fb0d6c72"
      unitRef="usd">613740000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtNC0xLTEtMA_53bc23b1-d19d-4407-bba8-13cc29edf3c3"
      unitRef="usd">86000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtNi0xLTEtMA_0c0800b7-f301-4679-b0c5-69519894e713"
      unitRef="usd">37000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOmU2YzllYzNmNWExMTQ1NjdhNTRiZjJiZmI0MTllNjUxL3RhYmxlcmFuZ2U6ZTZjOWVjM2Y1YTExNDU2N2E1NGJmMmJmYjQxOWU2NTFfMjgtOC0xLTEtMA_fb9f1faf-e0c8-49bb-bc3a-64764b2039e3"
      unitRef="usd">613789000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTk1OQ_6871e6f2-4590-4e32-86c1-7bc88ea6654d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMS0yLTEtMS0w_6c356b37-befb-4467-8c20-74ac1e5e68d9"
      unitRef="usd">359775000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMS00LTEtMS0w_17c85cfa-9430-4e4b-8e9c-964ca4de0296"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMi0yLTEtMS0w_905f8e1d-4e48-4ef2-99d7-3ac5ca44d3da"
      unitRef="usd">49205000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMi00LTEtMS0w_aad328f7-e54c-48ce-90fb-77c4c5f46434"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMy0yLTEtMS0w_3cb90d4d-3b76-461a-b0d0-bffa35cf726d"
      unitRef="usd">408980000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RhYmxlOjQ0MWIyZWUyODNkYTRlMWFiMjRmNjc1MTQ3ODBhYTc3L3RhYmxlcmFuZ2U6NDQxYjJlZTI4M2RhNGUxYWIyNGY2NzUxNDc4MGFhNzdfMy00LTEtMS0w_64a8964b-1ab1-4dbd-b233-8129fe36d78b"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_02d67287-d78d-4483-8b9d-5877382e8a3f"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_0bf20720-26f5-40b9-9356-2dd5940ea62e"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_1f85eebe-2765-416e-b339-dd51d73330ee"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_2c374a95-95bd-462f-a6cc-958c2a10e4f8"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_6ab4aca8-9704-4799-9866-2a6cc02a6acd"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_96ba8c91-ef6e-47b5-b0a4-75d580a070ab"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_a983d3d5-0d64-4c72-9eee-dc698171b1b0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMzg0ODI5MDY5OTQ2Mw_fc60bd72-93f2-44c4-90f4-22f4bf5a820a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTg3Mg_198b8df6-06c1-464a-8400-e81703c58b65"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i6ad6e61fa5a14049a4a165e22c9557b6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80Ni9mcmFnOjU2ODFlYjU5MGI4NDRkZmU5MTcwYzFiMzUzOTFhMjAwL3RleHRyZWdpb246NTY4MWViNTkwYjg0NGRmZTkxNzBjMWIzNTM5MWEyMDBfMTg3Mg_9b2b9188-2a47-4dd2-a08d-46566a8a13c1"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA3NA_3ee11b0b-49f6-4144-bce5-00a9a5024858">BASIC AND DILUTED NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares subject to stock options and restricted stock units (&#x201c;RSUs&#x201d;) outstanding and the employee stock purchase plan (&#x201c;ESPP&#x201d;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2021 and 2020 totaled 16,978,884 and 14,964,567, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA1MA_760718cf-4e1d-4fdd-b656-ef91655954ca"
      unitRef="shares">16978884</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF80OS9mcmFnOmE5YjY1ODE2Mjg4MTRlNDhiZmUxNmM5NTdjZjJhNjY0L3RleHRyZWdpb246YTliNjU4MTYyODgxNGU0OGJmZTE2Yzk1N2NmMmE2NjRfMTA1Nw_2ace78a7-1200-43b1-8be4-f35c2ca22d9a"
      unitRef="shares">14964567</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MTk_6e8cf694-75dc-4845-bee0-9f0173099c9c">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#x201c;ZFP&#x201d;) transcription factors (&#x201c;ZFP-TFs&#x201d;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#x2019;s proprietary adeno-associated viruses (&#x201c;AAVs&#x201d;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its performance obligation. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $57.1&#160;million and $70.9&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASC Topic&#160;340&#x201d;). The Company amortized $0.2&#160;million and $0.3&#160;million during the three and six months ended June&#160;30, 2021, respectively. No amounts were amortized during the three and six months ended June&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 for tauopathies including Alzheimer&#x2019;s disease, ST-502 for synucleinopathies including Parkinson&#x2019;s disease, a neuromuscular disease target and a fourth neurological disease gene target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#x2019;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#x2019;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the two-year anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#x2019;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $168.6&#160;million and $183.2&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $0.2&#160;million and $0.3&#160;million during the three and six months ended June&#160;30, 2021, respectively. No amounts were amortized during the three and six months ended June&#160;30, 2020. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), a Gilead company, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T-cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#x2019;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $69.0&#160;million and $81.4&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Giroctocogene Fitelparvovec Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company is responsible for conducting the Phase&#160;1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $0.3&#160;million and $2.5&#160;million of upfront license fee and research services revenue during the three and six months ended June&#160;30, 2020, respectively, and $0.1&#160;million and $1.1&#160;million milestone achievement revenue during the three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $3.4&#160;million and $3.8&#160;million of upfront license fee and research services as revenue related to this agreement during the three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST&lt;/span&gt;&lt;span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $0.5&#160;million and $1.2&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST&lt;/span&gt;&lt;span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.9&#160;million as of June&#160;30, 2021 and included $0.1&#160;million recognized in each of the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.4&#160;million as of June&#160;30, 2021 and included $0.1&#160;million and $0.2&#160;million recognized during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST&lt;/span&gt;&lt;span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"&gt;&#x2011;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2021, the Company had received $5.2&#160;million under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the &lt;/span&gt;&lt;/div&gt;option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2021 and December&#160;31, 2020, $6.8&#160;million and $6.4&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie97ab57d631741109dd7c1a32d722ecf_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTc4Nw_e4d5abd6-b133-4995-bc3b-62dc6826db15"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i16b4febff3d343589497559b4dbc5f8b_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2MQ_62ef347f-4ac2-42f5-b332-5b55bdd86390"
      unitRef="usd">420000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i8b84cec3c18f41669b32e9a32a83d4da_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjAwMA_ec2b0e05-a3c8-4117-8e98-7df9896c9dfe"
      unitRef="usd">300000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjk0Mw_f91d4add-20dc-4740-822d-fa81bbeeede9"
      unitRef="usd">95100000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementLicenseFee
      contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjk4Mg_88916afd-464f-441a-905e-b1872a5452bb"
      unitRef="usd">75000000.0</sgmo:CollaborativeArrangementLicenseFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="ie232ff9914b54e42b06d6dff9b67eae5_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzAxNw_cf1d5141-29d9-469b-95cb-487d0e4056f3"
      unitRef="usd">20100000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8586e51ff5384c2b9ada2a4f735e3e0f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDYzOA_76e6fda7-a975-47c3-b3e0-397cccc36356"
      unitRef="usd">57100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2e4879cf2b1844a59c47a50b6bf44286_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDY0NQ_b2a6dc1c-39c3-4aba-97dd-7cddf63a3b6e"
      unitRef="usd">70900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNg_7ffc78d1-5f12-4671-90a0-6ce1108d5223">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Novartis agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront license fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fbe30a7032d47a7a786786e1076584a_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy0xLTEtMS04MTM_c4274b51-5793-480c-9bf3-565327d39d36"
      unitRef="usd">7559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cff57d2627245a98dea197fe78cc195_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy0zLTEtMS04MTM_4dde5efe-ae08-45c0-a471-ac392921d233"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic486fd39de0248c3bf81822737de9125_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy01LTEtMS04MTM_09dacb8a-9bce-415e-9e86-078593faebe8"
      unitRef="usd">13759000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib688d56d6edc44adbe31811d44707d1b_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfMy03LTEtMS04MTM_cd03198f-b9c8-49fa-bbc7-7ad425f91dca"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i835ea8e2ca074d12bcb1b9c6349fbd74_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC0xLTEtMS04MTM_e9905eb3-2f50-42e5-be82-ee006d278645"
      unitRef="usd">2022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9188107d02544fb9b95edda10fc6daf_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC0zLTEtMS04MTM_101a78df-c133-45a3-87e1-3b27af7901c5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d858ffe5d284f3fb40b15c110d4d661_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC01LTEtMS04MTM_03263c49-656f-4203-b2dc-50fbabc2ba06"
      unitRef="usd">3683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc0a358e8ea34e7d96de8f674d8a0733_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNC03LTEtMS04MTM_5ac53571-8fde-451a-90d1-cbc73d2e4bc8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bf78996e51842fd8c577ced5c319f9e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS0xLTEtMS04MTM_ed233868-ab5e-4e16-96b4-b5f789456826"
      unitRef="usd">9581000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c078f8f84f44092b1c987d2f9ba3780_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS0zLTEtMS04MTM_09b23eb7-59c3-486d-bae3-0ada75aeffb7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i158ac189c740410bb0aa53e1fde36334_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS01LTEtMS04MTM_3a1a8069-3f0c-442b-80ec-fb864c9894c7"
      unitRef="usd">17442000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cd324fe4f6a48e79647a1e6e13a939d_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjUwYWFjYzBmMTNhMDQ3ZTFiNDliYzdjYzJhMGZlZjE4L3RhYmxlcmFuZ2U6NTBhYWNjMGYxM2EwNDdlMWI0OWJjN2NjMmEwZmVmMThfNS03LTEtMS04MTM_7264d21b-ce73-4854-ac1e-006540b07c55"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDk2NQ_c83a1094-4a12-458c-90ba-4636b71a8254"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTA0Ng_aa8277b7-672e-487d-b3eb-6b172f6274e0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTA1Mg_81c85185-1faa-4c7f-bd14-bf6b8ec9bd45"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="id6e6f0dc87e243e683ef1912bbf803d5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTE4MQ_c83a1094-4a12-458c-90ba-4636b71a8254"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i4f0fa707fab440019c997c6ac3943ca0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNTUxNg_56c2052a-3605-468f-bd49-6e3a677ecce5"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i5850fbbe650b4f7ca149d58bba066b5b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4ODc5Nw_cebe9b89-08dc-4286-9840-269778d57607"
      unitRef="usd">300000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjIyNA_974bda9a-9af5-4e96-bdf6-89c3d5864709"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i6d9cb92b6b80443c83fcad54e2dcea08_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjMxMQ_b159519a-c61f-48fd-9143-4c2bb816d215"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjM2NA_838c47e2-9d64-4450-9a0f-46680f45c2ba"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjYzMg_58d77c2d-94fa-4ea4-9f1b-06a1fc49007b"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ibee042a0e57b44b08fcec9b88eb3ff1b_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjc1OQ_2f0f9042-c12c-453c-9e13-2efa92933ae2"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNjkyMA_337915e1-0d64-4538-a93e-eb7c73888d38"
      unitRef="usd">2370000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i80a6feacaa574ddd9bd1767b41d0d48e_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzA4Mw_1302361a-f170-4e21-bb9b-83afdbaf97e8"
      unitRef="usd">925000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ie7c1b1cdac1240e2ab1190ed09b03af4_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzEzMQ_95d276bf-7ba4-4bc8-b289-fef62ba1778f"
      unitRef="usd">1450000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNzg0Mg_d83a98d5-cf0d-4556-8d20-348dad085259"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODE1NA_a7a7d232-0167-4310-b473-1c8343b50906"
      unitRef="product_target">9</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODIxMA_c4e8fcc6-e832-4cc3-a33f-8229931a8f4e">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfODc5Ng_0a12768c-dfed-42cc-9936-8ef8e377a0e8"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="ia808be1f58f54cccaab1ff5dea2e968c_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTA0Nw_33bae89f-f976-43af-914d-4097734ca679"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationArrangementResearchPeriod
      contextRef="i07f79ab0561647e6811dcce07cb91d83_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTE1OA_11ce890f-ed19-4c6e-8f4d-3f6c6f184ee7">P7Y</sgmo:CollaborationArrangementResearchPeriod>
    <sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
      contextRef="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfOTc4Nw_5bb51c63-e1bd-4440-9a14-7b3b49e8b528"
      unitRef="product_target">10</sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjA_1271ac46-e2cc-4479-a992-f3c936485c0e">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA3NTE_c28bbd66-9ce1-4ca5-9bfc-daa6bbb4fe39"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
      contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA5ODQ_256eef1b-3360-469c-89ef-45f98368a9ca"
      unitRef="number">0.50</sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld>
    <sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod
      contextRef="i753f509b9880405096a4935eabfbbe0b_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjE_76283eba-66cd-4b85-994a-cef8690e54d8">P2Y</sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod>
    <sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
      contextRef="iee0d594216f84c7c8299b126f82ebab2_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTE4Nzk_340a5058-94fb-4e0c-ba23-3b25142efb49"
      unitRef="number">0.05</sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage>
    <sgmo:SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments
      contextRef="id9faa6283ef34194a79f8217e05b3bac_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIyODc_37806157-c79f-414b-a5cf-26141eda7db0"
      unitRef="usd">204600000</sgmo:SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIzMjY_ced2a0de-a7bc-41f2-a53c-57b476f274ec"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTIzODU_94c72905-dcc5-4d05-ac2c-585b00098335"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTI0MzM_9885d0fc-6984-45be-89ca-34e7ab9afbbe"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTI0OTE_e5b0d257-222f-4155-be25-619a79281394"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2feef78f3b79481c95ab041ca41b6d27_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ1MTI_7673c660-2860-4a8f-b28d-8513314a423b"
      unitRef="usd">168600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i91eecccd242942a7817f59f45d876655_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ1MTk_15569c67-0252-4f99-8275-32221e012987"
      unitRef="usd">183200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNQ_562df54e-44b5-4e45-ba27-7758e916389c">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Biogen agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6aabab5ee264688a6d71a905f925e4b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy0xLTEtMS0yMjc3_43db914f-4b30-4ce0-95a9-f364bf56cd36"
      unitRef="usd">7306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcc2dd941800420886a2af2fa1765639_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy0zLTEtMS0yMjc3_7ece8952-7ee0-403e-9471-d996b81888c1"
      unitRef="usd">6744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbabaf0c6e544c5696a66609bb1a32f2_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy01LTEtMS0yMjc3_0219833c-354b-4e1a-bf48-6e463420d8de"
      unitRef="usd">14612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d932e2741554bd4a83bff4554127b46_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfMy03LTEtMS0yMjc3_3f521514-543d-448b-a6f8-2705741cd831"
      unitRef="usd">6744000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia45f3ae8095146d9b1f030e6d1b3c45e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC0xLTEtMS0yMjc3_59f89659-def0-49fb-adf8-f4367beaf1ea"
      unitRef="usd">3461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfd23694ec1c40ae9f6a4c23849d8ab3_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC0zLTEtMS0yMjc3_be335b59-b071-4f85-be64-8704973d6e4b"
      unitRef="usd">1434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03284b31d89d49b79fcb22265c258ce9_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC01LTEtMS0yMjc3_be2cccb0-36e6-48a1-82a6-4bdc394471f6"
      unitRef="usd">6605000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic897ac864eec4950857bfb672f25b043_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNC03LTEtMS0yMjc3_3842ff19-bee3-4ca7-9505-fc784645d58b"
      unitRef="usd">1434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4323b438c56c49ddbd9f8c4452cc5cbb_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS0xLTEtMS0yMjc3_4913e5f3-1e3e-4712-8d9d-ba9ea50fe1e3"
      unitRef="usd">10767000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64d854a46e26420aba7a79befd4d3e77_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS0zLTEtMS0yMjc3_813d85e9-6fe6-4117-8cac-aebd23085708"
      unitRef="usd">8178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2569f4e393f64a1ebb5eb6a2b99bd564_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS01LTEtMS0yMjc3_45d08d5f-5c5a-4307-804c-12e71e51d7f9"
      unitRef="usd">21217000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i633a41af52284d31bdc9e6504274de2c_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmM4ZTVlNjUzODdhODQ0NzJhMGFiYzU0M2QzMzUwNWFlL3RhYmxlcmFuZ2U6YzhlNWU2NTM4N2E4NDQ3MmEwYWJjNTQzZDMzNTA1YWVfNS03LTEtMS0yMjc3_101eb56a-fa50-472b-88dc-c8ee43e398b8"
      unitRef="usd">8178000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ4ODc_d390fd27-fb43-48b0-8c25-c8c833fbd0a0"
      unitRef="usd">7000000.0</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ5Njg_0e8c2669-63a8-44c5-b539-8ee4d4eaa599"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTQ5NzQ_9885d0fc-6984-45be-89ca-34e7ab9afbbe"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUwMTM_28f2851c-1115-46e9-850e-3161aa23dff1"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUwMTk_ced2a0de-a7bc-41f2-a53c-57b476f274ec"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i3572522eb86c427da2f7e25c65c67b1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzMzE_615c7b16-868b-46c7-be80-ab52cad26801"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzNTI_9e29e81d-6a4d-4c15-9ec5-1a0038b77302"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTUzODM_2d211192-3136-446f-b6e1-ffcbab9324e6"
      unitRef="usd">204600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i03b2f05be78a47058af5e123836007ae_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU2NTc_8d94cbdb-e93e-4a97-8f6e-19f044a0cda2"
      unitRef="usd">200000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i49bbe267b9a34d67a0bf12f76855023e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjE5OTAyMzMwMzI5OA_875e3a17-32e2-4641-a70d-b2f805a7ee76"
      unitRef="usd">300000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="ie0d564efa3a54efdbab0331632c968f5_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjU0Ng_99a20fe9-4462-4d9e-bc47-aedbf24dafc1"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="id7b52cec79ab48a2ba640cefacfbece0_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjU0Ng_ea6a8783-3e34-4b4f-b488-e701ed4f73b7"
      unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NDU_c27be853-968f-463a-a595-d3cfc2ff9f27"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="id8316f2453e64f2ba4d9e3061d8c839d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NjY_f05e32d8-be4b-44df-a2d1-6cb26b4607a6"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="i64265b83cb264db7a2f9b1598f078ac1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTU3NzY_e5b0d257-222f-4155-be25-619a79281394"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTgxMDE_179baaa8-2bb9-4aaa-bc94-059a7bc0409c"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i98eaac3b8aa14c85849647f25d59a1e7_D20180401-20180430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTgzMzE_eac698c1-a8c3-4428-bf64-2a6d9997dae2"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="ib8501312825a4e209788ef85d358bc38_D20180401-20180430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTg0NDE_d11a87c4-49bd-49ea-aa5f-ebd2cba2d6bd"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTg1ODM_5ae8ad58-5163-4168-91f1-94d1123cc12d"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment
      contextRef="ibeef38e4884f42de920ffa940b3149b1_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1NTMzNQ_b0c41390-f270-43cf-b8fb-c8438f67f1bd"
      unitRef="milestone">10</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk1Mzc_9e9a540a-54f7-4403-9acc-7674d6bf2555">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2MTU_053796e8-e0a8-454c-879b-affe3c608961"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjQ_eb291d05-c331-4d08-904d-56f010d2c5e7">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="i613bf80917ad434ab3e3289b84abd459_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk2NzU_89010291-417e-4de1-959b-919b9012c035"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTk5ODg_11aebab2-59aa-4fc8-a3d0-e18a49c76240"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="iee47bb64fa1a42879c4cb810e7ffb6c9_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTA5OTUxMTY4Mzg3Mw_554509ca-76fa-4dff-80b1-89af2762ddd2"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM5ODA0NjU2NTU2MA_9aa913e0-65c0-4da2-8e75-3e303fad72c2"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i38a22c73258c4fd2827b514d666dee04_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc1MjUwMQ_91cc9951-54eb-4a09-beb8-5e64c554b5ef"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i96eec01b5a724940ba35b94c5052e547_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjI2ODI_10a2429c-3948-49f4-a0bd-746906a51d49"
      unitRef="usd">69000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i513cb6fdd03a4af6a95f35c66fa0287f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjI2ODk_d016d190-2b3b-42c9-b649-055c12389ef1"
      unitRef="usd">81400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjI_e6930f25-424d-4d5d-a412-bb42373212fb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0d915090bdc4052aaca779390bc0142_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS03OTc_f07c23e7-7f40-42b3-92c4-b0b8a5900645"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieee2cbdd740b48d58e90428fd2477bdb_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0zLTEtMS03OTc_cc4da144-7e85-43d6-b3ea-d2fb1d58169d"
      unitRef="usd">6227000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80babf04d54545919679cc087e35d0f7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS0w_8a832201-bbea-4ec2-a2d8-0661e3925621"
      unitRef="usd">12386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80babf04d54545919679cc087e35d0f7_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0xLTEtMS0w_9c4de449-d07e-4a77-b1b9-73b99e16bb93"
      unitRef="usd">12386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30a3cd7910e54e3ba3fb080b6faa69ac_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfMy0zLTEtMS0w_db978b11-e311-4723-b35b-219b58b19688"
      unitRef="usd">12454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0d5461382a74ce0b82725ff6d4dffd8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0xLTEtMS03OTc_672055d8-84ec-42f8-81f1-2e8916da1f08"
      unitRef="usd">97000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb3c41b97bcb4c6893772a2384819bbd_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0zLTEtMS03OTc_7b889e1f-32e7-4fec-a7a6-5d2a1ed4fbd7"
      unitRef="usd">1195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cc29534661e4306917bc72380c1ea3d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0xLTEtMS0w_9f2d5dc8-6aa0-4175-b0b6-ebb3c48bd999"
      unitRef="usd">226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i972f741b215341248c20287be9d34ec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNC0zLTEtMS0w_a60813b3-881e-45eb-a34c-841b8e0db2b1"
      unitRef="usd">2187000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2f6b10a317f4701aac7778e60fc00f1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0xLTEtMS03OTc_8ffde39f-7ad5-460c-bc92-63261e7a5ace"
      unitRef="usd">6324000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc812ad521304f0ab6d3a2b04029f0f8_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0zLTEtMS03OTc_7513b544-54e9-4a85-a13e-f4075a04bf64"
      unitRef="usd">7422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb945f85bf2b43cd9094b6518518bca8_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0xLTEtMS0w_908af429-0469-4927-b0dc-f5d364380702"
      unitRef="usd">12612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i654a42c3511c4a73913c506f1153cab0_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOmZmZmQ1YTc5MDMzZTQyZjU5YTU2ZDU3YjQzYzdiMWMzL3RhYmxlcmFuZ2U6ZmZmZDVhNzkwMzNlNDJmNTlhNTZkNTdiNDNjN2IxYzNfNS0zLTEtMS0w_dadb9974-aa6c-4690-8cbe-9430b6e0dbf6"
      unitRef="usd">14641000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:AgreementTerminationTerm
      contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjQ3ODE_b938b65d-04fa-4115-a7bb-6c5e7c36dae1">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i284384bda5c84aba85f546f831ef8980_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU3MDI_643cfd6d-3122-42cf-860c-02165b57df49"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i59545cce221e43deb1db8aa0c8c8619f_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU3Mzg_e01e4c8c-a58d-4b45-a2c3-8c39f390557e"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="i284384bda5c84aba85f546f831ef8980_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjU4Njc_5dc11811-7f2b-433b-a524-2d4bf9cd3797"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i4902644de3a643778c13659e688fac50_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYxOTY_c29a107c-4fab-4ca8-81f5-6135ab2a09d4"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="iaf27be7caa634555848e2064b64db08a_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYyMjE_9ad24984-61fd-475e-8c4d-ca0aa9b33036"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i1599f0d2349045a39ceba19a613ae914_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjYyNjY_a87c9b0e-c1a5-47cf-97a7-124c0634173c"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY4NDU_9aaa52e0-dd2e-459e-916e-50254fb86831"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <sgmo:MilestonePaymentsReceived
      contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY4NjI_ddd72c48-a465-460f-a1ff-9867223ed628"
      unitRef="usd">55000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i75557659a8d24752a662921819a09f1c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY5MTU_7597924b-b7cb-495a-9e3c-21cfc5a841d9"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i75557659a8d24752a662921819a09f1c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjY5NjA_5b683190-acdf-495b-bb88-ddf66a33bb5e"
      unitRef="royaltyfee">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcxODc_8977d847-8340-4b47-b348-eaa7db7b69bb"
      unitRef="usd">134000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcyNTQ_dd7174e2-a22f-43c5-a944-2a1c7a1930fc"
      unitRef="usd">79000000.0</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:CollaborativeArrangementNumberOfMilestonesAchieved
      contextRef="ifc8c265842404d7e82c0e91c7ff7c610_D20170501-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjcyNjE_eb53699f-43fe-4e67-9f78-02675c19340c"
      unitRef="milestone">2</sgmo:CollaborativeArrangementNumberOfMilestonesAchieved>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjczMjQ_2b0fb607-e134-4cd9-a88b-b616943ade85"
      unitRef="usd">55000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icafc6c9e5da64fc39cba314fee725d9a_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNw_8e80661a-1943-4f02-809a-5b06af833d32"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i66297a2a682c45f0854bb92635ef6ffa_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEyNw_8fc50228-8ec4-4464-98aa-c22d0b24a886"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="i29f42ad77a67406fbca238b8af8a5ff2_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4OTgyMA_a83f149f-d320-4f92-abc8-06465a427444"
      unitRef="usd">300000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="i4b2ac5d2705044b993a63db847d92bd0_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzA2NTg_1a5ee442-c49d-4e41-88aa-418b0dd63549"
      unitRef="usd">2500000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="iedd52702a7604029a53060995365270a_D20200401-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ4OTg0OQ_0eae51db-f228-4210-b900-b1d26f32f231"
      unitRef="usd">100000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="i02d5cb930a144a9cbb549d7b9e0cb689_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzA3MTA_14e69a85-69bf-41a2-ae04-2968fced32a5"
      unitRef="usd">1100000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:AgreementTerminationTerm
      contextRef="i123d6bac6b904da084b4648b22e9cceb_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzIyNDU_63ef95f3-fef7-40a7-a3bd-f1ab16589591">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="if1d3391092d7417eac346ff77c7d0fcc_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzM5NDE_68c1a8e8-b6fd-437b-80c2-432a733e88dc"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ifc852cf62580436a97598e1e2e7bf50b_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQwMDU_8181eff1-77f9-4e85-b991-63ba74d83acb"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i78f2298db25940a68086c2f2eb497a03_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQxOTE_2f954a09-3a84-442b-941b-6947c1d7c510"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQ5Mzg_bcea8242-e267-4a79-9c67-fe9201d26966"
      unitRef="usd">5000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzQ5Nzc_dc2a5c69-7f3a-4470-8b14-2dd931130f4b"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i846b10c13c0e40eb8ae22a3dbb37691b_D20171201-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUwMjI_3da2e48b-4bfc-4e65-98f0-a0b3aec10a33"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUyODY_385d5e36-b751-444d-aa54-8ba4a86a9d4d"
      unitRef="usd">17000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:MilestonePaymentsReceived
      contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUzMjc_daab53dc-d7c2-4e50-b0e2-b03e75daa750"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ica52c191a8ab450ba7a1fbed505cd60d_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzUzNzk_dd0cd9f6-d64e-4fdf-a9ee-6e490671c5ec"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i4dff6bb9876a41ea8f14c14d974128b0_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzY5MzM_da49f467-c083-4a92-b216-a8e49416302a"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i816dc751251a43bc8a0c475d4f25692d_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEzNg_b9f08757-3060-4395-a33d-6807d3cab0f8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd8b8b826b1842fc8ed899c4dbf877d6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzg0ODI5MDc0NzEzNg_fd69f02e-85fb-4119-bd66-dfc10df51710"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4750f84c1fc4cd28df96b044fc89692_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMjE5OTAyMzMwMzQzNQ_5b2007df-41af-4a77-bac4-d6e12ff48bda"
      unitRef="usd">3400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id613ed24d16b4765acccce91ced04655_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzcyNDM_221fc00b-639c-436f-ad10-fc1c554011a8"
      unitRef="usd">3800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:NumberOfResearchProgram
      contextRef="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzc3NzE_606898ad-2a4a-4e34-b3e9-b20b9e0b9ee9"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <sgmo:AgreementTerminationTerm
      contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMzk3OTU_0583df08-5e6b-4871-8969-4f20eb84cc43">P180D</sgmo:AgreementTerminationTerm>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ic2beb734db4e48cfb1eb7bd9d484ac27_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAxMTI_b047c47b-e448-4574-9b03-6abd109cd2fa"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i265ca64c9422418893702f8fafcef2d2_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAxNDg_40b2a1ca-d5c9-43a1-b78c-569ed933083c"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i4e4aeedad67245b6b57656cba94ee249_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDAyNjI_18d93d6c-c5e9-4242-b7df-cc1120f86c4c"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA1MDI_8f9eff02-1638-4425-abeb-1a49a2814387"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="iae65106e3a964b398c60b12ac672bd06_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA4MTE_0d855564-3061-49a3-a090-188ec5b57b63"
      unitRef="usd">6000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i5b2e93e3f8e44d4f8070ca3215e04801_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA4OTM_df580fe9-eec5-4a45-b256-4b436bab8c0d"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA5NDg_fad3add4-3f42-432e-b892-8260efed196b"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDA5OTM_7003a1be-259e-4736-894e-c53e4aa5efb2"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDExODA_e90d044e-2da0-4661-8114-2e76a3e564f1"
      unitRef="usd">93300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEyMTk_9fa5931c-2f65-4d48-bf59-f14c4f31aa94"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i65fc4f7975b44d38bd7edb0af5fa7902_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEyNjk_c494a921-e03e-4c6d-9eb1-921e6453441e"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="ie0bc1adb2c1f48be8335ca685c6f58b3_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDEzMDQ_9bc32eb5-4bdd-40c0-9c07-3f9a963ebcb6"
      unitRef="usd">59800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4f67506e89ce44568390610e8d2b4c62_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMxMzc_33c28f1e-88c0-4a8b-904c-fb655157d6fe"
      unitRef="usd">500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i89c77516ab934aaaa96b5a86b02b8088_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMxNDQ_889bc54f-7b4f-45c1-95c0-bf7543507429"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestonePaymentsReceived
      contextRef="ie375b8492a12465a99eabff9410bf3a4_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDMyMjg_9ae2554b-83cf-46d9-b320-411c872d6a8a"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0Mjc_5016273b-9e6e-4948-96a6-1dcb7181f88c"
      unitRef="usd">5900000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueRecognized
      contextRef="i1e4b7f5e53bf4145a5c9dc69b98cd1f1_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0NTI_28a122c0-d79c-4e3d-b70a-4eb94d257dc2"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueRecognized>
    <sgmo:CollaborativeArrangementMilestoneRevenueRecognized
      contextRef="id1512a9ddf574d86903b981a4ce57329_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM0NTI_f675a17d-704b-421f-bfb8-979059fdd105"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueRecognized>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i585d0b863b2e455eb3b8ea38806281f2_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM1Mzg_ebfbb3da-6228-49aa-a351-c38a9f9d39ad"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementCumulativeMilestoneAchieved
      contextRef="ie95a95e21fe548d9997a3d62efc005f6_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM3MTc_fb397782-dba9-4376-91e3-19343d67eb79"
      unitRef="usd">7400000</sgmo:CollaborativeArrangementCumulativeMilestoneAchieved>
    <sgmo:CollaborativeArrangementMilestoneRevenueRecognized
      contextRef="i5b7cd206e83e4758904b5e5fc3f1286e_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDM3NDI_13f115b7-2c86-44ee-9036-0b1460732cad"
      unitRef="usd">100000</sgmo:CollaborativeArrangementMilestoneRevenueRecognized>
    <sgmo:CollaborativeArrangementMilestoneRevenueRecognized
      contextRef="i710717b98c6d41c0b46518ae1f4899ff_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfMTY0OTI2NzQ5MTQ2Mw_f9c633e4-9a11-490b-890b-1a5d25829e48"
      unitRef="usd">200000</sgmo:CollaborativeArrangementMilestoneRevenueRecognized>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU5MjM_d7b24d6b-9754-4a06-b3c2-f8ed786bb237">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18d41eac62204415b943de1ef2ecb501_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0xLTEtMS05NTk_007cf8c2-7cb8-452e-afc8-1ef22000834f"
      unitRef="usd">206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05b743385b4d48ca9fe7791ecbb5bb8f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0zLTEtMS05NTY_39e5a360-bd78-4411-af47-e63a92a00744"
      unitRef="usd">380000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6900d77cd9b42d4b868148dfc43e2dd_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0xLTEtMS0w_75542865-d962-4611-81c2-43e76281ebdd"
      unitRef="usd">433000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ac0654b4e2f48dbaec56149181d417a_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfMy0zLTEtMS0w_60db08b3-e6f7-4c0b-bba3-b7ac935d1eff"
      unitRef="usd">-349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b5cd1c78eb547b6a7cf66897094551c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0xLTEtMS05NTk_d0cfed88-5441-44ad-9b23-2811d166473e"
      unitRef="usd">613000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8f6533454f547909bd615768ac32c21_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0zLTEtMS05NTY_c9bb4df2-20ae-4992-847d-27b931991ee1"
      unitRef="usd">1155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8302d557aa5476eb1873deb8ef6875d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0xLTEtMS0w_e0b67b98-27f6-438c-a833-1dbaca27918e"
      unitRef="usd">1292000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bbca3607d7f4b9dbfe618a574b3cf7f_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNC0zLTEtMS0w_6a692d46-c972-4c72-91b5-e3ec6e4bdb93"
      unitRef="usd">2875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38026dfb9ff54ab38444e2c29717dc5d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0xLTEtMS05NTk_cfb8b4bf-99b6-400b-985f-7b9e7bb0086f"
      unitRef="usd">138000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8627855bb84142d381d3d87efbd3557b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0zLTEtMS05NTY_da7536e6-b13a-4cd8-b81c-ca2207a27cad"
      unitRef="usd">257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3deb558477ad44f6a2d0a235b31ff428_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0xLTEtMS0w_c45356d8-42c3-444c-9cd8-962d6932c17f"
      unitRef="usd">292000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i703707af95494f1883c80ff59a982ada_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNS0zLTEtMS0w_34735fff-6a62-41f7-b96d-c7791817dfc3"
      unitRef="usd">-235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1f96a8d30f2472682f523526a58819b_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0xLTEtMS05NTk_c70a9b17-9522-4beb-8e49-2cc63b3e81aa"
      unitRef="usd">957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbaf08395b3f410388bfae8549a7f1ec_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0zLTEtMS05NTY_d3aaa9a2-ac23-4fab-8d61-0565f491cfe2"
      unitRef="usd">1792000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa486bef18c84ec3ae484338ea80db43_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0xLTEtMS0w_c8d6ae22-70ec-4918-b8fe-153e26a9e653"
      unitRef="usd">2017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaafcd0ad264e48e3aa1e5d6b42480cf1_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RhYmxlOjc3NDI3YjYxNGI2NDQzNmE4MjdkM2YzMzNhYjhiZWFkL3RhYmxlcmFuZ2U6Nzc0MjdiNjE0YjY0NDM2YTgyN2QzZjMzM2FiOGJlYWRfNi0zLTEtMS0w_5f4bc596-eaaa-4172-aceb-66cba3bd5cf1"
      unitRef="usd">2291000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:GrantFundingAmount
      contextRef="i7d369449f64a4fe9802fbfa50d7c5894_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDQ1OTY_9918b029-0f38-4c0c-9e07-71ce9c35dd34"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i486e45b737f34ead89ccdfd67614cc80_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDUwMDg_1f2cd8dd-84d1-47de-81df-caf830f6a7d5"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if65442cfd04e40d3ae655da86b882810_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU2NTY_a777afcb-4195-4a36-abd5-28199b58d951"
      unitRef="usd">6800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id6a2fee8655546779fce8418e68deeb6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81Mi9mcmFnOjkxNzQyODk3MTA5YTQ0M2M4ZTFjNjI1NjM1MjQwYWM3L3RleHRyZWdpb246OTE3NDI4OTcxMDlhNDQzYzhlMWM2MjU2MzUyNDBhYzdfNDU2NjM_b1253fdb-35b6-468d-9077-25b32daa38d9"
      unitRef="usd">6400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfODcx_5b4d8c82-22b6-4362-8043-74876fe6b365">INCOME TAXESThe Company&#x2019;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. In the six months ended June&#160;30, 2021, the Company recorded income tax expense of $0.3&#160;million, and no such expense was recorded in the six&#160;months ended June&#160;30, 2020. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three and six months ended June&#160;30, 2021 was due to foreign income tax expense.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfNDM5ODA0NjUxMjQxMg_10a58fe8-d3ad-4a28-acf1-79fb299bd053"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81NS9mcmFnOmQwMDUwZGI5NThmYzQxOWJiZmM0NDcwZGFiMjBlYWFiL3RleHRyZWdpb246ZDAwNTBkYjk1OGZjNDE5YmJmYzQ0NzBkYWIyMGVhYWJfMzg0ODI5MDY5ODUzMQ_d75e24ba-3a5b-4c88-9796-8c5f14f6c671"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyNQ_fcdce8d7-6bba-412d-8c4e-03c69924a29b">COMMITMENTS&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 59,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately 25,600 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjc3_08762a14-8ec2-41bb-9293-f9377bdafc34"&gt;five&lt;/span&gt; to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. Components of operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease expenses were not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2021 and 2020, was $3.4&#160;million and $3.1&#160;million, respectively, and was included in net cash (used in) provided by operating activities in the Company&#x2019;s Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ending December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the weighted-average remaining lease term is 7.3 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $0.9&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France, which expires in January 2030. Total lease payments over the life of this amended lease are approximately $0.8&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also had $0.9&#160;million of license obligations related to its intellectual property as of June&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ia382d9bdbbdf435a8b54bc9a6f870e20_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjI_748824ff-1331-407f-9187-f55b4903fde5"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="idf88ce12a67f455e9a78d4bf52333bd6_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjM5_0f4db11e-ced3-4a85-be81-690ae172b24a"
      unitRef="sqft">59200</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="i77ccec543f23406c8dce0f2a0b6c2285_I20210630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDAx_9ee4683c-8efe-4496-ab65-13db6078579d"
      unitRef="sqft">25600</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i54bc17f50cf74a93848b137afc7fba91_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjgz_695770e6-9df2-4a74-8582-4af81cc02e08">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzg0ODI5MDcwMjAyNA_76535701-da1f-44d6-a68d-d0bc4e5e1730">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. Components of operating leases were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi0xLTEtMS0xNjAz_189dbf53-9be6-402c-8e90-978130852c11"
      unitRef="usd">2697000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi0zLTEtMS0xNjAz_daa4f581-be3b-4ff1-aa2e-2e7cffd0d209"
      unitRef="usd">2572000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi01LTEtMS0xNjAz_e850da92-83a9-4d2d-86a8-f78f10b0ba4e"
      unitRef="usd">5385000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMi03LTEtMS0xNjAz_6215dd2e-ccf3-442b-b5fb-11f567036e80"
      unitRef="usd">5145000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy0xLTEtMS0xNjAz_b276100a-0284-4945-9005-f145debf2800"
      unitRef="usd">614000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy0zLTEtMS0xNjAz_0643b62d-ad2d-4ca4-92df-697aa288d356"
      unitRef="usd">552000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy01LTEtMS0xNjAz_1d35278a-bcce-4699-a81b-d03cbbe52cd3"
      unitRef="usd">1326000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfMy03LTEtMS0xNjAz_74a3dd90-dc1e-4689-9704-090fd90c616f"
      unitRef="usd">1009000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC0xLTEtMS0xNjAz_cb0e5e87-16f6-479f-9ca7-be0401e90a67"
      unitRef="usd">3311000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC0zLTEtMS0xNjAz_a79e3ad2-a115-4d0d-b81f-71b0bf5b5085"
      unitRef="usd">3124000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC01LTEtMS0xNjAz_cde30828-4769-42c4-b414-8a1e4e16d8ac"
      unitRef="usd">6711000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjcwYWJjNjhlODNkMTQ0MGNhYThkYWVjZjFlMDNiNGY2L3RhYmxlcmFuZ2U6NzBhYmM2OGU4M2QxNDQwY2FhOGRhZWNmMWUwM2I0ZjZfNC03LTEtMS0xNjAz_0f343bb1-aeb3-40ec-9969-c627f36b9489"
      unitRef="usd">6154000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE5OTAyMzI2MDE5Mw_32ab3615-f562-4e4d-8802-a37ddf1511dd"
      unitRef="usd">3400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE5OTAyMzI2MDE4Nw_5166cf13-2781-4571-a105-9f5e19baf488"
      unitRef="usd">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyMg_dc88b19b-7688-4fcc-b5f1-25c46e3b7d45">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six months ending December 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of June 30, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMS0xLTEtMS0w_5a078451-79cf-418a-9e1e-84afcce20afb"
      unitRef="usd">2938000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMi0xLTEtMS0w_40905fc7-f896-4d19-9fe9-973183e4b84f"
      unitRef="usd">6995000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMy0xLTEtMS0w_fa9bca85-08fe-4580-bb4b-cbdde2912c63"
      unitRef="usd">7094000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNC0xLTEtMS0w_40929149-a3f6-4be2-9b7f-a6eabc59de3b"
      unitRef="usd">7242000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNS0xLTEtMS0w_de711f84-1e71-42e5-be50-9a8b92891b21"
      unitRef="usd">7312000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNi0xLTEtMS0w_88d6b5da-8cdd-4c5e-b28c-5ea8a6a439ea"
      unitRef="usd">20044000</sgmo:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfNy0xLTEtMS0w_7858d3e6-9274-4e5e-af6b-e244952832a4"
      unitRef="usd">51625000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfOS0xLTEtMS0w_e91f6d58-e6ab-46f0-b98c-e492052c5f56"
      unitRef="usd">10331000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTEtMS0xLTEtMA_ecd88dea-691a-4bcd-a353-cc7044a4d8f2"
      unitRef="usd">41294000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTQtMS0xLTEtMA_6364d61f-8215-4eb8-bd02-72552e6f8003"
      unitRef="usd">3966000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTUtMS0xLTEtMA_29d07455-5537-44c4-90dc-b4b14eda7d37"
      unitRef="usd">37328000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjY2NjEzYTc4YmZmODQyZWM4NmU3MjdmOTI1MjA3ZDVlL3RhYmxlcmFuZ2U6NjY2MTNhNzhiZmY4NDJlYzg2ZTcyN2Y5MjUyMDdkNWVfMTYtMS0xLTEtMA_8aafcf1f-f097-40c8-8370-27da7270bacd"
      unitRef="usd">41294000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjE0Mw_cbc2d74d-ea15-4352-b977-10b3dbe75530">P7Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjI1MA_2ca2003b-d57d-4658-a22f-64adea7ebd7f"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <sgmo:LesseeOperatingLeaseAreaOfRealEstate
      contextRef="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMjM5MA_286d17c2-c211-4573-a0e0-1e02fc217958"
      unitRef="sqft">5000</sgmo:LesseeOperatingLeaseAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="ib34e0fb3739a48d7a9b32c6d6f17e945_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkxNw_6e0a83c7-2b50-4293-99fc-12e376d5b96e"
      unitRef="usd">900000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="ie759a817c5c842dc869ef8337be7e5b5_I20210201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkzMA_39dbf189-5df4-4996-a67d-4fad802b9800"
      unitRef="usd">700000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAreaOfRealEstate
      contextRef="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzAwNQ_fe156fb2-2c4d-47de-845f-a9202c192230"
      unitRef="sqft">5800</sgmo:LesseeOperatingLeaseAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="ib4e2de7ee1c64732a87e4af4e73953e0_I20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTkzOA_63b1b328-8dcd-4990-a35c-cda9a3aa8a2e"
      unitRef="usd">800000</sgmo:LesseeOperatingLeaseAmount>
    <sgmo:LesseeOperatingLeaseAmount
      contextRef="ic293643aa8de4967836920062840361b_I20210129"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNDM5ODA0NjUxNTk0Ng_10e15307-a084-4de8-8d4b-529c940179b6"
      unitRef="usd">600000</sgmo:LesseeOperatingLeaseAmount>
    <us-gaap:OtherCommitmentsTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzgyMw_0b0c57e7-0a72-4e06-b9c9-97c8bb79c67b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of June&#160;30, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="ib32b37dab57243ff923131f59634e7db_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMS0yLTEtMS0w_246e7f1e-7349-4e91-8d74-bc4f1d8957d3"
      unitRef="usd">4579000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i4481f3dcb92a483898be17cb32b7bf7f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMi0yLTEtMS0w_cd77f6bb-c7f4-4107-9c04-819ea0c477cd"
      unitRef="usd">9513000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RhYmxlOjUzMTQ5OGYyMDQ5YjQyYzU5MjQ3ZDZjYjM4NDhhNDQyL3RhYmxlcmFuZ2U6NTMxNDk4ZjIwNDliNDJjNTkyNDdkNmNiMzg0OGE0NDJfMy0yLTEtMS0w_64cef207-faf2-412f-b674-0b036b84a68c"
      unitRef="usd">14092000</us-gaap:ContractualObligation>
    <sgmo:LicenseObligations
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfMzc1MQ_b91e08ae-4ee6-455a-a387-6ddf31440fe5"
      unitRef="usd">900000</sgmo:LicenseObligations>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RleHRyZWdpb246NTU0ZjIwYjlmYmU0NDU2NTliYThlYjNkYTYzZjY4NTlfMjE4_2d8e8f13-2287-4a29-9b20-1b07de6efc9b">STOCK-BASED COMPENSATION&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RleHRyZWdpb246NTU0ZjIwYjlmYmU0NDU2NTliYThlYjNkYTYzZjY4NTlfMjE5_55d6b343-dd75-4d94-9f4d-60cc4c389150">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.349%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id91afce1bd2045ce87ebb34073d3ebb3_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0xLTEtMS0xMDEx_9ecfbd3b-3688-4e9d-bc0b-80adf591d36d"
      unitRef="usd">5458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5dbf6eee474c485286ce46451d007985_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0zLTEtMS0xMDEx_94d7aa0a-70cd-47ff-b57e-507946d64ab0"
      unitRef="usd">3578000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e9b0b01e53e4cc1ad161df3748b4306_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0xLTEtMS0w_261a3882-7a78-442c-a2d0-a89fafd414b9"
      unitRef="usd">9710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib2337f42bb8a494cb58c83594f9439eb_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMi0zLTEtMS0w_64bd8262-3d64-4f57-a3c5-71de44d65311"
      unitRef="usd">6417000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife2d5e93bac84cb9b315459ace950026_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0xLTEtMS0xMDEx_a2c3c841-ff98-420a-8963-452a1b165eb8"
      unitRef="usd">4025000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64c0de19663e46b5a34f83368fe2a0c0_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0zLTEtMS0xMDEx_95b5b694-3db6-422d-ab6d-2907c44d0935"
      unitRef="usd">3186000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i193dfd8314f24ec6b3d6b58709ed8e14_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0xLTEtMS0w_424814e2-355c-4224-ac49-b3d421e9e2c8"
      unitRef="usd">7297000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e988a6d8f274d49aef75fec334e2456_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfMy0zLTEtMS0w_0b6f7563-d135-4a93-aeed-40970121157f"
      unitRef="usd">5967000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0xLTEtMS0xMDEx_9fa2c58d-02a0-42ef-8314-38efe1e277dd"
      unitRef="usd">9483000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd59ee793afe4b7eb34ca7d658778971_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0zLTEtMS0xMDEx_617b700e-940b-4ccc-818c-e022f5eab570"
      unitRef="usd">6764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0xLTEtMS0w_c52831f0-d7b1-4b95-a62f-06ade86ae9f9"
      unitRef="usd">17007000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if53d95c4f09b452589c92741496adec4_D20200101-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82MS9mcmFnOjU1NGYyMGI5ZmJlNDQ1NjU5YmE4ZWIzZGE2M2Y2ODU5L3RhYmxlOjhhM2UxMDFlZmQ2OTQyNGY5MTg3NzhjM2Q5NmJlYmZkL3RhYmxlcmFuZ2U6OGEzZTEwMWVmZDY5NDI0ZjkxODc3OGMzZDk2YmViZmRfNC0zLTEtMS0w_56cb2d5d-45fa-41ae-b807-387d7e64a59c"
      unitRef="usd">12384000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNjQ4_32e71c21-1454-48d1-a573-93c86733a04f">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three and six months ended June&#160;30, 2021, the Company sold 770,465 and 1,805,227 shares of its common stock for net proceeds of approximately $9.1&#160;million, and $24.7&#160;million, respectively, of which approximately $2.5&#160;million was received in July 2021 and recorded within prepaid expenses and other current assets on the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <sgmo:StockOfferingProgramMaximumValue
      contextRef="i287279db3cc248a09fec60c8d435c802_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfMzg4_af744bab-99a3-47e2-b735-0e5c60b2b786"
      unitRef="usd">150000000.0</sgmo:StockOfferingProgramMaximumValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNTc1_3b4dc875-b79e-4081-9fb4-e48c54ce365a"
      unitRef="shares">770465</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNDM5ODA0NjUxMTc3NA_7c8fca83-a051-46ba-967f-b4f925ac35a7"
      unitRef="shares">1805227</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i278e9eb30d474f52bd02bb65c1c510a8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNjQ0_06a55e1a-958f-46e7-8847-0f70cf35c8e3"
      unitRef="usd">9100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5df08e19800c41d48f9ace5fc14db98e_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfNDM5ODA0NjUxMTc5MA_ae7d2162-481c-448c-8e65-eef8b0a18fc0"
      unitRef="usd">24700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i68bfdf24a47d45d792d479c5f84033cb_D20210701-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82NC9mcmFnOmZiMWIzYmE3YzBkYjQ3NGM4NmFhZGI4MzE2NzU3ODE4L3RleHRyZWdpb246ZmIxYjNiYTdjMGRiNDc0Yzg2YWFkYjgzMTY3NTc4MThfMzg0ODI5MDY5ODE4Ng_2f589031-e39b-4289-b548-b75c769953e9"
      unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjAxMQ_27977090-c38a-454c-a157-52a53cb50e0d">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#x2019;s share capital, including arrangements with the holders of approximately 477,000 free shares of Sangamo France pursuant to which the Company had the right to purchase such shares from the holders, and such holders had the right to sell to the Company such shares from time to time through mid-2021. As of June&#160;30, 2021, the Company acquired all of the 477,000 free shares, resulting in 100% ownership of Sangamo France.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in exchange for total consideration of approximately $45.9&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#x2019;s Condensed Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no goodwill impairment during any of the periods presented and, as noted below, all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the acquisition of all the free shares, the fair value of the remaining non-controlling interest was determined based on the number of outstanding free shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the October 2018 acquisition date. The non-controlling interest was presented as a component of stockholders&#x2019; equity on the Company&#x2019;s Condensed Consolidated Balance Sheets. As of June&#160;30, 2021, upon acquisition of 100% of ordinary shares of Sangamo France, the carrying amount of the non-controlling interest was recorded as additional paid-in capital on the Company&#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buy-out of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="i5ced8520ef3f4fabbda53a780b5dc09d_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTUw_4a4d30c9-2385-4908-8814-2d62f0798362"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="i86824b279b6b42b7b4dfaf3312f1c64e_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjQ1_c48f3d9a-9426-47f5-b430-c556f521c972"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i381be31f4a96421eaace1530a63600f0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfNDM5ODA0NjUxMzU4NA_9e130e04-62d7-4a55-b8db-ab733b68064d"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="icc3d33b771494438a51064004b2d92d3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfNDM5ODA0NjUxNzA4OQ_e6104301-18d8-49bb-90c2-5c35b832e710"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i192244a99ff14df4a634c33f2294f707_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTAyNw_2c23817a-cdaa-4fce-bd31-dfb4eafeab30"
      unitRef="usd">45900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i302cfc143c434200849acab7c19e79ec_D20200101-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTI0NA_92d02dc5-f4c1-445d-bdf3-be8feee99188"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i9d0d661e140c49a08925fdca70921940_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTI0NA_cd1596a0-3594-4977-948e-e3f176e22268"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="iaedb801aae5d487896c33c8747f89875_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMTczNA_c853598d-fd66-464b-9e1d-b546c99309b3"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="icc3d33b771494438a51064004b2d92d3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMzg0ODI5MDcwNDIxNQ_ec53b3c8-d08d-4927-b6db-5db2175ed8d8"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RleHRyZWdpb246MWQwNjk5NWJmOTIxNGJhMmI1ZDE0OTY0OWMwYjMzNTNfMjAxMA_464a0845-a86d-4d35-a639-45a2a4178f25">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buy-out of non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="if338f7d54d3a4f0cbc40c646455f0cca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMS0xLTEtMS0w_e7fdb784-f152-4c0b-a760-866a9d36d5d1"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMi0xLTEtMS0w_8c07bee9-1739-4640-82cc-6e6f9be1e89b"
      unitRef="usd">64000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfMy0xLTEtMS0w_9bdfb284-114e-4945-83cf-78c3f747bb32"
      unitRef="usd">-11000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ic8ea400821bf458997c74f535136745d_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfNC0xLTEtMS0zMjUw_b5e44fbd-142f-4413-9d98-b3f1ebd7e7aa"
      unitRef="usd">943000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterest
      contextRef="ia45a1fa516b24d509732822dedf80969_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF82Ny9mcmFnOjFkMDY5OTViZjkyMTRiYTJiNWQxNDk2NDljMGIzMzUzL3RhYmxlOmYzNTdjYzc4OWVjYzQyODE4ZTg5ZmM3MWFiYTk3MTAwL3RhYmxlcmFuZ2U6ZjM1N2NjNzg5ZWNjNDI4MThlODlmYzcxYWJhOTcxMDBfNC0xLTEtMS0w_f9310eb0-2dab-4bd9-be13-56ec9a2feb70"
      unitRef="usd">0</us-gaap:MinorityInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710385659736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,337,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293949448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,878<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">359,775<span></span>
</td>
<td class="nump">510,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">807<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">6,882<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">16,722<span></span>
</td>
<td class="nump">11,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">554,064<span></span>
</td>
<td class="nump">659,668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">49,205<span></span>
</td>
<td class="nump">50,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">49,588<span></span>
</td>
<td class="nump">41,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">56,298<span></span>
</td>
<td class="nump">58,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">41,501<span></span>
</td>
<td class="nump">42,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">68,304<span></span>
</td>
<td class="nump">71,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">14,903<span></span>
</td>
<td class="nump">13,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">835,363<span></span>
</td>
<td class="nump">938,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,132<span></span>
</td>
<td class="nump">12,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">17,406<span></span>
</td>
<td class="nump">20,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">15,448<span></span>
</td>
<td class="nump">18,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">93,957<span></span>
</td>
<td class="nump">91,644<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">136,943<span></span>
</td>
<td class="nump">143,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">201,251<span></span>
</td>
<td class="nump">245,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">37,328<span></span>
</td>
<td class="nump">38,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">6,959<span></span>
</td>
<td class="nump">7,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">7,425<span></span>
</td>
<td class="nump">7,011<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">389,906<span></span>
</td>
<td class="nump">441,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,313,102<span></span>
</td>
<td class="nump">1,269,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(871,083)<span></span>
</td>
<td class="num">(777,981)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">5,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">445,457<span></span>
</td>
<td class="nump">498,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">445,457<span></span>
</td>
<td class="nump">497,366<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 835,363<span></span>
</td>
<td class="nump">$ 938,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710295005896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 27,872,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 54,152,000<span></span>
</td>
<td class="nump">$ 34,629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">60,086,000<span></span>
</td>
<td class="nump">41,523,000<span></span>
</td>
<td class="nump">116,520,000<span></span>
</td>
<td class="nump">83,002,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">16,486,000<span></span>
</td>
<td class="nump">17,927,000<span></span>
</td>
<td class="nump">32,634,000<span></span>
</td>
<td class="nump">34,046,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">76,572,000<span></span>
</td>
<td class="nump">59,450,000<span></span>
</td>
<td class="nump">149,154,000<span></span>
</td>
<td class="nump">117,048,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,700,000)<span></span>
</td>
<td class="num">(37,897,000)<span></span>
</td>
<td class="num">(95,002,000)<span></span>
</td>
<td class="num">(82,419,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">1,550,000<span></span>
</td>
<td class="nump">1,932,000<span></span>
</td>
<td class="nump">2,176,000<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest', window );">Loss before taxes</a></td>
<td class="num">(47,150,000)<span></span>
</td>
<td class="num">(35,965,000)<span></span>
</td>
<td class="num">(92,826,000)<span></span>
</td>
<td class="num">(78,939,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(47,174,000)<span></span>
</td>
<td class="num">(35,965,000)<span></span>
</td>
<td class="num">(93,113,000)<span></span>
</td>
<td class="num">(78,939,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
<td class="num">(97,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (47,169,000)<span></span>
</td>
<td class="num">$ (35,929,000)<span></span>
</td>
<td class="num">$ (93,102,000)<span></span>
</td>
<td class="num">$ (78,842,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">143,984<span></span>
</td>
<td class="nump">138,977<span></span>
</td>
<td class="nump">143,550<span></span>
</td>
<td class="nump">127,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">143,984<span></span>
</td>
<td class="nump">138,977<span></span>
</td>
<td class="nump">143,550<span></span>
</td>
<td class="nump">127,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294876792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (47,174)<span></span>
</td>
<td class="num">$ (35,965)<span></span>
</td>
<td class="num">$ (93,113)<span></span>
</td>
<td class="num">$ (78,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="num">(3,441)<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(45,901)<span></span>
</td>
<td class="num">(33,790)<span></span>
</td>
<td class="num">(96,545)<span></span>
</td>
<td class="num">(78,143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (45,896)<span></span>
</td>
<td class="num">$ (33,754)<span></span>
</td>
<td class="num">$ (96,534)<span></span>
</td>
<td class="num">$ (78,046)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294822872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 432,739<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">$ 1,090,828<span></span>
</td>
<td class="num">$ (656,985)<span></span>
</td>
<td class="num">$ (2,449)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">142,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">409,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">852<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Buy-out of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(78,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,973,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2020</a></td>
<td class="nump">511,206<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="nump">1,247,527<span></span>
</td>
<td class="num">(735,827)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,278,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2020</a></td>
<td class="nump">394,415<span></span>
</td>
<td class="nump">$ 1,163<span></span>
</td>
<td class="nump">1,096,854<span></span>
</td>
<td class="num">(699,898)<span></span>
</td>
<td class="num">(3,828)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">142,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">1,187<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(35,965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,973,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2020</a></td>
<td class="nump">511,206<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
<td class="nump">1,247,527<span></span>
</td>
<td class="num">(735,827)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,063,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2020</a></td>
<td class="nump">497,366<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">1,269,375<span></span>
</td>
<td class="num">(777,981)<span></span>
</td>
<td class="nump">5,419<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,805,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">24,732<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">24,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">993,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(3,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Buy-out of non-controlling interest</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(93,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,106,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2021</a></td>
<td class="nump">445,457<span></span>
</td>
<td class="nump">$ 1,451<span></span>
</td>
<td class="nump">1,313,102<span></span>
</td>
<td class="num">(871,083)<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,713,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Mar. 31, 2021</a></td>
<td class="nump">469,417<span></span>
</td>
<td class="nump">$ 1,437<span></span>
</td>
<td class="nump">1,292,118<span></span>
</td>
<td class="num">(823,914)<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="num">(938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">9,081<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">9,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain on marketable securities, net of tax</a></td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Buy-out of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(47,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,106,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Jun. 30, 2021</a></td>
<td class="nump">$ 445,457<span></span>
</td>
<td class="nump">$ 1,451<span></span>
</td>
<td class="nump">$ 1,313,102<span></span>
</td>
<td class="num">$ (871,083)<span></span>
</td>
<td class="nump">$ 1,987<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293803032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (93,113)<span></span>
</td>
<td class="num">$ (78,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,120<span></span>
</td>
<td class="nump">2,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="num">(1,146)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in operating lease right-of-use assets</a></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">3,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainLossOnFreeShares', window );">Gain on free shares</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17,007<span></span>
</td>
<td class="nump">12,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(1,658)<span></span>
</td>
<td class="nump">31,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(4,441)<span></span>
</td>
<td class="num">(7,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(3,204)<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="num">(3,253)<span></span>
</td>
<td class="num">(248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="num">(41,481)<span></span>
</td>
<td class="nump">178,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(2,102)<span></span>
</td>
<td class="num">(1,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">998<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(121,117)<span></span>
</td>
<td class="nump">141,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(180,049)<span></span>
</td>
<td class="num">(43,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">323,099<span></span>
</td>
<td class="nump">151,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities', window );">Sales of marketable securities</a></td>
<td class="nump">6,870<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,213)<span></span>
</td>
<td class="num">(6,694)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional shares of Sangamo France</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">134,588<span></span>
</td>
<td class="nump">101,328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromAtTheMarketOffering', window );">Proceeds from at-the-market offering, net of offering expenses</a></td>
<td class="nump">22,223<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">142,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(2,725)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">3,702<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">1,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,254<span></span>
</td>
<td class="nump">144,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(176)<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">38,549<span></span>
</td>
<td class="nump">387,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">132,829<span></span>
</td>
<td class="nump">81,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">171,378<span></span>
</td>
<td class="nump">468,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in unpaid liabilities</a></td>
<td class="nump">2,267<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Buy-out of non-controlling interest</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainLossOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on free shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainLossOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term portion of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromAtTheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Proceeds From At-The-Market Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromAtTheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289896872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of June&#160;30, 2021 and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its currently planned operations through at least the next 12&#160;months from the date these Condensed Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, if at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in estimates during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $3.1&#160;million, decreased net loss by $3.1&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for the six months ended June&#160;30, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of June&#160;30, 2021, no impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of June&#160;30, 2021, no impairment of long-lived assets was identified.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted as needed to approximate fair value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts. Restricted cash consists of a letter of credit for $1.5&#160;million, representing a deposit for the lease of the corporate headquarters in Brisbane, California.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,878&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,443&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,378&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,943&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions or issuers of investments holding its cash, cash equivalents and investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710292039960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset. Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3: Prices or valuation techniques that require inputs that are both significant to the fair value measurements and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities as Level&#160;2. Instruments are classified as Level&#160;2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 10 &#8212; Acquisition of Sangamo Therapeutics France S.A.S.), the Company entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mid-2021 (a put option). As of June&#160;30, 2021, the Company had purchased all 477,000 free shares for an aggregate cash payment of approximately $1.1&#160;million, upon exercise of the put options. As of June&#160;30, 2021, there were no free shares outstanding subject to purchase by the Company. The fair value of the free shares&#8217; asset was zero at June&#160;30, 2021 and immaterial at December&#160;31, 2020.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:86.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293413240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">CASH EQUIVALENTS AND MARKETABLE SECURITIES</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages credit risk associated with its investment portfolio through its investment policy, which limits purchases to high-quality issuers and also limits the amount of its portfolio that can be invested in a single issuer. The Company did not record an allowance for credit losses or other impairment charges related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had unrealized losses related to its marketable securities for the three and six months ended June&#160;30, 2021 and 2020. These unrealized losses were not attributed to credit risk and were associated with changes in market conditions. The Company periodically reviews the marketable securities for other-than-temporary impairment losses. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i)&#160;it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii)&#160;the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen </span></div>to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at either June&#160;30, 2021 or December&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289936072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text">BASIC AND DILUTED NET LOSS PER SHARE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and restricted stock units (&#8220;RSUs&#8221;) outstanding and the employee stock purchase plan (&#8220;ESPP&#8221;) shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of June&#160;30, 2021 and 2020 totaled 16,978,884 and 14,964,567, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710290006888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company will perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million to be provided over the estimated research period. All clinical or regulatory milestone amounts were considered fully constrained at inception of the agreement. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic&#160;606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $57.1&#160;million and $70.9&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.5&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic&#160;340, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC Topic&#160;340&#8221;). The Company amortized $0.2&#160;million and $0.3&#160;million during the three and six months ended June&#160;30, 2021, respectively. No amounts were amortized during the three and six months ended June&#160;30, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. The companies plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12&#160;neurological disease gene targets selected by Biogen. Biogen has already selected four of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, a neuromuscular disease target and a fourth neurological disease gene target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs of which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to ten targets. Each party has the right to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that from the first anniversary of the effectiveness of the collaboration agreement, through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule&#160;144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the SEC.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i)&#160;the two-year anniversary of the effectiveness of the collaboration agreement, (ii)&#160;the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock and (iii)&#160;the date the collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic&#160;606 and concluded that Biogen is a customer. The transaction price of $204.6&#160;million includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $168.6&#160;million and $183.2&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.1&#160;million, which represents 2% of the transaction price of $204.6&#160;million, as a contract asset. This balance is amortized and included in general and administrative expenses on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic&#160;340. The Company amortized $0.2&#160;million and $0.3&#160;million during the three and six months ended June&#160;30, 2021, respectively. No amounts were amortized during the three and six months ended June&#160;30, 2020. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as a reduction in proceeds.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a Gilead company, which became effective in April 2018, and was amended and restated in September 2019, for the research, development, and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T-cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T-cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, the Company received a $150.0&#160;million upfront payment from Kite. Kite reimburses the Company&#8217;s direct costs to conduct the joint research program. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved regardless of the number of licensed products that may achieve such milestone event. In addition, the Company is entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term in the agreement is six years. Kite has an option to extend the research term of the agreement for up to two additional one-year periods for a separate upfront fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service cost of approximately $3.4&#160;million, which is included in the total estimated reimbursable service costs. The Company concluded the total transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. Further, the Company concluded the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future events which are uncertain at this time. The Company will re-evaluate the transaction price including the estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic&#160;606 and concluded that Kite is a customer. Kite has the right to terminate this agreement in its entirety or on a per licensed product or per candidate target basis for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1)&#160;a license to the technology along with the stand-ready obligation to perform research services, and (2)&#160;the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $69.0&#160;million and $81.4&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia&#160;A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase&#160;1/2 clinical trial and for certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia&#160;A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer is permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;fifteen years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon execution of the agreement, the Company received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory and first commercial sale milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third-party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The total transaction price under this agreement is $134.0&#160;million, which represents the upfront fee and research services fees of $79.0&#160;million and fees related to two achieved milestones in an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within the agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company satisfied the deliverables and research services responsibilities within the arrangement. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020 and no revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $0.3&#160;million and $2.5&#160;million of upfront license fee and research services revenue during the three and six months ended June&#160;30, 2020, respectively, and $0.1&#160;million and $1.1&#160;million milestone achievement revenue during the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic&#160;606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fees of $12.0&#160;million and fees related to achievement of one milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligations within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognized revenue from the upfront payment based on proportional performance of the ongoing research services through 2020, the period the Company performed research services. The estimation of progress towards the satisfaction of its performance obligation and project cost was reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company satisfied the deliverables and research services responsibilities within the arrangement in September 2020, and as a result, earned a $5.0&#160;million milestone, which the Company recognized on a cumulative basis during the year ended December&#160;31, 2020. In addition, the Company recognized the remaining deferred revenue from the upfront payment in September 2020 and no revenues have been recognized during the three and six months ended June&#160;30, 2021. The Company recognized $3.4&#160;million and $3.8&#160;million of upfront license fee and research services as revenue related to this agreement during the three and six months ended June&#160;30, 2020, respectively.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones in the amount of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic&#160;606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through 2022, the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of June&#160;30, 2021 and December&#160;31, 2020, the Company had deferred revenue of $0.5&#160;million and $1.2&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $6.0&#160;million milestone with Sanofi upon dosing of the third subject in the ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400 beta thalassemia Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.9&#160;million as of June&#160;30, 2021 and included $0.1&#160;million recognized in each of the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $7.5&#160;million milestone with Sanofi upon dosing of the first subject in the SCD Phase&#160;1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.4&#160;million as of June&#160;30, 2021 and included $0.1&#160;million and $0.2&#160;million recognized during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST</span><span style="color:#2b2e2f;font-family:'Lucida Sans Unicode',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">400, a gene-edited cell therapy candidate for people with transfusion-dependent beta thalassemia. As of June&#160;30, 2021, the Company had received $5.2&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the </span></div>option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these financial statements. If the Company terminates a CIRM-funded clinical trial, it is obligated to repay any unused CIRM funds received. Therefore, as of June&#160;30, 2021 and December&#160;31, 2020, $6.8&#160;million and $6.4&#160;million, respectively, including interest, related to this award are recorded as a loan in other long-term liabilities on the accompanying Condensed Consolidated Balance Sheets as the Company does not expect to repay these amounts within the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710384546264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXESThe Company&#8217;s provision for income taxes for interim periods is determined using an estimate of its annual effective tax rate, adjusted for discrete items, if any, that arise during the period. Each quarter, the Company updates its estimate of the annual effective tax rate, and if the estimated annual effective tax rate changes, the Company makes a cumulative adjustment in such period. In the six months ended June&#160;30, 2021, the Company recorded income tax expense of $0.3&#160;million, and no such expense was recorded in the six&#160;months ended June&#160;30, 2020. The Company continues to maintain a full valuation allowance on its U.S. federal and state net deferred tax assets and on the Sangamo France net deferred tax assets, as the Company believes it is not more likely than not that these benefits will be realized. The tax expense for the three and six months ended June&#160;30, 2021 was due to foreign income tax expense.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710290051784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS</a></td>
<td class="text">COMMITMENTS<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 59,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company leases approximately 25,600 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through January 2030.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4YTI0ODQwNzhlMzQyNjRhMDhhY2M5ODc0MmJiY2UwL3NlYzo4OGEyNDg0MDc4ZTM0MjY0YTA4YWNjOTg3NDJiYmNlMF81OC9mcmFnOjI3M2YwN2NkMmUzNjQyMGZiZWVkNDFiMjljOGIzMDcxL3RleHRyZWdpb246MjczZjA3Y2QyZTM2NDIwZmJlZWQ0MWIyOWM4YjMwNzFfNjc3_08762a14-8ec2-41bb-9293-f9377bdafc34">five</span> to ten years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain that it would exercise the options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. Components of operating leases were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease expenses were not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. This variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense, due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the six months ended June&#160;30, 2021 and 2020, was $3.4&#160;million and $3.1&#160;million, respectively, and was included in net cash (used in) provided by operating activities in the Company&#8217;s Condensed Consolidated Statements of Cash Flows.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"/><td style="width:87.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,625&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,331)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of June 30, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,294&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the weighted-average remaining lease term is 7.3 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.2% for the Company&#8217;s operating leases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into an amendment to an existing lease to acquire approximately 5,000&#160;square feet of research and office space in Richmond, California. With this amendment, the existing lease expires in August 2026. Total lease payments over the life of this amended lease are approximately $0.9&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On February&#160;1, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company also entered into a new lease to acquire approximately 5,800&#160;square feet of research and office space in Valbonne, France, which expires in January 2030. Total lease payments over the life of this amended lease are approximately $0.8&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. On January&#160;29, 2021, the lease commencement date, the Company recorded an operating lease right-of-use asset and a corresponding lease liability of $0.6&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,092&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $0.9&#160;million of license obligations related to its intellectual property as of June&#160;30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291984552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289883848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. During the three and six months ended June&#160;30, 2021, the Company sold 770,465 and 1,805,227 shares of its common stock for net proceeds of approximately $9.1&#160;million, and $24.7&#160;million, respectively, of which approximately $2.5&#160;million was received in July 2021 and recorded within prepaid expenses and other current assets on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291529576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</a></td>
<td class="text">ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#8217;s share capital, including arrangements with the holders of approximately 477,000 free shares of Sangamo France pursuant to which the Company had the right to purchase such shares from the holders, and such holders had the right to sell to the Company such shares from time to time through mid-2021. As of June&#160;30, 2021, the Company acquired all of the 477,000 free shares, resulting in 100% ownership of Sangamo France.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic&#160;805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $45.9&#160;million at the October 2018 acquisition date. The operating results of Sangamo France after the October 2018 acquisition date have been included in the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no goodwill impairment during any of the periods presented and, as noted below, all of the non-controlling interest on the October 2018 acquisition date was subsequently acquired by the Company.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the acquisition of all the free shares, the fair value of the remaining non-controlling interest was determined based on the number of outstanding free shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the October 2018 acquisition date. The non-controlling interest was presented as a component of stockholders&#8217; equity on the Company&#8217;s Condensed Consolidated Balance Sheets. As of June&#160;30, 2021, upon acquisition of 100% of ordinary shares of Sangamo France, the carrying amount of the non-controlling interest was recorded as additional paid-in capital on the Company&#8217;s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of June&#160;30, 2021 was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-out of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710299196888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of these financial statements for the periods presented have been included. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021. The Condensed Consolidated Balance Sheet data at December&#160;31, 2020 was derived from the audited Consolidated Financial Statements included in Sangamo&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 (the &#8220;2020 Annual Report&#8221;) as filed with the SEC on February&#160;24, 2021.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Condensed Consolidated Financial Statements. For consolidated entities where the Company owns or are exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on the Company&#8217;s Condensed Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements and related financial information should be read together with the audited Consolidated Financial Statements and footnotes for the year ended December&#160;31, 2020, included in the 2020 Annual Report.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Condensed Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the </span></div>basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic&#160;606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic&#160;606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. As of June&#160;30, 2021, the Company had not incurred any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as the Company fulfills its performance obligations, which are satisfied over time (i.e., stand ready obligations) or by using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition, be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase price over the fair value of net assets acquired is recorded as goodwill. The determination of fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill represents the excess of the consideration transferred over the fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted as needed to approximate fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashSangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of cash and deposits in demand money market accounts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12&#160;months as non-current marketable securities in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Condensed Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments that bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions or issuers of investments holding its cash, cash equivalents and investments to the extent recorded on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug application (&#8220;IND&#8221;) filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers were interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12&#160;months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Condensed Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291499432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,878&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,443&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,378&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,943&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the Condensed Consolidated Balance Sheets to the amounts reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,878&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467,443&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,378&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,943&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289940536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Shares Valuation Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:86.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.521%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Free Shares valuation assumptions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation between Sangamo and Sangamo France stock prices</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR / USD exchange rate volatility estimate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291489976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>(Losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,371&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,435&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,293&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair value of investments available-for-sale</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.496%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,980&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294029752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Novartis agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront license fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Biogen agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,605&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,767&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,217&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,178&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,422&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,612&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,641&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">957&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289939976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Operating Leases</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. Components of operating leases were as follows (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,711&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"/><td style="width:87.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.478%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six months ending December 31, 2021:</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,938&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,094&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,312&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,625&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Imputed interest</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,331)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of June 30, 2021:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,294&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Other Commitments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,513&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,092&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710290047720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense included in the Condensed Consolidated Statements of Operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.137%"><tr><td style="width:1.0%"/><td style="width:50.349%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.494%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,007&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,384&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710292069000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of June&#160;30, 2021 was as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.395%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buy-out of non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293881528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail) - Revenue from contract with customer - Customer concentration risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi Genzyme</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294130440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 27,872,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 54,152,000<span></span>
</td>
<td class="nump">$ 34,629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (47,174,000)<span></span>
</td>
<td class="num">$ (35,965,000)<span></span>
</td>
<td class="num">$ (93,113,000)<span></span>
</td>
<td class="num">$ (78,939,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.33)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (0.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill or indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit established as a deposit</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Change in collaboration agreement scope | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710288147640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,878<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 467,443<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 171,378<span></span>
</td>
<td class="nump">$ 132,829<span></span>
</td>
<td class="nump">$ 468,943<span></span>
</td>
<td class="nump">$ 81,928<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710295441704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 408,980<span></span>
</td>
<td class="nump">$ 560,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">160,336<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">143,465<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,938<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">45,742<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">22,499<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">408,980<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">466,351<span></span>
</td>
<td class="nump">613,789<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">160,336<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">143,465<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,938<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">45,742<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">22,499<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">408,980<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">408,980<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">160,336<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">143,465<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">36,938<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">45,742<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">22,499<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities and free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293412776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Narrative (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Share purchase agreement and tender offer agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase', window );">Number of free shares outstanding subject to purchase (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset', window );">Business Acquisitions, Fair Value of Free Shares' Asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisitions, Fair Value of Free Shares' Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294213576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sangamo stock price (USD) (in dollars per share)</a></td>
<td class="nump">$ 15.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember', window );">Exchange rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">EUR / USD exchange rate</a></td>
<td class="nump">0.82<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock price volatility estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France stock price (EUR) (in euros per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France stock price (EUR) (in euros per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimated correlation between Sangamo and Sangamo France stock prices</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Sangamo France | Stock price volatility estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility estimate</a></td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputExchangeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710295331112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">$ 169,878<span></span>
</td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 467,443<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">408,922<span></span>
</td>
<td class="nump">560,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">408,980<span></span>
</td>
<td class="nump">560,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, Amortized Cost</a></td>
<td class="nump">466,293<span></span>
</td>
<td class="nump">613,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">466,351<span></span>
</td>
<td class="nump">613,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash equivalents, Amortized Cost</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax', window );">Cash equivalents, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax', window );">Cash equivalents, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, Estimated Fair Value</a></td>
<td class="nump">57,371<span></span>
</td>
<td class="nump">53,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">160,310<span></span>
</td>
<td class="nump">257,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">160,336<span></span>
</td>
<td class="nump">257,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">143,435<span></span>
</td>
<td class="nump">213,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">143,465<span></span>
</td>
<td class="nump">213,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">36,942<span></span>
</td>
<td class="nump">59,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">36,938<span></span>
</td>
<td class="nump">59,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">45,743<span></span>
</td>
<td class="nump">17,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">45,742<span></span>
</td>
<td class="nump">17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, Amortized Cost</a></td>
<td class="nump">22,492<span></span>
</td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, Gross Unrealized Gains</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, Gross Unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, Estimated Fair Value</a></td>
<td class="nump">$ 22,499<span></span>
</td>
<td class="nump">$ 12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents Gross Unrealized Gain Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Equivalents, Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710288104136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Maturing in one year or less</a></td>
<td class="nump">$ 359,775<span></span>
</td>
<td class="nump">$ 510,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Maturing after one year through five years</a></td>
<td class="nump">49,205<span></span>
</td>
<td class="nump">50,530<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 408,980<span></span>
</td>
<td class="nump">$ 560,624<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294254520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded', window );">Allowance for credit loss related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings', window );">Other impairment charges related to marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporarily impaired investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291417032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and RSUs outstanding (in shares)</a></td>
<td class="nump">16,978,884<span></span>
</td>
<td class="nump">14,964,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710269803272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">40 Months Ended</th>
<th class="th" colspan="1">50 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>product_target</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>option </div>
<div>milestone </div>
<div>product_target </div>
<div>product </div>
<div>royaltyFee</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>product </div>
<div>milestone</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,872,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 54,152,000<span></span>
</td>
<td class="nump">$ 34,629,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California institute for regenerative medicine agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California institute for regenerative medicine agreement | Research grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,581,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,442,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,559,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,759,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">$ 95,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementLicenseFee', window );">License fee</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of specified preclinical development clinical development and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Collaboration and license agreement | Achievement of commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,767,000<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="nump">21,217,000<span></span>
</td>
<td class="nump">8,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,306,000<span></span>
</td>
<td class="nump">6,744,000<span></span>
</td>
<td class="nump">14,612,000<span></span>
</td>
<td class="nump">6,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Financial advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional product targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementResearchPeriod', window );">Research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace', window );">Maximum number of product targets replaced | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Portion of contract asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement | Pre-approval milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Collaboration and license agreement | Sales-based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Stock purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Standstill restriction period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Standstill restriction, ownership threshold percentage ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld', window );">Agreement restriction, percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod', window );">Voting provisions expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage', window );">Voting provisions, ownership threshold percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Recognized portion of equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,324,000<span></span>
</td>
<td class="nump">7,422,000<span></span>
</td>
<td class="nump">12,612,000<span></span>
</td>
<td class="nump">14,641,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="nump">12,386,000<span></span>
</td>
<td class="nump">12,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment', window );">Maximum amount of achieved milestones to receive payment | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of specified preclinical development clinical development and first commercial sale milestones | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of commercial milestones | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of specified clinical development intellectual property and regulatory milestones | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer Inc. | Achievement of first commercial sale milestones | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | SB-525 and other products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved', window );">Number of milestones achieved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | royaltyFee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
<td class="nump">1,792,000<span></span>
</td>
<td class="nump">$ 2,017,000<span></span>
</td>
<td class="nump">2,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="nump">433,000<span></span>
</td>
<td class="num">(349,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="nump">292,000<span></span>
</td>
<td class="num">$ (235,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueRecognized', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | ST-40 Beta Thalassemia Phase 1 clinical trial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved', window );">Cumulative milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMilestoneRevenueRecognized', window );">Milestone revenue reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified clinical development And regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Achievement of specified sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementCumulativeMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cumulative Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementCumulativeMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Number Of Product Targets To Replace</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Milestones Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received On Transaction, Net Of Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710291634072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 27,872<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 54,152<span></span>
</td>
<td class="nump">$ 34,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,581<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,559<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,759<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes for BioMedical Research, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,022<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,683<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,767<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
<td class="nump">21,217<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,306<span></span>
</td>
<td class="nump">6,744<span></span>
</td>
<td class="nump">14,612<span></span>
</td>
<td class="nump">6,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,461<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">6,605<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">7,422<span></span>
</td>
<td class="nump">12,612<span></span>
</td>
<td class="nump">14,641<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">12,386<span></span>
</td>
<td class="nump">12,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">2,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">957<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of license and stand-ready fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">380<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">613<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="num">$ (235)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710288228472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 287,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294336232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 29, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities included net cash used in operating activities | $</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted-average remaining lease term</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted-average discount rate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseObligations', window );">License obligations | $</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate', window );">Area of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAmount', window );">Lease payment amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember', window );">Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate', window );">Area of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseAmount', window );">Lease payment amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office and laboratory | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating lease one | Office and laboratory | Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">59,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating lease one | Research and office space | Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft)</a></td>
<td class="nump">25,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not Yet Commenced, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseAreaOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area Of Real Estate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseAreaOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710289928120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS - Components of Operating Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,697<span></span>
</td>
<td class="nump">$ 2,572<span></span>
</td>
<td class="nump">$ 5,385<span></span>
</td>
<td class="nump">$ 5,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 3,311<span></span>
</td>
<td class="nump">$ 3,124<span></span>
</td>
<td class="nump">$ 6,711<span></span>
</td>
<td class="nump">$ 6,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710295598136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Six months ending December 31, 2021:</a></td>
<td class="nump">$ 2,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">6,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">7,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">7,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">7,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">20,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">51,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(10,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">41,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)</a></td>
<td class="nump">3,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">37,328<span></span>
</td>
<td class="nump">$ 38,396<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 41,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments Due After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710288138392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 14,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember', window );">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">4,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember', window );">Lonza Netherlands, B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 9,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710294980552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,483<span></span>
</td>
<td class="nump">$ 6,764<span></span>
</td>
<td class="nump">$ 17,007<span></span>
</td>
<td class="nump">$ 12,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">9,710<span></span>
</td>
<td class="nump">6,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,025<span></span>
</td>
<td class="nump">$ 3,186<span></span>
</td>
<td class="nump">$ 7,297<span></span>
</td>
<td class="nump">$ 5,967<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710403771112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Detail) - Jefferies LLC - At-The-Market Offering Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,465<span></span>
</td>
<td class="nump">1,805,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 24.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember', window );">Prepaid Expenses and Other Current Assets | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293003368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail) - Sangamo France - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">Share purchase agreement and tender offer agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139710293136744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Fair value of additional shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Loss attributable to non-controlling interest</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">$ (97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Buy-out of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Balance at June 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MVN_H[4^T7*>;8G.IM8S2PQ5G/E?F ;B_D%(?3\P+LGW5_G]02P,$%     @
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M@1:'B, +S%J$O1;A22WVK]2QHQ\>4O3\V!GLU<P PSB,G0%1 PSNAS?0+#7
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MI]\^H]^0R-'C5I8%RY/B=*8!C=$YBYLO7]9?)@-?GJ,?,M?; MWD"4\.Q\_
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M'Z7AN%Q6)"#B>"%AT-;1*B)1HBN3D'_83@8SO6<6I>+6B>XORU/[1M3X*@=
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MKB? .0Q\HD<22<CU?SJ;?Y<:$:.[RQ26E6/;$9[&R.)H.9-=;;1J)/].0+X
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MN6(>M[ZG!:.#FN0H[R,^=F#CH#[:<T_;6.I ']GSA1;A&XKN;'\2N3&X+ND
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M"WV5?-2.H!F#%>4JI?)'"!%47)B;6TFE'R'<%62#Q[$D,;"DFNLRO@,>Q[*
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M:9%+4EP/YP7  K;06L:E6/%>6-VGO38 R!L.+Z8-(<A&$;3#4E7&F0130W!
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MXWXBMPK(N#L>!_K?LD(O 4%=9@*"+5] P50=S)NS#6:;[L39) :"C;D3*HQ
MO'_P ZB_O:NLK.N]RQ)<HC(Y P>^KC )^'9!66<._<\X SMZ=G),[A> 4Y#_
M16JCY>J9R(7"!&13K%[@\J">.9W8B3VM%TN1>4@7)TV.G :E:)_"=.A:)C0C
MNJG1_FPH@C**0 &BOQ,KHPKORQP:>]ZO5N*:0*1B@NR!R[M0_)*538[,CAX-
M9SG;_#0X.$DF%M:9Q9<["C0%JC;73IDI>E3>K?$7;6Q+)M,EJ8(TP/HJ M>F
M.(<PM05 E\(Q&=IG;=*"<MJSY9$^(@39W='@\,AC"CRB*MW)I7*H2)Q(J=4]
MCI"Z,T>)[HTI:KNG6Z6 _ZRL+Q+_@1E?20E4 &*B0%"!0J+R8!A?TV2#GSH#
MO(7<]A6' 2C#WG^UZC":9/AV'] ' VR8SA%SJH"'# +,S*-QK]$-:Z':R##7
M+QEOYXMAVD7DV-^T\J_-RL;ZNUH^3ZZN]XZ&(]X2T92 ZER1X;<J^"S_?2X5
M8./LHP$CY;%CKK2NBB;+)5B)[@P7P!ZJT&71G4$P@HM&9PUREL4P*/0*@AA4
MR7VDB-!V^\Y)<6+5HC1)<:8N1",RK.5:@E*&UR;K$]]T90PDD&Z&\V(\!_KA
M35^!NKLG,:N:3(+>5 YK%:M)=-&@T:1UZ!L"&=6"\\3X/'11G?.UF 1F/W03
M,Q1PTCW5+2: .6ZR[N(JN97<E(!;81H2DJ\ 9Z^U6(\B;UM6_CHHXP9%7I$3
MKD:HR,&,617S,)Q5XGH[-148>=*U]YX?5F#/3:K*&554-Q5[)/=6RUNFO-T*
MT*K>^JX&"ZK"O(8(R@$UUE+\]VR>.,IRFJ#?94;M"D& CJ( U%.JV,-DC6Q!
MDXFER(" 5'VI)+L$L.] #F=X71(L7[6*IVYG'H+U1*Y*4P V=C="VW=S& S[
ML(]H[C1&7^>(+9M9P;79 Y]8=<4:([N8P,7*[:<,@P.-Z2F68V](O1\]1571
M+K<D7ZF!'*0N'^H\[9.O']Q:L955^U*-%J&U"?V^/G.R*?RP-5G]J)KLVI(L
MNI=K2K*QTMA0]UQ+W_[Z[--49U/C'?>592L) IQ9^U-+NZ:.2KH;L0HSIT]<
MSEWKZ2[$:CO*!I$%Q&/@T5%UBK.F[$$Y3];8,+N$\]D&R46K&$);[A)T:S("
M:61'./9G84\I65 V_24 D%Z@R5VE:MP-3!':^"9PD_U.^R"5B\A.N%,C3SG1
M6!7N+Y%1.]H]&0< CTI*' C[[$,*XB@_XI14N4&,D6W0045-^HD+@##KC)^
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M=>1+H:E:B(2)1YY5W&^*323",$8(4J"9&BLK--(:S>7 KYXD$X G5Q+#C4>
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M7B+TKLL !7Q!X#C6%>7?SC35^/F@7V]XY@)P0<VH>>\2U7PZ99]5L?X=.HR
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M<2^SW/%&.)]6(L,5NL_5G:%5V*&DLD1EI59@<#/K+09O+X9L[PU^E[BU1]_
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M)V%4WHW_$2__87P4=J&THU3.H=KK'!^VRF.X7GB3AYORS'C<N\-K@C\ZTK(
MOL\-QF"U8 /KOTZ7?P-02P,$%     @ 3X(%4^#,@/!E&@  _U,  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&ULM3QI;QM'EG^EH$4&-D#1DNPX3GP
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M*)ZU_ 32&/% 3D@'2<J6Q9@<@ERM0-:8IS5;&DL4_BYKP&9F*)O$>O!X& ^
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MX2MDDH<(9\_SVW.JA==K][U*XTZRE!8_*,Z>'\]-\8)^EVZY]K '- ,=( >
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MR@;0_D9*\V)8@7*"#_X"4$L#!!0    ( $^"!5,U+(^6V@,  -D/   9
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MO4&O$&5HF?.=!(8<V J$ZG3MK!9U78GRGA'U8<<ND>]<(,_QW!/TZ&7ZF&1
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M=@D!.81*-,->8!T+A!"UL3IL3UA61(MH5HZL>N([9^LTCPK5-!""++%,A(I
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M+7^N:;2DN02(YRO&^*\+^47._ANO\?]02P,$%     @ 3X(%4TSL_UJN @
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ML]#%EP'?.&[-SAC<3I9*W;G)/!MY'9<0"DRM8V#T=X]3%,(141J_:DZOD73
MW?$C^ZS<.^UER0Q.E?C.,YN/O/<>9+AB&V&OU/8#UOL9.+Y4"5/^PK:.[7B0
M;HQ510VF# HNJW_VN_9A!T \^P%!#0B> _H' +T:T'NI0K\&]%^J,*@!@^>
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MZE;E,*=/'-0N@)ZOE+*/$R?0?#2-_P!02P,$%     @ 3X(%4X>RUZ9E @
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M1Y5UP/.UE&9OV NZN9G\ 5!+ P04    " !/@@53K#W9\V<3  "MB0  &0
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M:''J=Q)^+%D/!=Y;Y'M^OV4_L]?#O38[_Z>>_+/Z7\4(FO,.+%]PZ;Q9R@M
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MB&N >KYD3&XG.D#SPS'\ U!+ P04    " !/@@53_M"A+V4#   S"@  &0
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M [0+P/V%4O9UXKI8\P_*_@)02P,$%     @ 3X(%4\W8R?@_ P  "@L  !D
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3X(%4R-C2P8-!   <QX
M  \   !X;"]W;W)K8F]O:RYX;6S%F5N3FS84@/^*AI>F,]G:7-9)=N+,*)A=
MDQAP$=Y)^M+1@AQK L@CY-TFO[X"UZU()V?RHO $""Q_Z'(^'?'Z2<C/#T)\
M1G\U==LMG8-2QYO9K"L/K*'=;^+(6GUG+V1#E;Z4GV;=43):=0?&5%//O/E\
M,6LH;YTWKR]U;>7,O!"*E8J+5A?V!?></77_W>\OT2/O^ .ON?JR=(;SFCFH
MX2UO^%=6+9VY@[J#>%H+R;^*5M&:E%+4]=)QSS?NF52\_%\QZ2$+^M -)8H^
MY%2#+)W%7%>XY[)3PQ-#_50S/C+]\/GJI,0MKQ63*ZK8G12G(V\_]=7HMY@9
MKS&TP^5X;L0;^2/-*/9[7K*5*$\-:]6Y'26K>\"V._!CYZ"6-FSIA.*1R?Y]
M]!_$U?G=E(8R6DK><'U#QM6 9Q$E2U=12J(5TF<DV\0K7.B+MWB#TS!"!J0'
M0'J30))"'Y(H-2!] -*?$/)/SX , ,A@2DC?@+P&(*^GA P,R 4 N; +F>5W
M.(W_P$6<I<_U?"$Q0=DMVN81B=("&Y O ,@7=B%O<9RC>[S912B),-GE_70I
MB 'W$H![:;F;,5FCZ/==K %[*H33%4IP_CXJ\-M-9$"^ B!?V87L.S8<R%;Q
M9M</PS0JT"8C!&VCW(R/[AR*XG.[F E^E^4HW)$B2Z*</$=;G!>I/EO'6]VP
M)B8H&\NVB=-0\Z$"?XC,0>A";G&MRR5)XN+;>>%")G$MJT3W8OC^2@^](00F
M6QT,ASAC\D$2<2U;9.!;9YN5'F"_#%.X^&BR0>YP+<L#AQJ'Q'US]?&8X/0.
M)QDJUE&.M]'.Q(3LX4ZIC]%JP87\X5H6"(QIKA=<R"2N995\QW/H"CW3R__:
MQ(1<XEJ6"6B\4:=[D$R\*64RQH1DXEE/7?X-W)>.9MVO)AV8LEC6RO=B^#^H
M)B:D&L^R:L!P.>YKR#B>9>/ <<A,"3Q(/IYE^<"8UR8F)!]O4ODL3$Q(/MXT
MV8N>0>34--3$A.3C32:?E$HYPH3DXUF6#]B:HYGN0_+Q+<L'=J2YXO A^?BV
MY0-BF@')ARSDVTYN0$PS(/G@UIEE"X%9]GAL0A;R+5L(7AB-QB9D(=^RA6#,
MT=B$+.1;MI"Y&8">K9BBO!ZMWWQ(/KYE^8Q7E[BJ>/\(K5'<]O69F)!\?-N;
M:"/,4#1'T>I?=$CL479D)B8D']]VYC/"'/0MO_2,"54GR<W-<4@^@6WYC#!3
MT5Z5M"WUDQI#HYJ8D'P"R_(!<@NB1&EB0O()?D8*],TVT655I/BCB0G))Y@T
M!3*C>@!^N;$L'QC3C.H!))]@D,_L\I&S8GO>LBK5?]'I\I+6Y5:B_G#>F VN
M^QV3_:FN0UV6M1M!J\LWT\OWWC=_ U!+ P04    " !/@@53N#;$W*D!   N
M&P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=F[;L) $(7A5T%^
M ):966X14*6AC7@!"Y:+,-CR;A1X^R HX%@ITJ ]E;6V//X;?[+6LZ]0E>E0
MG^/^T,3>Y52=X[S8I]1\.!?7^W J8[]NPOEV95NWIS+=ENW.->7Z6.Z"T\%@
MY-K7&<5B]CJSM[HVX3\3Z^WVL Z?]?K[%,[IC\'NIVZ/<1]"*GJKLMV%-"_<
MI7J>CNY^D/YM<M%;;N9%N]Q(X7('*01I_B"#(,L?Y"'(YP\:0M P?] (@D;Y
M@\80-,X?-(&@2?Z@*01-\P?) &4<$"1UL";06I!K(?!:$&PA$%N0;"$P6Q!M
M(5!;D&TA<%L0;B&06Y!N(;!;$&\AT%M1;R706U%O)=!;.Q_;!'HKZJT$>BOJ
MK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMG
MLX1 ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3V
MJ+<GT-NCWIY ;]_9[";0VZ/>_IUZQW2M0GSV/-;X_'=2G6[WAN?C[\O'R<X+
M=<?9P>^QQ2]02P,$%     @ 3X(%4U/9*RFR 0  4QL  !,   !;0V]N=&5N
M=%]4>7!E<UTN>&ULS9G-;L(P$(1?!>6*B+&=TA\!E[;7ED-?P$TV)"*)+=M0
M>/LZX4=J1:,B*G4NL1+OSHR]TG?)]&UGR VV==6X651X;QX8<VE!M7*Q-M2$
MG5S;6OGP:I?,J'2EEL3$>#QAJ6X\-7[D6XUH/GVB7*TK/WC>AL^NU,TLLE2Y
M:/"X+VR]9I$RIBI3Y<,^VS39-Y?1P2$.G5V-*TKCAJ$@8F<=VIV?#0Y]KQNR
MMLQHL%#6OZ@Z5+%MQ9S?5>3B?HDS&76>EREE.EW7H25VQI+*7$'DZRK>BP[[
MG7VX8=H_^=7^G4R?8:A<6&U<F)BER^V.(VF[1R8(D?5E_Q%/CD'ZZO-1.^V,
MLE]ZA^O]T';5S<.Q;KG^CK_.^*1_80X!DD."Y$A <MR Y)B Y+@%R7$'DN,>
M) <?HP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$
M(6N"0M8$A:P)"ED3%+(F*&1-_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"
M% ,4    " !/@@53!T%-8H$   "Q    $               @ $     9&]C
M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( $^"!5,:XIIZ[@   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $^"
M!5.97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ 3X(%4ZAOMAL\!0  8Q4  !@
M ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $^"
M!5-WN0+VCP8  ( ;   8              " @7\-  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " !/@@53W85.[6$%   )%@  &
M        @(%$%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ 3X(%4PW\0F+  P  TPL  !@              ("!VQD  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( $^"!5/51>:B$ H   ,\   8
M              " @=$=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " !/@@532OGR.PP(  #['P  &               @($7*   >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ 3X(%4Q?RQ9[M'0
M"5P  !@              ("!63   'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( $^"!5,&^L_?\P@  -(7   8              " @7Q.
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !/@@53WK N
M!60&  "5#P  &               @(&E5P  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ 3X(%4V5?RO-S P  P0@  !D
M ("!/UX  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !/
M@@53TW!7[L(@   PA@  &0              @('I80  >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( $^"!5-?NFL\B ,  /L'   9
M          " @>*"  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#
M%     @ 3X(%4U9>$,;R!P  7!4  !D              ("!H88  'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !/@@53@>4A\=8"   9
M!@  &0              @('*C@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;%!+ 0(4 Q0    ( $^"!5/U[V-*LP,  .X'   9              " @=>1
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ 3X(%4RR9
M6FQ-!0  1@T  !D              ("!P94  'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6Q02P$"% ,4    " !/@@53X,R \&4:  #_4P  &0
M    @(%%FP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M $^"!5-WXO$6000  '$,   9              " @>&U  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ 3X(%4TCK"QK?!   90T  !D
M             ("!6;H  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " !/@@53E,D/.HH$  #^"@  &0              @(%OOP  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( $^"!5,1;L^66@0
M !L/   9              " @3#$  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ 3X(%4W,CXD.:!   W0H  !D              ("!
MP<@  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !/@@53
M0+Q@"><"   3!@  &0              @(&2S0  >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( $^"!5/R M@?S (  ,T%   9
M      " @;#0  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ 3X(%4S4LCY;: P  V0\  !D              ("!L],  'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " !/@@53?\ER[T8$   *#P
M&0              @('$UP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( $^"!5-,T5)M+@,  (<(   9              " @4'<  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ 3X(%4Y^^=4,3
M"0  /4\  !D              ("!IM\  'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " !/@@53_9A0IE #  "P"0  &0
M@('PZ   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( $^"
M!5-+$/CST@,  *$0   9              " @7?L  !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ 3X(%4R+@MAJ&!@  [R4  !D
M         ("!@/   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
M    " !/@@533.S_6JX"   P!@  &0              @($]]P  >&PO=V]R
M:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( $^"!5.5!B?K"P,  $ )
M   9              " @2+Z  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL
M4$L! A0#%     @ 3X(%4X>RUZ9E @  0P4  !D              ("!9/T
M 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " !/@@53K#W9
M\V<3  "MB0  &0              @($   $ >&PO=V]R:W-H965T<R]S:&5E
M=#,U+GAM;%!+ 0(4 Q0    ( $^"!5,S:VEBP@4  ,,?   9
M  " @9X3 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
M3X(%4S*^PF=8 @  <@8  !D              ("!EQD! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " !/@@536,B$C< $  #2$P  &0
M            @($F' $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( $^"!5/9:(P:X@(  'P(   9              " @1TA 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ 3X(%4_[0H2]E P
M,PH  !D              ("!-B0! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " !/@@53BT,UR(("  "/!@  &0              @('2
M)P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( $^"!5/-
MV,GX/P,   H+   9              " @8LJ 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ 3X(%4]9K('M^ P  ]0D  !D
M     ("! 2X! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M" !/@@53/_XYA[L#  !V"P  &0              @(&V,0$ >&PO=V]R:W-H
M965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( $^"!5,*>H7M*0,  $@)   9
M              " @:@U 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!
M A0#%     @ 3X(%4Y$ B6-! P  %A0   T              ( !"#D! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !/@@53EXJ[',     3 @  "P
M        @ %T/ $ 7W)E;',O+G)E;'-02P$"% ,4    " !/@@53(V-+!@T$
M  !S'@  #P              @ %=/0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ 3X(%4[@VQ-RI 0  +AL  !H              ( !ET$! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3X(%4U/9*RFR 0
M4QL  !,              ( !>$,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #4 -0!J#@  6T4!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>327</ContextCount>
  <ElementCount>337</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>74</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2123106 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2125107 - Disclosure - COMMITMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTS</Role>
      <ShortName>COMMITMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - COMMITMENTS - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSTables</Role>
      <ShortName>COMMITMENTS - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/COMMITMENTS</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail</Role>
      <ShortName>ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail</Role>
      <ShortName>CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail</Role>
      <ShortName>BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/INCOMETAXES</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail</Role>
      <ShortName>COMMITMENTS - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - COMMITMENTS - Components of Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail</Role>
      <ShortName>COMMITMENTS - Components of Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail</Role>
      <ShortName>COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sgmo-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail</Role>
      <ShortName>ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sgmo-20210630.htm">sgmo-20210630.htm</File>
    <File>sgmo-20210630.xsd</File>
    <File>sgmo-20210630_cal.xml</File>
    <File>sgmo-20210630_def.xml</File>
    <File>sgmo-20210630_lab.xml</File>
    <File>sgmo-20210630_pre.xml</File>
    <File>sgmo-20210630xex312.htm</File>
    <File>sgmo-20210630xex321.htm</File>
    <File>sgmo-20210631xex101_employ.htm</File>
    <File>sgmo-20210631xex311.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20210630.htm": {
   "axisCustom": 1,
   "axisStandard": 21,
   "contextCount": 327,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20210630.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 444,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://www.sangamo.com/20210630": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 7
   },
   "keyCustom": 64,
   "keyStandard": 273,
   "memberCustom": 45,
   "memberStandard": 29,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123106 - Disclosure - INCOME TAXES",
     "role": "http://www.sangamo.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125107 - Disclosure - COMMITMENTS",
     "role": "http://www.sangamo.com/role/COMMITMENTS",
     "shortName": "COMMITMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - FAIR VALUE MEASUREMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i158ac189c740410bb0aa53e1fde36334_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i158ac189c740410bb0aa53e1fde36334_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - COMMITMENTS - (Tables)",
     "role": "http://www.sangamo.com/role/COMMITMENTSTables",
     "shortName": "COMMITMENTS - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - STOCK-BASED COMPENSATION - (Tables)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i9732e46a5fcc4e3fa8d15cb14f9f7918_D20210401-20210630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Cash and Cash Equivalents (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i1cc0cd49c9d441feab4a2812269fe281_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i381be31f4a96421eaace1530a63600f0_D20210101-20210630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i6117a419ac54480ab8e969b26e8ae160_I20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Estimated Fair Value of Free Shares Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i6117a419ac54480ab8e969b26e8ae160_I20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Summary of cost and estimated fair value of short-term investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail",
     "shortName": "BASIC AND DILUTED NET LOSS PER SHARE - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i7d369449f64a4fe9802fbfa50d7c5894_D20180501-20180531",
      "decimals": "-5",
      "lang": "en-US",
      "name": "sgmo:GrantFundingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
     "shortName": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i835ea8e2ca074d12bcb1b9c6349fbd74_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - INCOME TAXES (Details)",
     "role": "http://www.sangamo.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - COMMITMENTS - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail",
     "shortName": "COMMITMENTS - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - COMMITMENTS - Components of Operating Leases (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail",
     "shortName": "COMMITMENTS - Components of Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
     "shortName": "COMMITMENTS - Summary of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)",
     "role": "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
     "shortName": "COMMITMENTS - Non-cancelable Material Contractual Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ia45a1fa516b24d509732822dedf80969_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail",
     "shortName": "STOCK-BASED COMPENSATION - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i5ca39d9e2a45406c99ed3a577bbbe4d0_D20210401-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i287279db3cc248a09fec60c8d435c802_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i287279db3cc248a09fec60c8d435c802_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:StockOfferingProgramMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i192244a99ff14df4a634c33f2294f707_D20181001-20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i192244a99ff14df4a634c33f2294f707_D20181001-20181031",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "if338f7d54d3a4f0cbc40c646455f0cca_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
     "shortName": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S. - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "sgmo:ScheduleOfNoncontrollingInterestTableTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i1a22c45761394b75af4d6906696260fb_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "i1a22c45761394b75af4d6906696260fb_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "role": "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES",
     "shortName": "CASH EQUIVALENTS AND MARKETABLE SECURITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20210630.htm",
      "contextRef": "ic8ea400821bf458997c74f535136745d_D20210101-20210630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 74,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "verboseLabel": "Achievement of commercial milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development And regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "verboseLabel": "Achievement of specified preclinical development clinical development and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of specified sales milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "negatedLabel": "Amortization and other changes in operating lease right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "At-The-Market Offering Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen MA, Inc.",
        "label": "Biogen MA, Inc. [Member]",
        "terseLabel": "Biogen MA, Inc."
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrammerBioMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brammer Bio MA",
        "label": "Brammer Bio MA [Member]",
        "terseLabel": "Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary"
       }
      }
     },
     "localname": "BrammerBioMAMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brisbane, California",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "localname": "BrisbaneCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "label": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "terseLabel": "Number of free shares outstanding subject to purchase (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_BusinessAcquisitionsFairValueOfFreeSharesAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisitions, Fair Value of Free Shares' Asset",
        "label": "Business Acquisitions, Fair Value of Free Shares' Asset",
        "terseLabel": "Business Acquisitions, Fair Value of Free Shares' Asset"
       }
      }
     },
     "localname": "BusinessAcquisitionsFairValueOfFreeSharesAsset",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "verboseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California institute for regenerative medicine agreement"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "totalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedTotalLabel": "Total cash equivalents and available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "label": "Cash Equivalents Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "label": "Cash Equivalents, Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Cash equivalents, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "CashEquivalentsGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope [Member]",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in collaboration agreement scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional product targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "verboseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Financial advisory fees"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationArrangementResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Research Period",
        "label": "Collaboration Arrangement, Research Period",
        "terseLabel": "Research period"
       }
      }
     },
     "localname": "CollaborationArrangementResearchPeriod",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone [Domain]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "label": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "terseLabel": "Agreement restriction, percentage of shares held"
       }
      }
     },
     "localname": "CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementCumulativeMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "label": "Collaborative Arrangement, Cumulative Milestone Achieved",
        "terseLabel": "Cumulative milestone achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementCumulativeMilestoneAchieved",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License Fee",
        "label": "Collaborative Arrangement, License Fee",
        "terseLabel": "License fee"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseFee",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "label": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "terseLabel": "Maximum number of product targets replaced"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Revenue Recognized",
        "label": "Collaborative Arrangement, Milestone Revenue Recognized",
        "terseLabel": "Milestone revenue reversal"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestoneRevenueRecognized",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Milestones Achieved",
        "label": "Collaborative Arrangement, Number Of Milestones Achieved",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfMilestonesAchieved",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of product targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Standstill restriction, ownership threshold percentage ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Standstill restriction period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "label": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "terseLabel": "Voting provisions expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsExpirationPeriod",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "label": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "terseLabel": "Voting provisions, ownership threshold percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment",
        "label": "Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Receive Payment",
        "terseLabel": "Maximum amount of achieved milestones to receive payment"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToReceivePayment",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development - and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free shares asset.",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainLossOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on free shares.",
        "label": "Gain (Loss) On Free Shares",
        "negatedLabel": "Gain on free shares"
       }
      }
     },
     "localname": "GainLossOnFreeShares",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long-term portion of lease liabilities.",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc."
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LesseeOperatingLeaseAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not Yet Commenced, Amount",
        "label": "Lessee, Operating Lease, Amount",
        "terseLabel": "Lease payment amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAmount",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseAreaOfRealEstate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area Of Real Estate",
        "label": "Lessee, Operating Lease, Area Of Real Estate",
        "terseLabel": "Area of real estate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaOfRealEstate",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "label": "Lessee, Operating Lease, Liability, Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LicenseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Obligations",
        "label": "License Obligations",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligations",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LonzaNetherlandsBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza Netherlands, B.V.",
        "label": "Lonza Netherlands, B.V. [Member]",
        "terseLabel": "Lonza Netherlands, B.V."
       }
      }
     },
     "localname": "LonzaNetherlandsBVMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputExchangeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Exchange Rate [Member]",
        "label": "Measurement Input, Exchange Rate [Member]",
        "terseLabel": "Exchange rate"
       }
      }
     },
     "localname": "MeasurementInputExchangeRateMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Stock Price Correlation [Member]",
        "label": "Measurement Input, Stock Price Correlation [Member]",
        "terseLabel": "Stock price correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NetProceedsFromAtTheMarketOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Proceeds From At-The-Market Offering",
        "label": "Net Proceeds From At-The-Market Offering",
        "terseLabel": "Proceeds from at-the-market offering, net of offering expenses"
       }
      }
     },
     "localname": "NetProceedsFromAtTheMarketOffering",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes For BioMedical Research Inc.",
        "label": "Novartis Institutes For BioMedical Research Inc. [Member]",
        "terseLabel": "Novartis Institutes for BioMedical Research, Inc."
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office and laboratory.",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office and laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer Inc."
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer SB-525 [Member]",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PropertySubjectToOperatingLeaseOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property subject to operating lease one.",
        "label": "Property Subject To Operating Lease One [Member]",
        "terseLabel": "Operating lease one"
       }
      }
     },
     "localname": "PropertySubjectToOperatingLeaseOneMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and office space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Customer concentration risk"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveAndOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S B Five Two Five And Other Products",
        "label": "S B Five Two Five And Other Products [Member]",
        "terseLabel": "SB-525 and other products"
       }
      }
     },
     "localname": "SBFiveTwoFiveAndOtherProductsMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SBFiveTwoFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SB five two five.",
        "label": "S B Five Two Five [Member]",
        "terseLabel": "SB-525"
       }
      }
     },
     "localname": "SBFiveTwoFiveMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone",
        "label": "ST-40 Beta Thalassemia Phase 1 Clinical Trial Milestone [Member]",
        "terseLabel": "ST-40 Beta Thalassemia Phase 1 clinical trial milestone"
       }
      }
     },
     "localname": "ST40BetaThalassemiaPhase1ClinicalTrialMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received On Transaction, Net Of Adjustments",
        "label": "Sale of Stock, Consideration Received On Transaction, Net Of Adjustments",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionNetOfAdjustments",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo France",
        "label": "Sangamo France [Member]",
        "terseLabel": "Sangamo France"
       }
      }
     },
     "localname": "SangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi.",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi Genzyme",
        "verboseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Table Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTableTextBlock",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate upfront fee"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share purchase agreement and tender offer agreement"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Offering Program, Maximum Value",
        "label": "Stock Offering Program, Maximum Value",
        "terseLabel": "Stock offering program, maximum value"
       }
      }
     },
     "localname": "StockOfferingProgramMaximumValue",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock purchase agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ValbonneFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valbonne, France",
        "label": "Valbonne, France [Member]",
        "terseLabel": "Valbonne, France"
       }
      }
     },
     "localname": "ValbonneFranceMember",
     "nsuri": "http://www.sangamo.com/20210630",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r42",
      "r44",
      "r92",
      "r93",
      "r241",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r240",
      "r247",
      "r292",
      "r294",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r511",
      "r514",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r240",
      "r247",
      "r292",
      "r294",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r511",
      "r514",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r156",
      "r277",
      "r279",
      "r470",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r156",
      "r277",
      "r279",
      "r470",
      "r510",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r240",
      "r247",
      "r282",
      "r292",
      "r294",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r511",
      "r514",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r240",
      "r247",
      "r282",
      "r292",
      "r294",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r467",
      "r511",
      "r514",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r43",
      "r44",
      "r92",
      "r93",
      "r241",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r277",
      "r280",
      "r513",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r277",
      "r280",
      "r513",
      "r530",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r20",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (discount) on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r48",
      "r50",
      "r51",
      "r498",
      "r522",
      "r526"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r51",
      "r57",
      "r58",
      "r59",
      "r95",
      "r96",
      "r97",
      "r362",
      "r517",
      "r518",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r308",
      "r309",
      "r310",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r295",
      "r296",
      "r313",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Recognized portion of equity issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r296",
      "r301",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHAREAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r177",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r89",
      "r145",
      "r148",
      "r154",
      "r187",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r356",
      "r363",
      "r396",
      "r433",
      "r435",
      "r477",
      "r496"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r41",
      "r89",
      "r187",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r356",
      "r363",
      "r396",
      "r433",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities and free shares asset"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, Gross Unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r169",
      "r199"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r165",
      "r170",
      "r199",
      "r480"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofcostandestimatedfairvalueofshortterminvestmentsDetails",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r167",
      "r199"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r167",
      "r199"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r291",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r291",
      "r293",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Sangamo France stock price (EUR) (in euros per share)",
        "verboseLabel": "Business acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r341",
      "r342",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "ACQUISITION OF SANGAMO THERAPEUTICS FRANCE S.A.S."
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESAS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r29",
      "r81"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash equivalents, Amortized Cost"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r406"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r107",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r107",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r345",
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper securities",
        "verboseLabel": "Commercial paper securities"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r225",
      "r481",
      "r503"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r226",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r63",
      "r485",
      "r507"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r55",
      "r62",
      "r352",
      "r353",
      "r367",
      "r484",
      "r506"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r55",
      "r61",
      "r351",
      "r367",
      "r483",
      "r505"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r159",
      "r393",
      "r394",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r159",
      "r393",
      "r394",
      "r528",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r159",
      "r393",
      "r394",
      "r528",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r134",
      "r135",
      "r159",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136",
      "r393",
      "r395",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r159",
      "r393",
      "r394",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r265",
      "r267",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Portion of contract asset recognized"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r265",
      "r266",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r265",
      "r266",
      "r278"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r283",
      "r290",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), for which no credit loss was previously recorded.",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously Recorded",
        "terseLabel": "Allowance for credit loss related to marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r143"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Volatility estimate"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r113",
      "r115",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r381",
      "r382",
      "r486",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r117",
      "r118",
      "r119",
      "r123",
      "r124",
      "r381",
      "r382",
      "r486",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/BASICANDDILUTEDNETLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r57",
      "r58",
      "r59",
      "r95",
      "r96",
      "r97",
      "r100",
      "r109",
      "r111",
      "r127",
      "r191",
      "r261",
      "r262",
      "r308",
      "r309",
      "r310",
      "r328",
      "r329",
      "r380",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r517",
      "r518",
      "r519",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Marketable Securities and Free Share Asset/Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Shares Valuation Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r384",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r387",
      "r388",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r242",
      "r283",
      "r284",
      "r289",
      "r290",
      "r384",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r283",
      "r284",
      "r289",
      "r290",
      "r384",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r384",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r440",
      "r441",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r389",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r177",
      "r178",
      "r184",
      "r185",
      "r186",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r203",
      "r204",
      "r243",
      "r259",
      "r371",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "EUR / USD exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r205",
      "r207",
      "r435",
      "r476"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Impairment of goodwill or indefinite-lived intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r79",
      "r206",
      "r208",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r79",
      "r215",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r214",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r67"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax",
        "totalLabel": "Loss before taxes"
       }
      }
     },
     "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r323",
      "r324",
      "r325",
      "r330",
      "r332",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r110",
      "r111",
      "r144",
      "r322",
      "r331",
      "r333",
      "r509"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r78",
      "r468"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r211",
      "r213"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair value of investments available-for-sale"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r183",
      "r474",
      "r492",
      "r529",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "CASH EQUIVALENTS AND MARKETABLE SECURITIES"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r429",
      "r431"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Operating Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Six months ending December 31, 2021:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit established as a deposit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r89",
      "r149",
      "r187",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r357",
      "r363",
      "r364",
      "r396",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r89",
      "r187",
      "r396",
      "r435",
      "r479",
      "r501"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r89",
      "r187",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r357",
      "r363",
      "r364",
      "r396",
      "r433",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Recognition of license and stand-ready fee"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock price volatility estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Stock price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r39",
      "r89",
      "r187",
      "r229",
      "r233",
      "r234",
      "r235",
      "r238",
      "r239",
      "r396",
      "r478",
      "r500"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at June 30, 2021",
        "periodStartLabel": "Balance at December 31, 2020",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r262",
      "r354",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "terseLabel": "Buy-out of non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r52",
      "r54",
      "r59",
      "r60",
      "r80",
      "r89",
      "r99",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r116",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r187",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r382",
      "r396",
      "r482",
      "r504"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r52",
      "r54",
      "r59",
      "r110",
      "r111",
      "r359",
      "r366"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r106",
      "r112",
      "r123",
      "r163",
      "r164",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r228",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r326",
      "r327",
      "r328",
      "r329",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r432",
      "r471",
      "r472",
      "r473",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r263",
      "r340",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "negatedTerseLabel": "Fair value of additional shares acquired"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r262",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r153",
      "r155"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r423",
      "r431"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short-term portion of lease liabilities (included in other accrued liabilities on the Condensed Consolidated Balance Sheets)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "verboseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSSummaryofMaturitiesofOperatingLeaseLiabilitiesDetail",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r420",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities included net cash used in operating activities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r427",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r6",
      "r94",
      "r140",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION, BASIS OF PRESENTATION, AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table Text Block]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r45",
      "r49",
      "r405",
      "r412"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r48"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax",
        "verboseLabel": "Net unrealized gain on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporarily impaired investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings": {
     "auth_ref": [
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings.",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings",
        "terseLabel": "Other impairment charges related to marketable securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Purchase of additional shares of Sangamo France",
        "terseLabel": "Purchase of additional Sangamo France shares"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r72",
      "r303"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r69",
      "r166"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the maturity, prepayments and calls (requests for early payments) of debt securities designated as held-to-maturity.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Held-to-maturity Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfHeldToMaturitySecurities": {
     "auth_ref": [
      "r69",
      "r166"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of securities that had been designated as held-to-maturity. Excludes proceeds from maturities, prepayments and calls by the issuer.",
        "label": "Proceeds from Sale of Held-to-maturity Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r52",
      "r54",
      "r59",
      "r74",
      "r89",
      "r99",
      "r110",
      "r111",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r187",
      "r229",
      "r230",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r351",
      "r358",
      "r360",
      "r366",
      "r367",
      "r382",
      "r396",
      "r487"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r217",
      "r435",
      "r493",
      "r502"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by property that could be leased or is available for lease.",
        "label": "Property Subject to or Available for Operating Lease [Axis]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A descriptive title of whether the property is subject to or available for operating lease.",
        "label": "Property Subject to or Available for Operating Lease [Domain]",
        "terseLabel": "Property Subject to or Available for Operating Lease"
       }
      }
     },
     "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r317",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "verboseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r316",
      "r469",
      "r545"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r11",
      "r17",
      "r81",
      "r86",
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESReconciliationofCashandCashEquivalentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r11",
      "r17",
      "r86",
      "r531"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r262",
      "r311",
      "r435",
      "r499",
      "r521",
      "r526"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r95",
      "r96",
      "r97",
      "r100",
      "r109",
      "r111",
      "r191",
      "r308",
      "r309",
      "r310",
      "r328",
      "r329",
      "r380",
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r159",
      "r276",
      "r277",
      "r470"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r134",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from contract with customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r426",
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r173",
      "r176",
      "r179",
      "r180",
      "r181",
      "r182",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues Recognized under Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r296",
      "r300",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r296",
      "r300",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r14",
      "r86",
      "r475",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r298",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sangamo stock price (USD) (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r38",
      "r57",
      "r58",
      "r59",
      "r95",
      "r96",
      "r97",
      "r100",
      "r109",
      "r111",
      "r127",
      "r191",
      "r261",
      "r262",
      "r308",
      "r309",
      "r310",
      "r328",
      "r329",
      "r380",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r517",
      "r518",
      "r519",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r127",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs (in shares)",
        "verboseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r261",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r261",
      "r262"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r262",
      "r297",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r89",
      "r162",
      "r187",
      "r396",
      "r435"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r58",
      "r89",
      "r95",
      "r96",
      "r97",
      "r100",
      "r109",
      "r187",
      "r191",
      "r262",
      "r308",
      "r309",
      "r310",
      "r328",
      "r329",
      "r349",
      "r350",
      "r365",
      "r380",
      "r396",
      "r407",
      "r408",
      "r413",
      "r518",
      "r519",
      "r564"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r246",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r414",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r414",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r414",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/STOCKHOLDERSEQUITYNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r177",
      "r178",
      "r184",
      "r185",
      "r186",
      "r243",
      "r259",
      "r371",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ACQUISITIONOFSANGAMOTHERAPEUTICSFRANCESASNarrativeDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSNarrativeDetail",
      "http://www.sangamo.com/role/MAJORCUSTOMERSPARTNERSHIPSANDSTRATEGICALLIANCESAdditionalInformationDetail",
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r283",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CASHEQUIVALENTSANDMARKETABLESECURITIESSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleMarketableSecuritiesandFreeShareAssetLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r137",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ORGANIZATIONBASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r424",
      "r431"
     ],
     "calculation": {
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/COMMITMENTSComponentsofOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Estimated correlation between Sangamo and Sangamo France stock prices"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FAIRVALUEMEASUREMENTSSummaryofEstimatedFairValueofFreeSharesValuationAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r114",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r113",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r547": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r548": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r549": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r551": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r552": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r553": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r559": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.18)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001628280-21-015869-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-015869-xbrl.zip
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MI1'9?&:A9N6?DBN@C22BP-1!>?3.V02%5,TFA+M+,%@2ZC"[S ?,1J,,HB;
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MDUL%"BL56/)8H.@0M+8^VZ(A2.6-)N=U+ F4L*JL8H&9J\ V]@>EN\+^W(,
ML#:(F)%Y?@*?DR\D48,.]?@IH\,J"%AA?VG9OS4,?1+@R$"MEZ9\=D6GHB34
M4QI6['^%_66E_3EJDD5XZ6KD:X174JNBM<^YA"!P1?M7V%]6O@]0?"Y28)W_
M=)E\).6"=MZ15DFO^/[LL7^V:6B%_;GS?:N<SED[DR*!EN2-C$6HXJQ-+NLF
MU>I>8;^YV)\+W]=.:B%E25@<9*E# 5E/^/'UN#UAFG3^V@K[S<7^?/B^L5$
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M B+3B9)TD<I;:H")7:'Q?MI/)X63KC)=FT$F$:$>L(I45T-#**4!W'<%W46
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M^;.W6Z]V7CW?;JUMK+>>_\^S_UK;>/F\]6RSTWFUO?UJ<V-QGDC=Z(G>X>B
M@34>]/_16G_X[&%+"0.A:4_QVY_\YR;/-W%8BP*\%YM;G=9/S*GZ@_[&R1%W
MDEKGU&NKNL5N\H3L4;V2L8#Q(;A4EYBTD=HZN+YD=:N/E>9FZCY>'Z23H_/9
MR@?G*<#ZU].X/OCP6FU]V-6=DWSX_,/>RW"X>;@/NSNOQ.;Z+Q\W/A_T.I]_
M.=TXW#KHK!\<[*J.V5Q/HG/T<W=7O?WX6F_T=C\/8//E\].-]7W164^PM],1
MG<-=L;NS!KOO-@XW=_;UQCJW/]KH=5[X3Z_5WNGNNV0W=CH?.R^?RXYZ)3L[
MNV+CY=[[S?4#;K\F]XYV3SMJZW#W<.MPXW#W0W[Y*^3_^KFWIWH?XN% =CZO
M?=S=>?MY]_#MIXW#7\3>T2]\#QW36?_U:._PU>>]EQO=C9<=M='SIYW#]/$W
M&U6MQ1/:Y"RUP0C1QE*@750.)@1?5,('3Y@8_S)AME^D\*2UTI7)\\W\:;[F
MB]<_S=_J-'-KLT]_G][GW;(UOHN'XHP8_%FZIAYR!#ESHA+,0V/=GR$J5UF)
MOB E4\ZACC]5UG$9P#TJOQ^;P?'-,;!63VUMO>UWTR!3J[/]EX.&LZ&?M6&L
M]6-PS+_^-'X<!X,><00\/*'K+.8O)SAD9>Z=;M'Q8#ANI/%\T8TOW]K=SV_%
M[KL71WQOL/?NYR.^YNGFRQ?O]_@W&^HM&\U?]-YZ4FPXSW_S*U_+]/=VC@\W
M=K8.=M_MPL;Z06_W:)>?[Q7?WU:OL_Y6[^ULO-];S^\W/O-]2__Q]<[:N+,M
M/O'?OX4DBTPZM25&WP:/NAVUQ+:Q616M=4DZ/WCRG_\1'-A_?FUZ+RS3.=#O
M&,,SM6._O%W;VGF^]7JWM?7\S>;63NO-VZWMMVL;.ZV=S1;3SAWFEBVI6YM;
M+6G^EO_^G_\AK?CGYHO6SG\];UVBI1>4=.W93HN_ED'#E7%:L*#A9J/S8C!L
MC0^H]>^ILK7.IJ%:=04JSYX87=;_7'/AN,>#C*>GA$/J7V<&WDSNY_G9!&8C
MC< /,*C/G=\LQ!)#W2]K67U!F=#V4!13*=9<DDJ$2J!^/NE32XM_M.I0+S"3
MNADJ-[<6DG-\BSFHAZ#][#F'?:BL6G&.67..@KW1M:1C9\AW/EDB:#SKZ/!]
MU<_8V.C.RU>G&R^WV+#\W.VL\]^?.W+O<%<SDWC?65_[BG4,/G4.:]N-@XV=
M]''W\)78>\E]';WZN/'RE>Y\_O5HXS ?,&OYR/=XA77(9%T 2&UO@%F'2?RJ
MF-Q.M11^R80QA'/6 4O-.G:VUC:V7TVXQ8IV?+T8\85VC"_4;<H[RG!P=.&O
M[O[6OK7P=":B'_]S?D_WX$EK/+@GH_LM53 +I K/!D='W5%=L6Z5+G.=_LED
M'?L6IR2?3Y:K7_#%-B;7:J2/^Z%I2?F;]C[;)%+;*@OLJ RT/<G<1F4CR9 3
M!3_)1VAK(=TB,^KYS4WZNW@^!3=ZOEM7ERW:GVS'ZH]K&O#]4YE/OSE7!*N%
M;5/!W(:@51MMUNV@M3;)ZJ@%J\PVDY6USF:E,5MK;YZ_W7GU;/L?K5<;SQ[^
M(=V;NPK=<$+\^2=,XPDP:A;'\ (0+1RU1L>4:II2;G7[K>YXU$H'DPF5O__A
M4S;=,MQQ[D9XZ*W\*XL!FH/D,/O5 ,D_M.8VNA7*SKQ;\U":V<].:/\PW+#;
MOSX[<:8<BQ/9W>;T!-]3JFF=8SH>#CY42W-U3O3,%=6MQ,/C<PH]V5$\V:4R
M/'TVR,WT3&<3%GM';S]S_]S^Z5'GL/-QX^6NZ+Q\97;?=?3N8?J\N?Y6=0[?
MBX[ZW3+)T=X.7__SVT^=E]SWYS6Q=_C+Q]W#WL'NYUPG.V!C9_=T<^>7SU\O
MDS -#,$8UU8ZA38X:=J(PK9=]%*5J V >?!DG7KX$8?T S,65_*+YM'T/JK6
MUYJS@Y]>G2<4GVUF:W  =-<Z\\N%SF2 F.JL7B2#;4#%81,5T_8Q25_/LY Y
M/7AB?5MHP[IEOZDULW8,9ZQAU@"^62[1WR;&N#48M@9U$V3K\&38'>5NFLQO
M#<I/<?CH2?>R\9XT'>YCO_MY\O[O2VE0YBJ25P^W'FX_;#T_.NX-3FDXD<%5
M&]#:&#S\^ZUB\A8LZLV>_JL9L64"U2*-Z;5XN92$_"=7+2[TY4ZCQ05QT6LY
M#^M>G;._7O,-R)5[_IY[_GR)TGX]T:/VUGM'FSL=M?'Y%]A;Y^=4NW)S?4WM
M'NWR.&SU.H>O1&>'QTYZ\5L2,7LGV*,;K]K (FT',J;-'S$O3B;F(A\\86R(
M5@>'W3ZVGO8^Y-_-[?SC]N>OSQ'RC%]N#G<&'_LKF-P53. W*W,MP:7;( *'
M36BA'3$&_D,3&:4XJN*P:7H.UQV@XT\'T>?PF3"VS>$;;LG,;!4]WQF&/G7V
M?TM.U"HII6USS&QLR+0YXO9M'45V@26?:R#QY9B(^5F9-P,&5&^O>[R:8KE3
MD&SL_Z8LBTTZVY8EIC9HI]L>I>#@,V:)(N>@XX,G@25MOKW"\*-4;<%XZ-_.
MH5G7(H[9$Z?N,?9:](G222T9R!_78\E&?V_]C6';JKB])LAI4-[(V4/?HL)7
M)K$V)&RLBO_0^M[I;ZQ 7F7F>E)$UP8O51L5F^2DBB$OHBC9/7ABI/A:S?Y^
MFV:XEIWJO3D8].]MLH+^S18MHM&Q38*8<NG$;$M&:GO/[M/7:H=%L ETHFU9
M_18W5^&&ANW+4OM__@?#QOUSU!I3CXXK",[38_[18H/7.ZFFNH6LLZUTQ;[=
M^5JKO5&JSY]=:OVK2[/?$K2="KK;K[-@CY6[@QUFUU4D>/!DFUW5L#ON<H]G
MB^DTI-PZ/AF.3NJJ^GC0XA9UANYLRD6JO\6_5V]7$P?7TOCQG%:BX:%3ZB^M
M1/N'5O^UM=UO?V=N8;>;= ^]A(;<+(^L\S>[V6:L-]PP57ZG.SXK*4*8#EJI
MAZ/1[4SV-F0XACCQ"-NG1W'0^]OHEI93FC$8&^=Y2A-HT*=T4 L0M@;]UL>#
M+G_RQ>+^F:6/<^LZV<5_/&Z-!KUN_ETIC85::;ZC/29?".NY5SN5*D[4LY&$
M=3I;\(O<?;?5W7NWU]M\]W-O8SU]VCU\_VGO<*WN)CGHO.-^WFT<= [W?S];
ML/[KP=Y+)KU';\WNT5NQ\?E%=W/GQ5%GO>XF><Y]<-_J^>EFO<=+"1G%9PU!
MRK;P/G 4HNHRL^97$)S3*&7T]BQIFJ$\*8_ZC]8Q#EL?L'="K?]?/!2R;B5H
MC0YN/5]CI0S?589SBWQFD%>:< -->'6A"<:7+ K:-AA(;9#2MP- ;@<E;="
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MM-P8?>>T._%?3P*RW6"^(!-AZ*],ZYNYZ&W\<ENW:"YRM^C<+7I.W:)7H,)
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M.!73AS/0:?VAD]>K"R\E(@\I"&,F(9A;@FT_S=<;A6][<(=>TGZC>-[4KLX
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MO'=X<)V6[HD_O7&/*;@4@I17B_*C],J2)F7O>'>_#O TR&;]R_6?DQF[J_W
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M=FLA;;?]89+0=B683$X/(*?I#! )&H0Y&I H/$?<J0)IIB2RB9RH,Z&@1<H
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MXCJI=A -8J)@D7I-B;,)1%=@O@JEM>>Y.&=13WEQ/NWBG"J_8)AR7A?(::?
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M+1^ZUS(2GC!X>=/<+8^Z_ON)1OY,V'HI>1>7B#R3]$PDO7\IT$%#X9BE'H5
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MC/@WTTH5AGL-TV_\,6B'!L/-1H+.8])>;*?K0Q?5XWK%8/9]9Y .%(V&,_Q
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M\#2B,]O_.^9^]PFNV#UI5=WZW>R#*GXYC]W!-^*SGF83@N5B9Q(V03DG'.>
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M:A<$+F(J8EI3,2VS4"9,HU$J.8LUYU$:E8@0*3":M V1EX5RG1;*61>7.O1
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MOQA';!0T(>M90EQRC#11%F'*O0\N.9+R!KDI):'63=<+)*^%F!ZS#V.!Y(9
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M"G+6ZS*OZS16@C<97Y?!JDW%;S_:K+'"0V#TG<[ZG1C;[X;%,W/MNS>PUC%
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MXA(7VACE%4^""<*DXB+4&:!DF@%*GFP&Z,'.U/FX=_'^['4'CI._7FW#]__
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M$==@S^M@$R)"4B&TYRKBC:W5[1X6GV/!HB?"#@M"_22$NEA *.QI2E$9Q%@
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MX=ADP.,NZ;5@OS_HQ9LTEG"N?<QARIQ187 RAF-*(S6:.K/Q+1U^)/U\.1K
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M?2[O51;,,%9WKN;QCB7'9,\>CF-M2I0G7MOA*/5[?\3AE]/CV$XY@S\O(K0
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M[0Z7263E;,[23-9Z^S! ?UP=3*4##H?900"S[%<4[.+T4XSS#ZI7]=.2=N-
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M>^7:#N0ZD+N[(*>"#<2ZF',1N#?!.D<LI<XDKH3!7\FUZN#LAN!LH;-QHX3
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MJ#$ 'RY8?3F$M;P0,+=/N_MO/^U^.@A*L'P[%H72'PR+@*P*&A&EM'>6)9+
MYAB.OHY9H\5N@_I>MGO);'"G;?E7''R]9/OCXN.;T^B*Y4+4KU7.;^\3V"/7
M*6+O66"Y41+AAG.FK0!Z T$.UFXP-+ 2:ELW"2Y"<FTR+#Z5CMXJ>ON\>WC
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M=H%PK(MWLMUF6#^%7DWIUWH$'E+!%\( E!%4T: 0YMXC[FQ.]1L=4I+%B(G
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M3O8Q#5)1K1!@4CXAI0&EG E(:*68IE%;EFZT@-TJ)K,5CO44#I<H5A0C*I-
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MWE(:3)82WC62=X4\F^*^FX'H&!8$F(7^Z>9UML:N9W,+NK'>9H_X,6;/\YQ
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MZ9"0+^FOA&5(JT@0<U39I PF7MP;^V@U>QTUFP8M=$I1!*IY8LEQ[(CPA.#
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M#;E"[ZBI2QR.X)&Y5$.IZAV_'E?EU$IEL?'I>!)S@GA?U12KJD&,)S,]F-6
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MPWXN&$8-%BAX+Q /\)OU%$1)"P>+J]&,Y>3XYBJD:>)T%[*,%^+2RUM ,:^
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MWM"8IB#:2>G$G#)<$V^$=9@3;SEQ,E!5M@'N6BOE;*79?\.:6 XZ/V'N^I8
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M+8:*M>F-[J?ZMP]KOZT;^ZYJZZOXG.G0/M*#+^^.M(%Q!7D KU1%$(8(7JD
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MGV\Y+O<5G5;M[U6U<.<+X3[NH<OFS2TDY^;>/JLAPP^A;#_BP&QDZ9ZR= -
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M)'(L6A1H<@2FFD@3-D"U :HG 50:.^L2YD%P^*\A1BKC/=8J,A%P4C<=.=X
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M8W:5K(*G.63DXO7!_NV\@=#L]PQBV3',/O),I>W)"G]NPWQ@HME\J#=;NH.
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M)PQ7T(K7!R]RTA;@T?2(_X=7?\QB4$ZM+0O5A%H-6OG4(H@5QE0C6DO0=@U
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M":865KA/<Y)0*)$::\&F.&J(GH:5D"P\L]X=+81D.=MD?%8QY!:0G0&MN?P
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M^Y/ZPQ]>'71 OF$%[(!HETKJT_+75:64(M6=^+F;:PPWM9J7%ORE3;7D3]T
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MSY'CF2O#DL@CD4%;O[4KM]7&YMP@YP8Y?X0 ZP8Y[XB<LX%5G!AGSA%DP4-
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M,(N]KMWI_-T=G8 PPLH\D;I*..>$+GZ^ ($K+)%[X^/Q<)3E6.YTEN73=OH
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M .BB7.>(N$"5'/A%5OYL_3W[AS@B=7OFY6&HD##ZJF6>S698S@0&"14+E )
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M2<;-KH;S-(4/%3V,,8K1Q@8,IB@]!N?[M#RJ7P5"JL2"PH\"%);,'J# .%O
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M(D<&3AAAH-'EX2^J)865&XMELUQF,IMK!B6FJR?6IK[V#'^._,>:G.$[(IG
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M79^@V?=[ZU($72L\'/4*).&"$]2!  7)TY0 AE=BW&:]CO[1:-MU7&5%'N.
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ME]L"_.!^K9H'SOP^.-,=@!IP]ILU#\2V'\0VZO<<YZ[=O0=:.]#:?=IP^[W
M'>TWK7VO)H?S \.-_2;&NLFARK-LGI7+@L9A;33#O.WA!C9*G1WC3K Z_#L'
M.CKVNA/ +C?>SSJI[L7]#'NA-[SK_6QFR]V]G_WDG[^[/=]WUXKV=H=U'J[_
M?H\4V]]'?]NFCO) R::=YO4&?7_7-<&6Y/P=:H*^WW/\.VOJKZT)'N)^]I-_
M4!.XWD$3[)@F\/]VIX+P^[AUN^77"&B6?&.[Y[:^=[-OI0^DF>05=HJJ+?R8
M\%(/?SH[+-.&@UYP9V#F!S^A78XR'KCDP"5!V/.#>V9N#EQRX)(?@TO<8<_U
M?FA=\IUF$>Z+,7V0*0>9\J4RQ0][;G#7H-5W)50.;')@D]MKBX8]Q[]G#O[
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MJS."]O@L:=I)0TQ9@CMYXG<T=TXPW,]!\]<J$L@\GX&ZGO/E+F[P"[;3T\*
M+.6?G$WIA8=4A!U"ZM:IXIG:AE@\\'F*8:S:FT'BEAD>C+W47RB$(],YZ]G(
M#8EIX\/-%0=+]LF*T7<#/P9^,Q<G=L'F5VR66R\*9,&=I/\') ^W+;H?7HO=
M1AQ>1U7(5R&.+D7_0,3QXU55##975>!RL^3_/KD]2S[RGAQ*,7:[BN$'+L7
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M0MDRH7)47"8=FIR[ (]FA 52PV"J&N3V-9CKP\+3NNX72UO@UB5JFP52:JH
MD\C'_ AR1M05+&ML%_PIIJZ%]Z)@F%Y*9[]OTAXIT3B.K(,:-,:H+%^94D'X
M%1>55_C;> JN>99F^*NR+F^Q02_;&%L3!#]C[W% B!SC@A>]_LE&23:.7YC
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M%&N!Z)I(-T85'(+BF%%#4F$ULB;6$EP5>;7 <1"LP-(U&BB(<#JZYD,D#NL
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MOB2-<2&:>TKZ=SQAU'4#UN02\WYP78>;>'3Q5>?"NN+\*@(DX(.6AWMX-([
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M\,:6U 2%KD+=1564%586(QG#YA)1["T_@981B!_9X2) [$NPH":,[NDZ+S[
MWV,];T'W5@HIHIZ&GR-K08+XZ_&:FL*QA<PZ!B,O7W%$I )7F/QK:46"L$PS
MX<^"S?(^C\ H$M!5\LE$#A.L81;Y7^F\PU?Q$_6?A0:I)WXF.:TK!^V)-WY*
MZ.$X_ 0^.)7SFJ7L%H .B'%+$EGT-BTFI,LD*)*TQ\20=***&>@$BZM]*=W8
M=4SJ?FEMY31'7!!#X5(7A%!_65E4BZ7\LSD@A.Y/5'[+T;@4_2FX,3-4TX7>
M^7)2T#:18+<PMT44!&B96CEL5-AJ24I[XKK0T(1UZ M>2;W2P 2KR?":1BE+
MM4MD1R$#-'68;$?4_(VQ$_%TO%M>2+.@04^WO$ZPO<'JA,HCS(_&;B2CROG&
M\B=16$WH2F9M?EXM*1;06*RTC.L3D6L^LDY!D.!DUIZ49>VY=C61FN0,WQ'8
M]EP6HF;4_?&92V@7"8#?J(   PN3X+PF#[T\)<'4?#RQE )>/6TAR!A'BYT;
M2(V-9A'1U:L_0V.,5N8L>[*#&HO4@+0TV0BC/?(>UJBJ:7<I#=OHR1+=7\02
M6;Y L!N02Y6HP5:Z483YX$5 WF1I*]-=ZUHJ\%4]H*:*,!NLWE?E<J:BB8T=
M:>.S*3Z27+K%4VJATHV.FUF(G$.)K(TOEK.X<7()]H;):]LW73_6QO)TU;N_
MFTW&64<( -T+O!1Y">0XJUGO<*;K1/]E943KPA(+'F8: X94@1P8H ;6KR??
M;Q@9L)QDI3H#TSI231ZI*"S\1._$7C+8,S6_&LC5IH#"EA VY7)<?'T<70LX
MLIJ7=4/DY4M"+<86F>#>UT<71V9M0J]]C;A6T*+::4R;M5I"=D5"2XMC, H=
MD VQ_07#\45&=B-PWI)ZJ:5?2&%GX7AC.QZ+4<@(/' ]T[L19Z$D0'N1QCNU
MC&Y8J9H4B-1H1+<6(P8(N0D++KB#3LM4'UU70YUUIGC15T4DK?9A#(EBUWI
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M1E8[G?8(KQ\,JSB4"\32W;!KK$JNO K65U5H_D) :J[0VOC\P_\#4$L#!!0
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M9D7 N[%M6E#U?.'6+>BI@EVS*FP%E%J.;B?CB1,I<ZG2(? KYR(3FD$4E:H
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M<"DJ=8-I;0K;2EA\/K3<C?9WG<CX8/:OOMUS#=#"_]<U]..W25@GR*R]D)X
M<$&D48Q8;A41*2D!,N2L7%U6+P>WJ]C]CEBSC+LM::_"[KS(\[P%.#T&:P*Q
M:B2_ <C=1.];5_ R K6LG1T1R6<F,F6!B%*M35*GB%4^$:95=II*Q6-Z601Z
M(D[_'/BSBE*VQ)O1[;H\C0T'*6Q KYDPXU &0FOB: ZE.+NP,9K@>)W.\4W0
M[=!I:$NM#6BSD4XJ!#'NO3JW7_[1A2$.\NG;6_@,O<G; ][+TDD(86DT/3VC
M^/: (PY?*FU---16#C$^BN^G?=2R#FOZG_??AH=X9^G0#<!NW5A:"G?G9E-K
M>F^RA+6JM&WMA4M!\Y*42*,G+'E1^NZB5YTLOHB@ E#0-#:[T_8C,JRY7?4\
M"+:*KFH2Z[A_=3T>323 9OMXI-DZZH@7H(B4%K^2H$DTTEC*4M"5:J \ NIY
MF%0MJ7,9<3;414V;ZAXT/H5FG4X!/$5M&IQR0J/2EF\-TZ4DBPM.ULD)?034
MOM%D'5UL:3414VC:4 :39O &R2N5*$4LK20Q([.9BY[G[=%$["=-UM%%#;NY
MV_?]V"TE&4?CX?5M&F(H%7>4B43YP$L+OM( EC$2F4PV4VVDKG.#;@F@/??!
M6M!2A6SS2>YAAF$1RSD,/W<C3ODT+T [*LFNH\4_FH5(&\REJD_6YFQVY+*U
M09/Y:PZ[UG&%O;'5.44!.41\D95UY0Z)X>B?"$<"FHC.EVPA72=!XOGS]2D'
M\+G3=1755J#INT$?OMWDC[ZY[J=9>G<0(&/FEG!;;@CD0(GCV1 -5%++>7"Z
MSJ6*Q7BV;[CM3L>#UA54P4'\</[[X#,,^Y-;C%>#_FB )LK1I"K$L#N:SSR;
MF:&A%'' -RU0E("D4J 9R@51+$D(RFM)Z]A[ZZ#=8\I55VZ5>SZ7EVAQHRS>
M^ZO;5DQ9:R^RQM?"EIJ,#N'9( 1A5$LPPLJ8ZIPS+X2SQY3:7#TURG$,AE?E
M%A(L)#2G45O%',E6(SBN# E,6Z)CE-%XGURL4\CP45A[S:&VU%7C4G1QW5_Y
M^">D!] \]YJFX(GQ7"(T;XB7BN.W692;0<"@3BCL$5![S*.V5%6AB.\A#,?=
MW,5?*_-_#5>#47=V+=)D:N*DR[P&3Z074 I$H-HC#<);@8ME'1_P$5![S**V
M5-5B =])Q9';2W^C"<]GUAECWE)AB(L">>VLQYDR32 JFY2/%NA<:O"22BX+
M'[^'-&A)U@^UK[=T?_FDW.\N%[!;OEL\_]Q*]WX?A3]W)Y>SK 0ZQ\JC<YR,
M<HEG0)^$*>XI]6GQG=SY$39;V<_C)TC7O5*,8>EUK;>W]R0LTSE"+N>]%!D9
M37&K0B825P^J/0L^U_&45X*YT3KUZGJ$SQF-#N*_KKNC"2M.KLO[@Z_J[6M5
MRNN_^O;'H(>OQJC#C=?9VU@B=;:T[M7E_EHFD3/K,T\!_VNTB*T^]O97N'J$
M^6X)JZR&&HV<_+>;=7TPP3R$^RW?QH!PQ\?]\^LPZJ:N'Y9[CQ"D XY>@?8V
M$2E5)MY%2AR5/$L1LPIUH@ K0WV)--N.WMHNDM?HO;C7N@&!_S?$\<7@_;1:
M;L=HJ702E 1K4%8YHQF0<R!.*M#2)26=;V^U>@S*2V35#I348@1J&?J[U)#[
M,Y@8EQU(4LFD%%$I*)0- S0K32(I,6&84"K29@6E5QMWG\C3EO@KQ)>:".4F
M!R1&'KR,N%8*6W)92_]IIBSNUI+KH*DTH4X:9V.(V[J[O+V]K8YVGLO=XP5O
MRDT9.5<*OM\D3!LBM6 X*Q=)-EJ!]"JJ2GTTEP#:5?Y6)>T/VM="A8.W1;!N
M[+O;%AX- %9-NGH2XFXRJ5I1: .2;*Z-G="&)XU;*W!B;,G02301#[@RYV0B
M* #E79WSMQW1Y8E$IMVP914EM.V"G=\$ M\,?3_.JF2[H&*)H!.5C45[':?L
M<[9HK^O$M4B<,=7("%[P\.U;NBW+?]"B\+968MQ$*Y(2#E'@JRA%0N<K949*
M.TW-*8CHZIBKSZK$^'9,B,TU4"$+8]7*LTW@_BPGWH*J-RS\O(Z>GD$Y<1I+
M]6'T^PR4/F4!(@E:21*U,R[2Y*3_64Y\=ZQ:13VM&R0E'/1^OAL:HKXHIXW#
MTYQA>/OQ%*_4SF85.>ZT@I8*GR@;(7!/X(XS*VP023<S6%8?_/E7$5])FX,M
MJN(9U!6?M:%)MT')P;V@9/G@IIG,:'1]>341:JTJX6LCJ5WSNQT1S64+:&9H
MRC*+Z&4Y<W*&9N6-\<8+0Q5[HH+WVIAV7QOS%MP%Q$_][K^N[X='$XO2:L\(
MKO;H/ 15JOQH43(M%<O"!.<J5UZJ-+.-(_.3I6C8C:4^JA;60G&^72EOB=)R
M')VW+-!"3\EP 75D=(?AQRQ<VQKS'@3FUU-.!>]W@:]_#YSAAE%9DL2$QHV0
MVDBL+:XYI19TLHSG.E[PH[!^DJF2"FO48A@,H?NQ?XB"*,7?CK[&26.RL]+(
MKAA>O8E(6"=YKX$&M,Y=@6D3FER99H29@H]@;(1*55Z: ?S)N>IJK1#$^>?$
MSI\([ZS[\=/X?M;%O=(7D]H4'<NSU]12HCV4$);GQ$W"FQ %2BIE'NID-ZZ"
M\B</MZ/@"KD2KV'8_3Q)W;WM>?, (@_ K44)2!8<0LSXOB0$ZX(32BKN6*6[
MJ W _:1>5756N+=327XW$7\A.)@$DGB0$0T+DTAPRI/L%<\HUZ "_Y$\KQ^N
M?T&]S?VYT.:Y9QI1&8R@/A)!%2,R4D^\$9IHQI.F03"OZO3K>&:91L^', V3
MDU91W$ZR3)H _)F<M*9"5TXW64<;.Z&-]IX%C28M#R:3<DV!!(^.5T2X5$EO
MLJC3:N7'2DZJRY95E+"-Y"0;+'K@H$M<49?&M8(X%RQ1U(@8G;0^-;N?]H,D
M)ZTD_Z>2DU817H7P[+Q'44ZZ;PJ%17""RU*$ER<BC0?B<\I$!8A22Z9TK%.\
M81FBG[;'?(6L-E17(2:V"->L1F$#9%6MCN78=F-NM*/#!L380 $UJN\M1YA
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MF7L22AL)2VWRSG%C1+.0P?(Q]HTW+4E[09'2.@GNLY#&74AT%B3M4%;:+,E
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M'.4X 1G?MB04O%Q:+0GN/!]6K:*>MAV_IY+#9[ZI599E1HD')M WE1&_XD!
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ML6'YDU.5%/*0.!M6OO"]+DZ^W_6W5S-0#LARZ,--P87)%8UN_\&9KA&>1U!
M,M6JU(5%XD]L44.]I(9&FYHU]%D;PMZ1:CO*>DBQS<IA?%^^XQ;8;068<I)@
M-*!K7SI7>0[X"FB*/HT'0F7BFLL4PGP=_$;55!8.MJ<GX55TT;9E_@2^Z0O4
M!.'B$^SU6+.3Z[Q5U+4"%S:0=<5DOD>0@N-,\DP1J2J5/'!M=4(J5+>77#EA
M8EJGPM=6V;#LPNXS(<,J(FZ;!.^'<%/ ]]Z1Q^PVA59,&!U(-M83&8,M6ZLB
M(G$C6:*04K/=8_D86[R.4DD=@_9EV7J"YL.8Z<S+ERQ$ PZ)7&9:NJ1XFC71
M.COO6. ^-ROGOG2(EZ7@=B39]BM\B^7BRV#F^]CHO$B,\,!*,-LS$B(N6"9I
MR:+-(!L>YSU\]LO2Z(:R:_LT[ X.:F7&+1 F4Y: >%M:A82$DW-*XBHB/21E
MLE-Z167>/?VEJG--^;5]LG-^(>DK&/N+3[[G1R.X[/KW)96;S>)@%\/NP]U"
M\7+JA!..23A<31PC7BA!-'+0)VJI\<UB26L-_[(H45\#;7IKPW%G>E9Y.IP6
M)Y]8H& ,5]%RP@0K=5RE([A(>1*MMS&E(#RT5\AK$8)]=>_;4$B;!R1W>,K%
MDRFBT>PE:0"J]<)=2^%LOU#7YIIZJ/:6Q-QR8:Y'P"E3+!1#<J01?56>2"C-
MZVT*(!T$&6*CWI?/4?>/%-[:ENI7D&[;=O[YJS>X0Z*A6OY":).U;09U=B6,
M4@@\*A*8A%)'P9!@BL'C.5/2.R=UP_MV3P^VW5H2+>ED4%&@K3ON]_'-TE"Y
MQCVL!!("-40Z9]$P29F4OA!2:ZD5;78^M.#A+TNA:PBL[3=V$:&D-CE;F4GF
MI;\'VB+$<RF(,"PXZ[R)T"PAZR6^D9L*K$)QCMF-Z]M)SF Q+XW.0)0HI?0"
MUR1H9Y!7P#3C00C&FNRS*U^/6@+H1]9]F[)NVX.?[ZEQ[_@W>:?0^0RE2T^Y
MU6T"<5)$ I1IQ\&6HD.K!68>C/$C:[5-\;5^(GK2[</IV9OSTN/B+O:7)\E&
M&1<7;9%H&KU#'Y(@+AHM%*<^S??36G;8M?#Y/[PV6Q!;A;I;D]X5LTI\C(7H
MI4<##4K;20HDB(A+A721IR@3V#JW5N^!^)'5O*E,EZ;@_?MO<])XB]].?C#Y
MO,SV#/(OY>\/9\>WDOGRY<M?1K[_T5\._A('E[]-I/+NX#]/SPX_G%^<OCLZ
M.W]_<'9Q@G__<?S^_.#D]?G%V<'%T>_'AP=OWQX?G!P>G4\;V8SN.ME<?]>K
M]#6,?;?W_0Q&W<NKWI/59^L ^>U.+-^+:XKF.^KL2D#P=0SX2^G77[KI;[]V
MLU0L92Z"UE3:F#T3R0B=6?!1>^4Z=2#M[*+\V]M^%59%QK@IIT0&/42CT3GD
M4#HC><EDL&BEUNK!N#GZ732M1((P)$M)DU-HT// B)71$LV<B,(&XT.=YCW[
MT[1R%4ZVT;1R%96V&"6I<$C@A >3+!!$[='50!FZS-"R$124"T(96<=^V--N
M/YLP=4=J?[;=?ICE4D4N"1->$IFA%!B+CO!LE>(,O/7M]>!XH=U^5B+"4]U^
M5E'(SCJW- &Y]]U^5M+D6BU<UE'#SC@C,L("S8@RUA&I..[\&B*!&!AD$;F-
MZ:5P9=5N/_6ILHKT=][M!_U ZFPN]_=*\("C8 *8TM9":P[:T-PP%?&E=/M9
M27L;=?M91?3UN_TDX,HYEHF7.I6KZ8:X)!*B,1)A6D%]LV3C'Z;;S]J:WDQX
MV^CVXY*-P2=#J"S44L7U4YR2K+0I6964YA?7[6=M=6XJP+:SC+_KF2%<QF4@
M)0(LXW:57$#?*RJBA1$V:N.L:E9@[$=H,[*V"M<669O'D<O2G )77AO@!#A%
M'SJ!+"%^113U'.FEHP#3FC7V0I-#U_7[-E9(FR_WHZ=!34#M77+H2IIJE"&X
MCIBWEARJ<>E"'X21DL!.I/5H4("/I;2L])I'RZ"]"-$S3PYM7_6K2+="V>=E
MV3,\>TE!!,*R%:4YG256!T.\-Q T-]DYV43I+RU3:25U-<Q46D76;;M<LSUP
M-LU;U\$YJC0"$<X2"1'1!"J("HZF$+0&WBQ+:?'S?V1MMB6V:C<Z'R9-F40-
M%\D3=/@HD<XG!"@= 2?Q)RE:D9HE>#__G+.U-=J2^)9:9FVFLAR>OGMW?/'N
MZ.3B_""ER=-\[[A?+-1)SY_U<U,:/GGS9)-UIC"7/9(2R]Q( $V5U*42)_5)
M1153*;T)LM-PC(VJ85Q>=L>%*H6*Q5WHHNO0CUVX=UJ9C1-:,TF2S89(72Z3
M<69(:>Y#I934B68=JYN,MK$]X/&5N@[_#<7K^7V('G%Z"^@DCSK6AHR[D2UE
M(1F1&3<HRR)^Y04+,E,63:7<Y660MG[GM&5E/[ /6I%]A52)MR5G TZO)I6M
M^A\GH,Z@#U]\[P*&EQT'GLH@$F$2?7 IK2,!HB.9:9<\,Y+-UT=NBQJ/ WMQ
M!&E1#Q5\B>^!O???)J+HB A6<B<(=QE1,2%(2"D32K.-F?/H>:-(T\KL6(SG
MI9&B!:E7N 'S/:I_0O?CIS&D@\_XZ4?D;)';[(>%NJSCI4;?.EN28@YH9#'$
M2]'1MDE)E5PIB5*G@>BJ2%\V?UK65(7.:X_B?=T=Q1+%/_-C> ]#]+?''<$
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M,YSO>W[2I>GH7]?=25[EO6;EPB?C<[*$ZO+"Z*2)Y\$30,\A1^U8TG5.!!J
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MR3<MWNV5?/6T$R?$R+4YC) O%M3$M6 88 ;M -L!HDYD(5N'2[0EF!K#M J
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MZ+V M49R,;^Q(2"5 M<I:-3:.L2ZB8]M [_#N.GL (P_?F,M_L<:1\UEOUG
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MCO,Y1\SQ',N'KF/)>D>V#T/.*0Q]ZC."N)@*M?(_]1=E:A/>??(=/&=I^50
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M5*1QO,51".&D0NW+?OK"'A;F;<YG+](BPHO5J4$3WAL'H8V8BV'$*8)BX>?
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MAON,=OH&:];^9ZT?VG4='O*4+40;19U.Z$Y,?)^R_ ^<LWGL.[[E86%,NRR
M*'9<&,8XAI0@UPTCVZ*15JRW9O]3FVA:\<&/K0(_22^231W^.VB37OU?\MZU
MQVV<6Q/]*P0&F-,-%-\1)4HB9W^J3B?O!)/NRDFJ]\:@/QB\)I[MLNNU7.FN
M_>L/*<FV?)-)F50).!]2J8M$KO70>K2XN"Y6#] JXGDVZ[M,;N9U1/ COVTB
MX#X@DW00>H'S2_UD&#GK=!! I[FHPX89Z%[X;NWZC\N] ^-]M9D_L8WJ%&8H
M*<VQS#%,"J2-O5UFD")9P%*FF4I309#R2UIUF'1JU-?(;)^ZCE=S*_:=8WF'
MX4O@Z$ (#&QLST$(3/V=!AX@A?46N$P\KIO  XH3_X#/O0-CYZQ]^(M-"'VW
M>K*MT9HM#4DXS=*2P52DPB;5*DA%22 I,58"85GX56 \/\W4"*A^"[3IL:(C
MIV?4VWE(W>CE=J#&V)6W&&VS53NNJSM@DXY8]7W;'S%@'%LO-&$#ULY/-6YD
M6J^Z)R%H_5</+6I_MJ9SZP1A$E,F4 *U^09B4B!(BC*'>5:4"(LR2W.OHY#>
MV:9&%4?%T.&^&+IO-?H^B-TX(QAPD:GC,F81ZG0X@1*X&'S?C"-7>W=0_K2<
MN\M- _= YHUPOY3V/[N]^L$6]JCW?O..K=>OQJYIZU<BFJ<IIU#BQ!XZH (2
M56I(&!)9HI(LT4Y5/+QFG1JS6&EKMVK]%E5[N3VW/$Z(EURJ-,LD%))(B&EA
M.\KE"!8RT4J5!"5)X9/"&1[Q$9(ZWQT!?0?NGVQZUW_5*5F^2>=NP#MN-D/#
M&7NWN?WLUM^\[T+*-F K=:A*K8-0"KO==)IYW/VF#Q@G&TZOFP<<1=^+[W/U
MH]XI/.BOSTK,]=R8K.;RN6"+3KDB(\47]<V&W*[6^SH=56L7)9EFB4@$E&9A
M[,&!@#Q%#):<(D9T1E,SH>OI=!B9IO8:Z6AEXPJKK5Y M(H!V2D.98]4USO=
M]A5O'%\Z(=?6X5Q[_!6+;1EW%NM!@YU*8*L3^/5HL?9J[:M'54..OP.MFL>)
M^/BK-](A^=$C=V45V:55#'5P'A;GWK/T0%.-=[P>%IN#$_? 0P_TW.P]<I69
MYW>SJ]O_YM%\5S%1%R]I'U]"99FR1$,IM3 OU$Q!1A&%25%DI:8YTL2O*[W?
M_)-[>7;$;UK%K):PHP'HJN#I\/%<&4<74#R\8V\9+H:V6MR[/S_4A30VW]D2
M'-X4_OQJ()QAW4F>,HSK8!H&T(G+:> P0X)@F<W/KD]XWO\M5%79Q(2Y;(LX
MM?7^Y,.R,^N,*%7(-".09Z6"F"<)))HKF)88)\SL-/+,R<,]5("IT6(CMRV1
MN1=\5RZV+F>SE]TG G/ TCCL$B(#'ON<C35=J&OY[T +_8$*V\JP-?2/HT'O
M$_P:=PG&"GZ-L!2>,;##<>R/@1TP[H@QL,.U/HR!O6&<(67,+V1U[,)LOQA+
M?SVOY_FLS&?4?("_60'M$6[UO]1"SK2@!<E+&PYK7SR9JFL4<:B$9FF:"*J5
M4UN30/),[3VTC_=?[T6_ \\[X6N/5RT^^&[D]RF=??OB.;R:QEV2M[+@[SJ)
M&5^Z"[57J?9V-0OUOT9?*)]:YZ,NV%@UST=8.,_BY\%@[B^"?OLT(Q9##X;)
M85'T<,,.<U&UP6.V=;SXU\M\K3ZO;4W=S>OG!:N=8_8$JG:4S3)"B429AEF>
M$(BQ8) G*H&8E:7*">.::;]J5>Z3.SVWHY:DVF;S5/8M]]S*77M+U%9H/Y>4
MQTJX>:,"HSO.:^QSIPM**S;8RFV8STI^5Z/\_BK*WOXF?\""NIH\IA_5R^0/
MR[&#:< ( RS^7^:K;VKYV_W'I6B]MFF6HX3K!!9(8HA3E4+&LP2F!6:$9;ED
M.'4VX$^&GYH]W@@(?KN_L\6_+Y]?N2#G8#W?A$=D%CF"8LB)["DF'H;J3=B,
M9'>Z?ES\;,>+FO>:@J=WC6?9793XP%"[?)4G4ZTWL[9[\S: FV+,F"*P8%3:
M1HD*4BD3F#&5\U07E!7*B:2.1YX:/[7".3Z#)SA=H:1;M(_,1MO6Z.'"JR]J
MVV>0F)LZQHCYZ=@0.1UUG*?PDC*[!_#B!</V//O"+@^ZFZ?Q1=6U)6VP:55O
ML.K\FJWQ<L^KNF_53"@L<T6I>4P+LP_2FD#"A'E@$T)$IA"G1>9S2G^;.%-[
MRCNED,S&J*L/:!6JHWFK.W FAZD"?V[U\LPMO7%-W794XZU4[&.M_O0QEU7P
MWEV% 2_HCNM&D4;=A86![WAG%FC4(9$ ZIFMS1Q_/!M=EYL/2LU*FBB=LQ26
MB""()2TA%^9+AE"F1:85H=K]H/]D_*DQY59"\-*("+3R:2]Z!D"'7=MML,2F
MI2TBK73@PZV(^)R2WX3,6(?@9SXSP4H\702@__3Z]+81#Z<ORGQX]GSYLEN;
MW5SRX+>15.+"G[MA58^VXOF^A"8I!-8RXY!G*8.8)M+8EPQ!B0MC</)<J,*K
M'GA$6:=&J5_4#[5\494-!%E]6]:Y8R]U6;3=@<K0WCGAU]G-YIS(ZD5F_A#Q
MI[5R($KYU1$6(5*KG_#ROE%CH&C 7VXC%&_*82^=3_NNA3.9)J(L66D3A6T9
M;,SMT48.,68EDGF>(YGZI QWQO8B]1$2@Q_M'-V6C7X4WD7-C7('8A&9(C\Y
M .!-;&=4#4I$W?%')8XSBAT_Z.<N&;"1_;Q>":5D93L]?ZRJ%]LNM-Y,/ZV:
M@G:_J\V#WOZEWE'/&"_,8YH7D$A;S1DE)228YI"D J5"9JSD3G7FA@HP-;MM
MJT+3U'G>BFH=B*)6 U16#UL_S2S_4M7<"OZ:;[[7K5O;DZP.']NV'EN#[PXL
M59T)N!M6K/I:J8=988>M>.1UBTQ'NR6SXH.ME#8@K=%@&Z=ME+"_W%WP;@3P
M/7;]D1=A)+= G,7P<Q_<@&2O?V'(N.,Y(&[0^L!#<<LXPZQ),Z"M,&$F_C&7
M2O[R^D>EY,=EVPMF^>W>L.R/IN_:]I1$Z105J."0DT)#S L"N10,YB5!A MC
M=_J=?/F+,+47UTY4L)?U?_K9IP/6P<V,C8MNY->+9:JZ?,U6?,!?P4]6 V,%
M_ S.X1[EU&HXB$'MZ %BC&IN#X?IV"J_8:0A,8,OU7RIJJJ.2ZSJPFN_O]@0
M@P?]P=B/39CUP\NFVK"E-+-_?>'_UYB?CZMM^.^LU)AB6J2PJ*,!5"XAS:6$
M.<[*1)>:2>9^:'6S.%/CQT9Z:WUK(_\V&VBUUP!4C0HVWG?7V.(G8^@WESIV
M\ VTE@Y&^Z@K%)ECM[J CC+&1FR6S)B)5J%M>DE')=#J!!Y7N[XPHRZ33R#F
MF,LU5N#F",OF&?09"N7^(-&;9QDQJ#04(H=!J,%&'>B -G,K]?!<Y^PNOWVR
M71NV7K37W]C&]FE^/3KE*G)6E G.85*F&<2:9I @J2%*BZ(H=9XKX?1^O$&&
MJ;T4O[X\/;'UJWTKM@+/FS2BG5:@5@NXN'R#+92C;SPN_+%]Z+7T=\= W^V0
M?KW;+LEKU /%&V ,ZY\?(,>X?OSA0)WX^V\8:AA?_F:F>%G77NB/R^>7C>T7
M<?_WO)IETNP8\D3!%)EEP2I#9M.0(\AE3HE4 F7"J]O6I8FFQGP=.4$M:-WZ
MQ(_;+H+J1F AH(K,4N=1 G]:,0-RT#4D@A+-Q<E&99-K*A]3QM7K!T:/G?2Y
MFF&-66K,(2@R\P438R91R@C,.$GS7*19:5VK[N?YIU-,\UC_J_D5>UJ!Q^^&
MEI_5RV8NJC9IK^JH\-__&TE1^6]U;O7FU3.&ZQ1M-ZJX#</()'&V)=[]9K.>
M\Y=-;;ALS#[/; A"9DA?1B1L^-+I-.-&'5U4\R18Z/*584R&AV>[R_OWU<+8
M++6=TC:&Q@R5I$10%SFUG:$*LZLRG(&PU@5--2ZD4^EMOVFG9D[4Z(/G]5PH
M\&,G*U!M>Z[;[(H+R ^S,F['<VR;PVZ2ZD"*O= 1^L/XX135(KDP]9O:)_UP
M7+-6KMP]L(?,_DBZ\3?9,VDE9YQ*7I1"0Z1X"7'*"LA9)F#)A=14"IEH-C-[
MK_E*?MVP]<:-ER[,YO/@',\9T3&KOLV72^M5^(4M[#%]Y7^2<0UFHC)N]H<"
M8I$E$.=<08(S#(WU6/ T3165>0OS^Z5C&9Y@(&]GC ?Q^\:5'0]?-WH/@%AD
M/C^,^VF$O .-F %[OO3C$+;+RX6YQNWKTJ_P22>7*Y</.+'^)YLO/ZVJZF&Y
M=_F;W:-2F<09%!2;W:,@"O(LUS KLYR7:<%26;B5YKHXA]-G>]0*7%9*6^BU
M<[+L<0QY%D>' ^#!V(SSW->@_&0%_!D\++MG@;=BXW'J>BM&(QVD-E@M:JP.
M/T>A4BK[@.@]ZSQ[XWC'EWUR'YQ(]EXXS, \;0O?-EZN/K-7Z]BX7TKSF[7A
MT6YJ1U+()!=80\&P,8RR1$%*L@RJ7*0HISG+D5?OC&%B3&V'O)49/#="U^ET
MJSJ%CC7"#T^L&;A0;A96?/@C$_%6 ?#35H6?._W?*_"YLR"M(D[GO=XVVFU(
M!C7A!HHRJH5W&US'!N"-HPVLZ=I65]R%?SRL[W^P^<+.]V&U/CP!;;JVS%A*
MD<8\@31-;*E$32&1DD!";0=IPHR!Z=7T=8 ,4^/.K0J[P*G-RBP#V*D!M/GI
M*)+ L^3K@(5RH\_(\$?FSB'(1^@_= .(80O##I!CW JQPX$Z*15[PU##V/*+
MJI2YR79<[;:%V^=SOULMZSCSQ]5GM3:?O"<KAS6AJE]>=\$')&4)8RF##)4"
MXH24D E6P#R5 F=%*40I9S_4FJ]<&32(7#X/=5>Z>,_V5JW:\#GHI]FM?+_5
MK3[$;+1K'OI:O[L!82-AEMF-?4=?NLA\'&[-@@>Q!(4Z*&N'D6Q4'@\*YC&S
MAQU\@.=T&RK='(M5CZOW?V_44GY<&IN;+;;B/:KUTRSG6NM")+"T_:QQ*1BD
M"%.(>"$8ISRGCC5Y_>:=F@6\S]Y9-;+;1UO5TIN];"V^[?W3<(,1R+6VK^=J
M.'AEXV <F5;W*1NMV#8UHQ$<M)*#'?4^1H/7P[$;!^:1W+WAX/9S ON#UNL:
M]AAN/(>QOXX';N0!MP\S]L]DT-1.Z\\VAFA6VMI)FBI8<I9;(]X>KC,!-9>:
M8)T*K+UR57IGFQK9;R,Q/ZSKTA!5)[;JI_=_?/FY/FM7+^M595N\-0<EGH?N
M_>AG"@NJC2'%*>$0$V5>NFE!8<:(S$J<%B5&?ENH8/B/LS7:)?:Q;F)?#?1V
M(<P22%OF9AUK$=PV.,& C?R&/9\J68L*:EG#;42<( FZP>B?<=2-@Y/RQQL"
MMYL&&/KWXOO<[#"L2?&@OSXK,==S)6W_T>JWN?FR69EIVW!.G64IH9+  J<)
MQ*K0D"#;:SI/>%:*D@CFE(GC._'4V+\C>MVV<RL\J*STX&DGOH<-ZK,.#C9^
M)'0C4U 76-NM<0=L+3C82SZD29$/PAYF?B2D1[+SCS[*EQ$/%>4Q *Y>"]]G
MO/%,_ %:'MCX0^X?6-G*:,.J[Q^7/VPFP/+;_5+NRL=\W*BG?2$EQG)-\DQ#
MI:V?)R.%[;VD8"KR+&=IDM,,>16T<IUY:O3_]>7Y>5&OC=D$6Q6 7JS^ G+7
M'L*[JI7S&KA9G%&0C>W?:60&.Z%K__F^=%4M=YRJ5;YHA2U6Y3S[N#6J?$$Y
M*4WE/<#0%(NE;?3;%#+],J_^\]U:R?G&?C>C,BU3C@UC%81"S%D&>6F,UI(@
MBKG B:1>B5\]<TV-HPY$K>ME-+("*VS]:#6UX>V/OLD EP%WHZ= ,$8FI ,I
M:YSNNAC>@<^KQ5R\@C_;_Z.4OG" *G#>P.7Y1LX=N*KX:?[ ]5L&.D*;#)JO
MWY7:?+)K9B:H3[@1YY+3A,.\+'.(:2$A9XC"'&LLLB+56'MU'[DTT=38I943
MU(*"K:37SJO]L'5TK@5 ++9?;1!8_CZU*TB$=:==FFQ<3]H5E4^<:->N'T8/
M%ZKD6 OH96UK"LP4PT)B@6#)"K-URHL4,J)M7B)GA O-.,W]O/57YYR>Q_[3
M:OD-VH-O\+Q:UX^ L4H6=3CBX+#ZZ]"G7)24$ $E10H:7L;0;&(QQ*C,:)I)
M0KE7JD-0X,?@ZK>!W8V]@X(9F<;[RJ#M!0['Y\[8!"7VZ[..RO#.(!Q3O?N-
MPSC_ YNO_YTM7E2GCL"'M?K7BUJ*US;Z/%-Y69""0*U3P_54:<BE*@WUR%(0
M1 J!O*Q#ASFG1CY69%#+? >Z53-V8OOQC@OJ;LP3&,O(W',6N@A!_!ZH!&4=
MEWE'Y1T/((Z9Q^?64$F?[Y^>%ZM7I=I.Q-T,PHPE*L&EA$6)K0\LRR%/N(0H
MY466,I;G$M^6ZGEY\JFQT39U4'0;K5M?F&I5 %PME9Z[]MP9M"!N_!0+YLA$
M=2&1<RO[KJO]2,F;US&+G++9(\ ;)VI>A^9Z>J;#&'X,)]5\]LZ8:?=F@G<K
MJ68TR3C2$D-!=&HVSMCF#+$<:LXSEB><9-@IT_)XX*DQT[NZ(*$1#ECIW-CG
M!*Q^9KD%@MBN=C?MG0GADJIG'O9*B7]\6_WX'^:6YCDWW]2/=_U@GPPTRD-[
M2?SM WGQ[P,+K.X#&C'F$F<D@U30PNQ8F#2/FRB@Y*+,<$9E1OVZ:4\^@/<@
M<O>/K[_^'"1LU#M&=)(!H5%"/R/'>;Y54.?U",Z;PS7WN6$;LX=0\CU;V_IY
ME;%J7YY>ZC?PK\9X%?/-C" NM4@I)$HSB+5((*&)A*E,4&;>G*E(O&+SKT\Y
MM>>[(R&0C8B^*;!7479[M,-B%_F1WPH+MM*"G[I(M@)?9L,!*:FNZ 3.-[TZ
M[<C)I*XPG&:*.M\YI.7;FCT]J?4O\]5O]VUH;((225-60MJT8RA+R"3B,#/F
M05HDI2B+Q+V'V\GX4R.25D+;-QG\=@\@8'7Y=9O[,Z]L!,U7,5?+S=Q W59B
M?^'57,[9VM&W>0GG?G8)@%YD*CD";D# ]AE0?+J9W03.6.W)#D *U6'LHN;]
M+<-.;QNQ!]A%F0^;>EV^; "[U;5&M^V^[K<]T-N/&D52YH79_*34L!OF&D'.
MJ/4_Y(+G.>,E<PIWOCK3U!BO+12_[2^YZPWO\>3V NM ;*'@BKU!JI':R@EV
M@@XANU[(/&@O%'0C$> E" -1H0L:O:38.\!X].BBQP%1.MUPX]'W?56I376_
M[#I^VT,O^;#\HNQ)>Q/Y_?MJN=[^^ NKYI6]O_YD/2KQ?3G_UXNJZF9B,Y(P
MA#27$"=805QH# G*4YC(G#%1*$RXU\XUIK!3(^[]83LXZ5!1U>=<.TW 7I6V
M=9]GV&;4#X';QGHJ2QOY)1-I58?'!D2$.TY000R!WR8:(2+T%\,88LXYM",<
MVVQ3(T]:2NU2Y<J$4&FL=*CR7$.<ECDD.L6PR 0192H2J;W2%9UFG=HK82=T
MG=Q[K@N:0T;=#8O@>/H1&MKH=G\ 5 ?TD_- *7"+.9>91^XZYP'&:2,ZGYMO
M:%O9=##Y]<4RXN>FM5)=]7\;.'%@I7\VG[%JEJHD-<Q50%XJ6YH?IY *SB'G
M@B.A95%JZ4=;@^28&I%9#>HL&O/$B:9=3W-T^[(T:[(/X*H.G1?/9I#A?8^&
MKJ$KZT5?F5'\'XT*H-$!-$KLNRCM0K^.=OJU+H&;;0X',WQ'S@&RC-^V<SA@
M9WM[WC!<L IUG\POZOSR&<<XS<M"04QS!K'-M^+4K)9*2BQ1DFA>^B5G]DPV
M-;H\5\L+_&G%;0HI^"9I]N'LQG:AT(M]:C48N!!%T$X0B5T#;3_A6Y= .U'=
MH0+:Z3T##H'>V5@OOK+90C\ZGM)ME9TVJT1A+HK"ECY#NC!FF4@AR9F$18XP
M20J&>4Z<3X.<IIP:I1P(W3GKV(E]/1]E*/@.)T;!(8W,,V^(IL=A4G!41SI5
MNHINH.,E+WQZSYG<1AKOP,E+LX.3)[\[!V;<V]HUC]_9\M%L_,Q4Z]>/3\]L
MOK8SV0Y[ORJ^^6I=D;6WLML3Q990FQ6,E"EG)2QEED%<D PR;+@=,9(799XF
M,G>J6!]&G*D1?:T-W!AUX*;59[YX!?-:)66+V=N23E8WWZSQVU;-S<X<;RTB
MOR'.+,,KV.L"K#)WP*H#]OK<[?L^0;U:0UN0-&!*>A!LP^:KWR;2N,GL0> [
MR70/,^I +Z?XKN3+0CWH+X83UG.Q4?(=JVS?$ON?]:C^,+,8JK#EL>KJ6#.=
M2493FD**RM1LSC6#5)<""IYP055*J7(*(+U!AJE1[E;PIE;;$EBYZZ/=^IN.
M!I[^RP&KX^B[C(MY9&IUAKL]18]3V^T&#,.Z*P?(,:ZK<CA0)V[*&X8:G*R_
M>E*[$Z?=R2A6:9X(I&&>:FULT$1"8NQ2F"2%HBA3E":E9U[^N7FFQG2-F&!_
M@CKT_/D2KF[\%0"MR!PU!*@A&?-],(1.CC\[U]AY\'T*GTEY[[W</[O]WHPC
MZY(@"_9MEO.RS.U33T@J(2:,0B:*S&Q$<\HQ+TB1$;>Z<"=C^WR4QZG_MA,/
M6/G<<]P/(>M_OF^"(?(3[:B_5Y;[65T'I;D?CC1:GOM9!;J)[N<ON-G/O^^D
M:)[NI:PV\\6B8Q8VIY<S20N%&6&PX)I#G(L$,H44E(IRI1.%9>X4C3Q4@*F]
MO?>BVE:&6UEMFKP1=K"CVFTMO \!@B,\[I% MUML!_>.!FVL163<!Q\7!,?_
M;0X/;E^'6\X4O$#T.&%P&_>MSAN\M.XY?? ;)U #@B:'H<A049940FT[(V*2
M:$A9KJ!.18)2*:E"7EZN\]-,[05Q6C1_6'K)!5#=-G>W0Q6=Z;U1NKUS0+Q$
MBPM3O6V_@-[DABM7#_7TF"?,D,O]4M8^^6;S..,,*\*PAKFPM;_3K( D-920
M)HBP@N84H<S/T7-NFJD1P5;*VJVZJEN-S&M![\!2>99BN0"LJZ?G5KBB.WHZ
M2#5-61H90[IY^C ([.4Y.]7(3IX^=4]]/+U7#]AI?E$_U/)%?3""=<R1U7(7
M#%']T]@E;4Z5X:%JOOQVPDAMYG=)"DW+%,.RM'U^%:&0%**$A.0Y486D7+BW
MW PHV-3XYMU+M5G92AKBX-VZ=FYO%'SE'/:K;[0>D0FMU0I8M<"!7OM(K.H.
M-*H!HQO8*0?.64;^M11"+J/']O>-EG.D;7'890VT68X >>\F.N1\XVVN(Z!T
ML.F.,?XMIZV/[._W?]L*W^J7II[W3".$)</,MN>R$7]20)9K"FG!<99B&_7G
MM1N_,,_4WHKM(>*&_0U4(^B00]93.%U-[YM!BFY[U_@8$4$K(_BIE3)@C<,K
M.$0X93V=ZPU.62\J?/Z4]?+E-R3@'F3VFGD6+]+FIC6-D.XWF_6<OVSLWO]Q
M95O#K PA&0*S+4K;7<&,4%(B+@@4MFL"-G1A#'"2PM)8X5J70J>(S#:K#5NX
M,4<8L;R(9B=<O ?IT<[1)-^VNOWW_T925/X;4+6. _)N;U\ZC-(LL17<BIPQ
MB#%BD&4:0\00X8AQG:9HUIQ=?=VP]6:J"W@L8KQE_$5]FR]M&5'0MLKS#3@,
MLW"J3%'&#;FQ%)<V?;.$E)NW-1=I)A&CB=))NW#OC4DQZ67;"AAOT<P,;[YB
M;@;!^&L0V7XX5_OC#NR4 JU6H*L6V*S H6)@JUG@=/A@2(?/CK]=M/&3Y8/!
M>39W/MSHP\RE>R%6+V:/]D4)-?]A)_I=;=YM^Y=2D98)+6T(C/F2F'<J)P)!
MA!/S0F5$Z]PKE;YOLJGMH;:R@O5.6#^*[476C3A#X169#G=0[>6\ TR;50+W
MB\7JK[J BUZMMWW4FQ2F=Z$[9[J@%932>B<<E:A<5#^F'Z=[ @;<O6OJTYM?
M[I)"[\7WN?JAY(Q*IC)CWL$<8>NG41(2E):0$8I*3+!BN?MQQP !ID8^>U'!
MTRXSG+7"!@C\ZEL+AP.,R A'IJN>0*\.[ON,_/MQ< \0<!<(_[</N!NV#F$"
M[AQ '!1PUS?NVP?<.6CM%'#G,LZ-Y3\;6_G=ZNG9#&Z/%_Z>5S/-\YS+4D.D
MI'F#6'\/+PL$25HHE5"*&'?J&.@TV]1>%VWUR;V0 VMZGD76=8\?"*_(Y'\"
M%?C32ABC7F<?$G'J=)Z=\6WJ<_8I?[$N9^]-L7,_'OY:FD?U^_SYT2Q.9??E
MG]7:GE6R;VKWM_VO9@4N$Y5*!DN"<MNC5$*:%QE,"\R*#*7V?#%.DHBGI%-C
MJ_/9)'=@M14=;+9ZV1235HO.G_>_C)4#X?M9N,%F'GN%W\ZX/I]%<0=V"H&=
MMF"O6^?/GR>W[K&29"*N_]L;]V-\#B+FW@Q<FW!).KX"O/WF(B2.P]-^ADYX
M8[N<7^>56*QLWX1J5ZT@*:A.N"P@%L@F!R .688R2*10(B]HGJ1T4+N;,Y--
M[?7?:6S2D79P08A>G-WV+J'0B_QJ'0[<\*8O/8C$:=IR;L*W:;K2H_K%IBE]
M]PP\GZO;L.P.Y'+.I408$IP*B#.IH2UI" 5+:(IR7N;6R^$>E70P^C2#BT0C
M'&"UJ)Y'< ?@.9ZY#84D]B%;+5>,8[-S"H<])SN88=R#L7/*G9R$G;UHH)>2
MV2I3]='^[V8U'_2C,4HJ5AL@;2%>7!8D$XK"G$@,,>(IY"3C4!*B:$E%CC*O
ME__U*:=F EB)=SUT/"L>>P#MZ+D,"E]D%O!$SM]YZ0Q&6 _F]6G'=6,ZPW#B
MRW2_<QC!?%*&K=3#L[*;GN6W3XJ9Q[5MT?;ZF;W6>1>_OJB9,EL,JK2MM\DR
MB,LLASQ1!112E!E%,N6B]+$57">>IAFQ4'5?H%9,/ZIQAMR-<&( &9EV&I'O
MP$YH4$M]!W9RW]GX1J[ 9S8/<$ [%*J@I.0\^:C4Y O),4%YWQ^J/(H9IWTO
M9TRFE# %$1>V34^20B;-CQ(599$+DG+J90#US#4UR^=,HJL5]M8J*7MLW2@H
M$&+1SQ+.@A7!['' (W+IE/U\;UP_Y43QZT543F\9G,6YMG3TJVK^_[B\%V+]
MHN0VUOD@5'&6*Z5+E6*($H(@UD1"6O(<*I7KC&.6,YK-ENH;VRC'9!$_ 9R>
M%-H\*5TQXCTPNYHB0V.6/5? C6PBH#I:FF@M,/AI*_K/8+X$K?2[](V#L.??
M>ZK<#,D@'8!<Z,12'Q'&SC<= ,^9--0AH_C7 'Z_W!@3Z\/<C/-2UYA($:=:
M: 0+@B7$,D.0(U)"RDJ%$IPI+IV:BYT;?&J&3R,?L *"1D+W2L GP/7SSJUP
M1&85#R2\:@)?4GE06>"3P4:K#'Q)C6YQX(O7#(@1^_K+A_D/]?C7ROZW+0;U
M>;V2+V)3M<5@&"J5+A2&2<9L3WFJ("^%@(7,M2ATB0UVSJ%>#A-.[>']^@O,
MT[Q3T^VY%=<C#L<%Y_[G.@9ZL=VUX!=@!05&X.:;^UVUMZW00RH=N8#I$9L4
M&-210HQ<P T4(.0!4&^<C\LXXX7K>&AU$'7C<]^-P3/-T5Q=0*AQ4<V5F8'9
M$W;YL/QB^UO9KM/F@M]7R_7VQU]8-:\^[3H5IXPF9:X*2&F:09Q+ 0DOS48Q
M-?M$)5"29V)0M$T(Z:;&]?LHDSO0Z%?S?D=#L%71]E#:*5E?U543U'K>T'TZ
M[(? ;:_Z9DL;^47T)JLZ/.PH)/IQXI2"2/@V@4TAP;T8"15TDAL3QA[TA_F2
M+<6<+3ZOFA;BNPA!07DJ))/0O :8V8-+"8DRZRYE0A.1$?-W.2AOK&?2J5'^
MOMG42H.=U& K]N#03*<%<./ET+#&MOMO1W1XWID#1''2S_HF?ILL- <H+B:C
MN=P[C)A^5>OYCSID?7?PVE*CG??C\OEE,TLI*Y#"# IION""EI"GJ88T,;].
MD% YX3Z\Y##GU&CIWU<VD=A*"E2UF3^9=?'C'Q><W>@G,'J1V6<O;3<^HR,P
MJ"4.1ST>\ 1E'I=Y1R4>#R".><?GUF&T<[Y^U/;XPU;Q_>6E,K975;U;/7'#
M?;7C"!=)JA1+8*HXAIB7*>0<8UB2E)H]M5)(B>TIZZ,['PT29L")Z^-86^8?
M=6*&>=TS*>N7A2V,^9W9# TF_O4R7[L6$+EMN=SX+![ZXS#<A4)Z=0V^YLC6
M/IM@JP3H:!&.]6X",2@/#I-D5&:\":QCKKQML!M=DAU6_KQ:S,5K\W7?2KW(
M,I8JJ6"B;>\.K K(,E9"*E,MN$)ED3N=%GG//#4#KI.PUA'=,_C6'7=/#U](
M-$?SWG6!O .-Q.#/]O\H[>J]\8KC;[LZ^]OXTEQ!N>@G<Q[ \VA[O9FU)S(/
MZZ]J_6,N5%W-)TND3 0O#=9Y 3')"61I*2%-RT+2+.>Y<HJ]O33!U#BHE;'V
M8[=B.IZS7D+PRB%U %PBL\D92((50;JF?A\YF'L[Q&!^.B:%BX./<V1Z1;7=
M$>FUZX;9'V;(9[7>O'XV:VF;EME:2<^6-CK!WRHO$5+(/-)%02"FI3#/M2R@
MS"G+F2!(8*_ >H<Y)_B\UR*;EZ,5NOZ0[\2^&Q!L[X*[F^41&,W(+/%IM?P&
M/\U_* D>S>_GMH1Y?:@3(?S> YF@UH7+O*/:%1Y '%L4/K<.C5VU'5O6SVV7
MI]I1_LZ6$%Z_OEM)-6.<);E(<T@I*FS+E!*2A"1F\R,(SQ$J.'4*LW"<;VK,
MT\9U'LA<%SO:*&!K7S>2 RNZ;^AK/^[][!,!S<C,$P+( 9&S3O#<$$S;/_[(
M\;5.RIZ&W+K=-O"X7GQ7\L5F3[]CU7?#8/8_RV(_V,*Z#>I>S?O=?BHI)I)K
MJ)$MA8)("AGF*522%5RFJ?G/JS>!W_13(Y^M]-8!;06O[9[ZFXX*GJ?W?NOA
M>(X?#>78)_HN +?MW.,X8H9!%_:DWT^$<<_\!\%S<OH_;)2A!M77)[98;'W5
M,ZPI3GFF(".IA%A(LWW+"8<9):I,9)(GS*E;Y87QI\99[7N^EG%W5.-K&ATB
MZ&H*#<9E'-/'$9(!1LY9Q6\P:@['&]F(.:O,J=%R_K(!J4+_>[Y1G[^S]1,S
M=E";92$28VD@@J% BAHS!".S_2$4%@5/-68R(ZER3@TZ,\'4'EHK(FADK$];
M_^&1M7(.ORO>U "H1'YD.X!8/(9D\YS#Q2-[YT9\1LK6.<+I\N?&+S.G1_G>
M3)QS]XV7>=,C]4&F3=]UPW991R7VMR7IB"RP$AFD";=1T$A#FBH;Y$-3FF*A
M%77JO]0[R]2H[+@5A-_VZ#R0;KN@F^&);88<(1/!Y=L+0=!-R_F91MV;]"I[
MO 7IO_B&IM@?J^I%R5]?;*+%YZ:W<!V?5G_]A55*VDG5LFK>.:1,2*&D[<$K
M$K,;$1PR2AA$)34&CY+<[$C\,B.\99@:8UCIZV:&*PW$ZNEIM6QZ7X,7LU9
M_:W68E[5?VU^O7JV6C2I5O.EN66Y5'4E0/#7?/-]U_U"R>TPR[DM\;I4==[
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M&Q4 ](/H<ID_SW'\[9=/9MT7G[^OENKWE_HHEO-<DK),82$UL?5N$DB%;?Z
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MC/)Q>2^$;3 [7W[;'GS\\OIHAJP_K5H5B,M"0(6XL2Y3R2 I;3<CG254BJ+
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M_Z<?5P5>13=R>[NUB<R&7<7^']"H=@=VRH%M897C8G^'"NX#6?[<ZAB01>.
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ME$&,4 (I+A.H,-(YQI(QXE1?RG_JJ1%V4\9OI4-DP7HL@/.V+@*L\3=YM=#
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M8U\Q3*#(2EP8\XI+FOA$BHRVC&,$EYQ?PG,K"%AE?F6+>)A?V-I+\R78?%>
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M]NTCQ-CHX.]D^KRJW:)%AY7LH!;>SKCJM2AFQI1OJ#U3RUI\]92#5H&#D%^
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M(T>G&9L%40D*:<43*Y/!XDMP'$^#;[H3E'R?E6T M";2'B6JCR-E\:%S@MA
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M"#5L$-5G\K'QY]KD9N6\:L>K+2\JEG\(,0/?U*7DL:SLLO;GC_/J:'.AC_+
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M-,1Z:3 45Q%!+04)WAEMN<I"RIW@L/JT]0#0<(IS:]'UK/)R+CKZ]&4ROLG
M..UU @TD>[1@$@1N=S0)DF*B6B=F0>]VXO7PB>NION%4YDXB[%G]9Q OIPA=
MQL/Y<#Z"@::<ZT(L3Y$2=&V0]@P>)6%1.DGH''=;]0^?N)[Z&\YA[B3"GM5_
M/O6E\N3LZB),1@-IN)'.!,*H0K-EN2T[E2)&6LC*9!74;A[BO<>MI_B&TY;;
M"Z^117_T/7[QX\^PR+=R055B,9.H(P:\D7(T6NBK1.6%,<KRM&.^Z:FGKH>!
MAE.2.XNRB7#@\'):Q+4\@2N01AU<S@:4!<]<D,0*@_M8])J$H!D))C#N+$W6
MP$Z0>.GIZT&C^11D!Z)M B+'8_PT%,?P&[SU<W_-U@!HR9>E8NN0!6FM+&D2
M1;QP$;V?%-$#ZN18XZFGKP>1YA.1'8BV"8B48]SIH9_#Y\GT:L -UX)%0Z*+
M 1%N$K$I(<P3F.S 2,I-!\BX]]#URJ::ST%N+\@F<'!VX4>C-Y>SX1AFLP$#
MT%%A\*NH#>4<EQ/'J"2.!Y=E%D+IW4KHGGCH>CAH/MNXO2";P,'1!4P_XY;W
MVW3RY_S+X>3BJQ]?#:R@UMF4B?8<S9K4E#@%EDAG)0./<K%='(0_^?#U<-%\
MFG%WP3:!C[,O,!K=4)]TS)IQ05C.BJ  <-^S*!L=6';!1,=R%X[$ZC/70T/#
M.<<=Q=@$")#PBU+&,8E_G'U!N<U.+N?E]D:)K < +J'?XXA2#DV>])DXCSLA
MS2S$9)5UIHNSS)=H6 \D#6<G.Q9S[Z7Z!Q<P3J5R]-W(?QY0:SA(EHDOI_:2
ML4 "4YI80UW4U@0/NZ6L[CUN/3 TG*O<7GB]Z_VF8/C=<!;]Z#_!3]_A*[,!
M8C=AE.0)>D69R&!+P)0% 0=),.\5QDH[(>"9!Z^'A8;3EUT(M)&R_"4+R]L%
M2R8B#\EDRTNIAB R!4.<-(QD$-S'",YXW2$J5AZ]'BX:3FEV(]0VG MD8^I'
MQ^,$W_\=K@924@$809.D32@,2!)*=;'.++(D4,&TDX3F_<>NAXCV,YD["+/O
MNH9E2NW.TMU<0?+9:#1GGLBLBN<3&?'.6!*UH,B!,-''W6H<GGGR>IAH.'79
MB4@[@\6__/I(CN_QA6VO9)]\?'OT\>SH+7YS=O+^^.W!^=';-P?O#SX>'IW]
M[>CH_.P^ VO>U_[QIW9RF7M#XG>\Z7TY(Y^]_SI8E,25;>,DOQN._3@.<>^8
M+&]VW8+-1^V<MXJ +\7Y$7'F+#?$&,YYLH@5_]+MR>QG80&$ZX<NUQR,YK.;
M5Q82)Y1=W\G_;YM0MZV!N7G&P6P&\]DMKTD87%(TD<0C;I8Z.F*]2+@89+1!
M>.M>O FT/:_WZ>CG3GDU5-R8H Z$WN.>=)_Z:U-ZRP2PQ)+5% 7@=.F]$8BU
M%F-R'2FWF8N<7CJ)WQ4Y#\CI%T"[Z/=)J.PB[ 80<^AG7P[&J?QS]+\OA]_\
M")F9'<P/_71Z-1Q__KL?7<* !Y$QG,<0SI0*)!TU"<93HI-A"9@4D;Y4P[<]
M@M8BKP5$[02#26V=- "T@V]^B"^/X-UD>H8<71>Z#&'V%L+\[J>;TVKJL@B.
M:6*<*9T=(A"?DR=&1AVD1TMNZFSM&Q+:3V>->N"KJ:<&8+BHC8#9_!0BX,I"
M/F\8\5EHD[4B(:9RA\\KX@)7)(.V2N'24K$.X)XEJ9\N'?6@U8WL&P#108SE
MAO#LCI&/,+_A)?&$(3"&O9$!(^72.;$B69)2=D9P)\*+!X\[&*X7J.JGNT=%
M*]65!AI TZ<I?/7#=/3]*XQG@!O_R?P+3._)#/W4G)Q@DGAJ#)%29A(D[OU2
M4@XF:1-Y'1=^#>+ZZ1E2#UM=ZZ,!B-TG/ANK693E*K)$SU'$1(+#&,A&H217
M*=D7R_([B@?[:3)2T21M+>/M 3*9^]%>O?./DW&\60).T^!QS\Y"%BL;(_&I
MM.?CAIF0+;/*]^J@W]':@H_>3<JAKIH:L%2?II.O,)U??1IY7)?C5 +@KR7A
MA_O[0'D1(LA$(GY#I'*+!F^4<. 41.GFY%XZA-UE%WR>JA:\]$[ U9GH&X 1
MAAI^_'F(*V4I(&3AZ'L<79;RI-\FD_3G<#0:!&4A.T^)$"(2R4$27 Z<,,:B
M9TSEP.M8L'6H:\%C[P16G:NB 7C=TBUY4$IZ7 PT.2)-J:67"DB*(E(75;"5
MLE0;P:2R\]T)3+82:0-0.$&;Z<M%K/?@9W!:.J6?Y-]G2[ /LD5'D*M,,M.(
MZVPX<1$EPK3D#(R*3+Q4G+X]/EXDJP77NQ/0="?\%I!T%V:N^&\473;I:"0\
M H8D.6OB0T@D&YJS#R)P]5(3E1T0]!0Y_73\JX&<G87= &). 24QC'-8G!6M
M\!&3IBH$0Z@%(%(&3SPK.0JGA F.,VY?JF'='C3/4=1/^[\*N.E$Y U 9RF2
M@<#-E%NZH%5A=,A*HRGA2*22L2P2>%<S%=1/X[]JM0 ;B;.!K,_[H0_#T2)C
M@/'>XC+'E\D(A3XKL=_\ZJZH+TIC'1?E%IA%T0 G 5!2Z)X+SH(.]L4>@-O#
M9%T*^\WP5*]*JJ*H!JS0"E\/4[%&N123\R2IA/8T)(_BR@R_TY'QY S(.I;I
M>9KZK3.I@X'G@;:+0AJ ULT)X2=_M7K2G#PD9C@0JZ%T4DL89W*CB)"0=<1=
MFL-+36YW/YV]3T\SD-I)V\\<SNX@^C8 -+V$='3Q=32Y G@#8\C#NP,>B+BF
M9*"E*1<NM0P2-WV6B7 Z"&U4T.RE=A0[ >D%NOK=".L!JBM5M .LQ[(:))?1
M%1"90.:Q]/G+Q(G(24XR9L&TS+J:<7J:I'X/-^K":4<%-("DP\EX(8U_#.=?
M#B]G\\D%3&^XNKH]B4[1:!6 Y"R@7,A1Q <OB7+1E/LS5H@Z]4CK4-?O*4<E
M?'6NE@:@]L1BL<Y(+C.ZF+GXF8)BO Q6XQ?!7$#NHK9[\M#[/06I!*,=1=Y
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M,")E"K%2OX\'E/1=U],,RG9240,0.TAI40[E1Y_\$"/P0_]UB/[G"EL#IF5
MOU<3S1 8,E-/G$X,O5Z>4Z#<LDI%9C^FK=]47$,P[%B-#0#S%.9^.(9TY*=C
ME-;L(,;+B\N1GT-Z"WD8AQB\,Y.8@]+^G&FTYEH2EZPCO-Q,TMPFFNJDB'],
M6[]9NX: V;$:&P#F"@>+Q%+IR#^%+S">#;_!,H7Y?C(KB<N3?.Z_#\"8D+RA
MA.> 89UQEKA<IM%':Z1S6;$76X_N5#RR":'])@(;@FQ-!3> W\>2'BB+7HD'
M23*4R><\6/19;!EDB<X*ER)C/+BGV+O?C&)#*-Q130VD'S\,QY/IS=@S%,M
M:R6CB(Q8"&5Z.DK""G2-M13)19JSLW5*,Q]2TF^BL2&0[:2B)FW9-J(<T"S
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M*&>H QI8M.7JB8% RVA0=/^R!2)2C"ES:8*L<P/Z$2G] J<#]3[?D'@+63<
MEF=:V5XS8Z3"(#0#<2$C,]9:XIC4)$E%O<HT2UFG5>&+9/5[PM(]B+K300.
M>MB"]IH+86C.E&=BC2]Q9[EP2_&+"HH%'P,/O$XBZVEZ^CV*Z!Y"'4B] >RL
MT0OVFK$<F&4>8XS(,L=-OL@J*T628]Z6EG&2U]G1UB:QWQ1_!2-513<-@.[I
MO.R-\154 N.<)*U5Z3',21"I=)>(3KJLI:N4TGR)JGZ3Z]U#JS,--("FV]CD
M/9KC8_QV-C#,BVBB(T:@0*3'6"047F*0/D=G91!UMK['M#12F])AQ+^=F!L
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MS-A(ACAC!-$N62T,T_EA!NJYBI)-'MOO1:IF<%E97_UC\>Z(]-T4EH7FLT$
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ME/722*4MW]O&O0Z]K;4@V1- .U=EHY"]68B?_%59A27)NMPAW@]]&(X6_M%
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M7$Q/0#ZF?CQ#\93\#6[MBQ]'J^F<U?@EQN"2(%F5GG>44^(S5\0"QC7"6EQ
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M3;RW@2AM $4FP>0ZU:)W-+S.M& W8-M2$PU@Z,A/QRB/V2>8GGU!29=9I''
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M?./C'Y >L>*YUS0%3XSG$EGQIEQEX?AC%C8'  9ULCTO$-5O+YQF,-B5VAI
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M)%)J7880"J(YM<B4]NC55DG[/4G.3W,,NDW6I#M%-8&WQV=2_NECJ.L%90P
M!\=("@P7%*6)^"P\L4Y 1@$FH2I-3-Z,T'XS>QV X^']U8IZZGO#6SDD7>3A
MWP\CC%=VB)MXSBK+,J/$ Q-EJ'G$[S@0$(#K5#-IN5MK*USO>3V/2JZI[TE=
MX?<_XN=L/HE_?'KH:5RS$E3V,96.EE3F4FZ'OJ!%[R Q)S5PY<W#CBO/N50O
M/*7G:<G[0D]G@FZ@R&<'=^+-5;'XRVL*//N0T<5,2KK2TTF1P(TA-G*/3BM0
M9>J<T'9"?BNC>WIU[?8/A"9<P5UDCH^XCML<2$T=:&(EYZ4TEI?20D44+PTZ
M&#>/1J?TC_\[\E]MX=JVP.L.^EMBH']GX0"U@KP6[D[RV5>(PSR$4@P2\>WE
MA&E%$H>/7T)1O1M.9RB9BPN8+@I&_ @^#$<PFT_&<+/%>@#G(J6$1VW+Q!QT
MI9@NK6.L9]%2L _WA6>\CKV0^VK7P;8HG#0-B,86R1UGC[AB&<V,=(H(782N
ME2>.!DFX<\YS+5W6ZUT,6O.!_?K9+0&U(Z4T!K7;Y7<CZB<6W"E\+A.1)].K
M-9>>3<%R[RTQH!*1-J$\%(I'FZC+O%R/DM_!%G=(:K_^>$OP[AT(?6?)GI9&
M86OV!H/O=,?<<3X8CR_]Z!^3Z2C].4SP$>:+]YWDZ^P.;F:3=!GG_W][7];<
M1I*D^;Z_8FW??3ONPVQMS2@55<T9B=2(K)J=)U@<'A1F2$ -@*I2__KQP$%2
M/*0$D(E,LM:LK'1G>+A_X>$>?LT_84B?;S_VOK)RPQN54] UQQ6%)>]=$EM\
M=@JR+49H;KV5>8]#TAGA_4[R'.21&09(AGF GE C)Y,%7EUA6A![B =?<+:H
M"N5.NSS2(\+J3%L58*H*4:9D",@2V,"$-2)@4,VBM-W1V.]TT4$>BX.+?E G
MH,G]J!*Y*)*N1E=$)(9C'<O'(QUO5W]$H^0.AE);=D_K&0I#1&O;8AH4!G]T
M%']\[))P5M?AT]ZXZCTS#<[5KL#"))3!9;J%VM6X^VM7^U? ZV%$.DP4+^VG
MQ_O2+C/M Q3E+#D9,@+Y'1RR4$4ENCPRW]N0W@F/[B^%Q_V%TS?HWH:K,3%K
M,@ZWI1#$-SI1.,%5"?FR)&(\>12)M3*(A!JA,%-GW' Z9$M;W;*@F&7)9=D(
M@CN3T B0_I4"\C""ZQV>WS4SN-W(YL0M8U/68([.&&!!(!TWP\A?# A,96&$
MRC$*T0R(/U^LWX> OHL[NY#(P!&V/J;H!5>B,-J1)CN"Z*<SHS2!*"BAO;0I
M-XNT-5JNI]*[3L2[!79VX'7?Z/DXPZ,O7V;3K_<B))LT<:.YM"9"L8Z<^!1K
MSV2A069A%<\,<VZFEIY?8[@XV464T_;YVC<\GG@DW;C7BL=DT=.AJ9P1&$G_
MUG%<IOC@>12AN$;H>':)GBHS#P".=KC:-S9N:;_X8[IQ'%SR068.(O+Z\AUX
M'9..8+-1/+F"JF$,\?&W>RK./  :]N3C<&! $MW@&*4MC&>$X'RUSC(QPVM5
M.U0'S-H6K\V60+C[>D^%F@>%PHZ\[!L,YQ>*O<%%N/@<KL)\CM?C\+%F0?/-
MP]?%;/SX1M2BAL:(02E+3UK/<PA22S"$]Y"98S8T>PS::?F>JCX/<<]T+HV>
M.]VL@[%GLW.<?1VGE76/U@J=G  N:Q\JI3R0,@V07' IYRA#LV'HC9K:/$5!
MOU'%OGWL-L0R#%C5*I'U#N:;HZAMO7LME+3L-BDRQ$R.I,L1E<>H8FK4EW0;
M;#TFH[_.-OM+]C%,]F1S[U?>FW>DO,EVJS_05I8':+.U3=$/8QA%TA"YPEJW
M;2':>H\'P;4*WBO3L+KJYXOU#HY]Y3GMD+F# LLF$5484K+U/2 R"\I[1_=M
M+F"+#,H8931K%H=XXN/]=3?J&@P[,*]OX3\%7F5L*4X5*"(9HM^D.@1%@K0\
M>N>#3=@L26I73=!)/Z,.A+\O\P902[FI(KYERF8;/"AK"H*6M35;% :B\98P
MC-QP$:7L:"[V,P3UUPBI7=RTR?>^=<== .,NCK]Y3PY>DQ]8AZ3(6J=L(W@E
M$R#CQ@MTM:G+=F\MC];HKS%2!YJD)5;VC8BWI^,)GGUZ=TY;F-P]'99EPE A
M)6@<@=J0NQ9BEN"3-5(+%G)H-M+LZ>_WUR6I R2TP,)!%"G_2A[]!L*,\YB"
M"F3^(A&?&4*4B92:\DGDI#*Z;DJ-[Q'13^)?=Q?(KOP=@,W1RMB/$ PSN0A0
M@DQKI5BI#Y"9$& $=R4;EE0GF#K8?*+.LJ9??O>&W6 P .B3+DB(>?Z.A'+W
MT#Z=S4=6>LZ]06#+:][YV@'5(I@DC,]&!:EM)WA^EJ076UJ^(SJF78BJ=XOL
MALS*:YQMN/5^'.+X:KRXR^K^&+Y5=AY?C2_'=8#1]!,F''_%$<:(3)1$U\BR
M%6=VX*2+Y,XF&87"7%*S"-CN-+S8HO']('A(R?4.T)]/UOHX(YMII$Q"(94$
M5+G6&J A<T?5\T<;1&^%4,W>JYNN^&)+NML 7Q=2&2K4UF\Q[Q!'+)7"DU&
ML68S!.ZK/6,AA>!"R4RFN!_([M9ZL>7/'<)K1TD,%5C'\\7X.BQJ*X3Q=;R9
MS:O-O/8!WT[GB_F(=+$6SCE(7I#][&T&1T<&/$>5BLDYYF;O9#N3\&++C3N$
M8;MR&X#;L>'BOX\7GS=VQ:T],>(V9YZY@1A]!,5B@J"*!H;:J40GS3P$84NN
MQP_)>K&5Q>VX'^V)K/]&0=^WKKW/P^OK\7Q.OTD:_^-TMIKG]^ML.I]OO*_?
MP]4-CAP33&4L$#WQ4(E21P8Q48,DPF*M.8W-1NWL2\F++1]N5UMV+\5A7>F;
M+$CB:EH6JYY,QHMQ'6F5II>3Y9S7$:>K(,92!P\G!ZHV5W$EU@EM9 +S5)+2
MS1JJ;;WTBZTA;OT*;UM.@[BZY[2/7Z?3?#^ <#Z]RD?7]:RM)J2.K*@# 2T"
M$U:"2K[.30D9=+#)&2F]>N@=MW:'-Z'OQ585MW69MR[$ 4"SE@R=E65G\=.;
M&HBB7WPF@<Q/YO,;S">3>Z\%HZ2L*BD90)MH;T(Y<*8P",$Z8W1!;):ENOU
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M^I.%FF'KE<9FVA1"WX Z1^)X6.!O7XC+DT7MAQA#\L+(#%YQTL"UO;LWUH!
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M[V$VKO&%NPU@+EC"<K936'9<#N",+%"T-*320Q0=.6:/2'E)76/V0=%^,A@
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M$-CO0^#AK^XVY#1 ^(V*<SX5)T$8;<DBJ658UA0H45KFDU:"=Z/Z=K(%.WL
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M_US>'32 LS!9+RO0(*4QHW!MPA4/5A"6B8Q2T-E$:)"*AB!D.0N%65E/,A2
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M@/U.8>Y?\O<^&%7/\JN6_;YV\A=02P,$%     @ 3X(%4\^GT-L$'   S)0
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M"78^I^T!G:OX659="[\.A$D00V@1!2XBN4=)HV65VPOV_1L-M"[R<0UK@"Z
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M?%#F/VT[_S]02P$"% ,4    " !/@@53^_GFL7I5 @!DI1@ $0
M    @ $     <V=M;RTR,#(Q,#8S,"YH=&U02P$"% ,4    " !/@@53'<Y8
M-(@4  "&U   $0              @ &I50( <V=M;RTR,#(Q,#8S,"YX<V10
M2P$"% ,4    " !/@@53WQKGJ,(=  !R)@$ %0              @ %@:@(
M<V=M;RTR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @ 3X(%4]>Z]K*M3
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M;6\M,C R,3 V,S!X97@S,3(N:'1M4$L! A0#%     @ 3X(%4]O>GS18!@
MNAL  !<              ( !.S($ '-G;6\M,C R,3 V,S!X97@S,C$N:'1M
M4$L! A0#%     @ 3X(%4\^GT-L$'   S)0  !X              ( !R#@$
M '-G;6\M,C R,3 V,S%X97@Q,#%?96UP;&]Y+FAT;5!+ 0(4 Q0    ( $^"
M!5.22S*F#P@  #4G   7              "  0A5! !S9VUO+3(P,C$P-C,Q
@>&5X,S$Q+FAT;5!+!08     "@ * *4"  !,700    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
